<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Maintenance treatment with antipsychotic drugs for schizophrenia - Ceraso, A - 2020 | Cochrane Library</title> <meta content="Maintenance treatment with antipsychotic drugs for schizophrenia - Ceraso, A - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008016.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Maintenance treatment with antipsychotic drugs for schizophrenia - Ceraso, A - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008016.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008016.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Maintenance treatment with antipsychotic drugs for schizophrenia" name="citation_title"/> <meta content="Anna Ceraso&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Brescia" name="citation_author_institution"/> <meta content="Jessie Jingxia LIN&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="The University of Hong Kong" name="citation_author_institution"/> <meta content="Johannes Schneider-Thoma" name="citation_author"/> <meta content="School of Medicine, Technical University of Munich" name="citation_author_institution"/> <meta content="Spyridon Siafis" name="citation_author"/> <meta content="School of Medicine, Technical University of Munich" name="citation_author_institution"/> <meta content="Magdolna Tardy" name="citation_author"/> <meta content="Technische Universität München Klinikum rechts der Isar" name="citation_author_institution"/> <meta content="Katja Komossa" name="citation_author"/> <meta content="University of Basel" name="citation_author_institution"/> <meta content="Stephan Heres" name="citation_author"/> <meta content="Werner Kissling" name="citation_author"/> <meta content="School of Medicine, Technical University of Munich" name="citation_author_institution"/> <meta content="John M Davis" name="citation_author"/> <meta content="Stefan Leucht" name="citation_author"/> <meta content="School of Medicine" name="citation_author_institution"/> <meta content="Stefan.Leucht@tum.de" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD008016.pub3" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/08/11" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008016.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008016.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008016.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antipsychotic Agents [adverse effects, *therapeutic use]; Bias; Dopamine Antagonists [adverse effects, therapeutic use]; Employment [statistics &amp; numerical data]; Hospitalization [statistics &amp; numerical data]; Maintenance Chemotherapy [*methods]; Patient Dropouts [statistics &amp; numerical data]; Placebos [therapeutic use]; Quality of Life; Randomized Controlled Trials as Topic; Recurrence; Schizophrenia [drug therapy, *prevention &amp; control]; Secondary Prevention" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008016.pub3&amp;doi=10.1002/14651858.CD008016.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008016.pub3&amp;doi=10.1002/14651858.CD008016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008016.pub3&amp;doi=10.1002/14651858.CD008016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008016.pub3&amp;doi=10.1002/14651858.CD008016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008016.pub3&amp;doi=10.1002/14651858.CD008016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008016.pub3&amp;doi=10.1002/14651858.CD008016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008016.pub3&amp;doi=10.1002/14651858.CD008016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008016.pub3&amp;doi=10.1002/14651858.CD008016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008016.pub3&amp;doi=10.1002/14651858.CD008016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008016.pub3&amp;doi=10.1002/14651858.CD008016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008016.pub3&amp;doi=10.1002/14651858.CD008016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008016.pub3&amp;doi=10.1002/14651858.CD008016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008016.pub3&amp;doi=10.1002/14651858.CD008016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008016.pub3&amp;doi=10.1002/14651858.CD008016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008016.pub3&amp;doi=10.1002/14651858.CD008016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008016.pub3&amp;doi=10.1002/14651858.CD008016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008016.pub3&amp;doi=10.1002/14651858.CD008016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008016.pub3&amp;doi=10.1002/14651858.CD008016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008016.pub3&amp;doi=10.1002/14651858.CD008016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008016.pub3&amp;doi=10.1002/14651858.CD008016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008016.pub3&amp;doi=10.1002/14651858.CD008016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008016.pub3&amp;doi=10.1002/14651858.CD008016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008016.pub3&amp;doi=10.1002/14651858.CD008016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="STpJR8yz";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008016\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008016\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008016\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008016\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ko","pt","th","ms","ja","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008016.pub3",title:"Maintenance treatment with antipsychotic drugs for schizophrenia",firstPublishedDate:"Aug 11, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=STpJR8yz&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008016.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008016.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008016.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008016.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008016.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008016.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008016.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008016.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008016.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008016.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>13494 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008016.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/full#CD008016-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/full#CD008016-sec-0203"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/full#CD008016-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/full#CD008016-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/full#CD008016-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/full#CD008016-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/full#CD008016-sec-0085"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/full#CD008016-sec-0174"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/appendices#CD008016-sec-0213"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/table_n/CD008016StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/table_n/CD008016StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Maintenance treatment with antipsychotic drugs for schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="These authors contributed equally to this work."><a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/information#CD008016-cr-0004">Anna Ceraso</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors contributed equally to this work."><a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/information#CD008016-cr-0005">Jessie Jingxia LIN</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/information#CD008016-cr-0006">Johannes Schneider-Thoma</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/information#CD008016-cr-0007">Spyridon Siafis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/information#CD008016-cr-0008">Magdolna Tardy</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/information#CD008016-cr-0009">Katja Komossa</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/information#CD008016-cr-0010">Stephan Heres</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/information#CD008016-cr-0011">Werner Kissling</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/information#CD008016-cr-0012">John M Davis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008016.pub3/information#CD008016-cr-0013"><i class="icon corresponding-author fa fa-envelope"></i>Stefan Leucht</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/information/en#CD008016-sec-0231">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 11 August 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008016.pub3">https://doi.org/10.1002/14651858.CD008016.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008016-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008016-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008016-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008016-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008016-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008016-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD008016-abs-0010">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008016-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008016-abs-0001" lang="en"> <section id="CD008016-sec-0001"> <h3 class="title" id="CD008016-sec-0001">Background</h3> <p>The symptoms and signs of schizophrenia have been linked to high levels of dopamine in specific areas of the brain (limbic system). Antipsychotic drugs block the transmission of dopamine in the brain and reduce the acute symptoms of the disorder. An original version of the current review, published in 2012, examined whether antipsychotic drugs are also effective for relapse prevention. This is the updated version of the aforesaid review. </p> </section> <section id="CD008016-sec-0002"> <h3 class="title" id="CD008016-sec-0002">Objectives</h3> <p>To review the effects of maintaining antipsychotic drugs for people with schizophrenia compared to withdrawing these agents. </p> </section> <section id="CD008016-sec-0003"> <h3 class="title" id="CD008016-sec-0003">Search methods</h3> <p>We searched the Cochrane Schizophrenia Group's Study‐Based Register of Trials including the registries of clinical trials (12 November 2008, 10 October 2017, 3 July 2018, 11 September 2019). </p> </section> <section id="CD008016-sec-0004"> <h3 class="title" id="CD008016-sec-0004">Selection criteria</h3> <p>We included all randomised trials comparing maintenance treatment with antipsychotic drugs and placebo for people with schizophrenia or schizophrenia‐like psychoses. </p> </section> <section id="CD008016-sec-0005"> <h3 class="title" id="CD008016-sec-0005">Data collection and analysis</h3> <p>We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CIs) on an intention‐to‐treat basis based on a random‐effects model. For continuous data, we calculated mean differences (MD) or standardised mean differences (SMD), again based on a random‐effects model. </p> </section> <section id="CD008016-sec-0006"> <h3 class="title" id="CD008016-sec-0006">Main results</h3> <p>The review currently includes 75 randomised controlled trials (RCTs) involving 9145 participants comparing antipsychotic medication with placebo. The trials were published from 1959 to 2017 and their size ranged between 14 and 420 participants. In many studies the methods of randomisation, allocation and blinding were poorly reported. However, restricting the analysis to studies at low risk of bias gave similar results. Although this and other potential sources of bias limited the overall quality, the efficacy of antipsychotic drugs for maintenance treatment in schizophrenia was clear. Antipsychotic drugs were more effective than placebo in preventing relapse at seven to 12 months (primary outcome; drug 24% versus placebo 61%, 30 RCTs, n = 4249, RR 0.38, 95% CI 0.32 to 0.45, number needed to treat for an additional beneficial outcome (NNTB) 3, 95% CI 2 to 3; high‐certainty evidence). </p> <p>Hospitalisation was also reduced, however, the baseline risk was lower (drug 7% versus placebo 18%, 21 RCTs, n = 3558, RR 0.43, 95% CI 0.32 to 0.57, NNTB 8, 95% CI 6 to 14; high‐certainty evidence). More participants in the placebo group than in the antipsychotic drug group left the studies early due to any reason (at seven to 12 months: drug 36% versus placebo 62%, 24 RCTs, n = 3951, RR 0.56, 95% CI 0.48 to 0.65, NNTB 4, 95% CI 3 to 5; high‐certainty evidence) and due to inefficacy of treatment (at seven to 12 months: drug 18% versus placebo 46%, 24 RCTs, n = 3951, RR 0.37, 95% CI 0.31 to 0.44, NNTB 3, 95% CI 3 to 4). </p> <p>Quality of life might be better in drug‐treated participants (7 RCTs, n = 1573 SMD ‐0.32, 95% CI to ‐0.57 to ‐0.07; low‐certainty evidence); probably the same for social functioning (15 RCTs, n = 3588, SMD ‐0.43, 95% CI ‐0.53 to ‐0.34; moderate‐certainty evidence). </p> <p>Underpowered data revealed no evidence of a difference between groups for the outcome ‘Death due to suicide’ (drug 0.04% versus placebo 0.1%, 19 RCTs, n = 4634, RR 0.60, 95% CI 0.12 to 2.97,low‐certainty evidence) and for the number of participants in employment (at 9 to 15 months, drug 39% versus placebo 34%, 3 RCTs, n = 593, RR 1.08, 95% CI 0.82 to 1.41, low certainty evidence). </p> <p>Antipsychotic drugs (as a group and irrespective of duration) were associated with more participants experiencing movement disorders (e.g. at least one movement disorder: drug 14% versus placebo 8%, 29 RCTs, n = 5276, RR 1.52, 95% CI 1.25 to 1.85, number needed to treat for an additional harmful outcome (NNTH) 20, 95% CI 14 to 50), sedation (drug 8% versus placebo 5%, 18 RCTs, n = 4078, RR 1.52, 95% CI 1.24 to 1.86, NNTH 50, 95% CI not significant), and weight gain (drug 9% versus placebo 6%, 19 RCTs, n = 4767, RR 1.69, 95% CI 1.21 to 2.35, NNTH 25, 95% CI 20 to 50). </p> </section> <section id="CD008016-sec-0007"> <h3 class="title" id="CD008016-sec-0007">Authors' conclusions</h3> <p>For people with schizophrenia, the evidence suggests that maintenance on antipsychotic drugs prevents relapse to a much greater extent than placebo for approximately up to two years of follow‐up. This effect must be weighed against the adverse effects of antipsychotic drugs. Future studies should better clarify the long‐term morbidity and mortality associated with these drugs. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008016-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008016-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008016-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008016-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008016-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD008016-abs-0013">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008016-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008016-abs-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD008016-abs-0009">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008016-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD008016-abs-0011">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008016-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008016-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008016-abs-0002" lang="en"> <h3>Maintenance treatment with antipsychotic drugs for schizophrenia</h3> <p>Antipsychotic drugs are the mainstay of treatment of schizophrenia, not only in the event of acute episodes, but also in the long‐term perspective. While people might want to stop their treatment at some stage, recurrences of psychotic symptoms are known to occur after treatment discontinuation. Relapses can lead to risk of harm, loss of autonomy and substantial distress for individuals and their families. </p> <p>The current report presents the update version of a systematic review previously published in 2012, and is based on 75 randomised controlled trials (RCTs) published over a long period since the 1950s and including more than 9000 participants. The effects of all antipsychotic drugs are here compared to those of placebo ‐ namely drug discontinuation ‐ for maintenance treatment, that is prevention of relapses. The aim is to explore the benefits and risks of each of the two options. </p> <p>The results of this review show very consistently that antipsychotic drugs effectively reduce relapses and need for hospitalisation. Indeed, in case of treatment discontinuation, the risk of relapse at one year is almost three times higher. Antipsychotic drugs appear to have a positive effect on the ability to engage in activities and relationships, and on the possibility to fulfil remission from symptoms, although less evidence is available in this regard. Though based again on a lower number of reports, people continuing their treatment tend to experience higher satisfaction with their life, which confirms the negative consequences on well‐being of being at higher risk for recurrence. Conversely, antipsychotic drugs are, as a group, associated with a number of side effects such as movement disorders, weight gain and sedation. However, this review allows more understanding of the fact that stopping treatment is far more harmful than thoughtfully maintaining it. </p> <p>Unfortunately, studies included in this review do generally last up to one year, and this makes difficult to clarify the longer‐term effect of these drugs. It is however true that the longer the study the more likely that other factors ‐ e.g. environmental – may accumulate and complicate the interpretation of results. Most of all, this review supports the advantages of antipsychotic drugs among many different types of participants. The best strategy would be therefore to continue treatment with antipsychotics, eventually discussing and adapting it if any adverse effect occurs. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008016-sec-0203" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008016-sec-0203"></div> <h3 class="title" id="CD008016-sec-0204">Implications for practice</h3> <section id="CD008016-sec-0204"> <section id="CD008016-sec-0205"> <h5 class="title">1. For people with schizophrenia</h5> <p>For people with schizophrenia it is important to know that antipsychotic drugs are more effective than placebo in preventing relapse. If people stop their antipsychotic drug many will relapse ‐ and quite soon ‐ and more than if they remained on the drug. Taking the drugs is likely to cause a number of adverse effects, such as movement disorders, weight gain and sedation (which differ between compounds). They might tell their doctors that they want to be involved in the choice of the antipsychotic. Stopping the drug could still be the choice of the recipient of care but this review allows more understanding of the risk of this action. </p> </section> <section id="CD008016-sec-0206"> <h5 class="title">2. For clinicians</h5> <p>Clinicians should know that most studies lasted no longer than one year and that the longest study lasted three years. Thus, nothing is known about the very long‐term effects of antipsychotic drugs compared with placebo. The clear superiority of antipsychotic drugs was consistent for different types of settings (e.g. inpatient and outpatients) and participants (people with a first and multiple episodes, duration of stability before study start), and it was robust to statistical assumptions. Whether antipsychotic drugs save lives by preventing suicides or increase mortality due to their adverse effects could not be clarified by this review. However, this review does make it easier for clinicians to advise the continuation of antipsychotic drugs for many people with schizophrenia. Recognising that this may not be the path chosen by the person with the illness, this review helps inform the clinician of the proportions who are likely to need relapse care in the short and medium term. </p> </section> <section id="CD008016-sec-0207"> <h5 class="title">3. For managers/policy makers</h5> <p>The data suggest that people maintained on antipsychotic drugs need to be hospitalised less frequently than those stopping medications in favour of placebo. In many countries hospitalisation accounts for a large proportion of the overall costs of schizophrenia. However, less than one third of relapsed participants had such severe relapses that rehospitalisation was necessary. Nevertheless there is such consistency in the findings of this review that it would be understandable that the guidance would adopt a strategy of maintenance of antipsychotic drugs for people with schizophrenia where possible. </p> </section> </section> <h3 class="title" id="CD008016-sec-0208">Implications for research</h3> <section id="CD008016-sec-0208"> <section id="CD008016-sec-0209"> <h5 class="title">1. General</h5> <p>Outcome reporting remains insufficient in antipsychotic drug trials. Strict adherence to the <a href="http://www.consort-statement.org/" target="_blank">CONSORT</a> statement (CONsolidated Standards Of Reporting Trials; <a href="./references#CD008016-bbs2-0221" title="MoherD , SchulzKF , AltmanD . The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. JAMA2001;285:1987-1.">Moher 2001</a>) would make such studies much more informative. This short‐coming has been highlighted by many reviews of the Cochrane Schizophrenia Group and others, but improvements are still necessary. </p> </section> <section id="CD008016-sec-0210"> <h5 class="title">2. Specific</h5> <p>Although difficult to conduct due to ethical concerns, it would be interesting to have more studies that last longer than two years. Such studies should not only examine relapse, but also other outcomes such as rehospitalisation, recovery status, outcomes reflecting social participation and death. Participants' compliance should be monitored. <a href="#CD008016-tbl-0002">Table 1</a> presents an outline. </p> </section> </section> <div class="table" id="CD008016-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Design of a future study</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Methods</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised ‐ clearly described generation of sequence and concealment of allocation<br/>Blinding: double ‐ described and tested<br/>Duration: 3 years </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>People with schizophrenia or schizophrenia‐like disorder in remission for at least one month<br/>N = 500<br/>Age: any<br/>Sex: both<br/>History: any (specify duration of illness) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interventions</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Any antipsychotic drug (flexible dose within appropriate range)</p> <p>2. Placebo (after gradual ‐ rather than abrupt ‐ withdrawal of the previous antipsychotic drug) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapse (primary outcome)</p> <p>Rehospitalisation for psychosis</p> <p>Global state (number of participants improved, in symptomatic and sustained remission)</p> <p>Global state (number of participants in recovery)</p> <p>Leaving the study early (including specific causes)</p> <p>Death (natural and unnatural causes)</p> <p>Violent behaviour</p> <p>Quality of life</p> <p>Satisfaction with care and other measures of subjective well‐being/recovery</p> <p>Side‐effects (well reported)</p> <p>Social functioning, employment and other measures of functioning</p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008016-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008016-sec-0008"></div> <div class="table" id="CD008016-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Maintenance treatment with antipsychotic drugs versus placebo/no treatment for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Maintenance treatment with antipsychotic drugs versus placebo/no treatment for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> schizophrenia<br/><b>Setting:</b> inpatients and outpatients<br/><b>Intervention:</b> maintenance treatment with antipsychotic drugs<br/><b>Comparison:</b> placebo/no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Maintenance treatment with antipsychotic drugs versus placebo/no treatment</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse: 7 to 12 months</b> </p> <p>Follow‐up: 7‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>606 per 1.000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>230 per 1.000</b><br/>(194 to 273) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.38</b><br/>(0.32 to 0.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4249<br/>(30 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>⊕⊕⊕⊕</b> <br/><b>HIGH</b><sup>1 2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early: due to any reason (acceptability of treatment)</b> </p> <p>Follow‐up: 1‐24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>541 per 1.000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>292 per 1.000</b><br/>(265 to 330) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.54</b><br/>(0.49 to 0.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7001<br/>(56 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>⊕⊕⊕⊕</b> <br/><b>HIGH</b><sup>5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use: number of participants hospitalised</b> </p> <p>Follow‐up: 1‐36 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>177 per 1.000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>76 per 1.000</b><br/>(57 to 101) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.43</b><br/>(0.32 to 0.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3558<br/>(21 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>⊕⊕⊕⊕</b> <br/><b>HIGH</b><sup>6 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death: due to suicide</b> </p> <p>Follow‐up: 1‐15 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1.000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1.000</b><br/>(0 to 4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.60</b><br/>(0.12 to 2.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4634<br/>(19 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>⊕⊕⊝⊝</b> <br/><b>LOW</b><sup>6 8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life (various scales; low score=better)</b> </p> <p>Follow‐up: 3‐18 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean quality of life in the intervention group was <b>0.32 standard deviations lower</b> (from 0.57 to 0.07 standard deviations lower), with lower scores reflecting a better condition. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1573<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>⊕⊕⊝⊝</b> <br/><b>LOW</b><sup>5 6 9 10 11</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.32 (‐0.57 to ‐0.07)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants in employment</b> </p> <p>Follow‐up: 9‐15 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>344 per 1.000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>372 per 1.000</b><br/>(282 to 486) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b><br/>(0.82 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>593<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>⊕⊕⊝⊝</b> <br/><b>LOW</b><sup>6 12 13</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Social functioning (various scales; low score=better)</b> </p> <p>Follow‐up: 1‐15 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean social functioning in the intervention group was <b>0.43 standard deviations lower</b> (from 0.53 to 0.34 standard deviations lower), with lower scores reflecting a better condition. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3588<br/>(15 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>⊕⊕⊕⊝</b> <br/><b>MODERATE</b><sup>6 14 15</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.43 (‐0.53 to ‐0.34)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Publication bias: rated 'undetected' ‐ although the funnel plot was asymmetrical, the trim and fill test did not change the point estimate and the point estimate was also similar when only large studies were included (<a href="./references#CD008016-fig-0057" title="">Analysis 3.5</a>). </p> <p><sup>2</sup> Risk of bias: rated 'no' ‐ many studies did not report the methods for sequence generation and/or allocation concealment. However, in subgroup analysis (<a href="./references#CD008016-fig-0051" title="">Analysis 2.8</a>) studies reporting high standards of methods showed a similar effect size as compared to studies with unclear methods. Also, in a sensitivity analysis excluding studies with unclear methods (<a href="./references#CD008016-fig-0062" title="">Analysis 3.10</a> and <a href="./references#CD008016-fig-0063" title="">Analysis 3.11</a>), the effect sizes did not change substantially. Early terminated studies were not judged to contribute substantial weight to this outcome. </p> <p><sup>3</sup> Inconsistency: rated 'no' ‐ the P value for heterogeneity was statistically significant and the I<sup>2</sup> higher than 50%. However, results of individual studies differed rather in magnitude of effect (which could be partly explained by subgroup analyses) rather than in direction of effect. Therefore, this inconsistency does not challenge the overall results. </p> <p><sup>4</sup> No indirectness was found in terms of study population nor of interventions. In terms of outcome, we followed the original authors definitions of relapse. These definitions used different criteria, but all addressed symptomatic deterioration related to relapse. Therefore, this was not judged to lead to indirectness. </p> <p><sup>5</sup> Inconsistency: rated 'no' ‐ the P value for heterogeneity was statistically significant and the I‐square higher than 50%. However, results of individual studies differed rather in magnitude of effect than in direction of effect, which was the same in almost all the studies. Therefore, this inconsistency does not challenge the overall results. </p> <p><sup>6</sup> Publication bias: it is unlikely that a study was unpublished because of unfavourable data in a secondary outcome. As a possible publication bias had no effect on the results for the primary outcome (relapse at 7 to 12 months), we deem that there was no relevant publication bias for this secondary outcome. </p> <p><sup>7</sup> Indirectness: hospitalisation due to relapse was our primary interest, but in some studies reasons for hospitalisation were unclearly reported. Overall, we do not deem that this uncertainty was an important source of indirectness. </p> <p><sup>8</sup> Imprecision: rated 'very serious' ‐ only few studies with few events contributed data to this outcome. The CI was wide, ranging from substantial harm to substantial benefit. </p> <p><sup>9</sup> Risk of bias: rated 'serious' ‐ five out of seven studies were terminated early after interim analyses, possibly leading to overestimation of effect. </p> <p><sup>10</sup> Indirectness: some rating scales used in the studies have been criticised for eventually not measuring what people understand by quality of life. However, it was decided not to further lower the quality of evidence for this outcome after downgrading for other factors, despite some uncertainty. </p> <p><sup>11</sup> Imprecise data ‐ only a few studies provided data for this outcome and the confidence interval was large. </p> <p><sup>12</sup> Indirectness: rated 'serious' ‐ the only three studies included mixed groups of employed and non‐employed participants at baseline, and it is unclear whether employment was supported or competitive employment. </p> <p><sup>13</sup> Imprecision: rated 'serious' ‐ only three studies contributed to this event which depends on various factors (e.g. the existence of supported employment, rural versus service economy etc). </p> <p><sup>14</sup> Risk of bias: rated 'serious' ‐ eleven out of fifteen studies were terminated early after interim analyses, possibly leading to overestimation of effects. </p> <p><sup>15</sup> Indirectness: rated 'no' ‐ different rating scales were used in the studies, but this was not judged to challenge the results. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008016-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008016-sec-0009"></div> <section id="CD008016-sec-0010"> <h3 class="title" id="CD008016-sec-0010">Description of the condition</h3> <p>Schizophrenia is often a chronic and disabling psychiatric disorder. It afflicts approximately 1% of the population worldwide with few gender differences (<a href="./references#CD008016-bbs2-0220" title="McGrathJ , SahaS , ChantD , WelhamJ . Schizophrenia: a concise overview of incidence, prevalence, and mortality.. Epidemiologic Reviews2008;30:67-76.">McGrath 2008</a>). Its typical manifestations are 'positive' symptoms such as fixed, false beliefs (delusions) and perceptions without cause (hallucinations); 'negative' symptoms such as apathy and lack of drive, disorganisation of behaviour and thought; and catatonic symptoms such as mannerisms and bizarre posturing (<a href="./references#CD008016-bbs2-0182" title="CarpenterWT , BuchananRW . Schizophrenia. New England Journal of Medicine1994;330:681-90.">Carpenter 1994</a>). The degree of suffering and disability is considerable with 80% to 90% of people not employed (<a href="./references#CD008016-bbs2-0219" title="MarwahaS , JohnsonS . Schizophrenia and employment? A review. Social Psychiatry and Psychiatric Epidemiology2004;39:337-49.">Marvaha 2004</a>) and up to 10% dying (<a href="./references#CD008016-bbs2-0241" title="TsuangMT . Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry1978;35:153-5.">Tsuang 1978</a>). </p> </section> <section id="CD008016-sec-0011"> <h3 class="title" id="CD008016-sec-0011">Description of the intervention</h3> <p>Antipsychotic drugs are the mainstay of treatment for schizophrenia. They can be classified according to their biochemical structure (e.g. butyrophenones, phenothiazines, thioxanthenes, etc.), the doses necessary for an antipsychotic effect (high‐potency versus low‐potency antipsychotic drugs), and their risk of producing movement disorders ('atypical' versus 'typical' antipsychotic drugs). What they all have in common is that they block, to a greater or lesser extent, the transmission of dopamine in the brain. Currently there is not a single antipsychotic drug available that is not a dopamine receptor antagonist and the hypothesis that dopamine plays a role in the causation of schizophrenia has been partly derived from the mechanism of action of antipsychotic drugs (<a href="./references#CD008016-bbs2-0176" title="BergerM . Psychische Erkrankungen. Klinik und Therapie. 2nd edition. München: Urban &amp; Fischer, 2003.">Berger 2003</a>). Furthermore, there is no firm evidence that ‐ except for clozapine and possibly some other second‐generation antipsychotic drugs (<a href="./references#CD008016-bbs2-0203" title="KaneJM , HonigfeldG , SingerJ , MeltzerH , and the Clozaril Collaborative study group. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry1988;45:789-96.">Kane 1988</a>; <a href="./references#CD008016-bbs2-0213" title="LeuchtS , CorvesC , ArbterD , EngelR , LiC , DavisJM . A meta-analysis comparing second-generation and first-generation antipsychotics for schizophrenia. Lancet2009;373:31-41.">Leucht 2009</a>; <a href="./references#CD008016-bbs2-0214" title="LeuchtS , KomossaK , Rummel-KlugeC , CorvesC , HungerH , SchmidF , et al. A meta-analysis of head to head comparisons of second generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry2009;166:152-63.">Leucht 2009a</a>; <a href="./references#CD008016-bbs2-0217" title="LeuchtS , CiprianiA , SpineliL , MavridisM , OreyD , RichterF , et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet2013;382(9896):951962.">Leucht 2013</a>; <a href="./references#CD008016-bbs2-0245" title="WahlbeckK , CheineM , EssaliMA , RezkE . Clozapine vs typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews1999, Issue 2. Art. No: CD000059. [DOI: 10.1002/14651858.CD000059]">Wahlbeck 1999</a>) ‐ any of these agents is more effective than another (<a href="./references#CD008016-bbs2-0208" title="KleinDF , DavisJM . Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore: Williams &amp; Wilkins, 1969.">Klein 1969</a>). Early (non‐systematic) reviews (<a href="./references#CD008016-bbs2-0174" title="BaldessariniRJ . Chemotherapy in Psychiatry: Principles and Practice. Cambridge, MA: Harvard University Press, 1985.">Baldessarini 1985</a>; <a href="./references#CD008016-bbs2-0184" title="DavisJM . Overview: maintenance therapy in psychiatry: I. Schizophrenia. American Journal of Psychiatry1975;132(12):1237-45.">Davis 1975</a>) have shown that keeping people with schizophrenia on antipsychotic drugs after successful treatment of the acute episode substantially lowers relapse risk, for example, from 53.2% to 15.6% within a period of approximately 9.7 months (<a href="./references#CD008016-bbs2-0196" title="GilbertP , HarrisMJ , McAdamsLA , BowersMB , CharneyDS , GlazerWM . Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Archives of General Psychiatry1995;52:173-88.">Gilbert 1995</a>). Conversely, the side‐effect burden can be considerable, as antipsychotic drugs produce movement disorders, sedation, weight gain and are even related with sudden death. Therefore, clinicians and those with schizophrenia often face a trade‐off between protection against further psychotic episodes and adverse effects. </p> </section> <section id="CD008016-sec-0012"> <h3 class="title" id="CD008016-sec-0012">How the intervention might work</h3> <p>The theory is that schizophrenia is a chronic disorder caused by hyperdopaminergic states in the limbic system (<a href="./references#CD008016-bbs2-0176" title="BergerM . Psychische Erkrankungen. Klinik und Therapie. 2nd edition. München: Urban &amp; Fischer, 2003.">Berger 2003</a>). All antipsychotic drugs block dopamine receptors. Continuous treatment with antipsychotic drugs may be necessary to keep the dopaminergic tone low and to avoid psychotic relapses. </p> </section> <section id="CD008016-sec-0013"> <h3 class="title" id="CD008016-sec-0013">Why it is important to do this review</h3> <p>Although previous reviews had shown that maintenance treatment with antipsychotic drugs reduces relapse rates (<a href="./references#CD008016-bbs2-0174" title="BaldessariniRJ . Chemotherapy in Psychiatry: Principles and Practice. Cambridge, MA: Harvard University Press, 1985.">Baldessarini 1985</a>; <a href="./references#CD008016-bbs2-0184" title="DavisJM . Overview: maintenance therapy in psychiatry: I. Schizophrenia. American Journal of Psychiatry1975;132(12):1237-45.">Davis 1975</a>; <a href="./references#CD008016-bbs2-0196" title="GilbertP , HarrisMJ , McAdamsLA , BowersMB , CharneyDS , GlazerWM . Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Archives of General Psychiatry1995;52:173-88.">Gilbert 1995</a>), they did not meet modern systematic review criteria and addressed only one outcome (relapse). The present review is an update of the previous Cochrane Review of <i>Maintenance treatment with antipsychotic drugs for schizophrenia</i> (<a href="./references#CD008016-bbs2-0254" title="LeuchtS , TardyM , KomossaK , HeresS , KisslingW , DavisJM . Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD008016. [DOI: 10.1002/14651858.CD008016.pub2]">Leucht 2012b</a>). This update is important, because a lot of evidence has emerged since 2012. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008016-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008016-sec-0014"></div> <p>To review the effects of maintaining antipsychotic drug treatment for people with schizophrenia compared with withdrawing these agents. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008016-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008016-sec-0015"></div> <section id="CD008016-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008016-sec-0017"> <h4 class="title">Types of studies</h4> <p>All relevant randomised controlled trials (RCTs). We excluded quasi‐randomised trials, such as those where allocation is undertaken on surname. If a trial was described as double‐blind, but it was implied it had been randomised, we included it, but excluded such trials in a sensitivity analysis. Randomised cross‐over studies were eligible but only data up to the point of first cross‐over were used because of the instability of the problem behaviours and the likely carry‐over effects of the treatments (<a href="./references#CD008016-bbs2-0192" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31:140-9.">Elbourne 2002</a>). </p> </section> <section id="CD008016-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included people with schizophrenia and schizophrenia‐like psychoses (schizophreniform and schizoaffective disorders) who had stabilised on antipsychotic medications. There is no clear evidence that the schizophrenia‐like psychoses are caused by fundamentally different disease processes or require different treatment approaches (<a href="./references#CD008016-bbs2-0182" title="CarpenterWT , BuchananRW . Schizophrenia. New England Journal of Medicine1994;330:681-90.">Carpenter 1994</a>). </p> </section> <section id="CD008016-sec-0019"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD008016-list-0001"> <li> <p>Antipsychotic drugs: any dose or mode of administration (oral or by injection). There is no evidence for large differences in the efficacy of the available antipsychotic drugs (e.g. <a href="./references#CD008016-bbs2-0185" title="DavisJM , BarterJT , KaneJM . Antipsychotic drugs. In: KaplanHI , SadockBJ , editors(s). Comprehensive Textbook of Psychiatry. 5th edition. Baltimore: Williams &amp; Wilkins, 1989:1591-626.">Davis 1989</a>; <a href="./references#CD008016-bbs2-0189" title="DugganL , FentonM , RathboneJ , DardennesR , El-DosokyA , IndranS . Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001359. [DOI: 10.1002/14651858.CD001359.pub2]">Duggan 2005</a>; <a href="./references#CD008016-bbs2-0213" title="LeuchtS , CorvesC , ArbterD , EngelR , LiC , DavisJM . A meta-analysis comparing second-generation and first-generation antipsychotics for schizophrenia. Lancet2009;373:31-41.">Leucht 2009</a>; <a href="./references#CD008016-bbs2-0238" title="SrisurapanontM , ManeetonB , ManeetonN . Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews2004, Issue 2. Art. No: CD000967. [DOI: 10.1002/14651858.CD000967.pub2]">Srisurapanont 2004</a>). All currently available antipsychotic drugs have in common that they act via the blockade of dopamine and their classification according to their chemical properties (e.g. butyrophenones, thioxanthenes or phenothiazines) does not have an important clinical impact. Other classifications into 'low‐ versus high‐potency' or 'typical versus atypical' are continuums, at best (<a href="./references#CD008016-bbs2-0213" title="LeuchtS , CorvesC , ArbterD , EngelR , LiC , DavisJM . A meta-analysis comparing second-generation and first-generation antipsychotics for schizophrenia. Lancet2009;373:31-41.">Leucht 2009</a>). We therefore decided to include all antipsychotic drugs that are currently on the market in at least one country. </p> </li> <li> <p>Active or inactive placebo, or no treatment.</p> </li> </ol> </p> </section> <section id="CD008016-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>The outcomes were analysed for different lengths of follow‐up: up to three months, four to six months, seven months to one year and more than one year. </p> <section id="CD008016-sec-0021"> <h5 class="title">Primary outcomes</h5> <p><b>Relapse at one year</b> (seven to 12 months) as defined by the original studies or by a deterioration in mental state requiring further treatment. Overall relapse and relapse at other time points were considered as secondary outcomes. </p> </section> <section id="CD008016-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p>The following outcomes were added to the list for this update: number of participants in symptomatic remission, number of participants in sustained remission, number of participants in recovery, social functioning. </p> <section id="CD008016-sec-0023"> <h6 class="title">1. Relapse</h6> <p>1.1 Across the pre‐specified time periods (please see above).<br/>1.2 Independent of duration </p> </section> <section id="CD008016-sec-0024"> <h6 class="title">2. Leaving the study early</h6> <p>2.1 Due to any reason (acceptability of treatment)<br/>2.2 Due to adverse events (overall tolerability)<br/>2.3 Due to inefficacy </p> </section> <section id="CD008016-sec-0025"> <h6 class="title">3. Global state</h6> <p>3.1 Improved (at least minimally)<br/>3.2 In symptomatic remission<br/>3.3 In sustained remission<br/>3.4 In recovery </p> </section> <section id="CD008016-sec-0026"> <h6 class="title">4. Service use</h6> <p>4.1 Number hospitalised<br/>4.2 Number discharged </p> </section> <section id="CD008016-sec-0027"> <h6 class="title">5. Death</h6> <p>5.1 Due to any reason<br/>5.2 Due to natural causes<br/>5.3 Due to suicide </p> </section> <section id="CD008016-sec-0028"> <h6 class="title">6. Suicidal behaviour</h6> <p>6.1 Number with suicide attempts<br/>6.2 Number with suicide ideation </p> </section> <section id="CD008016-sec-0029"> <h6 class="title">7. Violent/aggressive behaviour</h6> </section> <section id="CD008016-sec-0030"> <h6 class="title">8. Adverse effects</h6> <p>8.1 General: at least one adverse event<br/>8.2 Specific: movement disorders<br/><i>8.2.1 At least one movement disorder<br/>8.2.2 Akathisia<br/>8.2.3 Akinesia<br/>8.2.4 Dyskinesia<br/>8.2.5 Dystonia<br/>8.2.6 Rigor<br/>8.2.7 Tremor<br/>8.2.8 Use of antiparkinson medication</i><br/>8.3 Specific: sedation<br/>8.4 Specific: weight gain </p> </section> <section id="CD008016-sec-0031"> <h6 class="title">9. Satisfaction with care (any published rating scale)</h6> <p>9.1 Participants satisfied<br/>9.2 Carers satisfied </p> <p><b>10. Quality of life (any published rating scale)</b> </p> <p><b>11. Functioning</b> </p> <p>11.1 Number in employment<br/>11.2 Social functioning (any published rating scale) </p> </section> <section id="CD008016-sec-0032"> <h6 class="title">'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings (<a href="http://archie.cochrane.org/sections/documents/view?version=38552780743861867379120314141945&amp;format=REVMAN#REF-Sch_x00fc_nemann-2008" target="_blank">Schünemann 2008</a>) and used <a href="http://ims.cochrane.org/revman/gradepro" target="_blank">GRADEPRO</a> to import data from <a href="http://www.ims.cochrane.org/revman" target="_blank">Review Manager</a> to create a 'Summary of findings' table. This table provides outcome‐specific information concerning the overall certainty of evidence from each included study in the comparison, the magnitude of effect of the interventions examined and the sum of available data on all outcomes that we rated as important to patient care and decision making. We anticipated including the following long‐term main outcomes in a 'Summary of findings' table: </p> <p> <ul id="CD008016-list-0002"> <li> <p>relapse: seven to 12 months;</p> </li> <li> <p>leaving the study early: due to any reason (acceptability of treatment);</p> </li> <li> <p>service use: number hospitalised;</p> </li> <li> <p>death: due to suicide;</p> </li> <li> <p>quality of life (any published rating scale);</p> </li> <li> <p>functioning: number in employment;</p> </li> <li> <p>functioning: social functioning (any published rating scale).</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD008016-sec-0033"> <h3 class="title">Search methods for identification of studies</h3> <p>No language restriction was applied within the limitations of the search tools.</p> <section id="CD008016-sec-0034"> <h4 class="title">Electronic searches</h4> <section id="CD008016-sec-0035"> <h5 class="title">Cochrane Schizophrenia Group’s Study‐Based Register of Trials</h5> <p>On 10 October 2017, the Information Specialist searched the register using the following search strategy which has been developed based on literature review and consulting with the authors of the review: </p> <p>((*Cessation* OR *Discontinu* OR *Halt* OR *Maintain* OR *Maintenance* OR *Recur* OR *Rehospitali* OR *Re‐Hospitali* OR *Relaps* OR *Stop* OR *Withdr*) in Title OR Abstract Fields of REFERENCE OR (Maintenance Treatment*) in Intervention Field of STUDY) AND ((*Amisulpride* OR *Aripiprazole* OR *Asenapine* OR *Benperidol* OR *Brexpiprazole* OR *Cariprazine* OR *Chlorpromazine* OR *Clopenthixol* OR *Clozapine* OR *Flupenthixol* OR *Fluphenazine* OR *Fluspirilene* OR *Haloperidol* OR *Iloperidone* OR *Levomepromazine* OR *Methotrimeprazine* OR *Loxapine* OR *Lurasidone* OR *Molindone* OR *Olanzapine* OR *Paliperidone* OR *Penfluridol* OR *Perazine* OR *Perphenazine* OR *Pimozide* OR *Quetiapine* OR *Risperidone* OR *Sertindole* OR *Sulpiride* OR *Thioridazine* OR *Thiothixene* OR *Trifluoperazine* OR *Ziprasidone* OR *Zotepine* OR *Zuclopenthixol*) in Intervention Field of STUDY) </p> <p>In such study‐based register, searching the major concept retrieves all the synonyms and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics (<a href="./references#CD008016-bbs2-0236" title="ShokranehF , AdamsCE . Study-based registers of randomized controlled trials: Starting a systematic review with data extraction or meta-analysis. BioImpacts2017;4:209-17.">Shokraneh 2017</a>). </p> <p>This register is compiled by systematic searches of major resources (AMED, BIOSIS, CINAHL, ClinicalTrials.Gov, Embase, MEDLINE, PsycINFO, PubMed, WHO ICTRP) and their monthly updates, ProQuest Dissertations and Theses A&amp;I and its quarterly update, Chinese databases (CBM, CNKI, and Wanfang) and their annual updates, handsearches, grey literature, and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group’s Module</a>). There is no language, date, document type, or publication status limitations for inclusion of records into the register. </p> <p>This search was conducted for a broader project and includes studies comparing antipsychotic drugs for relapse prevention (head‐to‐head studies). </p> <p>On 3 July 2018 first and then on 11 September 2019, a further updated search of the register was performed. The following search strategy, which was also developed consulting with the authors of the review, was used in both cases: </p> <p>(*<b>{AP}</b>* in Intervention Field of Study) AND ((*Cessation* OR *Discontinu* OR *Halt* OR *Maintain* OR *Maintenance* OR *Recur* OR *Rehospitali* OR *Re‐Hospitali* OR *Relaps* OR *Stop* OR *Withdr*) in Title OR Abstract Fields of REFERENCE OR (Maintenance Treatment*) in Intervention Field of STUDY); {AP} refers to all antipsychotic drugs in the register. </p> <p>For previous searches, please see <a href="./appendices#CD008016-sec-0214">Appendix 1</a>. </p> </section> </section> <section id="CD008016-sec-0036"> <h4 class="title">Searching other resources</h4> <section id="CD008016-sec-0037"> <h5 class="title">1. Reference searching</h5> <p>We inspected the references of all included studies and of previous reviews (e.g. <a href="./references#CD008016-bbs2-0184" title="DavisJM . Overview: maintenance therapy in psychiatry: I. Schizophrenia. American Journal of Psychiatry1975;132(12):1237-45.">Davis 1975</a>; <a href="./references#CD008016-bbs2-0196" title="GilbertP , HarrisMJ , McAdamsLA , BowersMB , CharneyDS , GlazerWM . Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Archives of General Psychiatry1995;52:173-88.">Gilbert 1995</a>) for more trials. The targeted update version of this review performed in 2016 was also inspected (New Reference). </p> </section> <section id="CD008016-sec-0038"> <h5 class="title">2. Personal contact</h5> <p>We contacted the first author of each included study for missing information and for the existence of further studies. </p> </section> <section id="CD008016-sec-0039"> <h5 class="title">3. Drug companies</h5> <p>We contacted the manufacturers of antipsychotic drugs and asked them about further relevant studies and for missing information on identified studies. </p> </section> </section> </section> <section id="CD008016-sec-0040"> <h3 class="title" id="CD008016-sec-0040">Data collection and analysis</h3> <section id="CD008016-sec-0041"> <h4 class="title">Selection of studies</h4> <p>For the 2019 search, two review authors (JS, AC) identified and independently inspected citations. For the 2018 search, identified citations were independently inspected by two review authors (AC, JL). For the 2017 search, identified citations were independently inspected by two review authors (among JS, AC and JL). For the original search, two review authors (SL, KK) identified and independently inspected citations. We identified potentially relevant reports and ordered full‐text papers for reassessment. Where disagreements arose we asked a third member of the team for help, and if it was impossible to decide, the full papers were ordered for assessment. This process was repeated for the full papers. If it was impossible to resolve disagreements these studies were added to those awaiting classification and we contacted the authors of the papers for clarification. </p> </section> <section id="CD008016-sec-0042"> <h4 class="title">Data extraction and management</h4> <section id="CD008016-sec-0043"> <h5 class="title">1. Extraction</h5> <p>For this update, three review authors (AC, JL, JS) independently extracted data from included studies. For the original review, three review authors (SL, MT, KK) independently extracted data from the included studies. Any disagreement was discussed with another member of the review team, decisions documented and, if necessary, we contacted authors of studies for clarification. The studies included in the original review were closely inspected in order to collect data on the outcomes that were added to the list within the updating process, and to look for potentially new information from eventual recent secondary publications. </p> </section> <section id="CD008016-sec-0044"> <h5 class="title">2. Management</h5> <p>For the original review, we extracted data onto standard simple forms. For the review update, we extracted data using electronic forms in Microsoft Access. </p> </section> <section id="CD008016-sec-0045"> <h5 class="title">3. Scale‐derived data</h5> <section id="CD008016-sec-0046"> <h6 class="title">3.1 Valid measures</h6> <p>We included continuous data from rating scales only if: (a) the psychometric properties of the measuring instrument had been described in a peer‐reviewed journal (<a href="./references#CD008016-bbs2-0218" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249-52.">Marshall 2000</a>); (b) the measuring instrument was not written or modified by one of the trialists. </p> </section> <section id="CD008016-sec-0047"> <h6 class="title">3.2 Endpoint versus change data</h6> <p>Since there is no principal statistical reason why endpoint and change data should measure different effects (<a href="./references#CD008016-bbs2-0201" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>, we decided primarily to use scale change data. If change data were not available we used endpoint data. Endpoint and change data were presented in separate subgroups, then pooled in the final analysis. </p> </section> </section> <section id="CD008016-sec-0048"> <h5 class="title">4. Common measure</h5> <p>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD008016-sec-0049"> <h5 class="title">5. Direction of graphs</h5> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicates a favourable outcome for maintenance treatment. </p> </section> </section> <section id="CD008016-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors (AC, JL, JS) for this update and three review authors (SL, MT, KK) for the original review worked independently by using criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008016-bbs2-0201" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>) to assess trial quality. This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article, such as sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting, other potential sources of bias (i.e. fraud, premature interruption of the studies, baseline clinical imbalances among study groups). </p> <p>Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies in order to obtain additional information. </p> <p>We noted the level of risk of bias in the text of the review, the 'Risk of bias' tables and in the <a href="./full#CD008016-tbl-0001">summary of findings Table 1</a>. </p> </section> <section id="CD008016-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <section id="CD008016-sec-0052"> <h5 class="title">1. Dichotomous data</h5> <p>The review focused on binary data, which are easier to interpret and can be more intuitively understood. For binary outcomes we calculated a standard estimation of the random‐effects (<a href="./references#CD008016-bbs2-0187" title="Der-SimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7:177-88.">Der‐Simonian 1986</a>) risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<a href="./references#CD008016-bbs2-0178" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie1999;54(4):405-11.">Boissel 1999</a>) than odds ratios (ORs) and that ORs tend to be interpreted as RR by clinicians (<a href="./references#CD008016-bbs2-0186" title="DeeksJ . Issues in the selection for meta-analyses of binary data. In: Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town, South Africa. 2000.">Deeks 2000</a>). This mis‐interpretation then leads to an overestimate of the impression of the effect. For statistically significant results we calculated the number needed to treat for an additional beneficial outcome/number needed to treat for an additional harmful outcome statistic (NNTB/NNTH), and its 95% CI as the inverse of the risk difference (RD). </p> <p>Where possible, efforts were made to convert outcome measures to dichotomous data. This could be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It was generally assumed that if there had been a 20% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD008016-bbs2-0224" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychological Reports1962;10:799-12.">Overall 1962</a>) or the Positive and Negative Syndrome Scale (PANSS; <a href="./references#CD008016-bbs2-0204" title="KaySR , OplerLA , FiszbeinA . Positive And Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.">Kay 1986</a>), this could be considered as a minimally significant response (<a href="./references#CD008016-bbs2-0211" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry2005;187:366-71.">Leucht 2005a</a>; <a href="./references#CD008016-bbs2-0212" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?Schizophrenia Research2005;79(2-3):231-8. [PMID: 15982856]">Leucht 2005b</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the original authors. </p> </section> <section id="CD008016-sec-0053"> <h5 class="title">2. Continuous data</h5> <section id="CD008016-sec-0054"> <h6 class="title">2.1 Summary statistic</h6> <p>For continuous outcomes we estimated a mean difference (MD) between groups. MDs were based on the random‐effects model as this takes into account any differences between studies even if there is no statistically significant heterogeneity. In the case of where scales were judged of such similarity to allow pooling, we calculated the standardised mean difference (SMD) and, whenever possible, transformed the effect back to the units of one or more of the specific instruments. </p> <p>All the numbers were entered in a way that a decrease in score should indicate improvement (for change data), and a lower score a better outcome (for endpoint data), in order to provide a similarity to the Positive and Negative Syndrome Scale (PANSS, <a href="./references#CD008016-bbs2-0204" title="KaySR , OplerLA , FiszbeinA . Positive And Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.">Kay 1986</a>), and make the numbers comparable and easy to interpret. When a rating scale construct provided for a higher score to indicate a better outcome, a minus (‐) was added before the numbers. </p> </section> <section id="CD008016-sec-0055"> <h6 class="title">2.3 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we applied the following standards to all data before inclusion: </p> <p>(a) data from studies of at least 200 participants were entered in the analysis irrespective of the following rules, because skewed data pose less of a problem in large studies; </p> <p>(b) change data: when continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to determine whether data are skewed or not. We entered the study, because change data tend to be less skewed and because excluding studies would also lead to bias, because not all the available information was used; </p> <p>(c) endpoint data: when a scale starts from the finite number zero, we subtracted the lowest possible value from the mean, and divided this by the standard deviation. If this value was lower than 1, it strongly suggested a skew and the study was excluded. If this ratio was higher than 1 but below 2, there is suggestion of skew. We entered the study and tested whether its inclusion or exclusion substantially changed the results. If the ratio was larger than 2 the study was included, because skew is less likely (<a href="./references#CD008016-bbs2-0170" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313:1200.">Altman 1996</a>; <a href="./references#CD008016-bbs2-0201" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> </section> </section> </section> <section id="CD008016-sec-0056"> <h4 class="title">Unit of analysis issues</h4> <section id="CD008016-sec-0057"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. First, authors often fail to account for intra‐class correlation in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD008016-bbs2-0188" title="DivineGW , BrownJT , FrazerLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7:623-9.">Divine 1992</a>) whereby P values are spuriously low, CIs unduly narrow and statistical significance overestimated. This causes type I errors (<a href="./references#CD008016-bbs2-0177" title="BlandJM , KerrySM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600.">Bland 1997</a>; <a href="./references#CD008016-bbs2-0198" title="GullifordMC , UkoumunneOC , ChinnS . Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876-83.">Gulliford 1999</a>). </p> <p>Where clustering is not accounted for in primary studies, we presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra‐class correlation coefficients (ICCs) for their clustered data and to adjust for this by using accepted methods (<a href="./references#CD008016-bbs2-0198" title="GullifordMC , UkoumunneOC , ChinnS . Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876-83.">Gulliford 1999</a>). Where clustering had been incorporated into the analysis of primary studies, we present these data as if from a non‐cluster randomised study, but adjusted for the clustering effect. </p> <p>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICCs [design effect = 1 + (m ‐ 1)*ICC] (<a href="http://www.archie.cochrane.org/sections/documents/view?document=2ECF56A482E26AA200264DD8C8BE4A9F&amp;format=REVMAN#REF-Donner-2002" target="_blank">Donner 2002</a>). If the ICC was not reported it was assumed to be 0.1 (<a href="http://www.archie.cochrane.org/sections/documents/view?document=2ECF56A482E26AA200264DD8C8BE4A9F&amp;format=REVMAN#REF-Ukoumunne-1999" target="_blank">Ukoumunne 1999</a>). </p> <p>If cluster studies have been appropriately analysed taking into account ICCs and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique. </p> </section> <section id="CD008016-sec-0058"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash‐out phase. For the same reason cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD008016-bbs2-0192" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31:140-9.">Elbourne 2002</a>). As both effects are very likely in schizophrenia, randomised cross‐over studies were eligible but only data up to the point of first cross‐over. </p> </section> <section id="CD008016-sec-0059"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>Where a study involved more than two treatment arms, especially two appropriate dose groups of an antipsychotic drug, the different dose arms were pooled and considered to be one. Where the additional treatment arms were not relevant, we did not reproduce these data. </p> </section> </section> <section id="CD008016-sec-0060"> <h4 class="title">Dealing with missing data</h4> <section id="CD008016-sec-0061"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss to follow‐up, data must lose credibility (<a href="./references#CD008016-bbs2-0249" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El-SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254-7.">Xia 2009</a>). The loss to follow‐up in randomised schizophrenia trials is often considerable calling the validity of the results into question. Nevertheless, it is unclear which degree of attrition leads to a high degree of bias. We did not exclude trials from outcomes on the basis of the percentage of participants completing them. However, we used the 'Risk of bias' tool described above to indicate potential bias when more than 25% of the participants left the studies prematurely, when the reasons for attrition differed between the intervention and the control group and when no appropriate imputation strategies were applied. </p> </section> <section id="CD008016-sec-0062"> <h5 class="title">2. Dichotomous data</h5> <p>We presented data on a 'once‐randomised‐always‐analyse' basis, assuming an intention‐to‐treat (ITT) analysis. If the authors applied such a strategy, we used their results. If the original authors presented only the results of the per‐protocol or completer population, we assumed that those participants lost to follow‐up would have had the same percentage of events as those who remained in the study. </p> </section> <section id="CD008016-sec-0063"> <h5 class="title">3. Continuous data</h5> <section id="CD008016-sec-0064"> <h6 class="title">3.1 General</h6> <p>ITT was used when available. We anticipated that in some studies, in order to perform an ITT analysis, the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<a href="./references#CD008016-bbs2-0209" title="LeonAC , MallinckrodtCH , Chuang-SteinC , ArchibaldDG , ArcherGE , ChartierK . Attrition in randomised controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry2006;59:1001-5.">Leon 2006</a>). Therefore, where LOCF data have been used in the analysis, they are indicated in the review. </p> </section> <section id="CD008016-sec-0065"> <h6 class="title">3.2 Missing standard deviations</h6> <p>Where there are missing measures of variance for continuous data but an exact standard error and CI are available for group means, either 'P' value or 't' value are available for differences in mean, we calculated the standard deviation value according to method described in Section 7.7.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008016-bbs2-0201" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). If standard deviations were not reported and could not be calculated from available data, we asked authors to supply the data. In the absence of data from authors, we used the mean standard deviation from other studies. </p> </section> </section> </section> <section id="CD008016-sec-0066"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD008016-sec-0067"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations that we had not predicted would arise and, where found, discussed such participant groups or situations. </p> </section> <section id="CD008016-sec-0068"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods, which we had not predicted, would arise and discussed any such methodological outliers. </p> </section> <section id="CD008016-sec-0069"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD008016-sec-0070"> <h6 class="title">3.1. Visual inspection</h6> <p>We inspected graphs visually to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD008016-sec-0071"> <h6 class="title">3.2. Employing the I² statistic</h6> <p>We investigated heterogeneity between studies by considering the I² statistic alongside the Chi² P value. The I² statistic provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD008016-bbs2-0200" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). The importance of the observed value of I² statistic depends on both the magnitude and direction of effects and the strength of evidence for heterogeneity (e.g. P value from the Chi² test, or 95% CIs for the I² statistic). An I² statistic estimate equal or greater than 50% accompanied by a statistically significant Chi² statistic would be interpreted as evidence of substantial levels of heterogeneity (<a href="./references#CD008016-bbs2-0201" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). When substantial levels of heterogeneity were found in the primary outcome, we explored reasons for heterogeneity (<a href="#CD008016-sec-0074">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD008016-sec-0072"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD008016-bbs2-0191" title="EggerM , Davey-SmithG , SchneiderM , MinderCS . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;13:629-34.">Egger 1997</a>). These are described in Section 10.1 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008016-bbs2-0201" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We did not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar sizes. In other cases, where funnel plots were possible, we sought statistical advice in their interpretation. </p> </section> <section id="CD008016-sec-0073"> <h4 class="title">Data synthesis</h4> <p>We employed a random‐effects model for analyses (<a href="./references#CD008016-bbs2-0187" title="Der-SimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7:177-88.">Der‐Simonian 1986</a>). We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This does seem true to us and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. Therefore, the random‐effects model is usually more conservative in terms of statistical significance, although as a disadvantage it puts added weight onto smaller studies, which can either inflate or deflate the effect size. We examined in a secondary analysis whether using a fixed‐effect model markedly changed the results of the primary outcome. </p> </section> <section id="CD008016-sec-0074"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Reasons for heterogeneity in the primary outcome were explored by the following subgroup analyses and restricted‐maximum‐likelihood‐random‐effect meta‐regressions, the latter performed using meta v4.9‐9 (<a href="./references#CD008016-bbs2-0233" title="Schwarzer G. Meta: an R package for meta-analyses. R News2007;7(3):40-5.">Schwarzer 2007</a>) in R statistical language v3.6.2 (<a href="./references#CD008016-bbs2-0228" title="Foundation for Statistical ComputingR: A language and environment for statistical computing. R Core Team, Version 3.6.2. Vienna: Foundation for Statistical Computing, 2018.">R Core Team 2018</a>). The R code used for meta‐regressions is reported in <a href="./appendices#CD008016-sec-0227">Appendix 2</a>. Post‐hoc analyses are marked with an asterisk. </p> <p>Subgroup analyses addressed people with only one episode of schizophrenia and people in remission at baseline, who may both have a better prognosis. We examined people who had been stable for different durations before study entry (at least three, six, nine, 12 and more than 12 months) to find out whether after long‐term stability antipsychotic drugs are no longer necessary. Abrupt versus gradual withdrawal of the pre‐study antipsychotic drug, defined as a minimum taper period of three weeks or depot treatment before the study following <a href="./references#CD008016-bbs2-0243" title="VigueraAC , BaldessariniRJ , HegartyJD , vanKammenDP , TohenM . Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Archives of General Psychiatry1997;54:49-55.">Viguera 1997</a>*, was examined because abrupt withdrawal may lead to rebound psychoses. Other subgroup analyses addressed: single antipsychotic drugs*, depot versus oral medication* (depot drugs are thought to be superior due to better compliance), first‐ versus second‐generation antipsychotic drugs* (to address the debate whether the more expensive second‐generation drugs are more efficacious), unblinded versus blinded trials* and studies with appropriate and unclear allocation concealment methods*. </p> <p>Duration of stability before study entry and duration of taper in the placebo group were also examined by meta‐regressions. Other meta‐regressions addressed severity of illness at baseline, mean dose in chlorpromazine equivalents and study duration. Meta‐regressions were performed only if at least 10 studies per comparison were available (<a href="./references#CD008016-bbs2-0201" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). For the dose conversion to chlorpromazine equivalents, doses were transferred following the conversion factors provided by available publications (<a href="./references#CD008016-bbs2-0183" title="DavisJM . Dose equivalence of the antipsychotic drugs. Journal of Psychiatric Research1974;11:65-9.">Davis 1974</a>, <a href="./references#CD008016-bbs2-0195" title="GardnerDM , MurphyAL , O'DonnellH , CentorrinoF , BaldessariniRJ . International consensus study of antipsychotic dosing. American Journal of Psychiatry2010;167(6):686-93.">Gardner 2010</a>, <a href="./references#CD008016-bbs2-0197" title="GopalS , Gassman-MayerC , PalumboJ , SamtaniMN , ShiwachR , AlphsL . Practical guidance or dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Current Medical Research and Opinion2010;26(2):377-87.">Gopal 2010</a>). Regarding long‐acting injectable drugs, the mean daily dose was obtained by dividing the given dose by the injection interval, and then transferred to chlorpromazine equivalents. </p> </section> <section id="CD008016-sec-0075"> <h4 class="title">Sensitivity analysis</h4> <p>All sensitivity analyses were made only for the primary outcome. Some of them were performed post‐hoc, due to the fact that reviewers of the original Lancet publication (<a href="./references#CD008016-bbs2-0253" title="LeuchtS , TardyM , KomossaK , HeresS , KisslingW , SalantiG , et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: systematic review and meta-analysis. Lancet2012;379(9831):2063-71.">Leucht 2012a</a>) asked for them. </p> <section id="CD008016-sec-0076"> <h5 class="title">1. Implication of randomisation</h5> <p>We excluded studies in a sensitivity analysis if they were described in some way as to imply randomisation. If there was no substantive difference when the implied randomised studies were excluded or added to those with better description of randomisation, then all data were employed from these studies. </p> </section> <section id="CD008016-sec-0077"> <h5 class="title">2. Implication of non double‐blind trials</h5> <p>We excluded trials in a sensitivity analysis if they were not double‐blinded. If there was no substantive difference when the non double‐blind studies were excluded or added to the double‐blind studies, then all data were employed from these studies. </p> </section> <section id="CD008016-sec-0078"> <h5 class="title">3. Fixed‐effect model</h5> <p>A sensitivity analysis was performed employing a fixed‐effect model for the analysis of data for all the relevant studies, in order to examine whether applying a different approach markedly changed the results of the primary outcome or not. </p> </section> <section id="CD008016-sec-0079"> <h5 class="title">4. Assumptions for lost binary data</h5> <p>Where assumptions had to be made regarding people lost to follow‐up (see <a href="#CD008016-sec-0060">Dealing with missing data</a>), we compared the findings when we used our assumption compared with completer data only. If there was a substantial difference, we reported results and discussed them but continued to employ our assumption. </p> </section> <section id="CD008016-sec-0080"> <h5 class="title">5. Inclusion of large studies only</h5> <p>We included trials in a sensitivity analysis only if at least 200 participants were enrolled. </p> </section> <section id="CD008016-sec-0081"> <h5 class="title">6. Exclusion of studies that used clinical criteria to diagnose the participants</h5> <p>We excluded trials in a sensitivity analysis if either enrolled participants were diagnosed with schizophrenia only on a clinical basis, or no mention to the use of specific operational diagnostic criteria was made. </p> </section> <section id="CD008016-sec-0082"> <h5 class="title">7. Inclusion of only those participants who had been in the trials without a relapse for specific time intervals </h5> <p>Secondary analyses were performed entering only data of those participants who had not relapsed for various durations after study start (three months, six months, nine months). Relapse risks resulted therefore from the number of relapse events from the beginning at the time interval till the end of a study, divided by the patients at risk of relapse, who had not relapsed before. </p> </section> <section id="CD008016-sec-0083"> <h5 class="title">8. Exclusion of studies with unclear randomisation/allocation concealment methods</h5> <p>We excluded trials in a sensitivity analysis if a detailed description of the randomisation method used was not provided. In another sensitivity analysis, trials were excluded whether the method of allocation concealment was judged to be inadequately clarified </p> </section> </section> <section id="CD008016-sec-0084"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008016-sec-0085" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008016-sec-0085"></div> <section id="CD008016-sec-0086"> <h3 class="title">Description of studies</h3> <p>For substantive description of studies please see <a href="./references#CD008016-sec-0238" title="">Characteristics of included studies</a> and <a href="./references#CD008016-sec-0239" title="">Characteristics of excluded studies</a> tables. </p> <section id="CD008016-sec-0087"> <h4 class="title">Results of the search</h4> <p>The original search in the CSG register yielded 1163 reports and two previous reviews contained 66 (<a href="./references#CD008016-bbs2-0196" title="GilbertP , HarrisMJ , McAdamsLA , BowersMB , CharneyDS , GlazerWM . Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Archives of General Psychiatry1995;52:173-88.">Gilbert 1995</a>) and 24 studies (<a href="./references#CD008016-bbs2-0184" title="DavisJM . Overview: maintenance therapy in psychiatry: I. Schizophrenia. American Journal of Psychiatry1975;132(12):1237-45.">Davis 1975</a>). The update search in 2011 identified another 669 reports. Overall, 185 studies were closely inspected. We included 116 publications on 65 studies and we excluded 69 publications on 49 studies. See Study flow diagram (<a href="#CD008016-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD008016-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram (results of the original search)For the review update in 2018: 3 reports describing the 2 studies originally excluded from quantitative synthesis were moved to excluded studies (no usable data for outcomes of interest); 3 reports on 1 study, originally excluded (short duration of follow‐up), were moved to included studies; one report originally included as independent study was moved as secondary publication of another included study." data-id="CD008016-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram (results of the original search)</p> <p>For the review update in 2018: 3 reports describing the 2 studies originally excluded from quantitative synthesis were moved to excluded studies (no usable data for outcomes of interest); 3 reports on 1 study, originally excluded (short duration of follow‐up), were moved to included studies; one report originally included as independent study was moved as secondary publication of another included study. </p> </div> </div> </div> <p>The update search performed in October 2017 yielded 3562 reports; the update search performed in July 2018 yielded 295 reports; the update search performed in September 2019 yielded 137 reports. An additional five reports were identified through other sources (handsearch in our research group's database of schizophrenia trials). Overall, 198 reports were closely inspected within the update process. We included 80 publications on 12 studies, and we excluded 35 studies (81 publications); five reports are still awaiting classification after contacting the corresponding authors, and three reports on three ongoing and potentially relevant trials were also identified. Twenty‐nine reports were moved as secondary publications of already included/excluded studies. See Study flow diagram (<a href="#CD008016-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD008016-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram (results of the 2017/2018/2019 update search and combined results of the original search and the update search)" data-id="CD008016-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram (results of the 2017/2018/2019 update search and combined results of the original search and the update search) </p> </div> </div> </div> <p>For this update, one study (originally referenced as 'Pfizer 2000', previously included as an independent study obtained from a pharmaceutical company) was found to be an unpublished report of another included study (<a href="./references#CD008016-bbs2-0074" title="AratoM , O'ConnorR , BradburyJE , MeltzerH . Long-term ziprasidone in schizophrenia. In: Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 - Jun 4; Toronto, Ontario, Canada. 1998. [CSZG: 3189]AratoM , O'ConnorR , BradburyJE , MeltzerH . The efficacy of ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. In: Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK. Amsterdam, Netherlands: Cambridge University Press, 1998. [CSZG: 3188]AratoM , O'ConnorR , BradburyJE , MeltzerH . Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. In: Proceedings of the 9th Congress of the Association of European Psychiatrists; 1998 Sep 20-24; Copenhagen, Denmark. 1998. [CSZG: 3190]AratoM , O'ConnorR , BradburyJE , MeltzerH . Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. Schizophrenia Research1999;36(1-3):270. [CSZG: 5626]AratoM , O'ConnorR , MeltzerH , BradburyJ . Ziprasidone: efficacy in the prevention of relapse and in the long-term treatment of negative symptoms of chronic schizophrenia. In: Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria. 1997. [CSZG: 245]AratoM , O'ConnorR , MeltzerHY . A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. International Clinical Psychopharmacology2002;17:207-15. [CSZG: 18486]BernardoM , AranzaJR , Rubio-TerresC , RejasJ . Cost-effectiveness analysis of schizophrenia relapse prevention. Clinical Drug Investigation. New Zealand2006;26(8):447-57. [CSZG: 13898]BernardoM , AranzaJR , Rubio-TerresC , RejasJ . Cost-effectiveness analysis of the prevention of relapse in schizophrenia in the ZEUS longitudinal study Ziprasidone Extended Use in Schizophrenia (ZEUS). Acta Espanolas de Psiquiatria2007;35(4):259-62. [CSZG: 15396]MeltzerHY , O´ConnorR . Long-term efficacy of ziprasidone in schizophrenia. Schizophrenia research2001;(1-2):S. 239. [CSZG: 6050]MeltzerHY , O´ConnorR . Path analysis of the ZEUS study provides evidence of a direct effect of ziprasidone on primary negative symptoms in chronic, stable schizophrenia. Conference Poster1997. [CSZG: 2033]MeltzerHY , O'ConnorR . Long-term efficacy of ziprasidone in schizophrenia: results of two controlled trials. In: Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico. 2000. [CSZG: 7609]O'ConnorR , SchoolerNR . Penultimate observation carried forward (POCF): a new approach to analysis of long-term symptom change in chronic relapsing conditions [letter]. Schizophrenia Research2003;60:319-20. [CSZG: 9365]Pfizer 2000. Multicentre double-blind study of ziprasidone versus placebo in relapse prevention for hospitalised patients with chronic or subchronic schizophrenia. Study report Unpublished. SchoolerN . A basis for optimism: the implications of long term treatment. In: Proceedings of the 9th Congress of the Association of European Psychiatrists; 1998 Sep 20-24; Copenhagen, Denmark. 1998. [CSZG: 5864]">Ziprasidone 2002</a>), and was therefore moved into this study; the references reported a slightly different sample size, as one recruiting centre was removed due to protocol deviation, but the reported study ID was the same (128‐303). One study (<a href="./references#CD008016-bbs2-0029" title="DellvaMA , TollefsonGD , MattlerCA , KinonBJ , GrundySL . A controlled, double-blind investigation of the clozapine discontinuation syndrome with conversion to either olanzapine or placebo. Schizophrenia Research1999;36:277-8. [CSZG: 5651]TollefsonGD , DellvaMA , MattlerCA , KaneJM , WirshingDA , KinonBJ , et al. Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. Journal of Clinical Psychopharmacology1999;19:435-43. [CSZG: 5305]TollefsonGD , DellvaMA , MattlerCA , KinonBJ , GrundySL . A controlled, double-blind investigation of the clozapine discontinuation syndrome with conversion to either olanzapine or placebo. In: Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31 - Nov 4; Paris, France. 1998. [CSZG: 4859]">Olanzapine 1999</a>) was previously excluded due to short duration of follow‐up (one to three days), but was then moved to included studies (a sensitivity analysis of the outcome relapse excluding this study was performed and found no different results); two studies (<a href="./references#CD008016-bbs2-0103" title="GitlinMJ , MidhaKK , FogelsonD , NuechterleinKH . Persistence of fluphenazine in plasma after decanoate withdrawal. Journal of Clinical Psychopharmacology1988;8:53-6. ">Gitlin 1988</a> and <a href="./references#CD008016-bbs2-0111" title="HirschSR , BowenJT , EmamiJ , CramerP , JolleyA , HawC , et al. A one year prospective study of the effect of life events and medication in the aetiology of schizophrenic relapse. British Journal of Psychiatry1996;168:49-56. HirschSR , BowenJT , EmamiJ . The effect of life events and medication in the aetiology of schizophrenic relapse. Schizophrenia Research1993;9:266. ">Hirsch 1996</a>) were previously included in the qualitative synthesis but not in the meta‐analysis, due to the absence of usable outcome data. For this update, they were moved to excluded studies (see <a href="#CD008016-fig-0001">Figure 1</a>). </p> <p>Overall, 225 publications on 75 studies were included and 150 publications on 85 studies were excluded. See Study flow diagram (<a href="#CD008016-fig-0002">Figure 2</a>). </p> </section> <section id="CD008016-sec-0088"> <h4 class="title">Included studies</h4> <p>Seventy‐five studies (9145 participants) met the inclusion criteria.</p> <section id="CD008016-sec-0089"> <h5 class="title">1. Length of trials</h5> <p>Of the included studies, 17 had a duration up to three months. Twenty‐six studies lasted up to six months and 25 up to 12 months. Seven studies lasted more than 12 months. The longest study had a duration of three years. </p> </section> <section id="CD008016-sec-0090"> <h5 class="title">2. Participants</h5> <p>In 33 of the 65 studies, participants were diagnosed according to clinical diagnoses (i.e. specific diagnostic criteria were not mentioned). The others used a variety of tools, combinations of tools and versions of those tools. </p> <p> <div class="table" id="CD008016-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Diagnostic tool</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Version</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>+ additional tool</b> </p> </th> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>Diagnostic and Statistical Manual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III‐R</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV‐TR</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV Axis I Disorders (Structured Clinical Interview)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Present State Examination (PSE)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign=""> <p>Research Diagnostic Criteria (RDC)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+ Schedule for Affective Disorder</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+ PSE + Feighner's criteria</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Feighner's criteria</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign=""> <p>International Statistical Classification of Diseases and Related Health Problems (ICD‐9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+ RDC</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+ PSE</p> </td> </tr> </tbody> </table> </div> </p> <p>The average age of participants was around 45 years old, and the mean duration of illness well over two decades (26.2 years). In 13 studies, participants were in remission at baseline. </p> </section> <section id="CD008016-sec-0091"> <h5 class="title">3. Setting</h5> <p>Twenty‐nine studies were conducted in hospitals (at least at the start of the trial) and 34 studies in outpatients. Seven studies included both inpatients and outpatients. Several important and [mostly] quite recent studies did not report on setting (<a href="./references#CD008016-bbs2-0004" title="KaneJM , MackleM , Snow-AdamiL , ZhaoJ , SzegediA , PanagidesJ . A randomised placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. Journal of Clinical Psychiatry2011;72(3):349-55. [CSZG: 22873]KaneJM , MackleM , Snow-AdamiL , ZhaoJ , SzegediA , PanagidesJ . Double-blind, placebo-controlled trial of asenapine in prevention of relapse after long-term treatment of schizophrenia. International Journal of Neuropsychopharmacology2010;13:223. [CSZG: 21634]MackleM , Snow-AdamiL , ZhaoJ , SzegediA , PanagidesJ . Double-blind, placebo-controlled trial of asenapine in prevention of relapse after long-term treatment of schizophrenia. European Neuropsychopharmacology2009;19(Suppl 3):S543. [CSZG: 19377]NCT00150176. A randomized, placebo-controlled, double-blind trial of asenapine in the prevention of relapse after long-term treatment of schizophrenia. https://www.ClinicalTrials.gov/ct/show/2005. [CSZG: 14708] The NHSC . Asenapine (Saphris) for schizophrenia. Report2010. [CSZG: 21910]">Asenapine 2011</a>, <a href="./references#CD008016-bbs2-0028" title="NCT01435928. PEARL Schizophrenia Maintenance. http://ClinicalTrials.gov/show/NCT014359282011. [CSZG: 23439]TandonR , CucchiaroJ , PhillipsD , HernandezD , MaoY , PikalovA , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Journal of Psychopharmacology2016;30(1):69-77. [CSZG: 33434]TandonR , LoebelA , PhilipsD , PikalovA , Hernandez D MaoY , et al. Lurasidone for maintenance of efficacy in patients with schizophrenia. European Neuropsychopharmacology2014;24(Suppl 2):S559-560. [CSZG: 27840]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , CucchiaroJ . A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Schizophrenia Research2014;153(1):S372. [CSZG: 29681]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Int J Neuropsychopharmacol2014;17:S153-154. [CSZG: 29954]">Lurasidone 2016</a>, <a href="./references#CD008016-bbs2-0033" title="AlphsL , BossieC , Kern-SliwaJ , Ma Y-W, HaskinsJT . Paliperidone palmitate: clinical response in subjects with schizophrenia with recent vs. longer-term duration of illness. In: Proceedings of the 162nd Annual Meeting of the American Psychiatric Association. San Francisco, CA., 2009 May 16-21. [CSZG: 19067]EmsleyR , NuamahI , GopalS , HoughD , FleischhackerWW . Relapse after antipsychotic discontinuation in schizophrenia as a withdrawal phenomenon vs illness recurrence: a post hoc analysis of a randomized placebo-controlled study. Journal of Clinical Psychiatry 2018 Jun;79(4):17m11874. [CSZG: 38184]EmsleyR , NuamahI , HoughD , GopalS . Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophrenia Research2012;138(1):29-34. [CSZG: 24214]GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM , HoughD . A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. Journal of Psychopharmacology2011;25(5):685-97. [CSZG: 22903]GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Long-term efficacy, safety and tolerability of paliperidone palmitate in patients with schizophrenia. In: Proceedings of the 162nd Annual Meeting of the American Psychiatric Association. San Francisco, CA, 2009 May 16-21. [CSZG: 19076]HoughD , GopalS , VijapukarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate in prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. In: Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8, Washington DC, USA. 2008. [CSZG: 16486]HoughD , GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. In: Proceedings of the 63rd Annual Convention of the Society of Biological Psychiatry. Washington, DC, USA: Elsevier Science Inc, 2008:S285-6. [CSZG: 20281]HoughD , GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Biological Psychiatry2008;63(7 Suppl):285S-6S. [CSZG: 19530]HoughD , GopalS , VjapukarU , LimP , MorozowaM , EerdekensM . Paliperidone palmitate maintenance treatment in delaying the time to relapse in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. Schizophrenia Research2010;116:107-17. [CSZG: 19704]HulihanJ , BossieCA , FuDJ , Kern SliwaJ , Ma Y-W, AlphsLD . Remission with continued paliperidone palmitate treatment in stable subjects with schizophrenia. Schizophrenia Research2012;136:S252. [CSZG: 29467]KozmaCM , SlatonT , DiraniR , FastenauJ , GopalS , HoughD . Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate. Current Medical Resarch and Opinion2011;27(8):1603-11. SliwaJK , BossieCA , Fu DJ, TurkozI , AlphsL . Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia. Neuropsychiatric Disease and Treatment2012;8:375-85. [CSZG: 28007]SliwaJK , FuDJ , BossieCA , et al. Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate. BMC Psychiatry2014;14:S52. [CSZG: 29148]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone depot1M 2010</a>, <a href="./references#CD008016-bbs2-0041" title="ChannabasavannaSM , MichaelA . Penfluridol maintenance therapy in schizophrenia: a controlled study. Indian Journal of Psychiatry1987;29(4):333-6. [CSZG: 1094]">Penfluridol 1987</a>, <a href="./references#CD008016-bbs2-0045" title="D1441C00131. A 1-year, international, multicenter, randomized, double-blind, parallel-group, placebo-controlled phase IV study to evaluate prevention of relapse in patients in stable condition with chronic schizophrenia receiving either quetiapine fumarate IR (SEROQUEL) or placebo. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=3852003. D1444C00004. A 1-year, international, multicenter, randomized, double-blind, parallelgroup, placebo-controlled phase iii study to evaluate prevention of relapse in patients in stable condition with chronic schizophrenia receiving either sustained-release quetiapine fumarate (SEROQUEL) or placebo. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=14182006. NCT00228462. A 1-year, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study to evaluate prevention of relapse in patients in stable chronic schizophrenia receiving either sustained-release quetiapine fumarate (SEROQUEL) or placebo (abbreviated). https://www.ClinicalTrials.gov/ct/show/2005. [CSZG: 14874]PeuskensJ , TrivediJ , MalyarovS , BrecherM , SvenssonO , MillerF , et al. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomised, placebo-controlled trial in clinically stable patients. Psychiatry2007;4(11):34-50. [CSZG: 16025]PeuskensJ , TrivediJK , BrecherM , MillerF , Study I . Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: Post-hoc analysis of data from a randomized withdrawal, placebo-controlled study. International Clinical Psychopharmacology2010;25(3):183-7. [CSZG: 20670]PeuskensJ , TrivediJK , BrecherM , SvenssonO , MillerF , MeulienD . Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate. In: Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA. 2008. [CSZG: 16500]PeuskensJ , TrivediJK , BrecherM , SvenssonO , MillerF , MeulienD . Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate. Schizophrenia Research2008;98:14-5. [CSZG: 16344]PeuskensJ , TrivediJK , MalyarovS , BrecherM , SvenssonO , MillerF , et al. A randomized, placebo-controlled, relapse-prevention study with once-daily quetiapine sustained release in patients with schizophrenia. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28-Apr 1; Colorado Springs, Colorado, USA2007. [CSZG: 15271]PeuskensJC , TrivediJK , MalyarovS , BrecherM , SvenssonO , MillerF , et al. A randomized, placebo-controlled, relapse-prevention study with once daily quetiapine sustained release in patients with schizophrenia. Schizophrenia Bulletin2007;33(2):453. [CSZG: 15225]">Quetiapine 2007</a>). </p> </section> <section id="CD008016-sec-0092"> <h5 class="title">4. Study size</h5> <p>The average number of participants was 122 (median 67). <a href="./references#CD008016-bbs2-0009" title="CraneGE . Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie1968;9(2):209-16. [CSZG: 3170]De LongSL . Incidence and significance of chlorpromazine-induced eye changes. Diseases of the Nervous System1968;29:19-22. [CSZG: 18229]GardosG , ColeJO , LaBrieRA . A 12-year follow-up study of chronic schizophrenics. Psychopharmacology1982;33:983-4. [CSZG: 853]PrienRF , ColeJO , BelkinNF . Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. British Journal of Psychiatry1968;115:679-86. [CSZG: 3951]PrienRF , ColeJO . High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health - psychopharmacology research branch collaborative study group. Archives of General Psychiatry1968;18:482-95. [CSZG: 3950]PrienRF , DeLongSL , ColeJO , LevineJ . Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry1970;23:464-8. [CSZG: 3952]PrienRF , LevineJ , ColeJO . Indications for high dose chlorpromazine therapy in chronic schizophrenia. Diseases of the Nervous System1970;31:739-45. [CSZG: 2345]PrienRF , LevineJ , SwitalskiRW . Discontinuation of chemotherapy for chronic schizophrenics. Hospital and Community Psychiatry1971;22(1):4-7. [CSZG: 2346]">Chlorpromazine 1968</a> was the largest study with 420 participants, while <a href="./references#CD008016-bbs2-0011" title="ElieR , GagnonMA , GauthierR , JequierJC . Effects of neuroleptic withdrawal on the drug-induced extrapyramidal syndrome of chronic schizophrenia [Effets d'un sevrage neuroleptique sur le syndrome extrapyramidal medicamenteux de la schizophrenie chronique]. Union Medicale du Canada1975;104:909-14. [CSZG: 1911]">Chlorpromazine 1975</a> was the smallest, randomising only 14 people. Thirty‐four studies had fewer than 50 participants and 19 randomised more than 200. The oldest trials were some of the largest but, in recent years the size did seem to be increasing (<a href="#CD008016-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD008016-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Size of trial over time" data-id="CD008016-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-03.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Size of trial over time</p> </div> </div> </div> </section> <section id="CD008016-sec-0093"> <h5 class="title">5. Interventions</h5> <p>Seventy‐three studies compared maintenance treatment with antipsychotic drugs and inactive placebo; two open randomised controlled trials (RCTs) compared antipsychotic drugs with no treatment. No data on active placebo as a comparator were available. In most studies flexible doses of antipsychotic drugs were employed although some trials did use fixed doses (see table below). The older trials did have ranges which could have included using doses that would be considered very high now. For example, the doses in <a href="./references#CD008016-bbs2-0043" title="HuberW , SerafetinidesEA , ColmoreJP , ClarkM . Pimozide in chronic schizophrenic patients. Journal of Clinical Pharmacology1971;11(4):304-9. [CSZG: 1618]">Pimozide 1971</a> and <a href="./references#CD008016-bbs2-0049" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126:305-13. [CSZG: 2344]PrienRF , LevineJ , SwitalskiRW . Discontinuation of chemotherapy for chronic schizophrenics. Hospital and Community Psychiatry1971;22(1):4-7. [CSZG: 2346]">Trifluoperazine 1969</a> were very high (pimozide 40 mg/day and trifluoperazine 80 mg/day, respectively) and in <a href="./references#CD008016-bbs2-0066" title="NishikawaT , TsudaA , TanakaM , KogaI , UchidaY . Prophylactic effect of neuroleptics in symptom-free schizophrenia. Psychopharmacology1982;77:301-4. [CSZG: 2167]">Various drugs 1982</a> (chlorpromazine 75 mg/day, haloperidol 3 mg/day) they were very low. However, in most cases most participants would have been given doses of drugs well within the usual ranges employed in current day‐to‐day practice. </p> <p> <div class="table" id="CD008016-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Flexible doses</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Fixed doses</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Drug</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dose range</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Drug</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Fixed doses</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg/day to 30 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>aripiprazole long‐acting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300 mg or 400 mg four‐weekly</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>brexpiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 mg/day to 4 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>haloperidol decanoate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 mg four‐weekly</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cariprazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 mg/day to 9 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 mg/day, 15 mg/day or 20 mg/day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>chlorpromazine (equivalent)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 mg/day to 1000 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>paliperidone depot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 mg, 50 mg,100 mg or 150 mg four‐weekly or 175 mg, 263 mg, 350 mg or 525 mg twelve‐weekly</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>flupenthixol depot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg to 40 mg three‐weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>zotepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300 mg/day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>fluphenazine decanoate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.25 mg to 5 mg twice‐weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="13" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>fluphenazine depot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.5 mg to 25 mg three‐weekly or 25 mg to 50 mg four‐weekly</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>iloperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 mg/day to 24 mg/day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>paliperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 to mg/day 15 mg/day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>penfluridol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg/week to 160 mg/week</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>perphenazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 mg/day to 24 mg/day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pimozide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 mg/day to 40 mg/day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>prochlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg/day to 150 mg/day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>promazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 mg/day to 400 mg/day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg/day to 800 mg/day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>thioridazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75 mg/day to 1000 mg/day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>trifluoperazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg/day to 50 mg/day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ziprasidone.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 mg/day to 160 mg/day</p> </td> </tr> </tbody> </table> </div> </p> <p>In a number of studies various antipsychotic drugs could be administered.</p> </section> <section id="CD008016-sec-0094"> <h5 class="title">6. Sponsor</h5> <p>Most studies had either a neutral sponsor or sponsorship was not indicated. Twenty‐five studies were industry sponsored (<a href="./references#CD008016-bbs2-0001" title="BakerRA , MeyerJM , KaplitaS , ForbesA , GrossmanF , PikalovA , MarcusRN . Long-term effects of aripiprazole on the lipid profiles of patients with schizophrenia in a 26-week placebo-controlled trial. Schizophrenia Bulletin2007;33(2):S419. [CSZG: 15132]CarsonW , McQuadeR , SahaA , TorbeynsA , StockE . Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia. European Neuropsychopharmacology2002;12(Suppl 3):S288. [CSZG: 9067]CarsonW , PigottT , SahaA , AliM , McQuadeRD , TorbeynsAF , et al. Aripiprazole vs placebo in the treatment of stable, chronic schizophrenia. In: Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [CSZG: 9986]CarsonW , WeidenP , WaldeckR , TafesseE , CisloP , L'ItalienG , IwamotoT . Aripiprazole is not associated with increased diabetes risk: a long-term model. Schizophrenia Research2004;67(Suppl 1):181. [CSZG: 13175]CarsonWH , IngenitoGG , McQuadeRD , StockEG , IwamotoT . Schizophrenia: safety/tolerability of aripiprazole. In: Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan. 2002. [CSZG: 19426]CarsonWH , PigottTA , SahaAR , AliMW , McQuadeRD , TorbeynsAF , et al. Aripiprazole vs placebo in the treatment of chronic schizophrenia. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S187. [CSZG: 8326]CaseyD , SahaA , MarcusR , CarsonWH , McQuadeRD , TorbeynsAF , et al. Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia. Schizophrenia Research2003;60:276. [CSZG: 9689]CaseyD , StockE , JodyD , KaplitaS , SahaA , ListonH , et al. Long-term treatment with aripiprazole: effects on plasma lipis levels and glycaemic control. Int J Neuropsychopharmacol 2004 Jun;7(Suppl 2):S417. [CSZG: 13177]DubitskyGM , HarrisR , LaughrenT , HardemanS . Abilify (aripiprazole) tablets; medical review part 1. http://www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm2002:1-50. [CSZG: 9980]DubitskyGM , HarrisR , LaughrenT , HardemanS . Abilify (aripiprazole) tablets; medical review part 2. http://www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm2002:50-110. [CSZG: 9981]DubitskyGM , HarrisR , LaughrenT , HardemanS . Abilify (aripiprazole) tablets; medical review part 3. http://www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm2002:111-75. [CSZG: 9982]DubitskyGM , HarrisR , LaughrenT , HardemanS . Abilify (aripiprazole) tablets; medical review part 4. http://www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm2002:176-232. [CSZG: 9983]MarderSR , KaplitaS , SahaAR , Carson WH Jr, TorbeynsA , StockEG . Glycemic control and plasma lipids in long-term aripiprazole treatment. In: Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [CSZG: 9799]McQuadeR , KosticD , MarcusR , CarsonW , TorbeynsA , KerselaersW , YoccaF . Aripiprazole versus olanzapine in a 52-week, open-label extension study. Schizophrenia Bulletin2005;31:S496-7. [CSZG: 11624]MortimerAM . Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia. Evidence-Based Mental Health2004;7(2):41. [CSZG: 13962]PigottTA , CarsonWH , SahaAR , TorbeynsAF , StockEG , IngenitoGG . Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. Journal of Clinical Psychiatry2003;64:1048-56. [CSZG: 9896]PigottTA , SahaAR , AliMW , McQuadeRD , TorbeynsAF , WilliamHC , et al. Aripiprazole versus placebo in the treatment of chronic schizophrenia. In: Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [CSZG: 9018]StockE , MarderSR , JodyD , KaplitaS , SahaA , CarsonW , et al. Plasma lipids levels and glycemic control in long-term treatment with aripiprazole. European Neuropsychopharmacology2003;13(4):S327. [CSZG: 9854]TorbeynsA , MarderSR , CarsonW , JodyD , KaplitaS , SabaA , et al. Glycemic control and plasma lipids in long-term treatment with aripiprazole. Schizophrenia Research2004;67(1):192-3. [CSZG: 11339]">Aripiprazole 2003</a>; <a href="./references#CD008016-bbs2-0002" title="CorrellC , KohegyiE , ZhaoC , BakerRA , McQuadeR , SalzmanP , et al. Oral aripiprazole is an effective maintenance treatment in adolescents with schizophrenia. Neuropsychopharmacology2014:S349-S350. [CSZG: 29288]CorrellCU , KohegyiE , ZhaoC , BakerRA , McQuadeR , SalzmanPM , et al. Oral aripiprazole as maintenance treatment in adolescent schizophrenia: results from a 52-week, randomized, placebo-controlled withdrawal study. Journal of the American Academy of Child and Adolescent Psychiatry2017;56(9):784-92. [CSZG: 36321]NCT01149655. A long-term multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of aripiprazole (opc 14597) as maintenance treatment in adolescent patients with schizophrenia. http://ClinicalTrials.gov/show/NCT011496552010. [CSZG: 21085]">Aripiprazole 2017</a>; <a href="./references#CD008016-bbs2-0003" title="BakerR , FleischhackerW , SanchezR , PerryP , JinN , JohnsonB , et al. Long-term safety and tolerability of once-monthly aripiprazole intramuscular depot for maintenance treatment in schizophrenia. International Journal of Neuropsychopharmacology2012;15:111. [CSZG: 28035]BakerRA , CarsonWH , PerryPP , SanchezR , ZhaoJ , McQuadeRD , et al. Effects of aripiprazole once-monthly vs placebo on domains of personal and social performance in younger and older patients with schizophrenia. CNS Spectrums2013;18(6):376-7. [CSZG: 28526]BakerRA , EramoA , CarsonWH , PerryP , SanchezR , ZhaoJ , et al. Effects of aripiprazole once-monthly vs. placebo on domains of personal and social performance in younger and older patients with schizophrenia. Schizophrenia Bulletin2013;39(Suppl 1):S321-S322. [CSZG: 28131]BakerRA , EramoA , NylanderAG , TsaiLF , Peters-StricklandTS , KosticD , et al. The effect of previous dose or oral aripiprazole (10 or 30 mg/day) on the efficacy and tolerability of aripiprazole once-monthly: Results from post-hoc analyses from two double-blind, randomized, controlled trials. Schizophrenia Research2014;153:S293. [CSZG: 29386]CarsonWH , PerryPP , SanchezR , JinN , ForbesRA , McQuadeRD , et al. Effects of ARI-IM-depot on secondary efficacy outcomes in maintenance treatment of schizophrenia. International Journal of Neuropsychopharmacology2012;15:112-3. [CSZG: 28030]EramoA , FleischhackerWW , SanchezR , PerryP , JinN , JohnsonB , et al. A placebo-controlled study of efficacy and safety of aripiprazole oncemonthly for long-term maintenance treatment in schizophrenia. European Psychiatry2013;28(1):1. [CSZG: 28187]EramoA , FleischhackerWW , SanchezR , TsaiLF , Peters-StricklandTS , BakerRA , et al. All-cause discontinuation and safety of aripiprazole once-monthly for the treatment of schizophrenia: A pooled analysis of two double-blind, randomized, controlled trials. Schizophrenia Research2014;153:S174. [CSZG: 29437]FleischhackerWW , BakerRA , EramoA , SanchezR , TsaiLF , Peters-StricklandT , et al. Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies. Schizophrenia Research2014;159(2-3):415-20. [CSZG: 32163]FleischhackerWW , PerryP , SanchezR , JinN , Peters-StricklandT , JohnsonB , et al. Functional outcomes with aripiprazole once-monthly in two double-blind, placebo- and active-controlled studies (aspire us 246 and aspire eu 247) for the treatment of schizophrenia. Value in Health2013;16(7):A550. [CSZG: 28480]FleischhackerWW , SanchezR , JohnsonB , JinN , ForbesRA , McQuadeR , et al. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. International Clinical Psychopharmacology2013;28:171-6. [CSZG: 28391]FleischhackerWW , SanchezR , Lan-FengT , Peters-StricklandT , BakerRA , EramoA , et al. Safety and Effectiveness of Aripiprazole Oncemonthly for the Treatment of Schizophrenia: A Pooled Analysis of Two Double-blind, Randomized, Controlled Trials. Neuropsychopharmacology2013;38:S394-S395. [CSZG: 28459]KaneJM , SanchezR , BakerRA , EramoA , Peters-StricklandT , PerryPP , et al. Patient-centered outcomes with aripiprazole once-monthly for maintenance treatment in patients with schizophrenia: Results from two multicenter, randomized, double-blind studies. Clinical Schizophrenia and Related Psychoses2015;9(2):79-87. [CSZG: 32183]KaneJM , SanchezR , PerryPP , JinN , JohnsonB , ForbesRA , et al. Efficacy of aripiprazole-IM-depot for long-term maintenance treatment of schizophrenia. International Journal of Neuropsychopharmacology2012;15:S119. [CSZG: 28033]KaneJM , SanchezR , PerryPP , JinN , JohnsonBR , ForbesRA , et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: A 52-week, multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2012;73(5):617-24. [CSZG: 24369]LozeJ , CarsonWH , PerryPP , SanchezR , JinN , ForbesRA , et al. Psychosocial and overall effectiveness of aripiprazole intramuscular depot vs. placebo for maintenance treatment in schizophrenia. European Neuropsychopharmacology2012;22:S328. [CSZG: 24886]NCT00705783. Aripiprazole (OPC-14597) as maintenance treatment in patients with schizophrenia. https://www.ClinicalTrials.gov/ct/show/2008. [CSZG: 16546]SanchezR , JohnsonB , JinN , ForbesRA , CarsonWH , McQuadeRD , et al. Patient-reported outcomes (PROs) with aripiprazole intramuscular depot (ARI-IMD) for maintenance treatment in schizophrenia. International Journal of Neuropsychopharmacology2012;15:133. [CSZG: 28040]SanchezR , PerryPP , JinN , Johnson, RA Forbes, RD McQuade, WH, et al. A placebo-controlled study of efficacy/ safety of aripiprazole intramuscular depot for long-term maintenance treatment of schizophrenia. European Neuropsychopharmacology2012;(Suppl 2):S327. [CSZG: 24893]">Aripiprazole depot 2012</a>; <a href="./references#CD008016-bbs2-0004" title="KaneJM , MackleM , Snow-AdamiL , ZhaoJ , SzegediA , PanagidesJ . A randomised placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. Journal of Clinical Psychiatry2011;72(3):349-55. [CSZG: 22873]KaneJM , MackleM , Snow-AdamiL , ZhaoJ , SzegediA , PanagidesJ . Double-blind, placebo-controlled trial of asenapine in prevention of relapse after long-term treatment of schizophrenia. International Journal of Neuropsychopharmacology2010;13:223. [CSZG: 21634]MackleM , Snow-AdamiL , ZhaoJ , SzegediA , PanagidesJ . Double-blind, placebo-controlled trial of asenapine in prevention of relapse after long-term treatment of schizophrenia. European Neuropsychopharmacology2009;19(Suppl 3):S543. [CSZG: 19377]NCT00150176. A randomized, placebo-controlled, double-blind trial of asenapine in the prevention of relapse after long-term treatment of schizophrenia. https://www.ClinicalTrials.gov/ct/show/2005. [CSZG: 14708] The NHSC . Asenapine (Saphris) for schizophrenia. Report2010. [CSZG: 21910]">Asenapine 2011</a>; <a href="./references#CD008016-bbs2-0005" title="BakerR , HobartM , ForbesA , OuyangJ , WeillerE . Effect of brexpiprazole on long-term functioning in adults with schizophrenia. Australian and New Zealand Journal of Psychiatry2017;51(Suppl 1):148. [CSZG: 35955]CorrellCU , ShiL , WeissC , HobartM , EramoA , DuffyRA , et al. Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice of cross-titration schedules in a post-hoc analysis of a randomized double-blind maintenance treatment study. CNS Spectrums2019;24(5):507-17. FleischhackerWW , HobartM , OuyangJ , ForbesA , PfisterS , McQuadeR , et al. Brexpiprazole (OPC-34712) efficacy and safety as maintenance therapy in adults with schizophrenia: Randomised, double-blind, placebo-controlled study. European Neuropsychopharmacology2015;25:S527. [CSZG: 33322]FleischhackerWW , HobartM , OuyangJ , ForbesA , PfisterS , McQuadeRD , et al. Efficacy and sfety of Brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. International Journal of Neuropsychopharmacology2017;20(1):11-21. [CSZG: 35475]NCT01668797. Efficacy, Safety, and tolerability of Brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia. https://ClinicalTrials.gov/show/NCT016687972012. [CSZG: 35608]TherrienF , WeissC , JinN , BakerRA , MacKenzieE , MeehanSR . Effect of brexpiprazole on patient functioning in patients with schizophrenia: results from a long-term, randomised, double-blind, placebo-controlled, maintenance study. Neuropsychopharmacology2017;43((Suppl.1)):S244-S245. [CSZG: 37935]WeillerE , HobartM , PfsterS , ForbesA , OuyangJ , WeissC . Effect of brexpiprazole on long-term remission in adults with schizophrenia: Results from a randomized, double-blind, placebo-controlled, maintenance study. Schizophrenia Bulletin2017;43:S202-3. [CSZG: 36050]WeissC , ForbesA , HobartM , PfsterS , OuyangJ , WeillerE . Short-term and long-term efficacy of brexpiprazole in adults with schizophrenia: Effect across marder factors. Schizophrenia Bulletin2017;43:S155. [CSZG: 36051]WeissC , OuyangJ , EramoA , DuffyRA , WeillerE , BakerRA . Switching patients with acute schizophrenia to brexpiprazole: post-hoc analysis of a double-blind randomized maintenance treatment study. Neuropsychopharmacology2015;40:S227-8. [CSZG: 33450]WeissC , WeillerE , HobartM , OuyangJ . Effect of brexpiprazole on weight and metabolic parameters: analysis of a maintenance trial in schizophrenia. European Neuropsychopharmacology2016;26:S556. [CSZG: 35746]">Brexpiprazole 2017</a>; <a href="./references#CD008016-bbs2-0006" title='CorrellCU , PotkinSG , DurgamS , ChangCT , SzatmariB , LaszlovszkyI , et al. Sustained remission with cariprazine treatment: post-hoc analysis of a randomised, double-blind, schizophrenia relapse prevention trial. Europan Neuropsychopharmacology2017;27((Suppl. 4)):S935-S936. [CSZG: 37757]CorrellCU , PotkinSG , ZhongY , HarsányiJ , SzatmáriB , EarleyW . Long-term remission with cariprazine treatment in patients with schizophrenia: a post-hoc analysis of a randomized, double-blind, placebo.controlled relapse prevention trial. Journal of Clinical Psychiatry2019;80(2):18m12495. DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Corrigendum to "Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial" [Schizophr. Res. 176 (2016) 264-71]. Schizophrenia Research2017;InPress:InPress. [CSZG: 35204]DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A double-blind, placebo-controlled trial. European Neuropsychopharmacology2015;25:S512-3. [CSZG: 33317]DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophrenia Research2016;176(2-3):264-71. [CSZG: 35204]DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: additional analysis from a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2015;40:S380-1. [CSZG: 33316]EarleyW , GuoH , LuchiniR . Modified cariprazine relapse prevention clinical trial results. Schizophrenia Research2018;199:452-3. KunovacJ , KaneJ , DurgamS , ChangCT , NemethG , LaszlovszkyI , et al. Characteristics associated with relapse in patients with schizophrenia: Post hoc analysis of a randomized, double-blind, placebo-controlled, cariprazine relapse prevention trial. Schizophrenia Bulletin2017;43:S166-7. [CSZG: 36002]NCT01412060. Cariprazine relative to placebo in the prevention of relapse of symptoms in patients with schizophrenia. http://ClinicalTrials.gov/show/NCT014120602011. [CSZG: 23106]PotkinS , CorrellC , ChangCT , SzatmariB , LaszlovszkyI , EarleyW . Long-term remission with cariprazine treatment in patients with schizophrenia: a post hoc analysis of a randomized, double-blind, placebo-controlled, relapse prevention trial. Schizophrenia Bulletin2017;43:S118. [CSZG: 36026]'>Cariprazine 2016</a>; <a href="./references#CD008016-bbs2-0022" title="SampathG , ShahA , KrskaJ , SoniSD . Neuroleptic discontinuation in the very stable schizophrenic patient - relapse rates and serum neuroleptic levels. Human Psychopharmacology1992;7:255-64. [CSZG: 2493]SoniSD , MallikA , SchiffAA . Sulpiride in negative schizophrenia: a placebo-controlled double-blind assessment. Human Psychopharmacology1990;5:233-8. [CSZG: 2697]">Fluphenazine depot 1992</a>; <a href="./references#CD008016-bbs2-0027" title="CTRI/2010/091/001409. A clinical trial to study prevention of relapse in patients with schizophrenia reveiving either flexible dose iloperidone or placebo in long-term use.. http://ctri.nic.in/Clinicaltrials/login.php2010. NCT01291511. Efficacy in prevention of relapse of schizophrenia in subjects taking either placebo or iloperidone. http://ClinicalTrials.gov/show/NCT012915112011. [CSZG: 22671]WeidenPJ , ManningR , WolfgangCD , RyanJM , MancioneL , HanG , et al. A randomized trial of iloperidone for prevention of relapse in schizophrenia: the REPRIEVE study. CNS drugs2016;30(8):735-47. [CSZG: 35243]">Iloperidone 2016</a>; <a href="./references#CD008016-bbs2-0028" title="NCT01435928. PEARL Schizophrenia Maintenance. http://ClinicalTrials.gov/show/NCT014359282011. [CSZG: 23439]TandonR , CucchiaroJ , PhillipsD , HernandezD , MaoY , PikalovA , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Journal of Psychopharmacology2016;30(1):69-77. [CSZG: 33434]TandonR , LoebelA , PhilipsD , PikalovA , Hernandez D MaoY , et al. Lurasidone for maintenance of efficacy in patients with schizophrenia. European Neuropsychopharmacology2014;24(Suppl 2):S559-560. [CSZG: 27840]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , CucchiaroJ . A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Schizophrenia Research2014;153(1):S372. [CSZG: 29681]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Int J Neuropsychopharmacol2014;17:S153-154. [CSZG: 29954]">Lurasidone 2016</a>; <a href="./references#CD008016-bbs2-0030" title="Beasley C Jr, HamiltonS , DossenbachM . Relapse prevention with olanzapine. European Neuropsychopharmacology2000;10(Suppl 3):S304. [CSZG: 4620]BeasleyCM , HamiltonSH , DossenbachM . Relapse prevention with olanzapine. Schizophrenia Research2000;41(1):196-7. [CSZG: 4874]BeasleyCM , SuttonVK , HamiltonSH , WalkerDJ , DossenbachM , TaylorCC , et al. A double-blind, randomised, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. Journal of Clinical Psychopharmacology2003;23:582-94. [CSZG: 10010]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD , PickarD . Does maintenance treatment with atypical antipsychotics worsen quality of life among stable patients with schizophrenia?Neuropsychopharmacology2005;30(S1):S189. [CSZG: 13107]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD . Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?Journal of Clinical Psychopharmacology2006;26:40-4. [CSZG: 14454]BeasleyCM , WalkerDJ , SuttonVK , AlakaK , NaberD , NamjoshiM . The effectiveness of olanzapine versus placebo in maintaining the quality of life in stabilized patients with schizophrenia. European Neuropsychopharmacology2003;13:S342. [CSZG: 9849]EliLilly Company. Olanzapine relapse prevention versus placebo in the treatment of schizophrenia. http://www.Clinicalstudyresults.org/.2005. [CSZG: 18733]">Olanzapine 2003</a>; <a href="./references#CD008016-bbs2-0031" title="Eerdekens. Evaluate the efficacy in the prevention of recurrence of the symptoms of schizophrenia. Sponsor: Johnson &amp; Johnson Pharmaceutical Research &amp; Development, LL.C2010. [CTG: NCT00111189]KramerM , KushnerS , SherrJ , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study. Schizophrenia Bulletin2007;33(2):438. [CSZG: 15185]KramerM , KushnerS , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia treated with paliperidone extended-release tablets. European Neuropsychopharmacology2006;16(Suppl 4):S386. [CSZG: 13313]KramerM , KushnerS , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study. International Journal of Neuropsychopharmacology2006;9(Suppl 1):S274. [CSZG: 19545]KramerM , SimpsonG , MaciulisV , KushnerS , LiuY , LimP , et al. One-year open-label safety and efficacy study of paliperidone extended-release. CNS Spectrums2010;15(8):506-14. [CSZG: 20885]KramerM , SimpsonG , MaciulisV , KushnerS , VijapurkarU , LimP , et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2007;27:6-14. [CSZG: 13907]MarkowitzM , FuDJ , LevitanB , GopalS , TurkozI , AlphsL . Long-acting injectable paliperidone palmitate versus oral paliperidone extended release. Annals of General Psychiatry2013;12:22. [CSZG: 28633]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone 2007</a>; <a href="./references#CD008016-bbs2-0032" title="RuiQ , WangY , LiangS , LiuY , WuY , WuQ , et al. Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry2014;53:45-53. [CSZG: 29320]ZhangH , LiH , LiuY , WuC , WuQ , NuamahI . Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia. Neuropsychiatric Disease and Treatment2016;12:69-77. [CSZG: 33455]">Paliperidone 2014</a>; <a href="./references#CD008016-bbs2-0033" title="AlphsL , BossieC , Kern-SliwaJ , Ma Y-W, HaskinsJT . Paliperidone palmitate: clinical response in subjects with schizophrenia with recent vs. longer-term duration of illness. In: Proceedings of the 162nd Annual Meeting of the American Psychiatric Association. San Francisco, CA., 2009 May 16-21. [CSZG: 19067]EmsleyR , NuamahI , GopalS , HoughD , FleischhackerWW . Relapse after antipsychotic discontinuation in schizophrenia as a withdrawal phenomenon vs illness recurrence: a post hoc analysis of a randomized placebo-controlled study. Journal of Clinical Psychiatry 2018 Jun;79(4):17m11874. [CSZG: 38184]EmsleyR , NuamahI , HoughD , GopalS . Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophrenia Research2012;138(1):29-34. [CSZG: 24214]GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM , HoughD . A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. Journal of Psychopharmacology2011;25(5):685-97. [CSZG: 22903]GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Long-term efficacy, safety and tolerability of paliperidone palmitate in patients with schizophrenia. In: Proceedings of the 162nd Annual Meeting of the American Psychiatric Association. San Francisco, CA, 2009 May 16-21. [CSZG: 19076]HoughD , GopalS , VijapukarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate in prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. In: Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8, Washington DC, USA. 2008. [CSZG: 16486]HoughD , GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. In: Proceedings of the 63rd Annual Convention of the Society of Biological Psychiatry. Washington, DC, USA: Elsevier Science Inc, 2008:S285-6. [CSZG: 20281]HoughD , GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Biological Psychiatry2008;63(7 Suppl):285S-6S. [CSZG: 19530]HoughD , GopalS , VjapukarU , LimP , MorozowaM , EerdekensM . Paliperidone palmitate maintenance treatment in delaying the time to relapse in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. Schizophrenia Research2010;116:107-17. [CSZG: 19704]HulihanJ , BossieCA , FuDJ , Kern SliwaJ , Ma Y-W, AlphsLD . Remission with continued paliperidone palmitate treatment in stable subjects with schizophrenia. Schizophrenia Research2012;136:S252. [CSZG: 29467]KozmaCM , SlatonT , DiraniR , FastenauJ , GopalS , HoughD . Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate. Current Medical Resarch and Opinion2011;27(8):1603-11. SliwaJK , BossieCA , Fu DJ, TurkozI , AlphsL . Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia. Neuropsychiatric Disease and Treatment2012;8:375-85. [CSZG: 28007]SliwaJK , FuDJ , BossieCA , et al. Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate. BMC Psychiatry2014;14:S52. [CSZG: 29148]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone depot1M 2010</a>; <a href="./references#CD008016-bbs2-0034" title="BossieC , TurkozI , AlphsL , FuDJ . Monotherapy with once monthly paliperidone palmitate for psychotic, depressive, and manic symptoms in schizoaffective disorder. Schizophrenia Bulletin2015;41:S303. [CSZG: 29400]BossieCA , TurkozI , AlphsL , MahalchickL , FuDJ . Paliperidone palmitate once-monthly treatment in recent onset and chronic illness patients with schizoaffective disorder. Journal of Nervous and Mental Ddisease2017;205(4):324-8. [CSZG: 35417]FuDJ , AlphsL , LindenmayerJP , SchoolerN , SimonsonRB , TurkozI , et al. Paliperidone palmitate long-acting injectable delays psychotic and mood symptom relapse in schizoaffective disorder. European Neuropsychopharmacology2014;24:S534-5. [CSZG: 27785]FuDJ , BossieC , TurkozI , MahalchickL , AlphsL . Paliperidone palmitate treatment response in early and chronic illness schizoaffective disorder patients. Schizophrenia Bulletin2015;41:S312. [CSZG: 29446]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Effect of paliperidone palmitate once-monthly in improving and maintaining functioning in subjects with schizoaffective disorder using the domains of the personal and social performance scale. Neuropsychopharmacology2014;39:S365. [CSZG: 29278]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate delays relapse in patients with schizoaffective disorder. Biological Psychiatry2014;1:263S. [CSZG: 28974]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate long-acting injectable in acute exacerbation of schizoaffective disorder. Schizophrenia Bulletin2013;39:S331. [CSZG: 28167]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate once-monthly injectable treatment for acute exacerbations of schizoaffective disorder. Journal of Clinical Psychopharmacology2016;36(4):372-6. [CSZG: 35803]FuDJ , TurkozI , SimonsonRB , WallingDP , SchoolerNR , LindenmayerJP , et al. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. Journal of Clinical Psychiatry2015;76(3):253-62. [CSZG: 29752]FuDJ , TurkozI , WallingD , LindenmayerJP , SchoolerNR , AlphsL . Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder. Schizophrenia Research2018;192:185-93. [CSZG: 35804]JoshiK , LinJ , Lingohr-SmithM , FuD . Medical cost reductions for paliperidone palmitate versus placebo in randomized double-blind trial of patients with schizoaffective disorder. Journal of Managed Care and Specialty Pharmacy2015;21:536-7. JoshiK , LinJ , Lingohr-SmithM , FuDJ . Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder. Journal of Medical Economics2015;18:629-36. [CSZG: 33677]NCT01193153. A study to evaluate the efficacy of paliperidone palmitate in the prevention of relapse of the symptoms of schizoaffective disorder. http://ClinicalTrials.gov/show/NCT011931532010. [CSZG: 21094]TurkozI , FuDJ , WallingD , SchoolerNR , LindenmayerJP , SimonsonRB , et al. Effect of paliperidone palmitate once-monthly in improving and maintaining functioning in subjects with schizoaffective disorder using the domains of the personal and social performance scale. Schizophrenia Bulletin2015;41:S193-4. [CSZG: 29687]">Paliperidone depot1M 2015</a>; <a href="./references#CD008016-bbs2-0035" title="BellLKS , TurkozI , KimE . Paliperidone palmitate once-every-3-months in adults with early illness schizophrenia. Early Intervention in Psychiatry2019;13(3):667-72. BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of paliperidone palmitate 3 month formulation: a randomized, double-blind, placebo-controlled study. Schizophrenia Bulletin2015;41:S302. [CSZG: 29393]BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of paliperidone palmitate 3-month formulation in schizophrenia: a randomized, double-blind, placebo-controlled study. European Psychiatry2015;30:272. [CSZG: 32149]BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry2015;72(8):830-9. [CSZG: 33027]ChirilaC , ZhengQ , SawyerrG , NuamahI . Healthcare resource use of paliperidone palmitate 3-month injection vs placebo. In: 168th Annual Meeting of American Psychiatric Association; Toronto, Canada. May 16-20, 2015. [CSZG: 33035]GopalS , FureyM , HibarD , KolbH , SaadZ , SavitzA , et al. Potential biomarkers of impending schizophrenia relapse. Biological Psychiatry2017;(10 Suppl):S126-S127. [CSZG: 36107]GopalS , XuH , McQuarrieK , SavitzA , NuamahI , WoodruffK , et al. Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies. NPJ Schizophrenia2017;3(1):23. [CSZG: 36325]MathewsM , NuamahI , SavitzA , GopalS . Efficacy and safety of paliperidone palmitate 3-month formulation vs placebo for relapse prevention of Schizophrenia: Treatment effect using a number needed to treat analysis. Biological Psychiatry2017;81(10 Suppl 1):S350-1. [CSZG: 36437]NCT01529515. A study of paliperidone palmitate 3 month formulation for the treatment of patients with schizophrenia. http://ClinicalTrials.gov/show/NCT015295152012. [CSZG: 23705]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone depot3M 2015</a>; <a href="./references#CD008016-bbs2-0036" title="BaroF , BrugmansJ , DomR , Van LommelR . Maintenance therapy of chronic psychotic patients with a weekly oral dose of R 16341. A controlled double-blind study. Journal of Clinical Pharmacology1970;10:330-41. [CSZG: 297]">Penfluridol 1970</a>; <a href="./references#CD008016-bbs2-0038" title="RoelofsGA . Penfluridol (R 16341) as a maintenance therapy in chronic psychotic patients: a double-blind clinical evaluation. Acta Psychiatrica Scandinavica1974;50:219-24. [CSZG: 2440]">Penfluridol 1974b</a>; <a href="./references#CD008016-bbs2-0045" title="D1441C00131. A 1-year, international, multicenter, randomized, double-blind, parallel-group, placebo-controlled phase IV study to evaluate prevention of relapse in patients in stable condition with chronic schizophrenia receiving either quetiapine fumarate IR (SEROQUEL) or placebo. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=3852003. D1444C00004. A 1-year, international, multicenter, randomized, double-blind, parallelgroup, placebo-controlled phase iii study to evaluate prevention of relapse in patients in stable condition with chronic schizophrenia receiving either sustained-release quetiapine fumarate (SEROQUEL) or placebo. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=14182006. NCT00228462. A 1-year, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study to evaluate prevention of relapse in patients in stable chronic schizophrenia receiving either sustained-release quetiapine fumarate (SEROQUEL) or placebo (abbreviated). https://www.ClinicalTrials.gov/ct/show/2005. [CSZG: 14874]PeuskensJ , TrivediJ , MalyarovS , BrecherM , SvenssonO , MillerF , et al. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomised, placebo-controlled trial in clinically stable patients. Psychiatry2007;4(11):34-50. [CSZG: 16025]PeuskensJ , TrivediJK , BrecherM , MillerF , Study I . Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: Post-hoc analysis of data from a randomized withdrawal, placebo-controlled study. International Clinical Psychopharmacology2010;25(3):183-7. [CSZG: 20670]PeuskensJ , TrivediJK , BrecherM , SvenssonO , MillerF , MeulienD . Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate. In: Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA. 2008. [CSZG: 16500]PeuskensJ , TrivediJK , BrecherM , SvenssonO , MillerF , MeulienD . Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate. Schizophrenia Research2008;98:14-5. [CSZG: 16344]PeuskensJ , TrivediJK , MalyarovS , BrecherM , SvenssonO , MillerF , et al. A randomized, placebo-controlled, relapse-prevention study with once-daily quetiapine sustained release in patients with schizophrenia. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28-Apr 1; Colorado Springs, Colorado, USA2007. [CSZG: 15271]PeuskensJC , TrivediJK , MalyarovS , BrecherM , SvenssonO , MillerF , et al. A randomized, placebo-controlled, relapse-prevention study with once daily quetiapine sustained release in patients with schizophrenia. Schizophrenia Bulletin2007;33(2):453. [CSZG: 15225]">Quetiapine 2007</a>; <a href="./references#CD008016-bbs2-0046" title="NCT00658645. A multinational, randomised, double-blind, fixed-dose, bifeprunox study combining a 12-week placebo-controlled, quetiapine-referenced phase with a 12-month quetiapine-controlled phase in patients with schizophrenia. https://www.clinicaltrials.gov/ct2/show/NCT00658645?term=NCT00658645&amp;rank=1. [CSZG: 16241]">Quetiapine 2009a</a>; <a href="./references#CD008016-bbs2-0047" title="NCT00704509. A multinational, randomised, double-blind, fixed-dose, bifeprunox study combining a 12-week placebo-controlled, quetiapine-referenced phase with a 12-month quetiapine-controlled phase in patients with schizophrenia. https://www.clinicaltrials.gov/ct2/show/NCT00704509?term=NCT00704509&amp;rank=1. [CSZG: 16566]">Quetiapine 2009b</a>; <a href="./references#CD008016-bbs2-0048" title="ChenE , HuiC , ChangWC , ChanS , LeeE , HonerW . The effect of early medication discontinuation on long-term clinical outcome in first episode psychosis. Schizophrenia Bulletin2018;44(Suppl 1):S97. ChenE , HuiC , LamM , LawC , ChiuC , ChungD , et al. Assessing the efficacy of relapse prevention in single episode psychosis patients with stable maintenance treatment for at least 1 year: a double-blind randomized placebo-controlled. Early Intervention in Psychiatry2008;2(Suppl 1):A5. [CSZG: 19113]ChenEY , HuiCL , LamM , LawCW , ChiuCP , ChungDW , et al. A double-blind randomised placebo-controlled study of relapse prevention in remitted first-episode psychosis patients following one year of maintenance therapy. Schizophrenia Research2008;98:11-2. [CSZG: 16325]ChenEY , HuiCL , LamM , LawCW , ChiuCP , ChungDW , et al. A double-blind randomized placebo-controlled relapse prevention study in remitted first-episode psychosis patients following one year of maintenance treatment. Early Intervention in Psychiatry2010;4(Suppl 1):13. [CSZG: 23475]ChenEY , HuiCL , LamMM , ChiuCP , LawCW , ChungDW , et al. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ2010;341:c4024. [CSZG: 20857]ChenYH , HuiLM , LamM , LawCW , ChiuPY , ChungWS , et al. A double-blind randomized placebo-controlled relapse prevention study in remitted first-episode psychosis patients following one year of maintanence therapy. European Psychiatry2008;23:S107-S8. [CSZG: 20468]Hui CL , WongGH , TangJY , ChangWC , ChanSK , LeeEH , et al. Predicting 1-year risk for relapse in patients who have discontinued or continued quetiapine after remission from first-episode psychosis. Schizophrenia Research2013;150(1):297-302. [CSZG: 28601]HuiC , ChenE , LamM , LawC , ChiuC , ChungD , et al. Can we predict relapse in single episode psychosis patients with stable maintenance treatment for at least one year?Early Intervention in Psychiatry2008;2(Suppl 1):A124. [CSZG: 19123]HuiCL , ChenEY , LamM , LawCW , ChiuCP , ChungDW , et al. Predictors for relapse in a double-blind randomized placebo-controlled discontinuation study of remitted first-episode psychosis patients. Schizophrenia Research2008;98:13. [CSZG: 16333]HuiCL , HonerW , LeeE , ChanS , ChangWC , ChenE . The 10-year clinical outcome of early medication discontinuation in remitted first episode psychosis. Early Intervention in Psychiatry2018;12(1):46. HuiCL , HonerWG , LeeEH , ChangWC , ChanSK , ChenES , et al. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. Lancet Psychiatry 2018 May;5(5):432-42. [CSZG: 38003]HuiCL , HonerWG , LeeEH , ChangWC , ChanSK , ChenES , et al. Predicting first-episode psychosis patients who will never relapse over 10 years. Psychological Medicine2019;49(13):2206-14. HuiCL , HonerWG , LeeEH , ChangWC , ChanSK , ChenEY . Factors associated with successful medication discontinuation after a randomized clinical trial of relapse prevention in first-episode psychosis: a 10-year follow-up. JAMA Psychiatry2019;76(2):217-9. HuiCL , LiYK , LiAW , LeeEH , ChangWC , ChanSK , et al. Visual working memory deterioration preceding relapse in psychosis. Psychological Medicine2016;46:2435-44. [CSZG: 33663]HuiLM , ChenYH , LamM , LawCW , ChiuPY , ChungWS , et al. A double-blind randomized placebo-controlled study of relapse predictors in remitted first-episode psychosis patients. European Psychiatry2008;23:S120-S1. [CSZG: 20469]NCT00334035. Duration of maintenance anti-psychotic therapy after first –episode schizophrenia: a double-blind randomized placebo-control relapse prevention study. https://www.ClinicalTrials.gov/ct/show/2006. [CSZG: 14607]">Quetiapine 2010</a>; <a href="./references#CD008016-bbs2-0060" title="HirschSR , GaindR , RohdePD , StevensBC , WingJK . Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry. British Medical Journal1973;1(854):633-7. [CSZG: 3799]HirschSR , LeffJP , WingJK . Outpatient maintenance of chronic schizophrenics with long-acting. British Medical Journal1973;2(5868):715-6. [CSZG: 3839]LeffJP , HirschSR , GaindR , RohdePD , StevensBC . Life events and maintenance therapy in schizophrenic relapse. British Journal of Psychiatry1973;123:659-60. LeffJP , WingJK . Trial of maintenance therapy in schizophrenia. British Medical Journal1971;3:599-604. [CSZG: 3840]LeffJP . Influence of selection of patients on results of clinical trials. British Medical Journal1973;4(5885):156-8. [CSZG: 7717]StevensB . The social value of fluphenazine decanoate. Acta Psychiatrica Belgica1976;76(5):792-804. [CSZG: 2745]StevensBC . Role of fluphenazine decanoate in lessening the burden of chronic schizophrenics on the community. Psychological Medicine1973;3(2):141-58. [CSZG: 2739]">Various drugs 1971</a>; <a href="./references#CD008016-bbs2-0071" title="McCreadieRG , WilesD , GrantS , CrockettGT , MahmoodZ , LivingstonMG , et al. The Scottish first episode schizophrenia study. VII two-year follow-up. Acta Psychiatrica Scandinavica1989;80:597-602. [CSZG: 3968]Scottish Schizophrenia Research Group. The Scottish First Episode Schizophrenia Study II. Treatment. British Journal of Psychiatry1987;150:334-8. [CSZG: 3969]Scottish Schizophrenia Research Group. The Scottish First Episode Schizophrenia Study V. One-year follow-up. British Journal of Psychiatry1988;152:470-476. [CSZG: 3970]Scottish Schizophrenia Research Group. The Scottish First Episode Schizophrenia Study. III. Cognitive performance. British Journal of Psychiatry1987;150:338-340. [CSZG: 16867]Scottish Schizophrenia Research Group. The Scottish first episode schizophrenia study. VIII. Five-year follow-up. British Journal of Psychiatry1992;161:496-500. [CSZG: 2542]">Various drugs 1989</a>; <a href="./references#CD008016-bbs2-0074" title="AratoM , O'ConnorR , BradburyJE , MeltzerH . Long-term ziprasidone in schizophrenia. In: Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 - Jun 4; Toronto, Ontario, Canada. 1998. [CSZG: 3189]AratoM , O'ConnorR , BradburyJE , MeltzerH . The efficacy of ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. In: Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK. Amsterdam, Netherlands: Cambridge University Press, 1998. [CSZG: 3188]AratoM , O'ConnorR , BradburyJE , MeltzerH . Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. In: Proceedings of the 9th Congress of the Association of European Psychiatrists; 1998 Sep 20-24; Copenhagen, Denmark. 1998. [CSZG: 3190]AratoM , O'ConnorR , BradburyJE , MeltzerH . Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. Schizophrenia Research1999;36(1-3):270. [CSZG: 5626]AratoM , O'ConnorR , MeltzerH , BradburyJ . Ziprasidone: efficacy in the prevention of relapse and in the long-term treatment of negative symptoms of chronic schizophrenia. In: Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria. 1997. [CSZG: 245]AratoM , O'ConnorR , MeltzerHY . A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. International Clinical Psychopharmacology2002;17:207-15. [CSZG: 18486]BernardoM , AranzaJR , Rubio-TerresC , RejasJ . Cost-effectiveness analysis of schizophrenia relapse prevention. Clinical Drug Investigation. New Zealand2006;26(8):447-57. [CSZG: 13898]BernardoM , AranzaJR , Rubio-TerresC , RejasJ . Cost-effectiveness analysis of the prevention of relapse in schizophrenia in the ZEUS longitudinal study Ziprasidone Extended Use in Schizophrenia (ZEUS). Acta Espanolas de Psiquiatria2007;35(4):259-62. [CSZG: 15396]MeltzerHY , O´ConnorR . Long-term efficacy of ziprasidone in schizophrenia. Schizophrenia research2001;(1-2):S. 239. [CSZG: 6050]MeltzerHY , O´ConnorR . Path analysis of the ZEUS study provides evidence of a direct effect of ziprasidone on primary negative symptoms in chronic, stable schizophrenia. Conference Poster1997. [CSZG: 2033]MeltzerHY , O'ConnorR . Long-term efficacy of ziprasidone in schizophrenia: results of two controlled trials. In: Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico. 2000. [CSZG: 7609]O'ConnorR , SchoolerNR . Penultimate observation carried forward (POCF): a new approach to analysis of long-term symptom change in chronic relapsing conditions [letter]. Schizophrenia Research2003;60:319-20. [CSZG: 9365]Pfizer 2000. Multicentre double-blind study of ziprasidone versus placebo in relapse prevention for hospitalised patients with chronic or subchronic schizophrenia. Study report Unpublished. SchoolerN . A basis for optimism: the implications of long term treatment. In: Proceedings of the 9th Congress of the Association of European Psychiatrists; 1998 Sep 20-24; Copenhagen, Denmark. 1998. [CSZG: 5864]">Ziprasidone 2002</a>; <a href="./references#CD008016-bbs2-0075" title="CooperSJ , ButlerA , TweedJ , RaniwallaJ , WelchC . Zotepine in the prevention of relapse. Biological Psychiatry1997;42:41s. [CSZG: 17007]CooperSJ , ButlerA , TweedJ , RaniwallaJ , WelchC . Zotepine in the prevention of relapse. In: Proceedings of the 6th World Congress of Biological Psychiatry; 1997 June 22-27; Nice, France. 1997. [CSZG: 569]CooperSJ , ButlerA , TweedJ , WelchC , RaniwallaJ . Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacology2000;150:237-43. [CSZG: 5732]CooperSJ , ButlerA , TweedJA , WelchCP , WightonAJ , ApplebyP , et al. Zotepine is effective in preventing recurrence in patients with chronic schizophrenia. In: Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31 - Nov 4; Paris, France. 1998. [CSZG: 5784]CooperSJ , ButlerA , TweedJA , WelchCP , WightonAJ , ApplebyP , et al. Zotepine is effective in preventing recurrence in patients with chronic schizophrenia. Schizophrenia Research2000;41:207-8. [CSZG: 4925]">Zotepine 2000</a>). Frequently medication was provided by the manufacturers of the antipsychotic drugs, but we did not record such studies as primarily 'industry sponsored'. </p> </section> <section id="CD008016-sec-0095"> <h5 class="title">7. Outcomes</h5> <section id="CD008016-sec-0096"> <h6 class="title">7.1 Relapse</h6> <p>The main relapse criteria in 25 studies was clinical judgement. However, in 24 studies various rating‐scale‐based definitions of relapse were used, in another 16 studies we took relapse as 'need of medication', in four 'admission to hospital', in two 'dropout due to worsening of symptoms', and, finally, in four the criteria used for 'relapse' was not indicated. </p> </section> <section id="CD008016-sec-0097"> <h6 class="title">7.2 Leaving the study early</h6> <p>The number of participants leaving the study early was recorded by category ('any reason', 'adverse events' and 'lack of efficacy'). In the more recent trials, efficacy‐related adverse events (e.g. exacerbation of psychosis) are often grouped with tolerability‐related adverse events as "Leaving the study early due to adverse events". Where detailed data on leaving early were available, data on 'exacerbation of psychosis' were not entered as 'adverse events'. </p> </section> <section id="CD008016-sec-0098"> <h6 class="title">7.3 Service use</h6> <p>Service use was described as the number of people re‐hospitalised and the numbers discharged during the trial. When reasons for hospitalisation were provided, we decided to enter data relative to people rehospitalised due to relapse or exacerbation of psychosis. </p> </section> <section id="CD008016-sec-0099"> <h6 class="title">7.4 Scales</h6> <p>Scales that provided usable data are described below. We had, however, a priori<i>,</i> decided in the protocol to focus on dichotomous outcomes apart from quality of life and social functioning (see <a href="#CD008016-sec-0051">Measures of treatment effect</a>). However, a few authors used rating scales to examine extrapyramidal adverse effects and defined cut‐offs to decide whether participants had a particular side effect or not. We used these data and explain below which cut‐offs were used. </p> <section id="CD008016-sec-0100"> <p><b>7.4.1 Adverse effects scales</b></p> <p>7.4.1.1 Abnormal Involuntary Movement Scale (AIMS) (<a href="./references#CD008016-bbs2-0199" title="GuyW . ECDEU Assessment Manual for Psychopharmacology-revised 1976. Washington, DC: DHEW. National Institute of Mental Health, 1976.">Guy 1976</a>)<br/>This scale has been used to assess tardive dyskinesia, a long‐term, drug‐induced movement disorder and short‐term movement disorders such as tremor. A low score indicates low levels of abnormal involuntary movements. In <a href="./references#CD008016-bbs2-0021" title="OdejideOA , AderounmuAF . Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. Journal of Clinical Psychiatry1982;43:195-6. [CSZG: 2184]">Fluphenazine depot 1982</a>, all participants with any positive AIMS score were considered to have tardive dyskinesia. In <a href="./references#CD008016-bbs2-0030" title="Beasley C Jr, HamiltonS , DossenbachM . Relapse prevention with olanzapine. European Neuropsychopharmacology2000;10(Suppl 3):S304. [CSZG: 4620]BeasleyCM , HamiltonSH , DossenbachM . Relapse prevention with olanzapine. Schizophrenia Research2000;41(1):196-7. [CSZG: 4874]BeasleyCM , SuttonVK , HamiltonSH , WalkerDJ , DossenbachM , TaylorCC , et al. A double-blind, randomised, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. Journal of Clinical Psychopharmacology2003;23:582-94. [CSZG: 10010]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD , PickarD . Does maintenance treatment with atypical antipsychotics worsen quality of life among stable patients with schizophrenia?Neuropsychopharmacology2005;30(S1):S189. [CSZG: 13107]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD . Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?Journal of Clinical Psychopharmacology2006;26:40-4. [CSZG: 14454]BeasleyCM , WalkerDJ , SuttonVK , AlakaK , NaberD , NamjoshiM . The effectiveness of olanzapine versus placebo in maintaining the quality of life in stabilized patients with schizophrenia. European Neuropsychopharmacology2003;13:S342. [CSZG: 9849]EliLilly Company. Olanzapine relapse prevention versus placebo in the treatment of schizophrenia. http://www.Clinicalstudyresults.org/.2005. [CSZG: 18733]">Olanzapine 2003</a>, the cut‐off was 3 or more on any item, or 2 or more on any two of the items. In <a href="./references#CD008016-bbs2-0014" title="GelenbergAJ , DollerJC , SchoolerNR , MieskeM , SevereJ , MandelMR . Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate. American Journal of Psychiatry1979;136:217-9. [CSZG: 3961]LevineJ , SchoolerNR , SevereJ , EscobarJ , GelenbergA , MandelM , et al. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study. Advances in Biochemical Psychopharmacology1980;24:483-93. [CSZG: 1683]MandelMR , SevereJB , SchoolerNR , GelenbergAJ , MieskeM . Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics. Archives of General Psychiatry1982;39:197-203. [CSZG: 3962]SchoolerNR , LevineJ , NIMH-PRB Collaborative Fluphenazine Study Group. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine. Pharmacopsychiatry1976;9:159-69. [CSZG: 3964]SchoolerNR , LevineJ , SevereJB , BrauzerB , DiMascioA , KlermanGL , et al. Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate. Archives of General Psychiatry1980;37:16-24. [CSZG: 3965]SchoolerNR , LevineJ , SevereJB . Depot fluphenazine in the prevention of relapse in schizophrenia: evaluation of a treatment regimen. Psychopharmacology Bulletin1979;15:44-7. [CSZG: 2521]SchoolerNR , LevineJ . Dosage and side effect comparisons between oral and depot fluphenazine. Psychopharmacology Bulletin1977;13:29-31. ">Fluphenazine 1980</a> the cut‐off was any item rated 2. In <a href="./references#CD008016-bbs2-0048" title="ChenE , HuiC , ChangWC , ChanS , LeeE , HonerW . The effect of early medication discontinuation on long-term clinical outcome in first episode psychosis. Schizophrenia Bulletin2018;44(Suppl 1):S97. ChenE , HuiC , LamM , LawC , ChiuC , ChungD , et al. Assessing the efficacy of relapse prevention in single episode psychosis patients with stable maintenance treatment for at least 1 year: a double-blind randomized placebo-controlled. Early Intervention in Psychiatry2008;2(Suppl 1):A5. [CSZG: 19113]ChenEY , HuiCL , LamM , LawCW , ChiuCP , ChungDW , et al. A double-blind randomised placebo-controlled study of relapse prevention in remitted first-episode psychosis patients following one year of maintenance therapy. Schizophrenia Research2008;98:11-2. [CSZG: 16325]ChenEY , HuiCL , LamM , LawCW , ChiuCP , ChungDW , et al. A double-blind randomized placebo-controlled relapse prevention study in remitted first-episode psychosis patients following one year of maintenance treatment. Early Intervention in Psychiatry2010;4(Suppl 1):13. [CSZG: 23475]ChenEY , HuiCL , LamMM , ChiuCP , LawCW , ChungDW , et al. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ2010;341:c4024. [CSZG: 20857]ChenYH , HuiLM , LamM , LawCW , ChiuPY , ChungWS , et al. A double-blind randomized placebo-controlled relapse prevention study in remitted first-episode psychosis patients following one year of maintanence therapy. European Psychiatry2008;23:S107-S8. [CSZG: 20468]Hui CL , WongGH , TangJY , ChangWC , ChanSK , LeeEH , et al. Predicting 1-year risk for relapse in patients who have discontinued or continued quetiapine after remission from first-episode psychosis. Schizophrenia Research2013;150(1):297-302. [CSZG: 28601]HuiC , ChenE , LamM , LawC , ChiuC , ChungD , et al. Can we predict relapse in single episode psychosis patients with stable maintenance treatment for at least one year?Early Intervention in Psychiatry2008;2(Suppl 1):A124. [CSZG: 19123]HuiCL , ChenEY , LamM , LawCW , ChiuCP , ChungDW , et al. Predictors for relapse in a double-blind randomized placebo-controlled discontinuation study of remitted first-episode psychosis patients. Schizophrenia Research2008;98:13. [CSZG: 16333]HuiCL , HonerW , LeeE , ChanS , ChangWC , ChenE . The 10-year clinical outcome of early medication discontinuation in remitted first episode psychosis. Early Intervention in Psychiatry2018;12(1):46. HuiCL , HonerWG , LeeEH , ChangWC , ChanSK , ChenES , et al. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. Lancet Psychiatry 2018 May;5(5):432-42. [CSZG: 38003]HuiCL , HonerWG , LeeEH , ChangWC , ChanSK , ChenES , et al. Predicting first-episode psychosis patients who will never relapse over 10 years. Psychological Medicine2019;49(13):2206-14. HuiCL , HonerWG , LeeEH , ChangWC , ChanSK , ChenEY . Factors associated with successful medication discontinuation after a randomized clinical trial of relapse prevention in first-episode psychosis: a 10-year follow-up. JAMA Psychiatry2019;76(2):217-9. HuiCL , LiYK , LiAW , LeeEH , ChangWC , ChanSK , et al. Visual working memory deterioration preceding relapse in psychosis. Psychological Medicine2016;46:2435-44. [CSZG: 33663]HuiLM , ChenYH , LamM , LawCW , ChiuPY , ChungWS , et al. A double-blind randomized placebo-controlled study of relapse predictors in remitted first-episode psychosis patients. European Psychiatry2008;23:S120-S1. [CSZG: 20469]NCT00334035. Duration of maintenance anti-psychotic therapy after first –episode schizophrenia: a double-blind randomized placebo-control relapse prevention study. https://www.ClinicalTrials.gov/ct/show/2006. [CSZG: 14607]">Quetiapine 2010</a>, the cut‐off was 2 or more on the global severity item. </p> <p>7.4.1.2 Barnes Akathisia Scale (BAS) (<a href="./references#CD008016-bbs2-0175" title="BarnesTR . A rating scale for drug-induced akathisia. British Journal of Psychiatry1989;154:672-6.">Barnes 1989</a>)<br/>The scale comprises items rating the observable, restless movements that characterise akathisia, a subjective awareness of restlessness, and any distress associated with the condition. These items are rated from 0 (normal) to 3 (severe). In addition, there is an item for rating global severity (from 0 (absent) to 5 (severe)). A low score indicates low levels of akathisia. In <a href="./references#CD008016-bbs2-0030" title="Beasley C Jr, HamiltonS , DossenbachM . Relapse prevention with olanzapine. European Neuropsychopharmacology2000;10(Suppl 3):S304. [CSZG: 4620]BeasleyCM , HamiltonSH , DossenbachM . Relapse prevention with olanzapine. Schizophrenia Research2000;41(1):196-7. [CSZG: 4874]BeasleyCM , SuttonVK , HamiltonSH , WalkerDJ , DossenbachM , TaylorCC , et al. A double-blind, randomised, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. Journal of Clinical Psychopharmacology2003;23:582-94. [CSZG: 10010]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD , PickarD . Does maintenance treatment with atypical antipsychotics worsen quality of life among stable patients with schizophrenia?Neuropsychopharmacology2005;30(S1):S189. [CSZG: 13107]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD . Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?Journal of Clinical Psychopharmacology2006;26:40-4. [CSZG: 14454]BeasleyCM , WalkerDJ , SuttonVK , AlakaK , NaberD , NamjoshiM . The effectiveness of olanzapine versus placebo in maintaining the quality of life in stabilized patients with schizophrenia. European Neuropsychopharmacology2003;13:S342. [CSZG: 9849]EliLilly Company. Olanzapine relapse prevention versus placebo in the treatment of schizophrenia. http://www.Clinicalstudyresults.org/.2005. [CSZG: 18733]">Olanzapine 2003</a> all participants with a BAS score of 2 or more were considered to have akathisia. In <a href="./references#CD008016-bbs2-0048" title="ChenE , HuiC , ChangWC , ChanS , LeeE , HonerW . The effect of early medication discontinuation on long-term clinical outcome in first episode psychosis. Schizophrenia Bulletin2018;44(Suppl 1):S97. ChenE , HuiC , LamM , LawC , ChiuC , ChungD , et al. Assessing the efficacy of relapse prevention in single episode psychosis patients with stable maintenance treatment for at least 1 year: a double-blind randomized placebo-controlled. Early Intervention in Psychiatry2008;2(Suppl 1):A5. [CSZG: 19113]ChenEY , HuiCL , LamM , LawCW , ChiuCP , ChungDW , et al. A double-blind randomised placebo-controlled study of relapse prevention in remitted first-episode psychosis patients following one year of maintenance therapy. Schizophrenia Research2008;98:11-2. [CSZG: 16325]ChenEY , HuiCL , LamM , LawCW , ChiuCP , ChungDW , et al. A double-blind randomized placebo-controlled relapse prevention study in remitted first-episode psychosis patients following one year of maintenance treatment. Early Intervention in Psychiatry2010;4(Suppl 1):13. [CSZG: 23475]ChenEY , HuiCL , LamMM , ChiuCP , LawCW , ChungDW , et al. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ2010;341:c4024. [CSZG: 20857]ChenYH , HuiLM , LamM , LawCW , ChiuPY , ChungWS , et al. A double-blind randomized placebo-controlled relapse prevention study in remitted first-episode psychosis patients following one year of maintanence therapy. European Psychiatry2008;23:S107-S8. [CSZG: 20468]Hui CL , WongGH , TangJY , ChangWC , ChanSK , LeeEH , et al. Predicting 1-year risk for relapse in patients who have discontinued or continued quetiapine after remission from first-episode psychosis. Schizophrenia Research2013;150(1):297-302. [CSZG: 28601]HuiC , ChenE , LamM , LawC , ChiuC , ChungD , et al. Can we predict relapse in single episode psychosis patients with stable maintenance treatment for at least one year?Early Intervention in Psychiatry2008;2(Suppl 1):A124. [CSZG: 19123]HuiCL , ChenEY , LamM , LawCW , ChiuCP , ChungDW , et al. Predictors for relapse in a double-blind randomized placebo-controlled discontinuation study of remitted first-episode psychosis patients. Schizophrenia Research2008;98:13. [CSZG: 16333]HuiCL , HonerW , LeeE , ChanS , ChangWC , ChenE . The 10-year clinical outcome of early medication discontinuation in remitted first episode psychosis. Early Intervention in Psychiatry2018;12(1):46. HuiCL , HonerWG , LeeEH , ChangWC , ChanSK , ChenES , et al. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. Lancet Psychiatry 2018 May;5(5):432-42. [CSZG: 38003]HuiCL , HonerWG , LeeEH , ChangWC , ChanSK , ChenES , et al. Predicting first-episode psychosis patients who will never relapse over 10 years. Psychological Medicine2019;49(13):2206-14. HuiCL , HonerWG , LeeEH , ChangWC , ChanSK , ChenEY . Factors associated with successful medication discontinuation after a randomized clinical trial of relapse prevention in first-episode psychosis: a 10-year follow-up. JAMA Psychiatry2019;76(2):217-9. HuiCL , LiYK , LiAW , LeeEH , ChangWC , ChanSK , et al. Visual working memory deterioration preceding relapse in psychosis. Psychological Medicine2016;46:2435-44. [CSZG: 33663]HuiLM , ChenYH , LamM , LawCW , ChiuPY , ChungWS , et al. A double-blind randomized placebo-controlled study of relapse predictors in remitted first-episode psychosis patients. European Psychiatry2008;23:S120-S1. [CSZG: 20469]NCT00334035. Duration of maintenance anti-psychotic therapy after first –episode schizophrenia: a double-blind randomized placebo-control relapse prevention study. https://www.ClinicalTrials.gov/ct/show/2006. [CSZG: 14607]">Quetiapine 2010</a> the cut‐off was 2 or more on the global severity item. </p> <p>7.4.1.3 Simpson‐Angus Scale (SAS) (<a href="./references#CD008016-bbs2-0237" title="SimpsonEN , AngusJW . A rating scale for extrapyramidal side-effects. Acta Psychiatrica Scandinavica Supplementum1970;212:11-9.">Simpson 1970</a>)<br/>The 10‐item scale, with a scoring system of 0 to 4 for each item, measures drug‐induced parkinsonism, a short‐term drug‐induced movement disorder. A low score indicates low levels of parkinsonism. In <a href="./references#CD008016-bbs2-0030" title="Beasley C Jr, HamiltonS , DossenbachM . Relapse prevention with olanzapine. European Neuropsychopharmacology2000;10(Suppl 3):S304. [CSZG: 4620]BeasleyCM , HamiltonSH , DossenbachM . Relapse prevention with olanzapine. Schizophrenia Research2000;41(1):196-7. [CSZG: 4874]BeasleyCM , SuttonVK , HamiltonSH , WalkerDJ , DossenbachM , TaylorCC , et al. A double-blind, randomised, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. Journal of Clinical Psychopharmacology2003;23:582-94. [CSZG: 10010]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD , PickarD . Does maintenance treatment with atypical antipsychotics worsen quality of life among stable patients with schizophrenia?Neuropsychopharmacology2005;30(S1):S189. [CSZG: 13107]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD . Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?Journal of Clinical Psychopharmacology2006;26:40-4. [CSZG: 14454]BeasleyCM , WalkerDJ , SuttonVK , AlakaK , NaberD , NamjoshiM . The effectiveness of olanzapine versus placebo in maintaining the quality of life in stabilized patients with schizophrenia. European Neuropsychopharmacology2003;13:S342. [CSZG: 9849]EliLilly Company. Olanzapine relapse prevention versus placebo in the treatment of schizophrenia. http://www.Clinicalstudyresults.org/.2005. [CSZG: 18733]">Olanzapine 2003</a> all participants with a SAS score of 4 or more were considered to have parkinsonism. In <a href="./references#CD008016-bbs2-0048" title="ChenE , HuiC , ChangWC , ChanS , LeeE , HonerW . The effect of early medication discontinuation on long-term clinical outcome in first episode psychosis. Schizophrenia Bulletin2018;44(Suppl 1):S97. ChenE , HuiC , LamM , LawC , ChiuC , ChungD , et al. Assessing the efficacy of relapse prevention in single episode psychosis patients with stable maintenance treatment for at least 1 year: a double-blind randomized placebo-controlled. Early Intervention in Psychiatry2008;2(Suppl 1):A5. [CSZG: 19113]ChenEY , HuiCL , LamM , LawCW , ChiuCP , ChungDW , et al. A double-blind randomised placebo-controlled study of relapse prevention in remitted first-episode psychosis patients following one year of maintenance therapy. Schizophrenia Research2008;98:11-2. [CSZG: 16325]ChenEY , HuiCL , LamM , LawCW , ChiuCP , ChungDW , et al. A double-blind randomized placebo-controlled relapse prevention study in remitted first-episode psychosis patients following one year of maintenance treatment. Early Intervention in Psychiatry2010;4(Suppl 1):13. [CSZG: 23475]ChenEY , HuiCL , LamMM , ChiuCP , LawCW , ChungDW , et al. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ2010;341:c4024. [CSZG: 20857]ChenYH , HuiLM , LamM , LawCW , ChiuPY , ChungWS , et al. A double-blind randomized placebo-controlled relapse prevention study in remitted first-episode psychosis patients following one year of maintanence therapy. European Psychiatry2008;23:S107-S8. [CSZG: 20468]Hui CL , WongGH , TangJY , ChangWC , ChanSK , LeeEH , et al. Predicting 1-year risk for relapse in patients who have discontinued or continued quetiapine after remission from first-episode psychosis. Schizophrenia Research2013;150(1):297-302. [CSZG: 28601]HuiC , ChenE , LamM , LawC , ChiuC , ChungD , et al. Can we predict relapse in single episode psychosis patients with stable maintenance treatment for at least one year?Early Intervention in Psychiatry2008;2(Suppl 1):A124. [CSZG: 19123]HuiCL , ChenEY , LamM , LawCW , ChiuCP , ChungDW , et al. Predictors for relapse in a double-blind randomized placebo-controlled discontinuation study of remitted first-episode psychosis patients. Schizophrenia Research2008;98:13. [CSZG: 16333]HuiCL , HonerW , LeeE , ChanS , ChangWC , ChenE . The 10-year clinical outcome of early medication discontinuation in remitted first episode psychosis. Early Intervention in Psychiatry2018;12(1):46. HuiCL , HonerWG , LeeEH , ChangWC , ChanSK , ChenES , et al. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. Lancet Psychiatry 2018 May;5(5):432-42. [CSZG: 38003]HuiCL , HonerWG , LeeEH , ChangWC , ChanSK , ChenES , et al. Predicting first-episode psychosis patients who will never relapse over 10 years. Psychological Medicine2019;49(13):2206-14. HuiCL , HonerWG , LeeEH , ChangWC , ChanSK , ChenEY . Factors associated with successful medication discontinuation after a randomized clinical trial of relapse prevention in first-episode psychosis: a 10-year follow-up. JAMA Psychiatry2019;76(2):217-9. HuiCL , LiYK , LiAW , LeeEH , ChangWC , ChanSK , et al. Visual working memory deterioration preceding relapse in psychosis. Psychological Medicine2016;46:2435-44. [CSZG: 33663]HuiLM , ChenYH , LamM , LawCW , ChiuPY , ChungWS , et al. A double-blind randomized placebo-controlled study of relapse predictors in remitted first-episode psychosis patients. European Psychiatry2008;23:S120-S1. [CSZG: 20469]NCT00334035. Duration of maintenance anti-psychotic therapy after first –episode schizophrenia: a double-blind randomized placebo-control relapse prevention study. https://www.ClinicalTrials.gov/ct/show/2006. [CSZG: 14607]">Quetiapine 2010</a> the cut‐off was 1 or more on the mean SAS score. </p> <p><i>7.4.2 Satisfaction with care scales</i> </p> <p>7.4.2.1 Participant Satisfaction with Medication Questionnaire ‐ Modified (PSMQ‐M) (<a href="./references#CD008016-bbs2-0202" title="KalaliA . Patient satisfaction with, and acceptability of, atypical antipsychotics. Current Medical Research and Opinion1999;15:135-7.">Kalali 1999</a>) </p> <p>This self‐administered instrument consists of a 4‐part list of items rated according to 6‐point Likert scales, and measures the patient's satisfaction with current medication (ranging from "extremely satisfied" to "extremely unsatisfied") and the side effects burden (ranging from "no side effects" to "much more side effects"), with respect to previous antipsychotic medications. At the end, the patient is asked to state his preference for "current" versus "previous" medication. This instrument was applied in <a href="./references#CD008016-bbs2-0003" title="BakerR , FleischhackerW , SanchezR , PerryP , JinN , JohnsonB , et al. Long-term safety and tolerability of once-monthly aripiprazole intramuscular depot for maintenance treatment in schizophrenia. International Journal of Neuropsychopharmacology2012;15:111. [CSZG: 28035]BakerRA , CarsonWH , PerryPP , SanchezR , ZhaoJ , McQuadeRD , et al. Effects of aripiprazole once-monthly vs placebo on domains of personal and social performance in younger and older patients with schizophrenia. CNS Spectrums2013;18(6):376-7. [CSZG: 28526]BakerRA , EramoA , CarsonWH , PerryP , SanchezR , ZhaoJ , et al. Effects of aripiprazole once-monthly vs. placebo on domains of personal and social performance in younger and older patients with schizophrenia. Schizophrenia Bulletin2013;39(Suppl 1):S321-S322. [CSZG: 28131]BakerRA , EramoA , NylanderAG , TsaiLF , Peters-StricklandTS , KosticD , et al. The effect of previous dose or oral aripiprazole (10 or 30 mg/day) on the efficacy and tolerability of aripiprazole once-monthly: Results from post-hoc analyses from two double-blind, randomized, controlled trials. Schizophrenia Research2014;153:S293. [CSZG: 29386]CarsonWH , PerryPP , SanchezR , JinN , ForbesRA , McQuadeRD , et al. Effects of ARI-IM-depot on secondary efficacy outcomes in maintenance treatment of schizophrenia. International Journal of Neuropsychopharmacology2012;15:112-3. [CSZG: 28030]EramoA , FleischhackerWW , SanchezR , PerryP , JinN , JohnsonB , et al. A placebo-controlled study of efficacy and safety of aripiprazole oncemonthly for long-term maintenance treatment in schizophrenia. European Psychiatry2013;28(1):1. [CSZG: 28187]EramoA , FleischhackerWW , SanchezR , TsaiLF , Peters-StricklandTS , BakerRA , et al. All-cause discontinuation and safety of aripiprazole once-monthly for the treatment of schizophrenia: A pooled analysis of two double-blind, randomized, controlled trials. Schizophrenia Research2014;153:S174. [CSZG: 29437]FleischhackerWW , BakerRA , EramoA , SanchezR , TsaiLF , Peters-StricklandT , et al. Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies. Schizophrenia Research2014;159(2-3):415-20. [CSZG: 32163]FleischhackerWW , PerryP , SanchezR , JinN , Peters-StricklandT , JohnsonB , et al. Functional outcomes with aripiprazole once-monthly in two double-blind, placebo- and active-controlled studies (aspire us 246 and aspire eu 247) for the treatment of schizophrenia. Value in Health2013;16(7):A550. [CSZG: 28480]FleischhackerWW , SanchezR , JohnsonB , JinN , ForbesRA , McQuadeR , et al. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. International Clinical Psychopharmacology2013;28:171-6. [CSZG: 28391]FleischhackerWW , SanchezR , Lan-FengT , Peters-StricklandT , BakerRA , EramoA , et al. Safety and Effectiveness of Aripiprazole Oncemonthly for the Treatment of Schizophrenia: A Pooled Analysis of Two Double-blind, Randomized, Controlled Trials. Neuropsychopharmacology2013;38:S394-S395. [CSZG: 28459]KaneJM , SanchezR , BakerRA , EramoA , Peters-StricklandT , PerryPP , et al. Patient-centered outcomes with aripiprazole once-monthly for maintenance treatment in patients with schizophrenia: Results from two multicenter, randomized, double-blind studies. Clinical Schizophrenia and Related Psychoses2015;9(2):79-87. [CSZG: 32183]KaneJM , SanchezR , PerryPP , JinN , JohnsonB , ForbesRA , et al. Efficacy of aripiprazole-IM-depot for long-term maintenance treatment of schizophrenia. International Journal of Neuropsychopharmacology2012;15:S119. [CSZG: 28033]KaneJM , SanchezR , PerryPP , JinN , JohnsonBR , ForbesRA , et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: A 52-week, multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2012;73(5):617-24. [CSZG: 24369]LozeJ , CarsonWH , PerryPP , SanchezR , JinN , ForbesRA , et al. Psychosocial and overall effectiveness of aripiprazole intramuscular depot vs. placebo for maintenance treatment in schizophrenia. European Neuropsychopharmacology2012;22:S328. [CSZG: 24886]NCT00705783. Aripiprazole (OPC-14597) as maintenance treatment in patients with schizophrenia. https://www.ClinicalTrials.gov/ct/show/2008. [CSZG: 16546]SanchezR , JohnsonB , JinN , ForbesRA , CarsonWH , McQuadeRD , et al. Patient-reported outcomes (PROs) with aripiprazole intramuscular depot (ARI-IMD) for maintenance treatment in schizophrenia. International Journal of Neuropsychopharmacology2012;15:133. [CSZG: 28040]SanchezR , PerryPP , JinN , Johnson, RA Forbes, RD McQuade, WH, et al. A placebo-controlled study of efficacy/ safety of aripiprazole intramuscular depot for long-term maintenance treatment of schizophrenia. European Neuropsychopharmacology2012;(Suppl 2):S327. [CSZG: 24893]">Aripiprazole depot 2012</a>. The proportion of participants defined by the study authors as "at least very satisfied" was taken into the analysis for the present review. </p> <p>7.4.2.2 Medication Satisfaction Questionnaire (MSQ) (<a href="./references#CD008016-bbs2-0242" title="VernonMK , RevickiDA , AwadG , DiraniR , PanishJ , CanusoCM , et al. Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients. Schizophrenia Research2010;118(1-3):271-8.">Vernon 2010</a>) </p> <p>The instrument consists of a single question, read aloud by the clinician to the patient ("Overall, how satisfied are you with your current antipsychotic medication"). The answer has to be given according to a 7‐point Likert scale, ranging from 1 ("extremely dissatisfied") to 7 ("extremely satisfied). A 1‐point change over time may be considered as clinically meaningful. The proportion of participants defined as "satisfied with medication" according to this instrument was entered into the analysis for the current review, This scale was applied in <a href="./references#CD008016-bbs2-0034" title="BossieC , TurkozI , AlphsL , FuDJ . Monotherapy with once monthly paliperidone palmitate for psychotic, depressive, and manic symptoms in schizoaffective disorder. Schizophrenia Bulletin2015;41:S303. [CSZG: 29400]BossieCA , TurkozI , AlphsL , MahalchickL , FuDJ . Paliperidone palmitate once-monthly treatment in recent onset and chronic illness patients with schizoaffective disorder. Journal of Nervous and Mental Ddisease2017;205(4):324-8. [CSZG: 35417]FuDJ , AlphsL , LindenmayerJP , SchoolerN , SimonsonRB , TurkozI , et al. Paliperidone palmitate long-acting injectable delays psychotic and mood symptom relapse in schizoaffective disorder. European Neuropsychopharmacology2014;24:S534-5. [CSZG: 27785]FuDJ , BossieC , TurkozI , MahalchickL , AlphsL . Paliperidone palmitate treatment response in early and chronic illness schizoaffective disorder patients. Schizophrenia Bulletin2015;41:S312. [CSZG: 29446]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Effect of paliperidone palmitate once-monthly in improving and maintaining functioning in subjects with schizoaffective disorder using the domains of the personal and social performance scale. Neuropsychopharmacology2014;39:S365. [CSZG: 29278]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate delays relapse in patients with schizoaffective disorder. Biological Psychiatry2014;1:263S. [CSZG: 28974]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate long-acting injectable in acute exacerbation of schizoaffective disorder. Schizophrenia Bulletin2013;39:S331. [CSZG: 28167]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate once-monthly injectable treatment for acute exacerbations of schizoaffective disorder. Journal of Clinical Psychopharmacology2016;36(4):372-6. [CSZG: 35803]FuDJ , TurkozI , SimonsonRB , WallingDP , SchoolerNR , LindenmayerJP , et al. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. Journal of Clinical Psychiatry2015;76(3):253-62. [CSZG: 29752]FuDJ , TurkozI , WallingD , LindenmayerJP , SchoolerNR , AlphsL . Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder. Schizophrenia Research2018;192:185-93. [CSZG: 35804]JoshiK , LinJ , Lingohr-SmithM , FuD . Medical cost reductions for paliperidone palmitate versus placebo in randomized double-blind trial of patients with schizoaffective disorder. Journal of Managed Care and Specialty Pharmacy2015;21:536-7. JoshiK , LinJ , Lingohr-SmithM , FuDJ . Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder. Journal of Medical Economics2015;18:629-36. [CSZG: 33677]NCT01193153. A study to evaluate the efficacy of paliperidone palmitate in the prevention of relapse of the symptoms of schizoaffective disorder. http://ClinicalTrials.gov/show/NCT011931532010. [CSZG: 21094]TurkozI , FuDJ , WallingD , SchoolerNR , LindenmayerJP , SimonsonRB , et al. Effect of paliperidone palmitate once-monthly in improving and maintaining functioning in subjects with schizoaffective disorder using the domains of the personal and social performance scale. Schizophrenia Bulletin2015;41:S193-4. [CSZG: 29687]">Paliperidone depot1M 2015</a>. </p> </section> <section id="CD008016-sec-0101"> <p><b>7.4.3 Quality of life scales</b></p> <p>7.4.3.1 Heinrichs‐Carpenter Quality of Life Scale (QLS) (<a href="./references#CD008016-bbs2-0182" title="CarpenterWT , BuchananRW . Schizophrenia. New England Journal of Medicine1994;330:681-90.">Carpenter 1994</a>)<br/>This semi‐structured interview is administered and rated by trained clinicians. It contains 21 items rated on a 7‐point scale based on the interviewer's judgement of patient functioning. A total quality‐of‐life score and four subscale scores are calculated, with higher scores indicating less impairment. This scale was applied in <a href="./references#CD008016-bbs2-0030" title="Beasley C Jr, HamiltonS , DossenbachM . Relapse prevention with olanzapine. European Neuropsychopharmacology2000;10(Suppl 3):S304. [CSZG: 4620]BeasleyCM , HamiltonSH , DossenbachM . Relapse prevention with olanzapine. Schizophrenia Research2000;41(1):196-7. [CSZG: 4874]BeasleyCM , SuttonVK , HamiltonSH , WalkerDJ , DossenbachM , TaylorCC , et al. A double-blind, randomised, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. Journal of Clinical Psychopharmacology2003;23:582-94. [CSZG: 10010]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD , PickarD . Does maintenance treatment with atypical antipsychotics worsen quality of life among stable patients with schizophrenia?Neuropsychopharmacology2005;30(S1):S189. [CSZG: 13107]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD . Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?Journal of Clinical Psychopharmacology2006;26:40-4. [CSZG: 14454]BeasleyCM , WalkerDJ , SuttonVK , AlakaK , NaberD , NamjoshiM . The effectiveness of olanzapine versus placebo in maintaining the quality of life in stabilized patients with schizophrenia. European Neuropsychopharmacology2003;13:S342. [CSZG: 9849]EliLilly Company. Olanzapine relapse prevention versus placebo in the treatment of schizophrenia. http://www.Clinicalstudyresults.org/.2005. [CSZG: 18733]">Olanzapine 2003</a>. </p> <p>7.4.3.2 Symptom Questionnaire of Kellner and Sheffield (SQKS) (<a href="./references#CD008016-bbs2-0205" title="KellnerR , SheffieldBF . A self-rating scale of distress. Psychological Medicine1973;3:88-100.">Kellner 1973</a>) </p> <p>The 30‐item self‐completion questionnaire measures subjective well‐being. A total score and four subscale scores are obtainable from the questionnaire. This instrument was applied in <a href="./references#CD008016-bbs2-0064" title="CheungHK . Schizophrenics fully remitted on neuroleptics for 3-5 years - to stop or continue drugs?British Journal of Psychiatry1981;138:490-4. [CSZG: 460]">Various drugs 1981b</a>. </p> <p>7.4.3.3 Self‐report Quality of Life Scale (SQLS) (<a href="./references#CD008016-bbs2-0248" title="WilkinsonG , HesdonB , WildD , CooksonR , FarinaC , SharmaV , et al. Self-report quality of life measure for people with schizophrenia: the SQLS. British Journal of Psychiatry2000;177:42-6.">Wilkinson 2000</a>)<br/>The scale is a self‐administered rating scale that includes 33 items concerning the patient's symptoms and well‐being over the preceding seven days, on a scale from 0 (never) to 4 (always). Total scores range from 0 to 100, with low scores representing a better outcome. Results based on this rating scale were found in <a href="./references#CD008016-bbs2-0031" title="Eerdekens. Evaluate the efficacy in the prevention of recurrence of the symptoms of schizophrenia. Sponsor: Johnson &amp; Johnson Pharmaceutical Research &amp; Development, LL.C2010. [CTG: NCT00111189]KramerM , KushnerS , SherrJ , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study. Schizophrenia Bulletin2007;33(2):438. [CSZG: 15185]KramerM , KushnerS , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia treated with paliperidone extended-release tablets. European Neuropsychopharmacology2006;16(Suppl 4):S386. [CSZG: 13313]KramerM , KushnerS , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study. International Journal of Neuropsychopharmacology2006;9(Suppl 1):S274. [CSZG: 19545]KramerM , SimpsonG , MaciulisV , KushnerS , LiuY , LimP , et al. One-year open-label safety and efficacy study of paliperidone extended-release. CNS Spectrums2010;15(8):506-14. [CSZG: 20885]KramerM , SimpsonG , MaciulisV , KushnerS , VijapurkarU , LimP , et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2007;27:6-14. [CSZG: 13907]MarkowitzM , FuDJ , LevitanB , GopalS , TurkozI , AlphsL . Long-acting injectable paliperidone palmitate versus oral paliperidone extended release. Annals of General Psychiatry2013;12:22. [CSZG: 28633]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone 2007</a> and <a href="./references#CD008016-bbs2-0033" title="AlphsL , BossieC , Kern-SliwaJ , Ma Y-W, HaskinsJT . Paliperidone palmitate: clinical response in subjects with schizophrenia with recent vs. longer-term duration of illness. In: Proceedings of the 162nd Annual Meeting of the American Psychiatric Association. San Francisco, CA., 2009 May 16-21. [CSZG: 19067]EmsleyR , NuamahI , GopalS , HoughD , FleischhackerWW . Relapse after antipsychotic discontinuation in schizophrenia as a withdrawal phenomenon vs illness recurrence: a post hoc analysis of a randomized placebo-controlled study. Journal of Clinical Psychiatry 2018 Jun;79(4):17m11874. [CSZG: 38184]EmsleyR , NuamahI , HoughD , GopalS . Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophrenia Research2012;138(1):29-34. [CSZG: 24214]GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM , HoughD . A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. Journal of Psychopharmacology2011;25(5):685-97. [CSZG: 22903]GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Long-term efficacy, safety and tolerability of paliperidone palmitate in patients with schizophrenia. In: Proceedings of the 162nd Annual Meeting of the American Psychiatric Association. San Francisco, CA, 2009 May 16-21. [CSZG: 19076]HoughD , GopalS , VijapukarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate in prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. In: Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8, Washington DC, USA. 2008. [CSZG: 16486]HoughD , GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. In: Proceedings of the 63rd Annual Convention of the Society of Biological Psychiatry. Washington, DC, USA: Elsevier Science Inc, 2008:S285-6. [CSZG: 20281]HoughD , GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Biological Psychiatry2008;63(7 Suppl):285S-6S. [CSZG: 19530]HoughD , GopalS , VjapukarU , LimP , MorozowaM , EerdekensM . Paliperidone palmitate maintenance treatment in delaying the time to relapse in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. Schizophrenia Research2010;116:107-17. [CSZG: 19704]HulihanJ , BossieCA , FuDJ , Kern SliwaJ , Ma Y-W, AlphsLD . Remission with continued paliperidone palmitate treatment in stable subjects with schizophrenia. Schizophrenia Research2012;136:S252. [CSZG: 29467]KozmaCM , SlatonT , DiraniR , FastenauJ , GopalS , HoughD . Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate. Current Medical Resarch and Opinion2011;27(8):1603-11. SliwaJK , BossieCA , Fu DJ, TurkozI , AlphsL . Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia. Neuropsychiatric Disease and Treatment2012;8:375-85. [CSZG: 28007]SliwaJK , FuDJ , BossieCA , et al. Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate. BMC Psychiatry2014;14:S52. [CSZG: 29148]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone depot1M 2010</a>. </p> <p>7.4.3.4 Schizophrenia Quality of Life (S‐QoL) (<a href="./references#CD008016-bbs2-0173" title="AuquierP , SimeoniMC , SapinC , ReineG , AghababianV , CramerJ , et al. Development and validation of a patient-based health-related quality of life questionnaire in schizophrenia: the S-QoL. Schizophrenia Research2003;63(1-2):137-49.">Auquier 2003</a>, <a href="./references#CD008016-bbs2-0180" title="BoyerL , SimeoniMC , LoundouA , D'AmatoT , ReineG , LanconC , et al. The development of the S-QoL 18: a shortened quality of life questionnaire for patients with schizophrenia. Schizophrenia Research2010;121:241-50.">Boyer 2010</a>) </p> <p>The scale is a self‐administered questionnaire to assess health‐related quality of life among people with schizophrenia, defined as the discrepancy between expectation and current life experience. The original version is composed of 41 items, and a shortened 18‐item version has been validated, with high degree of comparability with the original one. It is a multidimensional instrument with high reliability, validity and sensitivity to change. It evaluates 8 dimensions (psychological well‐being, self‐esteem, family relationships, relationships with friends, resilience, physical well‐being, autonomy and sentimental life). Each of the items is accompanied by a 5‐point Likert scale (1 = less than expected; 5 = more than expected, with the negatively worded item scores reversed). The score of each of the eight dimensions can be obtained by computing the mean of each item score within the dimension; by summing up every dimension score a total score is obtained. <a href="./references#CD008016-bbs2-0046" title="NCT00658645. A multinational, randomised, double-blind, fixed-dose, bifeprunox study combining a 12-week placebo-controlled, quetiapine-referenced phase with a 12-month quetiapine-controlled phase in patients with schizophrenia. https://www.clinicaltrials.gov/ct2/show/NCT00658645?term=NCT00658645&amp;rank=1. [CSZG: 16241]">Quetiapine 2009a</a> and <a href="./references#CD008016-bbs2-0047" title="NCT00704509. A multinational, randomised, double-blind, fixed-dose, bifeprunox study combining a 12-week placebo-controlled, quetiapine-referenced phase with a 12-month quetiapine-controlled phase in patients with schizophrenia. https://www.clinicaltrials.gov/ct2/show/NCT00704509?term=NCT00704509&amp;rank=1. [CSZG: 16566]">Quetiapine 2009b</a> applied this instrument. </p> <p>7.4.3.5 EuroQol 5 Dimension ‐ Visual Analog Scale (EQ‐5D VAS) (<a href="./references#CD008016-bbs2-0194" title="The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy1990;16(3):199-208.">EuroQol 1990</a>) </p> <p>The EQ‐5D is a self‐administered standardised measure of health status, applicable to a wide range of health conditions, and it is used to evaluate health care from a clinical and economic point of view, as well as in population health surveys. It consists of two parts: the EQ‐5D descriptive system and the EQ 20‐cm visual analogue scale (VAS). The first parts consists of one question in each of five dimensions (mobility, self‐care, pain, usual activities, and anxiety) with five possible response levels per question (level 1= no problem; level 5= extreme problems). The 20‐cm VAS has endpoints labelled "best imaginable health state" (anchored at 100) and "worst imaginable health state" (anchored at 0). Respondents are asked to indicate how they rate their own health by drawing a line from an anchor box to that point on the EQ‐VAS, which best represents their own health on a specified time period (usually that day). This instrument was used in <a href="./references#CD008016-bbs2-0028" title="NCT01435928. PEARL Schizophrenia Maintenance. http://ClinicalTrials.gov/show/NCT014359282011. [CSZG: 23439]TandonR , CucchiaroJ , PhillipsD , HernandezD , MaoY , PikalovA , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Journal of Psychopharmacology2016;30(1):69-77. [CSZG: 33434]TandonR , LoebelA , PhilipsD , PikalovA , Hernandez D MaoY , et al. Lurasidone for maintenance of efficacy in patients with schizophrenia. European Neuropsychopharmacology2014;24(Suppl 2):S559-560. [CSZG: 27840]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , CucchiaroJ . A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Schizophrenia Research2014;153(1):S372. [CSZG: 29681]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Int J Neuropsychopharmacol2014;17:S153-154. [CSZG: 29954]">Lurasidone 2016</a>. </p> <p><i>7.4.4 Social functioning scales</i> </p> <p>7.4.4.1 Personal and Social Performance (PSP) (<a href="./references#CD008016-bbs2-0223" title="MorosiniPL , MaglianoL , BrambillaL , UgoliniS , PioliR . Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatrica Scandinavica2000;101:323-9.">Morosini 2000</a>) </p> <p>The scale is a validated clinician‐reported instrument that has been widely used in clinical trials to assess personal and social functioning of patients with psychiatric disorders. It is based on four distinct domains: (a) socially useful activities, (b) personal and social relationships, (c) self‐care, (d) disturbing and aggressive behaviour. Each PSP domain is assessed on a 6‐point severity scale ranging from "absent" to "very severe" difficulties in the specified area. After each domain is scored, raters determine one total score by selecting a 10‐point range within a 100‐point scale based on the domain scores following PSP scoring guidelines. The higher the score, the better the functioning. A variation of eight points over time should be classified as clinically significant. This scale was applied in the studies <a href="./references#CD008016-bbs2-0003" title="BakerR , FleischhackerW , SanchezR , PerryP , JinN , JohnsonB , et al. Long-term safety and tolerability of once-monthly aripiprazole intramuscular depot for maintenance treatment in schizophrenia. International Journal of Neuropsychopharmacology2012;15:111. [CSZG: 28035]BakerRA , CarsonWH , PerryPP , SanchezR , ZhaoJ , McQuadeRD , et al. Effects of aripiprazole once-monthly vs placebo on domains of personal and social performance in younger and older patients with schizophrenia. CNS Spectrums2013;18(6):376-7. [CSZG: 28526]BakerRA , EramoA , CarsonWH , PerryP , SanchezR , ZhaoJ , et al. Effects of aripiprazole once-monthly vs. placebo on domains of personal and social performance in younger and older patients with schizophrenia. Schizophrenia Bulletin2013;39(Suppl 1):S321-S322. [CSZG: 28131]BakerRA , EramoA , NylanderAG , TsaiLF , Peters-StricklandTS , KosticD , et al. The effect of previous dose or oral aripiprazole (10 or 30 mg/day) on the efficacy and tolerability of aripiprazole once-monthly: Results from post-hoc analyses from two double-blind, randomized, controlled trials. Schizophrenia Research2014;153:S293. [CSZG: 29386]CarsonWH , PerryPP , SanchezR , JinN , ForbesRA , McQuadeRD , et al. Effects of ARI-IM-depot on secondary efficacy outcomes in maintenance treatment of schizophrenia. International Journal of Neuropsychopharmacology2012;15:112-3. [CSZG: 28030]EramoA , FleischhackerWW , SanchezR , PerryP , JinN , JohnsonB , et al. A placebo-controlled study of efficacy and safety of aripiprazole oncemonthly for long-term maintenance treatment in schizophrenia. European Psychiatry2013;28(1):1. [CSZG: 28187]EramoA , FleischhackerWW , SanchezR , TsaiLF , Peters-StricklandTS , BakerRA , et al. All-cause discontinuation and safety of aripiprazole once-monthly for the treatment of schizophrenia: A pooled analysis of two double-blind, randomized, controlled trials. Schizophrenia Research2014;153:S174. [CSZG: 29437]FleischhackerWW , BakerRA , EramoA , SanchezR , TsaiLF , Peters-StricklandT , et al. Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies. Schizophrenia Research2014;159(2-3):415-20. [CSZG: 32163]FleischhackerWW , PerryP , SanchezR , JinN , Peters-StricklandT , JohnsonB , et al. Functional outcomes with aripiprazole once-monthly in two double-blind, placebo- and active-controlled studies (aspire us 246 and aspire eu 247) for the treatment of schizophrenia. Value in Health2013;16(7):A550. [CSZG: 28480]FleischhackerWW , SanchezR , JohnsonB , JinN , ForbesRA , McQuadeR , et al. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. International Clinical Psychopharmacology2013;28:171-6. [CSZG: 28391]FleischhackerWW , SanchezR , Lan-FengT , Peters-StricklandT , BakerRA , EramoA , et al. Safety and Effectiveness of Aripiprazole Oncemonthly for the Treatment of Schizophrenia: A Pooled Analysis of Two Double-blind, Randomized, Controlled Trials. Neuropsychopharmacology2013;38:S394-S395. [CSZG: 28459]KaneJM , SanchezR , BakerRA , EramoA , Peters-StricklandT , PerryPP , et al. Patient-centered outcomes with aripiprazole once-monthly for maintenance treatment in patients with schizophrenia: Results from two multicenter, randomized, double-blind studies. Clinical Schizophrenia and Related Psychoses2015;9(2):79-87. [CSZG: 32183]KaneJM , SanchezR , PerryPP , JinN , JohnsonB , ForbesRA , et al. Efficacy of aripiprazole-IM-depot for long-term maintenance treatment of schizophrenia. International Journal of Neuropsychopharmacology2012;15:S119. [CSZG: 28033]KaneJM , SanchezR , PerryPP , JinN , JohnsonBR , ForbesRA , et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: A 52-week, multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2012;73(5):617-24. [CSZG: 24369]LozeJ , CarsonWH , PerryPP , SanchezR , JinN , ForbesRA , et al. Psychosocial and overall effectiveness of aripiprazole intramuscular depot vs. placebo for maintenance treatment in schizophrenia. European Neuropsychopharmacology2012;22:S328. [CSZG: 24886]NCT00705783. Aripiprazole (OPC-14597) as maintenance treatment in patients with schizophrenia. https://www.ClinicalTrials.gov/ct/show/2008. [CSZG: 16546]SanchezR , JohnsonB , JinN , ForbesRA , CarsonWH , McQuadeRD , et al. Patient-reported outcomes (PROs) with aripiprazole intramuscular depot (ARI-IMD) for maintenance treatment in schizophrenia. International Journal of Neuropsychopharmacology2012;15:133. [CSZG: 28040]SanchezR , PerryPP , JinN , Johnson, RA Forbes, RD McQuade, WH, et al. A placebo-controlled study of efficacy/ safety of aripiprazole intramuscular depot for long-term maintenance treatment of schizophrenia. European Neuropsychopharmacology2012;(Suppl 2):S327. [CSZG: 24893]">Aripiprazole depot 2012</a>, <a href="./references#CD008016-bbs2-0005" title="BakerR , HobartM , ForbesA , OuyangJ , WeillerE . Effect of brexpiprazole on long-term functioning in adults with schizophrenia. Australian and New Zealand Journal of Psychiatry2017;51(Suppl 1):148. [CSZG: 35955]CorrellCU , ShiL , WeissC , HobartM , EramoA , DuffyRA , et al. Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice of cross-titration schedules in a post-hoc analysis of a randomized double-blind maintenance treatment study. CNS Spectrums2019;24(5):507-17. FleischhackerWW , HobartM , OuyangJ , ForbesA , PfisterS , McQuadeR , et al. Brexpiprazole (OPC-34712) efficacy and safety as maintenance therapy in adults with schizophrenia: Randomised, double-blind, placebo-controlled study. European Neuropsychopharmacology2015;25:S527. [CSZG: 33322]FleischhackerWW , HobartM , OuyangJ , ForbesA , PfisterS , McQuadeRD , et al. Efficacy and sfety of Brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. International Journal of Neuropsychopharmacology2017;20(1):11-21. [CSZG: 35475]NCT01668797. Efficacy, Safety, and tolerability of Brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia. https://ClinicalTrials.gov/show/NCT016687972012. [CSZG: 35608]TherrienF , WeissC , JinN , BakerRA , MacKenzieE , MeehanSR . Effect of brexpiprazole on patient functioning in patients with schizophrenia: results from a long-term, randomised, double-blind, placebo-controlled, maintenance study. Neuropsychopharmacology2017;43((Suppl.1)):S244-S245. [CSZG: 37935]WeillerE , HobartM , PfsterS , ForbesA , OuyangJ , WeissC . Effect of brexpiprazole on long-term remission in adults with schizophrenia: Results from a randomized, double-blind, placebo-controlled, maintenance study. Schizophrenia Bulletin2017;43:S202-3. [CSZG: 36050]WeissC , ForbesA , HobartM , PfsterS , OuyangJ , WeillerE . Short-term and long-term efficacy of brexpiprazole in adults with schizophrenia: Effect across marder factors. Schizophrenia Bulletin2017;43:S155. [CSZG: 36051]WeissC , OuyangJ , EramoA , DuffyRA , WeillerE , BakerRA . Switching patients with acute schizophrenia to brexpiprazole: post-hoc analysis of a double-blind randomized maintenance treatment study. Neuropsychopharmacology2015;40:S227-8. [CSZG: 33450]WeissC , WeillerE , HobartM , OuyangJ . Effect of brexpiprazole on weight and metabolic parameters: analysis of a maintenance trial in schizophrenia. European Neuropsychopharmacology2016;26:S556. [CSZG: 35746]">Brexpiprazole 2017</a>, <a href="./references#CD008016-bbs2-0006" title='CorrellCU , PotkinSG , DurgamS , ChangCT , SzatmariB , LaszlovszkyI , et al. Sustained remission with cariprazine treatment: post-hoc analysis of a randomised, double-blind, schizophrenia relapse prevention trial. Europan Neuropsychopharmacology2017;27((Suppl. 4)):S935-S936. [CSZG: 37757]CorrellCU , PotkinSG , ZhongY , HarsányiJ , SzatmáriB , EarleyW . Long-term remission with cariprazine treatment in patients with schizophrenia: a post-hoc analysis of a randomized, double-blind, placebo.controlled relapse prevention trial. Journal of Clinical Psychiatry2019;80(2):18m12495. DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Corrigendum to "Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial" [Schizophr. Res. 176 (2016) 264-71]. Schizophrenia Research2017;InPress:InPress. [CSZG: 35204]DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A double-blind, placebo-controlled trial. European Neuropsychopharmacology2015;25:S512-3. [CSZG: 33317]DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophrenia Research2016;176(2-3):264-71. [CSZG: 35204]DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: additional analysis from a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2015;40:S380-1. [CSZG: 33316]EarleyW , GuoH , LuchiniR . Modified cariprazine relapse prevention clinical trial results. Schizophrenia Research2018;199:452-3. KunovacJ , KaneJ , DurgamS , ChangCT , NemethG , LaszlovszkyI , et al. Characteristics associated with relapse in patients with schizophrenia: Post hoc analysis of a randomized, double-blind, placebo-controlled, cariprazine relapse prevention trial. Schizophrenia Bulletin2017;43:S166-7. [CSZG: 36002]NCT01412060. Cariprazine relative to placebo in the prevention of relapse of symptoms in patients with schizophrenia. http://ClinicalTrials.gov/show/NCT014120602011. [CSZG: 23106]PotkinS , CorrellC , ChangCT , SzatmariB , LaszlovszkyI , EarleyW . Long-term remission with cariprazine treatment in patients with schizophrenia: a post hoc analysis of a randomized, double-blind, placebo-controlled, relapse prevention trial. Schizophrenia Bulletin2017;43:S118. [CSZG: 36026]'>Cariprazine 2016</a>, <a href="./references#CD008016-bbs2-0031" title="Eerdekens. Evaluate the efficacy in the prevention of recurrence of the symptoms of schizophrenia. Sponsor: Johnson &amp; Johnson Pharmaceutical Research &amp; Development, LL.C2010. [CTG: NCT00111189]KramerM , KushnerS , SherrJ , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study. Schizophrenia Bulletin2007;33(2):438. [CSZG: 15185]KramerM , KushnerS , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia treated with paliperidone extended-release tablets. European Neuropsychopharmacology2006;16(Suppl 4):S386. [CSZG: 13313]KramerM , KushnerS , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study. International Journal of Neuropsychopharmacology2006;9(Suppl 1):S274. [CSZG: 19545]KramerM , SimpsonG , MaciulisV , KushnerS , LiuY , LimP , et al. One-year open-label safety and efficacy study of paliperidone extended-release. CNS Spectrums2010;15(8):506-14. [CSZG: 20885]KramerM , SimpsonG , MaciulisV , KushnerS , VijapurkarU , LimP , et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2007;27:6-14. [CSZG: 13907]MarkowitzM , FuDJ , LevitanB , GopalS , TurkozI , AlphsL . Long-acting injectable paliperidone palmitate versus oral paliperidone extended release. Annals of General Psychiatry2013;12:22. [CSZG: 28633]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone 2007</a>, <a href="./references#CD008016-bbs2-0032" title="RuiQ , WangY , LiangS , LiuY , WuY , WuQ , et al. Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry2014;53:45-53. [CSZG: 29320]ZhangH , LiH , LiuY , WuC , WuQ , NuamahI . Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia. Neuropsychiatric Disease and Treatment2016;12:69-77. [CSZG: 33455]">Paliperidone 2014</a>, <a href="./references#CD008016-bbs2-0033" title="AlphsL , BossieC , Kern-SliwaJ , Ma Y-W, HaskinsJT . Paliperidone palmitate: clinical response in subjects with schizophrenia with recent vs. longer-term duration of illness. In: Proceedings of the 162nd Annual Meeting of the American Psychiatric Association. San Francisco, CA., 2009 May 16-21. [CSZG: 19067]EmsleyR , NuamahI , GopalS , HoughD , FleischhackerWW . Relapse after antipsychotic discontinuation in schizophrenia as a withdrawal phenomenon vs illness recurrence: a post hoc analysis of a randomized placebo-controlled study. Journal of Clinical Psychiatry 2018 Jun;79(4):17m11874. [CSZG: 38184]EmsleyR , NuamahI , HoughD , GopalS . Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophrenia Research2012;138(1):29-34. [CSZG: 24214]GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM , HoughD . A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. Journal of Psychopharmacology2011;25(5):685-97. [CSZG: 22903]GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Long-term efficacy, safety and tolerability of paliperidone palmitate in patients with schizophrenia. In: Proceedings of the 162nd Annual Meeting of the American Psychiatric Association. San Francisco, CA, 2009 May 16-21. [CSZG: 19076]HoughD , GopalS , VijapukarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate in prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. In: Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8, Washington DC, USA. 2008. [CSZG: 16486]HoughD , GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. In: Proceedings of the 63rd Annual Convention of the Society of Biological Psychiatry. Washington, DC, USA: Elsevier Science Inc, 2008:S285-6. [CSZG: 20281]HoughD , GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Biological Psychiatry2008;63(7 Suppl):285S-6S. [CSZG: 19530]HoughD , GopalS , VjapukarU , LimP , MorozowaM , EerdekensM . Paliperidone palmitate maintenance treatment in delaying the time to relapse in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. Schizophrenia Research2010;116:107-17. [CSZG: 19704]HulihanJ , BossieCA , FuDJ , Kern SliwaJ , Ma Y-W, AlphsLD . Remission with continued paliperidone palmitate treatment in stable subjects with schizophrenia. Schizophrenia Research2012;136:S252. [CSZG: 29467]KozmaCM , SlatonT , DiraniR , FastenauJ , GopalS , HoughD . Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate. Current Medical Resarch and Opinion2011;27(8):1603-11. SliwaJK , BossieCA , Fu DJ, TurkozI , AlphsL . Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia. Neuropsychiatric Disease and Treatment2012;8:375-85. [CSZG: 28007]SliwaJK , FuDJ , BossieCA , et al. Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate. BMC Psychiatry2014;14:S52. [CSZG: 29148]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone depot1M 2010</a>, <a href="./references#CD008016-bbs2-0034" title="BossieC , TurkozI , AlphsL , FuDJ . Monotherapy with once monthly paliperidone palmitate for psychotic, depressive, and manic symptoms in schizoaffective disorder. Schizophrenia Bulletin2015;41:S303. [CSZG: 29400]BossieCA , TurkozI , AlphsL , MahalchickL , FuDJ . Paliperidone palmitate once-monthly treatment in recent onset and chronic illness patients with schizoaffective disorder. Journal of Nervous and Mental Ddisease2017;205(4):324-8. [CSZG: 35417]FuDJ , AlphsL , LindenmayerJP , SchoolerN , SimonsonRB , TurkozI , et al. Paliperidone palmitate long-acting injectable delays psychotic and mood symptom relapse in schizoaffective disorder. European Neuropsychopharmacology2014;24:S534-5. [CSZG: 27785]FuDJ , BossieC , TurkozI , MahalchickL , AlphsL . Paliperidone palmitate treatment response in early and chronic illness schizoaffective disorder patients. Schizophrenia Bulletin2015;41:S312. [CSZG: 29446]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Effect of paliperidone palmitate once-monthly in improving and maintaining functioning in subjects with schizoaffective disorder using the domains of the personal and social performance scale. Neuropsychopharmacology2014;39:S365. [CSZG: 29278]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate delays relapse in patients with schizoaffective disorder. Biological Psychiatry2014;1:263S. [CSZG: 28974]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate long-acting injectable in acute exacerbation of schizoaffective disorder. Schizophrenia Bulletin2013;39:S331. [CSZG: 28167]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate once-monthly injectable treatment for acute exacerbations of schizoaffective disorder. Journal of Clinical Psychopharmacology2016;36(4):372-6. [CSZG: 35803]FuDJ , TurkozI , SimonsonRB , WallingDP , SchoolerNR , LindenmayerJP , et al. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. Journal of Clinical Psychiatry2015;76(3):253-62. [CSZG: 29752]FuDJ , TurkozI , WallingD , LindenmayerJP , SchoolerNR , AlphsL . Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder. Schizophrenia Research2018;192:185-93. [CSZG: 35804]JoshiK , LinJ , Lingohr-SmithM , FuD . Medical cost reductions for paliperidone palmitate versus placebo in randomized double-blind trial of patients with schizoaffective disorder. Journal of Managed Care and Specialty Pharmacy2015;21:536-7. JoshiK , LinJ , Lingohr-SmithM , FuDJ . Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder. Journal of Medical Economics2015;18:629-36. [CSZG: 33677]NCT01193153. A study to evaluate the efficacy of paliperidone palmitate in the prevention of relapse of the symptoms of schizoaffective disorder. http://ClinicalTrials.gov/show/NCT011931532010. [CSZG: 21094]TurkozI , FuDJ , WallingD , SchoolerNR , LindenmayerJP , SimonsonRB , et al. Effect of paliperidone palmitate once-monthly in improving and maintaining functioning in subjects with schizoaffective disorder using the domains of the personal and social performance scale. Schizophrenia Bulletin2015;41:S193-4. [CSZG: 29687]">Paliperidone depot1M 2015</a>, <a href="./references#CD008016-bbs2-0035" title="BellLKS , TurkozI , KimE . Paliperidone palmitate once-every-3-months in adults with early illness schizophrenia. Early Intervention in Psychiatry2019;13(3):667-72. BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of paliperidone palmitate 3 month formulation: a randomized, double-blind, placebo-controlled study. Schizophrenia Bulletin2015;41:S302. [CSZG: 29393]BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of paliperidone palmitate 3-month formulation in schizophrenia: a randomized, double-blind, placebo-controlled study. European Psychiatry2015;30:272. [CSZG: 32149]BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry2015;72(8):830-9. [CSZG: 33027]ChirilaC , ZhengQ , SawyerrG , NuamahI . Healthcare resource use of paliperidone palmitate 3-month injection vs placebo. In: 168th Annual Meeting of American Psychiatric Association; Toronto, Canada. May 16-20, 2015. [CSZG: 33035]GopalS , FureyM , HibarD , KolbH , SaadZ , SavitzA , et al. Potential biomarkers of impending schizophrenia relapse. Biological Psychiatry2017;(10 Suppl):S126-S127. [CSZG: 36107]GopalS , XuH , McQuarrieK , SavitzA , NuamahI , WoodruffK , et al. Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies. NPJ Schizophrenia2017;3(1):23. [CSZG: 36325]MathewsM , NuamahI , SavitzA , GopalS . Efficacy and safety of paliperidone palmitate 3-month formulation vs placebo for relapse prevention of Schizophrenia: Treatment effect using a number needed to treat analysis. Biological Psychiatry2017;81(10 Suppl 1):S350-1. [CSZG: 36437]NCT01529515. A study of paliperidone palmitate 3 month formulation for the treatment of patients with schizophrenia. http://ClinicalTrials.gov/show/NCT015295152012. [CSZG: 23705]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone depot3M 2015</a>, <a href="./references#CD008016-bbs2-0046" title="NCT00658645. A multinational, randomised, double-blind, fixed-dose, bifeprunox study combining a 12-week placebo-controlled, quetiapine-referenced phase with a 12-month quetiapine-controlled phase in patients with schizophrenia. https://www.clinicaltrials.gov/ct2/show/NCT00658645?term=NCT00658645&amp;rank=1. [CSZG: 16241]">Quetiapine 2009a</a> and <a href="./references#CD008016-bbs2-0047" title="NCT00704509. A multinational, randomised, double-blind, fixed-dose, bifeprunox study combining a 12-week placebo-controlled, quetiapine-referenced phase with a 12-month quetiapine-controlled phase in patients with schizophrenia. https://www.clinicaltrials.gov/ct2/show/NCT00704509?term=NCT00704509&amp;rank=1. [CSZG: 16566]">Quetiapine 2009b</a>. </p> <p>7.4.4.2 Global Assessment of Functioning (GAF) (<a href="./references#CD008016-bbs2-0171" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd rev edition. Washington DC: American Psychiatric Association, 1987.">American Psychiatric Association 1987</a>) </p> <p>The scale is a numeric scale (0 to 100 points) used by clinicians to subjectively rate the severity of mental illnesses in terms of their impact on day‐to‐day life. It is a brief and easy‐to‐administer scale, although based on a single global impression. It is broken into 10 sections, so that the higher the score, the better the functioning of the patients. Results derived from this scale were found in <a href="./references#CD008016-bbs2-0074" title="AratoM , O'ConnorR , BradburyJE , MeltzerH . Long-term ziprasidone in schizophrenia. In: Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 - Jun 4; Toronto, Ontario, Canada. 1998. [CSZG: 3189]AratoM , O'ConnorR , BradburyJE , MeltzerH . The efficacy of ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. In: Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK. Amsterdam, Netherlands: Cambridge University Press, 1998. [CSZG: 3188]AratoM , O'ConnorR , BradburyJE , MeltzerH . Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. In: Proceedings of the 9th Congress of the Association of European Psychiatrists; 1998 Sep 20-24; Copenhagen, Denmark. 1998. [CSZG: 3190]AratoM , O'ConnorR , BradburyJE , MeltzerH . Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. Schizophrenia Research1999;36(1-3):270. [CSZG: 5626]AratoM , O'ConnorR , MeltzerH , BradburyJ . Ziprasidone: efficacy in the prevention of relapse and in the long-term treatment of negative symptoms of chronic schizophrenia. In: Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria. 1997. [CSZG: 245]AratoM , O'ConnorR , MeltzerHY . A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. International Clinical Psychopharmacology2002;17:207-15. [CSZG: 18486]BernardoM , AranzaJR , Rubio-TerresC , RejasJ . Cost-effectiveness analysis of schizophrenia relapse prevention. Clinical Drug Investigation. New Zealand2006;26(8):447-57. [CSZG: 13898]BernardoM , AranzaJR , Rubio-TerresC , RejasJ . Cost-effectiveness analysis of the prevention of relapse in schizophrenia in the ZEUS longitudinal study Ziprasidone Extended Use in Schizophrenia (ZEUS). Acta Espanolas de Psiquiatria2007;35(4):259-62. [CSZG: 15396]MeltzerHY , O´ConnorR . Long-term efficacy of ziprasidone in schizophrenia. Schizophrenia research2001;(1-2):S. 239. [CSZG: 6050]MeltzerHY , O´ConnorR . Path analysis of the ZEUS study provides evidence of a direct effect of ziprasidone on primary negative symptoms in chronic, stable schizophrenia. Conference Poster1997. [CSZG: 2033]MeltzerHY , O'ConnorR . Long-term efficacy of ziprasidone in schizophrenia: results of two controlled trials. In: Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico. 2000. [CSZG: 7609]O'ConnorR , SchoolerNR . Penultimate observation carried forward (POCF): a new approach to analysis of long-term symptom change in chronic relapsing conditions [letter]. Schizophrenia Research2003;60:319-20. [CSZG: 9365]Pfizer 2000. Multicentre double-blind study of ziprasidone versus placebo in relapse prevention for hospitalised patients with chronic or subchronic schizophrenia. Study report Unpublished. SchoolerN . A basis for optimism: the implications of long term treatment. In: Proceedings of the 9th Congress of the Association of European Psychiatrists; 1998 Sep 20-24; Copenhagen, Denmark. 1998. [CSZG: 5864]">Ziprasidone 2002</a>. </p> <p>7.4.4.3 Sheehan Disability Scale (SDS) (<a href="./references#CD008016-bbs2-0235" title="SheenanDV . The Sheenan Disability Scale. In: The Anxiety Disease and How to Overcome it. New York: Charles Scribner and Sons, 1983:151.">Sheenan 1983</a>) </p> <p>The SDS is a brief, 5‐item self‐administered tool that assesses functional impairment in three areas: work/school, social life and family life. The patient has to rate the extent to which each area is affected by his/her symptoms. Total score is obtained by summing the single dimension score into one measure, and ranges from 0 (unimpaired) to 30 (highly impaired). No cut‐off has been recommended, but a score of 5 or more on any of the three areas could be classified as significant functional impairment. This scale was applied in <a href="./references#CD008016-bbs2-0027" title="CTRI/2010/091/001409. A clinical trial to study prevention of relapse in patients with schizophrenia reveiving either flexible dose iloperidone or placebo in long-term use.. http://ctri.nic.in/Clinicaltrials/login.php2010. NCT01291511. Efficacy in prevention of relapse of schizophrenia in subjects taking either placebo or iloperidone. http://ClinicalTrials.gov/show/NCT012915112011. [CSZG: 22671]WeidenPJ , ManningR , WolfgangCD , RyanJM , MancioneL , HanG , et al. A randomized trial of iloperidone for prevention of relapse in schizophrenia: the REPRIEVE study. CNS drugs2016;30(8):735-47. [CSZG: 35243]">Iloperidone 2016</a>. </p> <p>7.4.4.4 Specific Level of Functioning (SLOF) (<a href="./references#CD008016-bbs2-0231" title="SchneiderLC , StrueningEL . SLOF: a behavioural rating scale for assessing the mentally ill. Social Work Research &amp; Abstracts 1983 Fall;19:9-21.">Schneider 1983</a>) </p> <p>The scale is a 43‐item multidimensional behavioural survey assessing schizophrenia patients' current functioning and observable behaviour, and it is focused on the person's skills rather than deficits. It can be administered to the patient him/herself or to his/her caregiver. It comprises six subscales: (a) physical functioning, (b) personal care skills, (c) interpersonal relationships, (d) social acceptability, (e) activities of community living and (f) work skills. Each question is rated on a 5‐point Likert scale. Total scores range from 43 to 215, with higher scores representing better overall functioning. This instrument was applied in <a href="./references#CD008016-bbs2-0028" title="NCT01435928. PEARL Schizophrenia Maintenance. http://ClinicalTrials.gov/show/NCT014359282011. [CSZG: 23439]TandonR , CucchiaroJ , PhillipsD , HernandezD , MaoY , PikalovA , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Journal of Psychopharmacology2016;30(1):69-77. [CSZG: 33434]TandonR , LoebelA , PhilipsD , PikalovA , Hernandez D MaoY , et al. Lurasidone for maintenance of efficacy in patients with schizophrenia. European Neuropsychopharmacology2014;24(Suppl 2):S559-560. [CSZG: 27840]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , CucchiaroJ . A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Schizophrenia Research2014;153(1):S372. [CSZG: 29681]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Int J Neuropsychopharmacol2014;17:S153-154. [CSZG: 29954]">Lurasidone 2016</a>. </p> <p>7.4.4.5 Global Assessment Scale (GAS) (<a href="./references#CD008016-bbs2-0193" title="EndicottJ , SpitzerRL , FleissJL , CohenJ . The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry1976;33(6):766-71.">Endicott 1976</a>) and Children Global Assessment Scale (CGAS) (<a href="./references#CD008016-bbs2-0234" title="ShafferD , GouldMS , BrasicJ , AmbrosiniP , FisherP , BirdH , et al. A Children's Global Assessment Scale (CGAS). JAMA Psychiatry1983;40:1228-31.">Shaffer 1983</a>) </p> <p>The GAS is a rating scale used to evaluate the overall functioning of a person seeking mental health services, during a specified time period, independently of specific mental health diagnoses. It has proven to have good reliability and high sensitivity to change over time. The scale values range from 1 to 100, with higher scores representing better functioning and scores above 70 indicating good functioning. The CGAS is and adaptation of the GAS, designed to reflect the lower level of functioning of children and adolescents with respect to adults. <a href="./references#CD008016-bbs2-0020" title="GoldbergSC , ShenoyRS , SadlerA , HamerR , RossB . The effects of a drug holiday on relapse and tardive dyskinesia in chronic schizophrenics. Psychopharmacology Bulletin1981;17:116-7. [CSZG: 5007]ShenoyRS , SadlerAG , GoldbergSC , HamerRM , RossB . Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics. Journal of Clinical Psychopharmacology1981;1:141-5. [CSZG: 2577]">Fluphenazine depot 1981</a> reported data from GAS, while the adaptation for children was used in <a href="./references#CD008016-bbs2-0002" title="CorrellC , KohegyiE , ZhaoC , BakerRA , McQuadeR , SalzmanP , et al. Oral aripiprazole is an effective maintenance treatment in adolescents with schizophrenia. Neuropsychopharmacology2014:S349-S350. [CSZG: 29288]CorrellCU , KohegyiE , ZhaoC , BakerRA , McQuadeR , SalzmanPM , et al. Oral aripiprazole as maintenance treatment in adolescent schizophrenia: results from a 52-week, randomized, placebo-controlled withdrawal study. Journal of the American Academy of Child and Adolescent Psychiatry2017;56(9):784-92. [CSZG: 36321]NCT01149655. A long-term multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of aripiprazole (opc 14597) as maintenance treatment in adolescent patients with schizophrenia. http://ClinicalTrials.gov/show/NCT011496552010. [CSZG: 21085]">Aripiprazole 2017</a>. </p> </section> </section> <section id="CD008016-sec-0102"> <h6 class="title">7.5 Other adverse effects</h6> <p>Other adverse events such as death, suicide, suicide attempts, suicidal ideation, violent/aggressive behaviour, at least one adverse event, at least one movement disorder, akathisia, akinesia, dystonia rigor, tremor, use of antiparkinson medication, tardive dyskinesia, sedation and weight gain were reported in a dichotomous manner in terms of the number of participants with a given side effect. </p> </section> <section id="CD008016-sec-0103"> <h6 class="title">7.6 Global state: number of participants improved (at least minimally)</h6> <p>The number of people who improved at the end of the studies was assessed by the Clinical Global Impression (CGI) scale (<a href="./references#CD008016-bbs2-0199" title="GuyW . ECDEU Assessment Manual for Psychopharmacology-revised 1976. Washington, DC: DHEW. National Institute of Mental Health, 1976.">Guy 1976</a>) or similar rating systems. The CGI compares the conditions of the person standardised against other people with the same diagnosis. A 7‐point scoring system is used with low scores showing decreased severity, overall improvement, or both. The outcome was defined as the number of participants 'at least minimally improved' (CGI score of 3 or less). When other scales were used in the original studies (e.g. PANSS, BPRS), data based on the '20% reduction of score' cut‐off were used. If data based on these thresholds were not available, we used the numbers presented by the original authors (study‐defined improvement), when available. </p> <p><b>7.7 Global state: number of participants in symptomatic remission</b> </p> <p>The number of participants in symptomatic remission was defined by either 'mild or better' at the Clinical Global Impression (CGI) or similar rating systems, or using the operational criteria for remission in schizophrenia proposed by Andreasen et al (<a href="./references#CD008016-bbs2-0172" title="AndreasenNC , Carpenter WT Jr, KaneJM , LasserRA , MarderSR , WeinbergerDR . Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry2005;162(3):441-9.">Andreasen 2005</a>), without employing any duration threshold. In this case, a score of 'mild or less' at all eight core symptoms (delusions, hallucinatory behaviour and unusual thought content for the positive dimension, conceptual disorganisation and mannerism/disorders of posture for the disorganisation dimension, blunted affect, social withdrawal and lack of spontaneity/flow of conversation for the negative dimension) constitutes the symptom severity level of remission. If data based on these criteria were not available, other definitions of remission used by the original Authors ‐ with no mention to its duration ‐ were accepted. It should be noted that we defined this outcome as cross‐sectional and representative of the clinical severity level of patients, independent on the fact that the patients were achieving or maintaining it. </p> <p><b>7.8 Global state: number of participants in sustained remission</b> </p> <p>This outcome was defined as either the number of participants achieving and maintaining the aforementioned symptom severity level (symptomatic remission) for a minimum period of six months, as proposed by <a href="./references#CD008016-bbs2-0172" title="AndreasenNC , Carpenter WT Jr, KaneJM , LasserRA , MarderSR , WeinbergerDR . Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry2005;162(3):441-9.">Andreasen 2005</a>, or the number already in remission at baseline and maintaining the same severity level for the whole duration of the study (if lasting at least six months). </p> <p><b>7.9 Global state: number of participants in recovery</b> </p> <p>At present, more research is needed in order to achieve consensus regarding operational criteria for recovery (<a href="./references#CD008016-bbs2-0172" title="AndreasenNC , Carpenter WT Jr, KaneJM , LasserRA , MarderSR , WeinbergerDR . Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry2005;162(3):441-9.">Andreasen 2005</a>). Therefore, every definition of recovery provided by the original studies, including symptom severity, social‐occupational functioning and data on subjective recovery, was accepted. </p> </section> <section id="CD008016-sec-0104"> <h6 class="title">7.10 Number of participants in employment</h6> <p>This outcome was described as the number of participants being employed at the end of the trials. </p> </section> </section> </section> <section id="CD008016-sec-0105"> <h4 class="title">Excluded studies</h4> <p>We excluded 85 studies. Twenty‐six studies were excluded because they were not (appropriately) randomised. Twenty‐four studies were excluded because they did not examine suitable participants (e.g. participants had not been stabilised on antipsychotic drugs before study start. Twenty‐two studies were excluded because the interventions were not appropriate for this review ‐ most, for example, did not use a placebo control group. Thirteen studies were excluded because they did not report any usable or relevant outcomes. </p> <p> <div class="table" id="CD008016-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Studies excluded because they were not randomised</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008016-bbs2-0076" title="AllenDN , GilbertsonMW , BarryE , KammenDP , GurklisJA . Haloperidol improves memory in schizophrenia. In: Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, California, USA. 1997. ">Allen 1997</a>, <a href="./references#CD008016-bbs2-0081" title="BrancheyMH , BrancheyLB , RichardsonMA . Effects of gradual decrease and discontinuation of neuroleptics on clinical condition and tardive dyskinesia. Psychopharmacology Bulletin1981;17:118-20. BrancheyMH , BrancheyLB , RichardsonMA . Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients. American Journal of Psychiatry1981;138:608-12. ">Branchey 1981</a>, <a href="./references#CD008016-bbs2-0082" title="BreierA , WolkowitzOM , DoranAR , RoyA , BoronowJ , HommerDW , et al. Neuroleptic responsivity of negative and positive symptoms in schizophrenia. American Journal of Psychiatry1987;144:1549-55. ">Breier 1987</a>, <a href="./references#CD008016-bbs2-0087" title="ChouinardG , AnnableL , JonesBD , ColluR . Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system. Acta Psychiatrica Scandinavica1980;64:353-62. ">Chouinard 1980</a>, <a href="./references#CD008016-bbs2-0091" title="CollinsAD , DundasJ . A double-blind trial of amitriptyline-perphenazine, perphenazine and placebo in chronic withdrawn inert schizophrenics. British Journal of Psychiatry1967;113:1425-9. ">Collins 1967</a>, <a href="./references#CD008016-bbs2-0092" title="CondrayR , Van KammenDP , SteinhauerSR , KasparekA , YaoJK . Language comprehension in schizophrenia: trait or state indicator?Biological Psychiatry1995;38:287-96. ">Condray 1995</a>, <a href="./references#CD008016-bbs2-0093" title="CursonDA , BarnesTR , BamberRW , PlattSD , HirschSR , DuffyJC . Long term depot maintenance of chronic schizophrenic out patients: the seven year follow up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side effects, neurotic symptoms and depression. British Journal of Psychiatry1985;146:469-74. CursonDA , BarnesTR , BamberRW , PlattSD , HirschSR , DuffyJC . Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine- placebo trial I. Course of illness, stability of diagnosis, and the role of a special maintenance clinic. British Journal of Psychiatry1985;146:464-9. CursonDA , BarnesTR , BamberRW , PlattSD , HirschSR , DuffyJC . Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. III. Relapse postponement or relapse prevention? The implications for long-term outcome. British Journal of Psychiatry1985;146:474-80. ">Curson 1985</a>, <a href="./references#CD008016-bbs2-0094" title="DegkwitzR , BauerMP , GruberM , HampelG , LuxenburgerO , RichartzM , et al. Time relationship between the appearance of persisting extrapyramidal hyperkineses and psychotic recurrences following sudden interruption of prolonged neuroleptic therapy of chronic schizophrenic patients. Arzneimittelforschung1970;20(7):890-3. ">Degkwitz 1970</a>, <a href="./references#CD008016-bbs2-0095" title="DiamondLS , MarksJB . Discontinuance of tranquilizers among chronic schizophrenic patients receiving maintenance dosage. Journal of Nervous and Mental Disease1960;131:247-51. ">Diamond 1960</a>, <a href="./references#CD008016-bbs2-0106" title="GoldbergSC , SchoolerNR , MattssonN . Paranoid and withdrawal symptoms in schizophrenia: differential symptom reduction over time. Journal of Nervous and Mental Disease1967;145:158-62. Mefferd RB Jr, LabrosseEH , GawienowskiAM , WilliamsRJ . Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics. Journal of Nervous and Mental Disease1958;127:167-79. ">Goldberg 1967</a>, <a href="./references#CD008016-bbs2-0109" title="HineFR . Chlorpromazine in schizophrenic withdrawal and in the withdrawn schizophrenic. Journal of Nervous and Mental Disease1958;127:220-7. ">Hine 1958</a>, <a href="./references#CD008016-bbs2-0112" title="HuntPV . A comparison of the effects of oxypertine and trifluoperazine in withdrawn schizophrenics. British Journal of Psychiatry1967;113:1419-24. ">Hunt 1967</a>, <a href="./references#CD008016-bbs2-0113" title="IonescuR , TiberiuC , MiklosR , AngelescuC , PersiceanuAM . Penfluridol in the maintenance therapy of schizophrenia. Neurologie et Psychiatrie1983;21:33-41. ">Ionescu 1983</a>, <a href="./references#CD008016-bbs2-0115" title="JohnstoneEC , CrowTJ , FrithCD , OwensDG . The Northwick Park &quot;functional&quot; psychosis study: diagnosis and treatment response. Lancet1988;2:119-25. JohnstoneEC , CrowTJ , OwensDGC , FrithCD . The Northwick Park 'functional' psychosis study. Phase 2 - maintenance treatment. Journal of Psychopharmacology1991;5:388-95. JohnstoneEC , OwensDGC . Does early treatment have an effect on outcome? In: Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria. 1997. ">Johnstone 1988</a>, <a href="./references#CD008016-bbs2-0117" title="KellamAM , JonesKS . A double-blind controlled trial of thiothixene and perphenazine in chronic schizophrenics shown to require maintenance therapy. Acta Psychiatrica Scandinavica1971;47:174-85. ">Kellam 1971</a>, <a href="./references#CD008016-bbs2-0127" title="BolaJR , MosherLR . Treatment of acute psychosis without neuroleptics: two-year outcomes from the Soteria project. Journal of Nervous and Mental Disease2003;191:219-29. MatthewsSM , RoperMT , MosherLR , MennAZ . A non neuroleptic treatment for schizophrenia: analysis of the two year postdischarge risk of relapse. Schizophrenia Bulletin1979;5:322-33. MosherLR , MennA , MatthewSM . Soteria: evaluation of a home-based treatment for schizophrenia. American Journal of Orthopsychiatry1975;45:455-67. MosherLR , MennAZ . Community residential treatment for schizophrenia: two year follow up. Hospital and Community Psychiatry1978;29:715-23. ">Mosher 1975</a>, <a href="./references#CD008016-bbs2-0128" title="MüllerP , HartmannW , JungF , KindJ , LohrengelS , SteuberH . To prevent relapse of schizophrenic psychoses [Zur Rezidivprophylaxe schizophrener Psychosen]. Ferdinand Enke Verlag Stuttgart1982;14:1-144. ">Müller 1982</a>, <a href="./references#CD008016-bbs2-0133" title='PaulGL , TobiasLL , HollyBL . Maintenance psychotropic drugs in the presence of active treatment programs. A "triple-blind" withdrawal study with long-term mental patients. Archives of General Psychiatry1972;27:106-15. '>Paul 1972</a>, <a href="./references#CD008016-bbs2-0135" title="PickarD , LabarcaR , DoranAR , WolkowitzOM , RoyA , BreierA , et al. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment. Archives of General Psychiatry1986;43:669-76. ">Pickar 1986</a>, <a href="./references#CD008016-bbs2-0136" title="PickarD , BartkoJJ . Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia. American Journal of Psychiatry2003;160:1133-8. ">Pickar 2003</a>, <a href="./references#CD008016-bbs2-0139" title="RassidakisNC , KondakisX , PapanastassiouA , MichalakeasA . Withdrawal of antipsychotic drugs from chronic psychiatric patients. Bulletin of the Menninger Clinic1970;34(4):216-22. ">Rassidakis 1970</a>, <a href="./references#CD008016-bbs2-0145" title="SinghH , HuntJI , VitielloB , SimpsonGM . Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis. Journal of Clinical Psychiatry1990;51:319-21. ">Singh 1990</a>, <a href="./references#CD008016-bbs2-0146" title="SmelsonDA , TunisSL , NyhuisAW , FariesDE , KinonBJ , Ascher-SvanumH . Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use. Journal of Clinical Psychopharmacology2006;26:666-7. ">Smelson 2006</a>, <a href="./references#CD008016-bbs2-0151" title="Van KammenDP , Bunney WE Jr, DochertyJP , MarderSR , EbertMH , RosenblattJE , et al. D-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia. American Journal of Psychiatry1982;139:991-7. Van KammenDP , BunneyWE , DochertyJP , JimersonDC , PostRM , SirisP , et al. Amphetamine-induced catecholamine activation in schizophrenia and depression: behavioral and physiological effects. Advances in Biochemical Psychopharmacology1977;16:655-9. Van KammenDP , DochertyJP , MarderSR , SchulzSC , Bunney WE Jr. Lack of behavioral supersensitivity to d-amphetamine after pimozide withdrawal. A trial with schizophrenic patients. Archives of General Psychiatry1980;37:287-90. Van KammenDP , DochertyJP , MarderSR , SirisSG , Bunney WE Jr. D amphetamine raises serum prolactin in man: evaluations after chronic placebo, lithium and pimozide treatment. Life Sciences1978;23:1487-92. ">Van Kammen 1982</a>, <a href="./references#CD008016-bbs2-0156" title="WrightRL , LynesPG . Value of continuous drug administration for chronic long-term mental hospital patients. Canadian Psychiatric Association Journal1964;60:352-7. ">Wright 1964</a>, <a href="./references#CD008016-bbs2-0158" title="ZellerWW , GraffagninoPN , CullenCF , RietmanHJ . Use of chlorpromazine and reserpine in the treatment of emotional disorders. Journal of the American Medical Association1956;160:179-84. ">Zeller 1956</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Randomised studies excluded because participants were not appropriate ‐ mostly not stable</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008016-bbs2-0077" title="BaiYM , YuSC , ChenJY , LinCY , ChouP , LinCC . Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study. International Clinical Psychopharmacology2005;20:79-85. BaiYM , YuSC , LinCC . Risperidone for severe tardive dyskinesia: a 12 week randomised, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2003;64:1342-8. ">Bai 2003</a>, <a href="./references#CD008016-bbs2-0078" title="BechdolfA , MuellerH , GaebelW , HasanA , MaierW , JuckelG , et al. PREVENT: a randomized controlled trial comparing cognitive behavioural therapy, clinical management and aripiprazole and clinical management and placebo for the prevention of first episode psychosis. Early Intervention in Psychiatry2016;10(Suppl 1):40. ">Bechdolf 2016</a>, <a href="./references#CD008016-bbs2-0080" title="BourinM , DebelleM , HeisterbergJ , JosiassenMK , OstergaardJB , SandsE . Efficacy of bifeprunox in patients in the post-acute, maintenance phase of schizophrenia: findings from a 6-month study. Schizophrenia Research2008;98:158. ">Bourin 2008</a>, <a href="./references#CD008016-bbs2-0086" title="ChopraS , FornitoA , FranceyS , O’DonoghueB , NelsonB , GrahamJ , et al. Gray matter changes in medicated and unmedicated first episode psychosis: a randomized placebo-controlled trial. Schizophrenia Bulletin2019;45:S172-3. ">Chopra 2019</a>, <a href="./references#CD008016-bbs2-0088" title="AndrisJ . Clinical trials van risperidone [Clinical trails van risperidone]. Unknown Source1997:14. ChouinardG , AlbrightPS . Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology1997;17(4):298-307. ChouinardG , ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biological Psychiatry1992;31:158. ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25-40. ChouinardG . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36-44. CzoborP , VolavkaJ , MeibachRC . Effect of risperidone on hostility in schizophrenia. Journal of Clinical Psychopharmacology1995;15(4):243-9. MarderSR , DavisJM , ChouinardG . The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychological Medicine1997;58(12):538-46. McEvoyJP . Efficacy of risperidone on positive features of schizophrenia. Journal of Clinical Psychiatry1994;55(5 Suppl):18-21. MollerHJ , MullerH , BorisonRL , SchoolerNR , ChouinardG . A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re- evaluation of the North American risperidone study. European Archives of Psychiatry and Clinical Neuroscience1995;245(1):45-9. MusserWS , KirisciL . Critique of the Canadian multicenter placebo-controlled study of risperidone and haloperidol. Journal of Clinical Psychopharmacology1995;15(3):226-8. NCT00249132. Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. https://www.ClinicalTrials.gov/ct/show/2005. SimpsonGM , LindenmayerJP . Extrapyramidal symptoms in patients treated with risperidone. Journal of Clinical Psychopharmacology1997;17(3):194-201. ">Chouinard 1993</a>, <a href="./references#CD008016-bbs2-0090" title="ClarkML , RayTS , ParedesA , RaglandRE , CostiloeJP , SmithCW , et al. Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol-behavior relationships. Psychosomatic Medicine1967;29(6):634-42. ">Clark 1967</a>, <a href="./references#CD008016-bbs2-0097" title="BarabassyA , SzatmàriB , LaszlovszkyI , HarsanyiJ , AcsaiK , SebeB , et al. Efficacy of cariprazine in the treatment of negative symptoms of schizophrenia: post hoc analysis versus aripiprazole. European Neuropsychopharmacology2019;29(Suppl 1):S417-8. CutlerAJ , DurgamS , LuK , LaszlovszkyI , SzalaiE , EdwardsJ , EarleyW . Efficacy of cariprazine in negative, cognitive, social function symptoms in schizophrenia: post hoc analysis of a randomized controlled trial. European Neuropsychopharmacology2016;26(2):S551-2. DurgamS , EarleyW , LuK , NémethG , LaszlovszkyI , SzatmariB , PatelM , NasrallahH . Cariprazine for negative symptoms of schizophrenia: a pooled post-hoc analysis of 2 randomized double-blind placebo and active controlled trials. In: 29th European College of Neuropsychopharmacology Congress. Vienna, Austria, 2016, Sep 17-20. MarderS , FleischhackerWW , EarleyW , KaifengL , ZhongY , NémethG . Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: pooled analysis from 3 phase II/III studies. European Neuropsychopharmacology2019;29(1):127-36. ">Durgam 2016</a>, <a href="./references#CD008016-bbs2-0098" title="EngelhardtDM , RosenB , FreedmanN , MargolisR . Phenothiazines in prevention of psychiatric hospitalisation. Archives of General Psychiatry1967;16:98-101. ">Engelhardt 1967</a>, <a href="./references#CD008016-bbs2-0100" title="FranceyS , NelsonB , JessicaG , LaraB , YuenHP , O'DonoghueB , et al. Antipsychotic medication in first episode psychosis: an RCT to assess the risk benefit ratio. Early Intervention in Psychiatry2018;12(Suppl 1):70. FranceyS . A randomized placebo-controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first episode psychosis with low risk of self harm of aggression. The STAGES study: staged treatment and acceptability guidelines in early psychosis. Early Interventions in Psychiatry2016;10(Suppl 1):9. O'DonoghueB , FranceySM , NelsonB , RatheeshA , AllottK , GrahanJ , et al. Staged treatment and acceptability guidelines in early psychosis study (STAGES): a randomized placebo-controlled trial of intensive psychosocial treatment plusof minus antipsychotic medication for first episode with low risk of self harm or aggression: study protocol and baseline characteristics of patients. Early Interventions in Psychiatry2019;13(4):953-60. ">Francey 2018</a>, <a href="./references#CD008016-bbs2-0101" title="FreedmanR , KirchD , BellJ , AdlerLE , PecevichM , PachtmanE , et al. Clonidine treatment of schizophrenia: double blind comparison to placebo and neuroleptic drugs. Acta Psychiatrica Scandinavica1982;65:35-45. ">Freedman 1982</a>, <a href="./references#CD008016-bbs2-0114" title="JanecekJ , SchieleBC , BellvilleT , AndersonR . The effects of withdrawal of trifluoperazine on patients maintained on the combination of tranylcypromine and trifluoperazine: a double-blind study. Current Therapeutic Research, Clinical and Experimental1963;85:608-15. ">Janecek 1963</a>, <a href="./references#CD008016-bbs2-0118" title="LaurielloJ , McEvoyJP , RodriguezS , BossieCA , LasserRA . Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophrenia Research2005;72:249-58. ">Lauriello 2005</a>, <a href="./references#CD008016-bbs2-0119" title="LecrubierY . Amisulpride in deficit schizophrenia. In: Proceedings of the 6th World Congress Biological Psychiatry, 1997 Jun 22-27; Nice, France. 1997. ">Lecrubier 1997</a>, <a href="./references#CD008016-bbs2-0121" title="LooH , Poirier-LittreMF , TheronM , ReinW , FleurotO . Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. British Journal of Psychiatry1997;170:18-22. ">Loo 1997</a>, <a href="./references#CD008016-bbs2-0123" title="AndrisJ . Clinical trials van risperidone [Clinical trails van risperidone]. Unknown Source1997:14. CzoborP , VolavkaJ , MeibachRC . Effect of risperidone on hostility in schizophrenia. Journal of Clinical Psychopharmacology1995;15(4):243-9. CzoborP , VolavkaJ . Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(5):332-42. LindenmayerJP , =TheRSG . Incidence of EPS with risperidone compared with haloperidol and placebo in patients with chronic schizophrenia. In: Proceedings of the 146th Annual Meeting of the American Psychiatric Association; 1993 May 22-27; San Francisco, California, USA. 1993. MarderS . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. Clinical Research Report (RIS-INT-3)1991. MarderSR , ChouinardG , DavisJM . The clinical actions of risperidone. In: Proceedings of the 10th Congress of the European College of Neuropsychopahrmacology; 1997 Sep 13-17, Vienna, Austria. 1997. MarderSR , ChouinardG , DavisJM . The clinical actions of risperidone. In: Proceedings of the 35th Annual Meeting of the American College of Neuropsychopharmacology; 1996 Dec 9-13; San Juan, Puerto Rico. 1996. MarderSR , ChouinardG , DavisJM . The clinical actions of risperidone. In: Proceedings of the 6th World Congress of Biological Psychiatry; 1997 Jun 22-27; Nice, France. 1997. MarderSR , DavisJM , ChouinardG . The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychological Medicine1997;58(12):538-46. MarderSR , MeibachRC . Risperidone in the treatment of schizophrenia. American Journal of Psychiatry1994;151(6):825-35. McEvoyJP . Efficacy of risperidone on positive features of schizophrenia. Journal of Clinical Psychiatry1994;55(5 Suppl):18-21. MollerHJ , MullerH , BorisonRL , SchoolerNR , ChouinardG . A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re- evaluation of the North American risperidone study. European Archives of Psychiatry and Clinical Neuroscience1995;245(1):45-9. NCT00249132. Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. https://www.ClinicalTrials.gov/ct/show/2005. SimpsonGM , LindenmayerJP . Extrapyramidal symptoms in patients treated with risperidone. Journal of Clinical Psychopharmacology1997;17(3):194-201. ">Marder 1994</a>, <a href="./references#CD008016-bbs2-0125" title="MeehanSR , ZhangP , HobartM , HeftingN , BakerRA , WeissC . Short term efficacy of brexpiprazole in patients with schizophrenia with clinically relevant levels of negative symptoms. European Neuropsychopharmacology2019;29(Suppl 1):S424. ">Meehan 2019</a>, <a href="./references#CD008016-bbs2-0131" title="OosthuizenPP . Treatment of first episode schizophrenia with low-dose haloperidol: a study in the Western Cape province of South Africa. Dissertation presented for the Degree of Doctor of Philosophy at the University of Stellenbosch 2003 March. ">Oosthuizen 2003</a>, <a href="./references#CD008016-bbs2-0132" title="DavisAE , DinitzS , PasamanickB . The prevention of hospitalization in schizophrenia: five years after an experimental program. American Journal of Orthopsychiatry1972;42(3):375-88. PasamanickB , ScarpittiFR , DinitzS . Schizophrenic in theCcommunity: an Experimental Study in the Prevention of Hospitalisation. New York: Meredith Publishing Company, 1967. PasamanickB , ScarpittiFR , LeftonM , DinitzF , WernertJJ , McPheetersH . Home vs hospital care for schizophrenics. JAMA1964;187(3):177-81. ">Pasamanick 1967</a>, <a href="./references#CD008016-bbs2-0143" title="SchlossbergA , ShadmiM . A comparative controlled study of two long-acting phenothiazines: pipotiazine palmitate and fluphenazine decanoate. Current Therapeutic Research1978;23(5):642-54. ">Schlossberg 1978</a>, <a href="./references#CD008016-bbs2-0147" title="SoniSD , MallikA , SchiffAA . Sulpiride in negative schizophrenia: a placebo-controlled double-blind assessment. Human Psychopharmacology1990;5:233-8. ">Soni 1990</a>, <a href="./references#CD008016-bbs2-0149" title="Sumitomo Dainippon Pharma. Randomized, placebo-controlled, double-blind, parallel-group, confirmatory study of SM-13496 (lurasidone HCl) in patients with schizophrenia: a phase III study. Summary of study results. Sumitomo Dainippon Pharma Reports2008. ">Sumitomo 2008</a>, <a href="./references#CD008016-bbs2-0152" title="VanoverK , DmitrienkoA , GlassS , KozauerS , SaillardJ , WeingartM , et al. Lumateperone (ITI-007) for the treatment of schizophrenia: placebo-controlled clinical trials and an open-label safety switching study. Schizophrenia Bulletin2018;44(Suppl 1):S341. ">Vanover 2018</a>, <a href="./references#CD008016-bbs2-0159" title="ZouX , ZhuY , JacksonJW , BellaviaA , FitxmauriceGM , CentorrinoF , et al. The role of PANSS symptoms and adverse events in explaining the effects of paliperidone on social functioning: a causal mediation analysis approach. NPJ Schizophrenia2018;4(1):13. ">Zou 2018</a>, <a href="./references#CD008016-bbs2-0160" title="Zwanikken 1973. Penfluridol (R 16341). A long-acting oral neuroleptic, as maintenance therapy for schizophrenic and mentally retarded patients. Psychiatria, Neurologia, Neurochirurgia1973;76:83-92. ">Zwanikken 1973</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Randomised studies, with appropriate participants, excluded because interventions were not appropriate ‐ mostly no placebo group</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008016-bbs2-0079" title="BoQ , LiF , LiX , WangZ , DongF , HeF , et al. Symptomatic remission in schizophrenia: results from a risperidone maintenance treatment study. Psychiatry Research2017;258:289-94. ">Bo 2017</a>, <a href="./references#CD008016-bbs2-0083" title="BrownD , DanielsK , PichereauS , SandM . A phase IC study evaluating the safety, tolerability, pharmacokinetics and cognitive outcomes of BI409306 in patients with mild to moderate schizophrenia. Neurology and Therapy2018;7(1):129-39. SandM , NakagomeK , CordesJ , BrennerR , GründerG , KeefeR , et al. Effects of BI409306 on positive and negative syndrome scale in schizophrenia: a randomized double-blind placebo-controlled phase II trial. Biological Psychiatry2018;83(9):S207-8. ">Brown 2018</a>, <a href="./references#CD008016-bbs2-0085" title='ChengZ , YuanY , HanX , YangL , ZengX , YangF , et al. Rates and predictors of one year antipsychotic treatment discontinuation in first episode schizophrenia: results from ab open-label randomized "real-world" clinical trial. Psychiatry Research2019;273:631-40. '>Cheng 2019</a>, <a href="./references#CD008016-bbs2-0089" title="ClaghornJL , JohnstoneEE , CookTH , ItschnerL . Group therapy and maintenance treatment of schizophrenics. Archives of General Psychiatry1974;31:361-5. ">Claghorn 1974</a>, <a href="./references#CD008016-bbs2-0096" title="DoubleDB , WarrenGC , EvansM , RowlandsRP . Efficacy of maintenance use of anticholinergic agents. Acta Psychiatrica Scandinavica1993;88:381-4. ElieR , MorinL , TetreaultL . Effects of ethopropazine and trihexyphenidyl on several parameters of the neuroleptic syndrome [Effets de l'ethopropazine et du trihexyphenidyle sur quelques parametres du syndrome neuroleptique]. Encephale1972;61:32-52. ">Double 1993</a>, <a href="./references#CD008016-bbs2-0099" title="FleischhackerWW , SanchezR , PerryPP , JinN , Peters-StricklandT , JohnsonBR , et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. British Journal of Psychiatriy2014;205(2):135-44. ">Fleischhacker 2014</a>, <a href="./references#CD008016-bbs2-0105" title="GleesonJ , WadeD , McgorryP , AlbistonD , CastleD , GilbertM , et al. Episode ii: prevention of relapse following early psychosis. Schizophrenia Research2004;70:61-2. ">Gleeson 2004</a>, <a href="./references#CD008016-bbs2-0108" title="GreenbergLM , RothS . Differential effects of abrupt versus gradual withdrawal of chlorpromazine in hospitalized chronic schizophrenic patients. American Journal of Psychiatry1966;123:221-6. ">Greenberg 1966</a>, <a href="./references#CD008016-bbs2-0084" title="CatherC , BrunetteMF , MueserKT , BabbinSF , RosenheckR , CorrellCU , et al. Impact of comprehensive treatment for first episode psychosis and substance use outcomes: a randomized controlled trial. Psychiatry Research2018;268:303-11. FulfordD , PiskulicD , AddingtonJ , KaneJM , SchoolerN , MueserKT . Prospective relationships between motivation and functioning in recovery after a first episode of schizophrenia. Schizophrenia Bulletin2018;44(2):369-77. MueserKT , Meyer-KalosPS , GlynnSM , LyndeDW , RobinsonDG , GingerichS , et al. Implementation and fidelity assessment of the NAVIGATE treatment program for first episode psychosis in a multi-site study. Schizophrenia Research2019;204:271-81. SchoolerN , MueserK , EstroffS , CorrellC , RobinsonD , MarcyP , et al. Elements of recovery in first episode psychosis: developing measurable criteria. Early Interventions in Psychiatry2016;10(Suppl 1):149. ">Cather 2018</a>, <a href="./references#CD008016-bbs2-0116" title="KeefeRS , HarveyPD , KhanA , SaoudJB , StanerC , DavidsonM , et al. Cognitive effects of MIN-101 in patients with schizophrenia and negative symptoms: results from a randomized controlled trial. Journal of Clinical Psychiatry2018;79(3):17m11753. ">Keefe 2018</a>, <a href="./references#CD008016-bbs2-0120" title="LiuCC . A proposed alternative between discontinuation and maintenance of antipsychotics: a guided dose reduction trial for patients with remitted psychosis. Schizophrenia Bulletin2018;44(Suppl 1):S414. ">Liu 2018</a>, <a href="./references#CD008016-bbs2-0130" title="NishikawaT , TanakaM , TsudaA , KogaI , UchidaY . Prophylactic effects of neuroleptics in symptom-free schizophrenics: a comparative dose-response study of timiperone and sulpiride. Biological Psychiatry1989;25(7):861-6. NishikawaT . Personal Communication. Personal Communication2009. ">Nishikawa 1989</a>, <a href="./references#CD008016-bbs2-0129" title="NCT03559426. Research into antipsychotic discontinuation and reduction (RADAR): a randomized controlled trial. https://clinicaltrials.gov/. ">NCT03559426</a>, <a href="./references#CD008016-bbs2-0134" title="PeetM , MiddlemissDN , YatesRA . Propranolol in schizophrenia II. Clinical and biochemical aspects of combining propranolol with chlorpromazine. British Journal of Psychiatry1981;138:112-7. ">Peet 1981</a>, <a href="./references#CD008016-bbs2-0138" title="RanMS , XiangMZ , ChanCL , LeffJ , SimpsonP , HuangMS , et al. Effectiveness of psychoeducational intervention for rural Chinese families experiencing schizophrenia. Social Psychiatry and Psychiatric Epidemiology2003;38:69-75. RanMS , XiangMZ , HuangMS . A control study of psychoeducational family intervention for relatives of schizophrenics in a Chinese rural community. Chinese Journal of Psychiatry2001;34(2):98-101. RanMS . Community mental health in China - A randomized controlled trial of psychoeducational family intervention for carers of persons with schizophrenia in a rural area in Chengdu. http://hdl.handle.net/10722/35402 submitted at the University of Hong Kong in March 2002. ">Ran 2002</a>, <a href="./references#CD008016-bbs2-0140" title="RavarisCL , WeaverLA , BrooksGW . A controlled study of fluphenazine enanthate in chronic schizophrenic patients. Diseases of the Nervous System1965;25:33-9. RavarisCL , WeaverLA , BrooksGW . Further studies with fluphenazine enanthate: II. Relapse rate in patients deprived of medication. American Journal of Psychiatry1967;124:248-9. ">Ravaris 1965</a>, <a href="./references#CD008016-bbs2-0148" title="DolmerS , NielsenM , BirkM , MorsO , SturupAE , AlbertN , et al. Tailor tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia spectrum disorders in remission of psychotic symptoms. Schizophrenia Bulletin2018;44(Suppl 1):S134-S135. EudraCT 2016-000565-23. TAILOR - a randomized clinical trial: Tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or schizophreniform psychosis in remission of psychotic symptoms. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000565-232017. StuerupAE , JensenH , DolmerS , AlbertN , BirkM , HjorthojC , et al. Discontinuation versus maintenance therapy with antipsychotic medication in schizophrenia. TAILOR: a randomized controlled trial. Early Interventions in Psychiatry2018;12:141. StuerupAE , JensenHD , DolmerS , BirkM , AlbertN , NielsenM , et al. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial. Trials2017;18(1):445. ">Stuerup 2017</a>, <a href="./references#CD008016-bbs2-0150" title="VaddadiKS , GilleardCJ , MindhamRH , ButlerR . A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patients. Psychopharmacology1986;88:362-7. ">Vaddadi 1986</a>, <a href="./references#CD008016-bbs2-0153" title="Van PraakHM , DolsLC . Fluphenazine enanthate and fluphenazine decanoate: a comparison of their duration of action and motor side effects. American Journal of Psychiatry1973;130:801-4. ">Van Praag 1973</a>, <a href="./references#CD008016-bbs2-0154" title="WellerA , KillackeyE , GleesonJ , AllottK , Alvarez-JimenezM , BendallS , et al. Less is more? An Australian RCT comparing dose reduction of anti-psychotic medication to maintenance treatment. Early Interventions in Psychiatry2018;12(Suppl 1):207. WellerA , et al. Can antipsychotic dose reduction lead to better functional recovery in first episode psychosis? A randomized controlled trial of antipsychotic dose reduction: the REDUCE trial: study protocol. Early Intervention in Psychiatry2019;13(6):1345-1356. ">Weller 2018</a>, <a href="./references#CD008016-bbs2-0155" title="WiedemannG , HahlwegK , MullerU , FeinsteinE , HankG , DoseM . Effectiveness of targeted intervention and maintenance pharmacotherapy in conjunction with family intervention in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience2001;251:72-84. ">Wiedemann 2001</a>, <a href="./references#CD008016-bbs2-0157" title="FaberG , SmidHG , Van GoolAR , WiersmaD , Van Den BoschRJ . The effect of guided discontinuation of antipsychotics on neurocognition in first onset psychosis. European Psychiatry2012;27:275-80. WunderinkA , Nienhuis, SytemaS , WiersmaD . Guided discontinuation versus maintenance treatment in remitted first episode psychosis: relapse rates and functional outcome. Schizophrenia Research2006;86:S51. ">Wunderink 2006</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Randomised studies, with appropriate participants and interventions, excluded because outcomes were not appropriate ‐ mostly no usable data</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008016-bbs2-0102" title="GallantDM , EdwardsCG , BishopMP , GalbraithGC . Withdrawal symptoms after abrupt cessation of antipsychotic compounds: clinical confirmation in chronic schizophrenics. American Journal of Psychiatry1964;121:491-3. ">Gallant 1964</a>, <a href="./references#CD008016-bbs2-0103" title="GitlinMJ , MidhaKK , FogelsonD , NuechterleinKH . Persistence of fluphenazine in plasma after decanoate withdrawal. Journal of Clinical Psychopharmacology1988;8:53-6. ">Gitlin 1988</a>, <a href="./references#CD008016-bbs2-0104" title="GitlinM , NuechterleinK , SubotnikKL , VenturaJ , MintzJ , FogelsonDL , et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. American Journal of Psychiatry2001;158:1835-42. ">Gitlin 2001</a>, <a href="./references#CD008016-bbs2-0107" title="GoodWW , SterlingM , HoltzmanWH . Termination of chlorpromazine with schizophrenic patients. American Journal of Psychiatry1958;115:443-8. MefferdRB , LabrosseEH , GawienowskiAM , WilliamsRJ . Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics. Journal of Nervous and Mental Disease1958;127:167-79. ">Good 1958</a>, <a href="./references#CD008016-bbs2-0110" title="HirschSR , JolleyAG , BarnesTR , LiddlePF , CursonDA , PatelA , et al. Dysphoric and depressive symptoms in chronic schizophrenia.. Schizophrenia Research1989;2(3):259-64. HirschSR , JolleyAG . The dysphoric syndrome in schizophrenia and its implications for relapse [Das dysphorische Syndrom in der Schizophrenie und seine Implikationen fuer den Rueckfall]. In: Boeker W//Brenner HD//WaldvogelDM , editors(s). Schizophrenie Als Systemische Stoerung. Die Bedeutung Intermediaerer Prozesse Fuer Theorie Und Therapie. Bern, Switzerland: Verlag Hans Huber, 1989:94-103. HirschSR , JolleyAG . The dysphoric syndrome in schizophrenia and its implications for relapse. British Journal of Psychiatry. Supplements1989;155(Suppl 5):46-50. ">Hirsch 1989</a>, <a href="./references#CD008016-bbs2-0111" title="HirschSR , BowenJT , EmamiJ , CramerP , JolleyA , HawC , et al. A one year prospective study of the effect of life events and medication in the aetiology of schizophrenic relapse. British Journal of Psychiatry1996;168:49-56. HirschSR , BowenJT , EmamiJ . The effect of life events and medication in the aetiology of schizophrenic relapse. Schizophrenia Research1993;9:266. ">Hirsch 1996</a>, <a href="./references#CD008016-bbs2-0122" title="MahalAS , JanakiramaiahN . A double blind placebo controlled trial of pimozide (R6238) on 49 hospitalized chronic schizophrenics. Indian Journal of Psychiatry1975;17(1):45-55. ">Mahal 1975</a>, <a href="./references#CD008016-bbs2-0124" title="MathurS , HallJN . Phenothiazine withdrawal in schizophrenics in a hostel. British Journal of Psychiatry1981;138:271-2. ">Mathur 1981</a>, <a href="./references#CD008016-bbs2-0126" title="MefferdRB , LabrosseEH , GawienowskiAM , WilliamsRJ . Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics. Journal of Nervous and Mental Disease1958;127(2):167-79. ">Mefferd 1958</a>, <a href="./references#CD008016-bbs2-0137" title="PigacheRM , NorrisHN . Measurement of drug action in schizophrenia. Clinical Science1973;44:28P. PigacheRM , NorrisHN . Selective attention as an index of the anti-psychotic action of chlorpromazine in schizophrenia. British Psychological Society Bulletin1973;20:160. PigacheRM . Effects of placebo, orphenadrine, and rising doses of chlorpromazine, on PAT performance in chronic schizophrenia. A two year longitudinal study. Schizophrenia Research1993;10:51-9. PigacheRM . The clinical relevance of an auditory attention task (PAT) in a longitudinal study of chronic schizophrenia with placebo substitution for chlorpromazine. Schizophrenia Research1993;10:39-50. ">Pigache 1993</a>, <a href="./references#CD008016-bbs2-0141" title="Ruiz RuizM , Miro QuintanaL , Sentis VilaltaJ . A clinical study with pimozide in chronic schizophrenics [Estudio clinico con pimocide en las esquizophrenias de evolucion cronica]. Revista de Psiquiatria Y Psicologia Medica de Europa Y America Latinas1975;12(4):247-56. ">Ruiz 1975</a>, <a href="./references#CD008016-bbs2-0142" title="NCT01765829. Clinical trial to evaluate the efficacy of treatment vs discontinuation in a first episode of non-affective psychosis (NONSTOP). https://www.clinicaltrials.gov/ct2/show/NCT01765829?term=NCT01765829&amp;rank=12013. ">Ruiz Veguilla 2013</a>, <a href="./references#CD008016-bbs2-0144" title="SingerK , ChengMN . Thiopropazate hydrochloride in persistent dyskinesia. British Medical Journal1971;4:22-25. ">Singer 1971</a>, </p> </td> </tr> </tbody> </table> </div> </p> </section> </section> <section id="CD008016-sec-0106"> <h3 class="title">Risk of bias in included studies</h3> <p>For graphical representations of our judgements of risk of bias please refer to <a href="#CD008016-fig-0004">Figure 4</a> and <a href="#CD008016-fig-0005">Figure 5</a>. Full details of judgements are seen in the 'Risk of bias' tables. </p> <div class="figure" id="CD008016-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008016-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD008016-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008016-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD008016-sec-0107"> <h4 class="title">Allocation</h4> <p>In 22 studies, random sequence generation was adequate. In the remaining 53 studies this was unclear. Among these, 50 studies were described as "randomised", but 39 of these did not provide any further details about random sequence generation. Eleven studies gave further information about randomisation, but these details were rather superficial and we still had to rate them as 'unclear'. Three further studies (<a href="./references#CD008016-bbs2-0023" title="OtaKY , KurlandAA . A double-blind comparison of haloperidol oral concentrate, haloperidol solutabs and placebo in the treatment of chronic schizophrenia. Journal of Clinical Pharmacology1973;13:99-110. [CSZG: 2318]">Haloperidol 1973</a>; <a href="./references#CD008016-bbs2-0041" title="ChannabasavannaSM , MichaelA . Penfluridol maintenance therapy in schizophrenia: a controlled study. Indian Journal of Psychiatry1987;29(4):333-6. [CSZG: 1094]">Penfluridol 1987</a>; <a href="./references#CD008016-bbs2-0071" title="McCreadieRG , WilesD , GrantS , CrockettGT , MahmoodZ , LivingstonMG , et al. The Scottish first episode schizophrenia study. VII two-year follow-up. Acta Psychiatrica Scandinavica1989;80:597-602. [CSZG: 3968]Scottish Schizophrenia Research Group. The Scottish First Episode Schizophrenia Study II. Treatment. British Journal of Psychiatry1987;150:334-8. [CSZG: 3969]Scottish Schizophrenia Research Group. The Scottish First Episode Schizophrenia Study V. One-year follow-up. British Journal of Psychiatry1988;152:470-476. [CSZG: 3970]Scottish Schizophrenia Research Group. The Scottish First Episode Schizophrenia Study. III. Cognitive performance. British Journal of Psychiatry1987;150:338-340. [CSZG: 16867]Scottish Schizophrenia Research Group. The Scottish first episode schizophrenia study. VIII. Five-year follow-up. British Journal of Psychiatry1992;161:496-500. [CSZG: 2542]">Various drugs 1989</a>) did not provide any information about sequence generation, but they were double‐blind and we assumed they were also randomised. </p> <p>In 26 studies, allocation concealment was rated as adequate. For example, some studies reported that the only people with access to the identity of patients were the hospital pharmacist (e.g. <a href="./references#CD008016-bbs2-0012" title="AndrewsP , HallJN , SnaithRP . A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients. British Journal of Psychiatry1976;128:451-5. [CSZG: 226]">Chlorpromazine 1976</a>; <a href="./references#CD008016-bbs2-0050" title="HershonHI , KennedyPF , McGuireRJ . Persistence of extra-pyramidal disorders and psychiatric relapse after withdrawal of long-term phenothiazine therapy. British Journal of Psychiatry1972;120(554):41-50. [CSZG: 1001]StevensBC . Role of fluphenazine decanoate in lessening the burden of chronic schizophrenics on the community. Psychological Medicine1973;3:141-58. [CSZG: 2739]">Trifluoperazine 1972</a>), a research assistant (e.g. <a href="./references#CD008016-bbs2-0017" title="HankoffLD , EngelhardtDM , FreedmanN , MannD , MaroolisR . Denial of illness in schizophrenic outpatients: effects of psychopharmacological treatment. Archives of General Psychiatry1960;3:657-66. [CSZG: 959]HirschSR , GaindR , RohdePD , StevensBC , WingJK . Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry. British Medical Journal1973;1:633-7. [CSZG: 3799]">Fluphenazine depot 1973</a>), a psychiatrist without contact to participants (<a href="./references#CD008016-bbs2-0054" title="TroshinskyC , AaronsonHG , StoneRK . Maintenance phenothiazines in aftercare of schizophrenic patients. Pennsylvania Psychiatric Bulletin1962;2:11-5. [CSZG: 2855]">Various drugs 1962b</a>) or a unit secretary (<a href="./references#CD008016-bbs2-0060" title="HirschSR , GaindR , RohdePD , StevensBC , WingJK . Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry. British Medical Journal1973;1(854):633-7. [CSZG: 3799]HirschSR , LeffJP , WingJK . Outpatient maintenance of chronic schizophrenics with long-acting. British Medical Journal1973;2(5868):715-6. [CSZG: 3839]LeffJP , HirschSR , GaindR , RohdePD , StevensBC . Life events and maintenance therapy in schizophrenic relapse. British Journal of Psychiatry1973;123:659-60. LeffJP , WingJK . Trial of maintenance therapy in schizophrenia. British Medical Journal1971;3:599-604. [CSZG: 3840]LeffJP . Influence of selection of patients on results of clinical trials. British Medical Journal1973;4(5885):156-8. [CSZG: 7717]StevensB . The social value of fluphenazine decanoate. Acta Psychiatrica Belgica1976;76(5):792-804. [CSZG: 2745]StevensBC . Role of fluphenazine decanoate in lessening the burden of chronic schizophrenics on the community. Psychological Medicine1973;3(2):141-58. [CSZG: 2739]">Various drugs 1971</a>). <a href="./references#CD008016-bbs2-0003" title="BakerR , FleischhackerW , SanchezR , PerryP , JinN , JohnsonB , et al. Long-term safety and tolerability of once-monthly aripiprazole intramuscular depot for maintenance treatment in schizophrenia. International Journal of Neuropsychopharmacology2012;15:111. [CSZG: 28035]BakerRA , CarsonWH , PerryPP , SanchezR , ZhaoJ , McQuadeRD , et al. Effects of aripiprazole once-monthly vs placebo on domains of personal and social performance in younger and older patients with schizophrenia. CNS Spectrums2013;18(6):376-7. [CSZG: 28526]BakerRA , EramoA , CarsonWH , PerryP , SanchezR , ZhaoJ , et al. Effects of aripiprazole once-monthly vs. placebo on domains of personal and social performance in younger and older patients with schizophrenia. Schizophrenia Bulletin2013;39(Suppl 1):S321-S322. [CSZG: 28131]BakerRA , EramoA , NylanderAG , TsaiLF , Peters-StricklandTS , KosticD , et al. The effect of previous dose or oral aripiprazole (10 or 30 mg/day) on the efficacy and tolerability of aripiprazole once-monthly: Results from post-hoc analyses from two double-blind, randomized, controlled trials. Schizophrenia Research2014;153:S293. [CSZG: 29386]CarsonWH , PerryPP , SanchezR , JinN , ForbesRA , McQuadeRD , et al. Effects of ARI-IM-depot on secondary efficacy outcomes in maintenance treatment of schizophrenia. International Journal of Neuropsychopharmacology2012;15:112-3. [CSZG: 28030]EramoA , FleischhackerWW , SanchezR , PerryP , JinN , JohnsonB , et al. A placebo-controlled study of efficacy and safety of aripiprazole oncemonthly for long-term maintenance treatment in schizophrenia. European Psychiatry2013;28(1):1. [CSZG: 28187]EramoA , FleischhackerWW , SanchezR , TsaiLF , Peters-StricklandTS , BakerRA , et al. All-cause discontinuation and safety of aripiprazole once-monthly for the treatment of schizophrenia: A pooled analysis of two double-blind, randomized, controlled trials. Schizophrenia Research2014;153:S174. [CSZG: 29437]FleischhackerWW , BakerRA , EramoA , SanchezR , TsaiLF , Peters-StricklandT , et al. Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies. Schizophrenia Research2014;159(2-3):415-20. [CSZG: 32163]FleischhackerWW , PerryP , SanchezR , JinN , Peters-StricklandT , JohnsonB , et al. Functional outcomes with aripiprazole once-monthly in two double-blind, placebo- and active-controlled studies (aspire us 246 and aspire eu 247) for the treatment of schizophrenia. Value in Health2013;16(7):A550. [CSZG: 28480]FleischhackerWW , SanchezR , JohnsonB , JinN , ForbesRA , McQuadeR , et al. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. International Clinical Psychopharmacology2013;28:171-6. [CSZG: 28391]FleischhackerWW , SanchezR , Lan-FengT , Peters-StricklandT , BakerRA , EramoA , et al. Safety and Effectiveness of Aripiprazole Oncemonthly for the Treatment of Schizophrenia: A Pooled Analysis of Two Double-blind, Randomized, Controlled Trials. Neuropsychopharmacology2013;38:S394-S395. [CSZG: 28459]KaneJM , SanchezR , BakerRA , EramoA , Peters-StricklandT , PerryPP , et al. Patient-centered outcomes with aripiprazole once-monthly for maintenance treatment in patients with schizophrenia: Results from two multicenter, randomized, double-blind studies. Clinical Schizophrenia and Related Psychoses2015;9(2):79-87. [CSZG: 32183]KaneJM , SanchezR , PerryPP , JinN , JohnsonB , ForbesRA , et al. Efficacy of aripiprazole-IM-depot for long-term maintenance treatment of schizophrenia. International Journal of Neuropsychopharmacology2012;15:S119. [CSZG: 28033]KaneJM , SanchezR , PerryPP , JinN , JohnsonBR , ForbesRA , et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: A 52-week, multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2012;73(5):617-24. [CSZG: 24369]LozeJ , CarsonWH , PerryPP , SanchezR , JinN , ForbesRA , et al. Psychosocial and overall effectiveness of aripiprazole intramuscular depot vs. placebo for maintenance treatment in schizophrenia. European Neuropsychopharmacology2012;22:S328. [CSZG: 24886]NCT00705783. Aripiprazole (OPC-14597) as maintenance treatment in patients with schizophrenia. https://www.ClinicalTrials.gov/ct/show/2008. [CSZG: 16546]SanchezR , JohnsonB , JinN , ForbesRA , CarsonWH , McQuadeRD , et al. Patient-reported outcomes (PROs) with aripiprazole intramuscular depot (ARI-IMD) for maintenance treatment in schizophrenia. International Journal of Neuropsychopharmacology2012;15:133. [CSZG: 28040]SanchezR , PerryPP , JinN , Johnson, RA Forbes, RD McQuade, WH, et al. A placebo-controlled study of efficacy/ safety of aripiprazole intramuscular depot for long-term maintenance treatment of schizophrenia. European Neuropsychopharmacology2012;(Suppl 2):S327. [CSZG: 24893]">Aripiprazole depot 2012</a>, <a href="./references#CD008016-bbs2-0005" title="BakerR , HobartM , ForbesA , OuyangJ , WeillerE . Effect of brexpiprazole on long-term functioning in adults with schizophrenia. Australian and New Zealand Journal of Psychiatry2017;51(Suppl 1):148. [CSZG: 35955]CorrellCU , ShiL , WeissC , HobartM , EramoA , DuffyRA , et al. Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice of cross-titration schedules in a post-hoc analysis of a randomized double-blind maintenance treatment study. CNS Spectrums2019;24(5):507-17. FleischhackerWW , HobartM , OuyangJ , ForbesA , PfisterS , McQuadeR , et al. Brexpiprazole (OPC-34712) efficacy and safety as maintenance therapy in adults with schizophrenia: Randomised, double-blind, placebo-controlled study. European Neuropsychopharmacology2015;25:S527. [CSZG: 33322]FleischhackerWW , HobartM , OuyangJ , ForbesA , PfisterS , McQuadeRD , et al. Efficacy and sfety of Brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. International Journal of Neuropsychopharmacology2017;20(1):11-21. [CSZG: 35475]NCT01668797. Efficacy, Safety, and tolerability of Brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia. https://ClinicalTrials.gov/show/NCT016687972012. [CSZG: 35608]TherrienF , WeissC , JinN , BakerRA , MacKenzieE , MeehanSR . Effect of brexpiprazole on patient functioning in patients with schizophrenia: results from a long-term, randomised, double-blind, placebo-controlled, maintenance study. Neuropsychopharmacology2017;43((Suppl.1)):S244-S245. [CSZG: 37935]WeillerE , HobartM , PfsterS , ForbesA , OuyangJ , WeissC . Effect of brexpiprazole on long-term remission in adults with schizophrenia: Results from a randomized, double-blind, placebo-controlled, maintenance study. Schizophrenia Bulletin2017;43:S202-3. [CSZG: 36050]WeissC , ForbesA , HobartM , PfsterS , OuyangJ , WeillerE . Short-term and long-term efficacy of brexpiprazole in adults with schizophrenia: Effect across marder factors. Schizophrenia Bulletin2017;43:S155. [CSZG: 36051]WeissC , OuyangJ , EramoA , DuffyRA , WeillerE , BakerRA . Switching patients with acute schizophrenia to brexpiprazole: post-hoc analysis of a double-blind randomized maintenance treatment study. Neuropsychopharmacology2015;40:S227-8. [CSZG: 33450]WeissC , WeillerE , HobartM , OuyangJ . Effect of brexpiprazole on weight and metabolic parameters: analysis of a maintenance trial in schizophrenia. European Neuropsychopharmacology2016;26:S556. [CSZG: 35746]">Brexpiprazole 2017</a>, <a href="./references#CD008016-bbs2-0027" title="CTRI/2010/091/001409. A clinical trial to study prevention of relapse in patients with schizophrenia reveiving either flexible dose iloperidone or placebo in long-term use.. http://ctri.nic.in/Clinicaltrials/login.php2010. NCT01291511. Efficacy in prevention of relapse of schizophrenia in subjects taking either placebo or iloperidone. http://ClinicalTrials.gov/show/NCT012915112011. [CSZG: 22671]WeidenPJ , ManningR , WolfgangCD , RyanJM , MancioneL , HanG , et al. A randomized trial of iloperidone for prevention of relapse in schizophrenia: the REPRIEVE study. CNS drugs2016;30(8):735-47. [CSZG: 35243]">Iloperidone 2016</a><a href="./references#CD008016-bbs2-0028" title="NCT01435928. PEARL Schizophrenia Maintenance. http://ClinicalTrials.gov/show/NCT014359282011. [CSZG: 23439]TandonR , CucchiaroJ , PhillipsD , HernandezD , MaoY , PikalovA , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Journal of Psychopharmacology2016;30(1):69-77. [CSZG: 33434]TandonR , LoebelA , PhilipsD , PikalovA , Hernandez D MaoY , et al. Lurasidone for maintenance of efficacy in patients with schizophrenia. European Neuropsychopharmacology2014;24(Suppl 2):S559-560. [CSZG: 27840]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , CucchiaroJ . A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Schizophrenia Research2014;153(1):S372. [CSZG: 29681]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Int J Neuropsychopharmacol2014;17:S153-154. [CSZG: 29954]">Lurasidone 2016</a>, <a href="./references#CD008016-bbs2-0030" title="Beasley C Jr, HamiltonS , DossenbachM . Relapse prevention with olanzapine. European Neuropsychopharmacology2000;10(Suppl 3):S304. [CSZG: 4620]BeasleyCM , HamiltonSH , DossenbachM . Relapse prevention with olanzapine. Schizophrenia Research2000;41(1):196-7. [CSZG: 4874]BeasleyCM , SuttonVK , HamiltonSH , WalkerDJ , DossenbachM , TaylorCC , et al. A double-blind, randomised, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. Journal of Clinical Psychopharmacology2003;23:582-94. [CSZG: 10010]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD , PickarD . Does maintenance treatment with atypical antipsychotics worsen quality of life among stable patients with schizophrenia?Neuropsychopharmacology2005;30(S1):S189. [CSZG: 13107]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD . Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?Journal of Clinical Psychopharmacology2006;26:40-4. [CSZG: 14454]BeasleyCM , WalkerDJ , SuttonVK , AlakaK , NaberD , NamjoshiM . The effectiveness of olanzapine versus placebo in maintaining the quality of life in stabilized patients with schizophrenia. European Neuropsychopharmacology2003;13:S342. [CSZG: 9849]EliLilly Company. Olanzapine relapse prevention versus placebo in the treatment of schizophrenia. http://www.Clinicalstudyresults.org/.2005. [CSZG: 18733]">Olanzapine 2003</a>, <a href="./references#CD008016-bbs2-0031" title="Eerdekens. Evaluate the efficacy in the prevention of recurrence of the symptoms of schizophrenia. Sponsor: Johnson &amp; Johnson Pharmaceutical Research &amp; Development, LL.C2010. [CTG: NCT00111189]KramerM , KushnerS , SherrJ , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study. Schizophrenia Bulletin2007;33(2):438. [CSZG: 15185]KramerM , KushnerS , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia treated with paliperidone extended-release tablets. European Neuropsychopharmacology2006;16(Suppl 4):S386. [CSZG: 13313]KramerM , KushnerS , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study. International Journal of Neuropsychopharmacology2006;9(Suppl 1):S274. [CSZG: 19545]KramerM , SimpsonG , MaciulisV , KushnerS , LiuY , LimP , et al. One-year open-label safety and efficacy study of paliperidone extended-release. CNS Spectrums2010;15(8):506-14. [CSZG: 20885]KramerM , SimpsonG , MaciulisV , KushnerS , VijapurkarU , LimP , et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2007;27:6-14. [CSZG: 13907]MarkowitzM , FuDJ , LevitanB , GopalS , TurkozI , AlphsL . Long-acting injectable paliperidone palmitate versus oral paliperidone extended release. Annals of General Psychiatry2013;12:22. [CSZG: 28633]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone 2007</a>, <a href="./references#CD008016-bbs2-0032" title="RuiQ , WangY , LiangS , LiuY , WuY , WuQ , et al. Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry2014;53:45-53. [CSZG: 29320]ZhangH , LiH , LiuY , WuC , WuQ , NuamahI . Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia. Neuropsychiatric Disease and Treatment2016;12:69-77. [CSZG: 33455]">Paliperidone 2014</a>, <a href="./references#CD008016-bbs2-0033" title="AlphsL , BossieC , Kern-SliwaJ , Ma Y-W, HaskinsJT . Paliperidone palmitate: clinical response in subjects with schizophrenia with recent vs. longer-term duration of illness. In: Proceedings of the 162nd Annual Meeting of the American Psychiatric Association. San Francisco, CA., 2009 May 16-21. [CSZG: 19067]EmsleyR , NuamahI , GopalS , HoughD , FleischhackerWW . Relapse after antipsychotic discontinuation in schizophrenia as a withdrawal phenomenon vs illness recurrence: a post hoc analysis of a randomized placebo-controlled study. Journal of Clinical Psychiatry 2018 Jun;79(4):17m11874. [CSZG: 38184]EmsleyR , NuamahI , HoughD , GopalS . Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophrenia Research2012;138(1):29-34. [CSZG: 24214]GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM , HoughD . A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. Journal of Psychopharmacology2011;25(5):685-97. [CSZG: 22903]GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Long-term efficacy, safety and tolerability of paliperidone palmitate in patients with schizophrenia. In: Proceedings of the 162nd Annual Meeting of the American Psychiatric Association. San Francisco, CA, 2009 May 16-21. [CSZG: 19076]HoughD , GopalS , VijapukarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate in prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. In: Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8, Washington DC, USA. 2008. [CSZG: 16486]HoughD , GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. In: Proceedings of the 63rd Annual Convention of the Society of Biological Psychiatry. Washington, DC, USA: Elsevier Science Inc, 2008:S285-6. [CSZG: 20281]HoughD , GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Biological Psychiatry2008;63(7 Suppl):285S-6S. [CSZG: 19530]HoughD , GopalS , VjapukarU , LimP , MorozowaM , EerdekensM . Paliperidone palmitate maintenance treatment in delaying the time to relapse in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. Schizophrenia Research2010;116:107-17. [CSZG: 19704]HulihanJ , BossieCA , FuDJ , Kern SliwaJ , Ma Y-W, AlphsLD . Remission with continued paliperidone palmitate treatment in stable subjects with schizophrenia. Schizophrenia Research2012;136:S252. [CSZG: 29467]KozmaCM , SlatonT , DiraniR , FastenauJ , GopalS , HoughD . Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate. Current Medical Resarch and Opinion2011;27(8):1603-11. SliwaJK , BossieCA , Fu DJ, TurkozI , AlphsL . Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia. Neuropsychiatric Disease and Treatment2012;8:375-85. [CSZG: 28007]SliwaJK , FuDJ , BossieCA , et al. Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate. BMC Psychiatry2014;14:S52. [CSZG: 29148]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone depot1M 2010</a>, <a href="./references#CD008016-bbs2-0034" title="BossieC , TurkozI , AlphsL , FuDJ . Monotherapy with once monthly paliperidone palmitate for psychotic, depressive, and manic symptoms in schizoaffective disorder. Schizophrenia Bulletin2015;41:S303. [CSZG: 29400]BossieCA , TurkozI , AlphsL , MahalchickL , FuDJ . Paliperidone palmitate once-monthly treatment in recent onset and chronic illness patients with schizoaffective disorder. Journal of Nervous and Mental Ddisease2017;205(4):324-8. [CSZG: 35417]FuDJ , AlphsL , LindenmayerJP , SchoolerN , SimonsonRB , TurkozI , et al. Paliperidone palmitate long-acting injectable delays psychotic and mood symptom relapse in schizoaffective disorder. European Neuropsychopharmacology2014;24:S534-5. [CSZG: 27785]FuDJ , BossieC , TurkozI , MahalchickL , AlphsL . Paliperidone palmitate treatment response in early and chronic illness schizoaffective disorder patients. Schizophrenia Bulletin2015;41:S312. [CSZG: 29446]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Effect of paliperidone palmitate once-monthly in improving and maintaining functioning in subjects with schizoaffective disorder using the domains of the personal and social performance scale. Neuropsychopharmacology2014;39:S365. [CSZG: 29278]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate delays relapse in patients with schizoaffective disorder. Biological Psychiatry2014;1:263S. [CSZG: 28974]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate long-acting injectable in acute exacerbation of schizoaffective disorder. Schizophrenia Bulletin2013;39:S331. [CSZG: 28167]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate once-monthly injectable treatment for acute exacerbations of schizoaffective disorder. Journal of Clinical Psychopharmacology2016;36(4):372-6. [CSZG: 35803]FuDJ , TurkozI , SimonsonRB , WallingDP , SchoolerNR , LindenmayerJP , et al. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. Journal of Clinical Psychiatry2015;76(3):253-62. [CSZG: 29752]FuDJ , TurkozI , WallingD , LindenmayerJP , SchoolerNR , AlphsL . Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder. Schizophrenia Research2018;192:185-93. [CSZG: 35804]JoshiK , LinJ , Lingohr-SmithM , FuD . Medical cost reductions for paliperidone palmitate versus placebo in randomized double-blind trial of patients with schizoaffective disorder. Journal of Managed Care and Specialty Pharmacy2015;21:536-7. JoshiK , LinJ , Lingohr-SmithM , FuDJ . Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder. Journal of Medical Economics2015;18:629-36. [CSZG: 33677]NCT01193153. A study to evaluate the efficacy of paliperidone palmitate in the prevention of relapse of the symptoms of schizoaffective disorder. http://ClinicalTrials.gov/show/NCT011931532010. [CSZG: 21094]TurkozI , FuDJ , WallingD , SchoolerNR , LindenmayerJP , SimonsonRB , et al. Effect of paliperidone palmitate once-monthly in improving and maintaining functioning in subjects with schizoaffective disorder using the domains of the personal and social performance scale. Schizophrenia Bulletin2015;41:S193-4. [CSZG: 29687]">Paliperidone depot1M 2015</a> and <a href="./references#CD008016-bbs2-0035" title="BellLKS , TurkozI , KimE . Paliperidone palmitate once-every-3-months in adults with early illness schizophrenia. Early Intervention in Psychiatry2019;13(3):667-72. BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of paliperidone palmitate 3 month formulation: a randomized, double-blind, placebo-controlled study. Schizophrenia Bulletin2015;41:S302. [CSZG: 29393]BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of paliperidone palmitate 3-month formulation in schizophrenia: a randomized, double-blind, placebo-controlled study. European Psychiatry2015;30:272. [CSZG: 32149]BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry2015;72(8):830-9. [CSZG: 33027]ChirilaC , ZhengQ , SawyerrG , NuamahI . Healthcare resource use of paliperidone palmitate 3-month injection vs placebo. In: 168th Annual Meeting of American Psychiatric Association; Toronto, Canada. May 16-20, 2015. [CSZG: 33035]GopalS , FureyM , HibarD , KolbH , SaadZ , SavitzA , et al. Potential biomarkers of impending schizophrenia relapse. Biological Psychiatry2017;(10 Suppl):S126-S127. [CSZG: 36107]GopalS , XuH , McQuarrieK , SavitzA , NuamahI , WoodruffK , et al. Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies. NPJ Schizophrenia2017;3(1):23. [CSZG: 36325]MathewsM , NuamahI , SavitzA , GopalS . Efficacy and safety of paliperidone palmitate 3-month formulation vs placebo for relapse prevention of Schizophrenia: Treatment effect using a number needed to treat analysis. Biological Psychiatry2017;81(10 Suppl 1):S350-1. [CSZG: 36437]NCT01529515. A study of paliperidone palmitate 3 month formulation for the treatment of patients with schizophrenia. http://ClinicalTrials.gov/show/NCT015295152012. [CSZG: 23705]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone depot3M 2015</a> used an interactive voice‐response system for allocation concealment. One study (<a href="./references#CD008016-bbs2-0074" title="AratoM , O'ConnorR , BradburyJE , MeltzerH . Long-term ziprasidone in schizophrenia. In: Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 - Jun 4; Toronto, Ontario, Canada. 1998. [CSZG: 3189]AratoM , O'ConnorR , BradburyJE , MeltzerH . The efficacy of ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. In: Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK. Amsterdam, Netherlands: Cambridge University Press, 1998. [CSZG: 3188]AratoM , O'ConnorR , BradburyJE , MeltzerH . Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. In: Proceedings of the 9th Congress of the Association of European Psychiatrists; 1998 Sep 20-24; Copenhagen, Denmark. 1998. [CSZG: 3190]AratoM , O'ConnorR , BradburyJE , MeltzerH . Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. Schizophrenia Research1999;36(1-3):270. [CSZG: 5626]AratoM , O'ConnorR , MeltzerH , BradburyJ . Ziprasidone: efficacy in the prevention of relapse and in the long-term treatment of negative symptoms of chronic schizophrenia. In: Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria. 1997. [CSZG: 245]AratoM , O'ConnorR , MeltzerHY . A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. International Clinical Psychopharmacology2002;17:207-15. [CSZG: 18486]BernardoM , AranzaJR , Rubio-TerresC , RejasJ . Cost-effectiveness analysis of schizophrenia relapse prevention. Clinical Drug Investigation. New Zealand2006;26(8):447-57. [CSZG: 13898]BernardoM , AranzaJR , Rubio-TerresC , RejasJ . Cost-effectiveness analysis of the prevention of relapse in schizophrenia in the ZEUS longitudinal study Ziprasidone Extended Use in Schizophrenia (ZEUS). Acta Espanolas de Psiquiatria2007;35(4):259-62. [CSZG: 15396]MeltzerHY , O´ConnorR . Long-term efficacy of ziprasidone in schizophrenia. Schizophrenia research2001;(1-2):S. 239. [CSZG: 6050]MeltzerHY , O´ConnorR . Path analysis of the ZEUS study provides evidence of a direct effect of ziprasidone on primary negative symptoms in chronic, stable schizophrenia. Conference Poster1997. [CSZG: 2033]MeltzerHY , O'ConnorR . Long-term efficacy of ziprasidone in schizophrenia: results of two controlled trials. In: Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico. 2000. [CSZG: 7609]O'ConnorR , SchoolerNR . Penultimate observation carried forward (POCF): a new approach to analysis of long-term symptom change in chronic relapsing conditions [letter]. Schizophrenia Research2003;60:319-20. [CSZG: 9365]Pfizer 2000. Multicentre double-blind study of ziprasidone versus placebo in relapse prevention for hospitalised patients with chronic or subchronic schizophrenia. Study report Unpublished. SchoolerN . A basis for optimism: the implications of long term treatment. In: Proceedings of the 9th Congress of the Association of European Psychiatrists; 1998 Sep 20-24; Copenhagen, Denmark. 1998. [CSZG: 5864]">Ziprasidone 2002</a>) used treatment cards numbered for each participant and investigators and pharmacists allocated numbers to people. <a href="./references#CD008016-bbs2-0048" title="ChenE , HuiC , ChangWC , ChanS , LeeE , HonerW . The effect of early medication discontinuation on long-term clinical outcome in first episode psychosis. Schizophrenia Bulletin2018;44(Suppl 1):S97. ChenE , HuiC , LamM , LawC , ChiuC , ChungD , et al. Assessing the efficacy of relapse prevention in single episode psychosis patients with stable maintenance treatment for at least 1 year: a double-blind randomized placebo-controlled. Early Intervention in Psychiatry2008;2(Suppl 1):A5. [CSZG: 19113]ChenEY , HuiCL , LamM , LawCW , ChiuCP , ChungDW , et al. A double-blind randomised placebo-controlled study of relapse prevention in remitted first-episode psychosis patients following one year of maintenance therapy. Schizophrenia Research2008;98:11-2. [CSZG: 16325]ChenEY , HuiCL , LamM , LawCW , ChiuCP , ChungDW , et al. A double-blind randomized placebo-controlled relapse prevention study in remitted first-episode psychosis patients following one year of maintenance treatment. Early Intervention in Psychiatry2010;4(Suppl 1):13. [CSZG: 23475]ChenEY , HuiCL , LamMM , ChiuCP , LawCW , ChungDW , et al. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ2010;341:c4024. [CSZG: 20857]ChenYH , HuiLM , LamM , LawCW , ChiuPY , ChungWS , et al. A double-blind randomized placebo-controlled relapse prevention study in remitted first-episode psychosis patients following one year of maintanence therapy. European Psychiatry2008;23:S107-S8. [CSZG: 20468]Hui CL , WongGH , TangJY , ChangWC , ChanSK , LeeEH , et al. Predicting 1-year risk for relapse in patients who have discontinued or continued quetiapine after remission from first-episode psychosis. Schizophrenia Research2013;150(1):297-302. [CSZG: 28601]HuiC , ChenE , LamM , LawC , ChiuC , ChungD , et al. Can we predict relapse in single episode psychosis patients with stable maintenance treatment for at least one year?Early Intervention in Psychiatry2008;2(Suppl 1):A124. [CSZG: 19123]HuiCL , ChenEY , LamM , LawCW , ChiuCP , ChungDW , et al. Predictors for relapse in a double-blind randomized placebo-controlled discontinuation study of remitted first-episode psychosis patients. Schizophrenia Research2008;98:13. [CSZG: 16333]HuiCL , HonerW , LeeE , ChanS , ChangWC , ChenE . The 10-year clinical outcome of early medication discontinuation in remitted first episode psychosis. Early Intervention in Psychiatry2018;12(1):46. HuiCL , HonerWG , LeeEH , ChangWC , ChanSK , ChenES , et al. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. Lancet Psychiatry 2018 May;5(5):432-42. [CSZG: 38003]HuiCL , HonerWG , LeeEH , ChangWC , ChanSK , ChenES , et al. Predicting first-episode psychosis patients who will never relapse over 10 years. Psychological Medicine2019;49(13):2206-14. HuiCL , HonerWG , LeeEH , ChangWC , ChanSK , ChenEY . Factors associated with successful medication discontinuation after a randomized clinical trial of relapse prevention in first-episode psychosis: a 10-year follow-up. JAMA Psychiatry2019;76(2):217-9. HuiCL , LiYK , LiAW , LeeEH , ChangWC , ChanSK , et al. Visual working memory deterioration preceding relapse in psychosis. Psychological Medicine2016;46:2435-44. [CSZG: 33663]HuiLM , ChenYH , LamM , LawCW , ChiuPY , ChungWS , et al. A double-blind randomized placebo-controlled study of relapse predictors in remitted first-episode psychosis patients. European Psychiatry2008;23:S120-S1. [CSZG: 20469]NCT00334035. Duration of maintenance anti-psychotic therapy after first –episode schizophrenia: a double-blind randomized placebo-control relapse prevention study. https://www.ClinicalTrials.gov/ct/show/2006. [CSZG: 14607]">Quetiapine 2010</a> reported that AstraZeneca prepared individually‐numbered study drugs and packed them according to the randomisation sequence. Two studies mentioned that codes were not broken until the time of the analysis and that the code was unknown to the investigators (<a href="./references#CD008016-bbs2-0025" title="ZissisNP , PsarasM , LyketsosG . Haloperidol decanoate, a new long-acting antipsychotic, in chronic schizophrenics: double-blind comparison with placebo. Current Therapeutic Research1982;31:650-5. [CSZG: 3256]">Haloperidol depot 1982</a>, <a href="./references#CD008016-bbs2-0075" title="CooperSJ , ButlerA , TweedJ , RaniwallaJ , WelchC . Zotepine in the prevention of relapse. Biological Psychiatry1997;42:41s. [CSZG: 17007]CooperSJ , ButlerA , TweedJ , RaniwallaJ , WelchC . Zotepine in the prevention of relapse. In: Proceedings of the 6th World Congress of Biological Psychiatry; 1997 June 22-27; Nice, France. 1997. [CSZG: 569]CooperSJ , ButlerA , TweedJ , WelchC , RaniwallaJ . Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacology2000;150:237-43. [CSZG: 5732]CooperSJ , ButlerA , TweedJA , WelchCP , WightonAJ , ApplebyP , et al. Zotepine is effective in preventing recurrence in patients with chronic schizophrenia. In: Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31 - Nov 4; Paris, France. 1998. [CSZG: 5784]CooperSJ , ButlerA , TweedJA , WelchCP , WightonAJ , ApplebyP , et al. Zotepine is effective in preventing recurrence in patients with chronic schizophrenia. Schizophrenia Research2000;41:207-8. [CSZG: 4925]">Zotepine 2000</a>). </p> <p>The remaining 49 studies ‐ often undertaken well beyond the period when the need for good reporting was widely recognised (<a href="http://www.consort-statement.org/" target="_blank">CONSORT</a>) ‐ did not provide any details on allocation concealment. Therefore, it was unclear for most of the studies whether adequate allocation concealment methods were used. </p> </section> <section id="CD008016-sec-0108"> <h4 class="title">Blinding</h4> <p>Concerning bias related to blinding of participants and personnel, we rated seven studies to have a low risk of bias. In them it was either tested that blinding had worked (<a href="./references#CD008016-bbs2-0008" title="FreemanLS , AlsonE . Prolonged withdrawal of chlorpromazine in chronic patients. Diseases of the Nervous System1962;23:522-5. [CSZG: 809]">Chlorpromazine 1962</a>; <a href="./references#CD008016-bbs2-0017" title="HankoffLD , EngelhardtDM , FreedmanN , MannD , MaroolisR . Denial of illness in schizophrenic outpatients: effects of psychopharmacological treatment. Archives of General Psychiatry1960;3:657-66. [CSZG: 959]HirschSR , GaindR , RohdePD , StevensBC , WingJK . Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry. British Medical Journal1973;1:633-7. [CSZG: 3799]">Fluphenazine depot 1973</a>; <a href="./references#CD008016-bbs2-0042" title="WhittakerCB , HoyRM . Withdrawal of perphenazine in chronic schizophrenia. British Journal of Psychiatry1963;109:422-7. ">Perphenazine 1963</a>; <a href="./references#CD008016-bbs2-0060" title="HirschSR , GaindR , RohdePD , StevensBC , WingJK . Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry. British Medical Journal1973;1(854):633-7. [CSZG: 3799]HirschSR , LeffJP , WingJK . Outpatient maintenance of chronic schizophrenics with long-acting. British Medical Journal1973;2(5868):715-6. [CSZG: 3839]LeffJP , HirschSR , GaindR , RohdePD , StevensBC . Life events and maintenance therapy in schizophrenic relapse. British Journal of Psychiatry1973;123:659-60. LeffJP , WingJK . Trial of maintenance therapy in schizophrenia. British Medical Journal1971;3:599-604. [CSZG: 3840]LeffJP . Influence of selection of patients on results of clinical trials. British Medical Journal1973;4(5885):156-8. [CSZG: 7717]StevensB . The social value of fluphenazine decanoate. Acta Psychiatrica Belgica1976;76(5):792-804. [CSZG: 2745]StevensBC . Role of fluphenazine decanoate in lessening the burden of chronic schizophrenics on the community. Psychological Medicine1973;3(2):141-58. [CSZG: 2739]">Various drugs 1971</a>), or the authors had applied specific measures to improve blinding (e.g. prophylactic antiparkinson medication to avoid unmasking by side effects, <a href="./references#CD008016-bbs2-0013" title="RifkinA , QuitkinF , KaneJ , KleinDF , RossD . The effect of fluphenazine upon social and vocational functioning in remitted schizophrenics. Biological Psychiatry1979;14:499-508. [CSZG: 2428]RifkinA , QuitkinF , KaneJ , KleinDF . Fluphenazine decanoate, oral fluphenazine, and placebo in the treatment of remitted schizophrenics. II. Rating scale data. Psychopharmacology Bulletin1977;13:40-50. [CSZG: 2424]RifkinA , QuitkinF , KleinDF . Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics. II. Rating scale data. Archives of General Psychiatry1977;34:15-9. [CSZG: 3959]RifkinA , QuitkinF , RabinerCJ , KleinDF . Comparison of fluphenazine decanoate, oral fluphenazine, and placebo in remitted outpatient schizophrenics. Psychopharmacology Bulletin1976;12:24-6. [CSZG: 2426]RifkinA , QuitkinF , RabinerCJ , KleinDF . Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year. Archives of General Psychiatry1977;34:43-7. [CSZG: 3960]">Fluphenazine 1979</a>; medication was administered by a person distinct from other study personnel, <a href="./references#CD008016-bbs2-0034" title="BossieC , TurkozI , AlphsL , FuDJ . Monotherapy with once monthly paliperidone palmitate for psychotic, depressive, and manic symptoms in schizoaffective disorder. Schizophrenia Bulletin2015;41:S303. [CSZG: 29400]BossieCA , TurkozI , AlphsL , MahalchickL , FuDJ . Paliperidone palmitate once-monthly treatment in recent onset and chronic illness patients with schizoaffective disorder. Journal of Nervous and Mental Ddisease2017;205(4):324-8. [CSZG: 35417]FuDJ , AlphsL , LindenmayerJP , SchoolerN , SimonsonRB , TurkozI , et al. Paliperidone palmitate long-acting injectable delays psychotic and mood symptom relapse in schizoaffective disorder. European Neuropsychopharmacology2014;24:S534-5. [CSZG: 27785]FuDJ , BossieC , TurkozI , MahalchickL , AlphsL . Paliperidone palmitate treatment response in early and chronic illness schizoaffective disorder patients. Schizophrenia Bulletin2015;41:S312. [CSZG: 29446]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Effect of paliperidone palmitate once-monthly in improving and maintaining functioning in subjects with schizoaffective disorder using the domains of the personal and social performance scale. Neuropsychopharmacology2014;39:S365. [CSZG: 29278]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate delays relapse in patients with schizoaffective disorder. Biological Psychiatry2014;1:263S. [CSZG: 28974]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate long-acting injectable in acute exacerbation of schizoaffective disorder. Schizophrenia Bulletin2013;39:S331. [CSZG: 28167]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate once-monthly injectable treatment for acute exacerbations of schizoaffective disorder. Journal of Clinical Psychopharmacology2016;36(4):372-6. [CSZG: 35803]FuDJ , TurkozI , SimonsonRB , WallingDP , SchoolerNR , LindenmayerJP , et al. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. Journal of Clinical Psychiatry2015;76(3):253-62. [CSZG: 29752]FuDJ , TurkozI , WallingD , LindenmayerJP , SchoolerNR , AlphsL . Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder. Schizophrenia Research2018;192:185-93. [CSZG: 35804]JoshiK , LinJ , Lingohr-SmithM , FuD . Medical cost reductions for paliperidone palmitate versus placebo in randomized double-blind trial of patients with schizoaffective disorder. Journal of Managed Care and Specialty Pharmacy2015;21:536-7. JoshiK , LinJ , Lingohr-SmithM , FuDJ . Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder. Journal of Medical Economics2015;18:629-36. [CSZG: 33677]NCT01193153. A study to evaluate the efficacy of paliperidone palmitate in the prevention of relapse of the symptoms of schizoaffective disorder. http://ClinicalTrials.gov/show/NCT011931532010. [CSZG: 21094]TurkozI , FuDJ , WallingD , SchoolerNR , LindenmayerJP , SimonsonRB , et al. Effect of paliperidone palmitate once-monthly in improving and maintaining functioning in subjects with schizoaffective disorder using the domains of the personal and social performance scale. Schizophrenia Bulletin2015;41:S193-4. [CSZG: 29687]">Paliperidone depot1M 2015</a> and <a href="./references#CD008016-bbs2-0035" title="BellLKS , TurkozI , KimE . Paliperidone palmitate once-every-3-months in adults with early illness schizophrenia. Early Intervention in Psychiatry2019;13(3):667-72. BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of paliperidone palmitate 3 month formulation: a randomized, double-blind, placebo-controlled study. Schizophrenia Bulletin2015;41:S302. [CSZG: 29393]BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of paliperidone palmitate 3-month formulation in schizophrenia: a randomized, double-blind, placebo-controlled study. European Psychiatry2015;30:272. [CSZG: 32149]BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry2015;72(8):830-9. [CSZG: 33027]ChirilaC , ZhengQ , SawyerrG , NuamahI . Healthcare resource use of paliperidone palmitate 3-month injection vs placebo. In: 168th Annual Meeting of American Psychiatric Association; Toronto, Canada. May 16-20, 2015. [CSZG: 33035]GopalS , FureyM , HibarD , KolbH , SaadZ , SavitzA , et al. Potential biomarkers of impending schizophrenia relapse. Biological Psychiatry2017;(10 Suppl):S126-S127. [CSZG: 36107]GopalS , XuH , McQuarrieK , SavitzA , NuamahI , WoodruffK , et al. Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies. NPJ Schizophrenia2017;3(1):23. [CSZG: 36325]MathewsM , NuamahI , SavitzA , GopalS . Efficacy and safety of paliperidone palmitate 3-month formulation vs placebo for relapse prevention of Schizophrenia: Treatment effect using a number needed to treat analysis. Biological Psychiatry2017;81(10 Suppl 1):S350-1. [CSZG: 36437]NCT01529515. A study of paliperidone palmitate 3 month formulation for the treatment of patients with schizophrenia. http://ClinicalTrials.gov/show/NCT015295152012. [CSZG: 23705]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone depot3M 2015</a>). </p> <p>Six studies were rated with a high risk of bias. <a href="./references#CD008016-bbs2-0073" title="BoonstraG , BurgerH , GrobbeDE , KahnRS . Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial. International Journal of Psychiatry in Clinical Practice2011;15(2):128-34. [CSZG: 22940]BoonstraG . Schizophrenia termination of pharmacotherapy-STOP-trial. Current Controlled Trials2005. [CSZG: 14487] [ISRCTN: 6332944]">Various drugs 2011</a> was an open study, without providing any further information. In <a href="./references#CD008016-bbs2-0055" title="CaffeyEM , DiamondLS , FrankTV , GrasbergerJC , HermanL , KlettCJ , et al. Discontinuation or reduction of chemotherapy in chronic schizophrenics. Journal of Chronic Diseases1964;17:347-58. [CSZG: 3153]CaffeyEM , ForrestIS , FrankTV , KlettCJ . Phenothiazine excretion in chronic schizophrenics. American Journal of Psychiatry1963;120:578-82. [CSZG: 420]">Various drugs 1964a</a>, the placebo group received medication only every other day and blinding was not fully maintained. <a href="./references#CD008016-bbs2-0059" title="MortonMR . A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia. American Journal of Psychiatry1968;124:1585-8. [CSZG: 2092]">Various drugs 1968</a> and <a href="./references#CD008016-bbs2-0063" title="BlackburnHL , AllenJL . Behavioral effects of interrupting and resuming tranquilizing medication among schizophrenics. Journal of Nervous and Mental Disease1981;133:303-8. [CSZG: 8369]">Various drugs 1981a</a> reported that nurses had made correct guesses as to who was on drug and who was on placebo. In <a href="./references#CD008016-bbs2-0021" title="OdejideOA , AderounmuAF . Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. Journal of Clinical Psychiatry1982;43:195-6. [CSZG: 2184]">Fluphenazine depot 1982</a> evaluating psychiatrists and participants were unaware of the contents of the injections, while treating psychiatrists seemed to be aware of it. <a href="./references#CD008016-bbs2-0072" title="GaebelW , FrickU , KopckeW , LindenM , MuellerP , Mueller SpahnF , et al. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse?British Journal of Psychiatry Supplementum1993;163:8-12. [CSZG: 831]GaebelW , JannerM , FrommannN , PietzckerA , KopckeW , LindenM , et al. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophrenia Research2002;53(1-2):145-59. [CSZG: 8197]GaebelW , MoellerHJ . Treatment strategies in first episode schizophrenia. In: Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan. 2002. [CSZG: 8597]PietzckerA , GaebelW , KoepckeW , LindenM , MuellerP , Mueller-SpahnF , et al. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia - 2-year results of a German multicenter study. Journal of Psychiatric Research1993;27:321-39. [CSZG: 3944]PietzckerA , GaebelW , KopckeW , LindenM , MullerP , Muller-Spahn, et al. A German multicenter study on the neuroleptic long-term therapy of schizophrenic patients. Preliminary report. Pharmacopsychiatry1986;19:161-6. [CSZG: 3943]">Various drugs 1993</a> was an open trial with rating scales being additionally rated by a second blind assessor. </p> <p>In the other 62 studies, we rated the risk of bias as unclear. All these studies were described as double‐blind, with no further relevant information. </p> <p>Concerning blinding of outcome assessment, all studies were rated as 'low risk of bias' concerning what we designated as 'more' objective outcomes, because we considered blinding to be less important for these. </p> <p>As to subjective outcomes, we rated seven studies to have a low risk of bias. In them it was either tested that blinding had worked (<a href="./references#CD008016-bbs2-0008" title="FreemanLS , AlsonE . Prolonged withdrawal of chlorpromazine in chronic patients. Diseases of the Nervous System1962;23:522-5. [CSZG: 809]">Chlorpromazine 1962</a>; <a href="./references#CD008016-bbs2-0017" title="HankoffLD , EngelhardtDM , FreedmanN , MannD , MaroolisR . Denial of illness in schizophrenic outpatients: effects of psychopharmacological treatment. Archives of General Psychiatry1960;3:657-66. [CSZG: 959]HirschSR , GaindR , RohdePD , StevensBC , WingJK . Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry. British Medical Journal1973;1:633-7. [CSZG: 3799]">Fluphenazine depot 1973</a>; <a href="./references#CD008016-bbs2-0042" title="WhittakerCB , HoyRM . Withdrawal of perphenazine in chronic schizophrenia. British Journal of Psychiatry1963;109:422-7. ">Perphenazine 1963</a>; <a href="./references#CD008016-bbs2-0060" title="HirschSR , GaindR , RohdePD , StevensBC , WingJK . Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry. British Medical Journal1973;1(854):633-7. [CSZG: 3799]HirschSR , LeffJP , WingJK . Outpatient maintenance of chronic schizophrenics with long-acting. British Medical Journal1973;2(5868):715-6. [CSZG: 3839]LeffJP , HirschSR , GaindR , RohdePD , StevensBC . Life events and maintenance therapy in schizophrenic relapse. British Journal of Psychiatry1973;123:659-60. LeffJP , WingJK . Trial of maintenance therapy in schizophrenia. British Medical Journal1971;3:599-604. [CSZG: 3840]LeffJP . Influence of selection of patients on results of clinical trials. British Medical Journal1973;4(5885):156-8. [CSZG: 7717]StevensB . The social value of fluphenazine decanoate. Acta Psychiatrica Belgica1976;76(5):792-804. [CSZG: 2745]StevensBC . Role of fluphenazine decanoate in lessening the burden of chronic schizophrenics on the community. Psychological Medicine1973;3(2):141-58. [CSZG: 2739]">Various drugs 1971</a>) or the authors had applied specific measures to improve blinding (e.g. prophylactic antiparkinson medication to avoid unmasking by side effects, <a href="./references#CD008016-bbs2-0013" title="RifkinA , QuitkinF , KaneJ , KleinDF , RossD . The effect of fluphenazine upon social and vocational functioning in remitted schizophrenics. Biological Psychiatry1979;14:499-508. [CSZG: 2428]RifkinA , QuitkinF , KaneJ , KleinDF . Fluphenazine decanoate, oral fluphenazine, and placebo in the treatment of remitted schizophrenics. II. Rating scale data. Psychopharmacology Bulletin1977;13:40-50. [CSZG: 2424]RifkinA , QuitkinF , KleinDF . Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics. II. Rating scale data. Archives of General Psychiatry1977;34:15-9. [CSZG: 3959]RifkinA , QuitkinF , RabinerCJ , KleinDF . Comparison of fluphenazine decanoate, oral fluphenazine, and placebo in remitted outpatient schizophrenics. Psychopharmacology Bulletin1976;12:24-6. [CSZG: 2426]RifkinA , QuitkinF , RabinerCJ , KleinDF . Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year. Archives of General Psychiatry1977;34:43-7. [CSZG: 3960]">Fluphenazine 1979</a>; medication was administered by a person distinct from other study personnel, <a href="./references#CD008016-bbs2-0034" title="BossieC , TurkozI , AlphsL , FuDJ . Monotherapy with once monthly paliperidone palmitate for psychotic, depressive, and manic symptoms in schizoaffective disorder. Schizophrenia Bulletin2015;41:S303. [CSZG: 29400]BossieCA , TurkozI , AlphsL , MahalchickL , FuDJ . Paliperidone palmitate once-monthly treatment in recent onset and chronic illness patients with schizoaffective disorder. Journal of Nervous and Mental Ddisease2017;205(4):324-8. [CSZG: 35417]FuDJ , AlphsL , LindenmayerJP , SchoolerN , SimonsonRB , TurkozI , et al. Paliperidone palmitate long-acting injectable delays psychotic and mood symptom relapse in schizoaffective disorder. European Neuropsychopharmacology2014;24:S534-5. [CSZG: 27785]FuDJ , BossieC , TurkozI , MahalchickL , AlphsL . Paliperidone palmitate treatment response in early and chronic illness schizoaffective disorder patients. Schizophrenia Bulletin2015;41:S312. [CSZG: 29446]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Effect of paliperidone palmitate once-monthly in improving and maintaining functioning in subjects with schizoaffective disorder using the domains of the personal and social performance scale. Neuropsychopharmacology2014;39:S365. [CSZG: 29278]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate delays relapse in patients with schizoaffective disorder. Biological Psychiatry2014;1:263S. [CSZG: 28974]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate long-acting injectable in acute exacerbation of schizoaffective disorder. Schizophrenia Bulletin2013;39:S331. [CSZG: 28167]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate once-monthly injectable treatment for acute exacerbations of schizoaffective disorder. Journal of Clinical Psychopharmacology2016;36(4):372-6. [CSZG: 35803]FuDJ , TurkozI , SimonsonRB , WallingDP , SchoolerNR , LindenmayerJP , et al. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. Journal of Clinical Psychiatry2015;76(3):253-62. [CSZG: 29752]FuDJ , TurkozI , WallingD , LindenmayerJP , SchoolerNR , AlphsL . Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder. Schizophrenia Research2018;192:185-93. [CSZG: 35804]JoshiK , LinJ , Lingohr-SmithM , FuD . Medical cost reductions for paliperidone palmitate versus placebo in randomized double-blind trial of patients with schizoaffective disorder. Journal of Managed Care and Specialty Pharmacy2015;21:536-7. JoshiK , LinJ , Lingohr-SmithM , FuDJ . Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder. Journal of Medical Economics2015;18:629-36. [CSZG: 33677]NCT01193153. A study to evaluate the efficacy of paliperidone palmitate in the prevention of relapse of the symptoms of schizoaffective disorder. http://ClinicalTrials.gov/show/NCT011931532010. [CSZG: 21094]TurkozI , FuDJ , WallingD , SchoolerNR , LindenmayerJP , SimonsonRB , et al. Effect of paliperidone palmitate once-monthly in improving and maintaining functioning in subjects with schizoaffective disorder using the domains of the personal and social performance scale. Schizophrenia Bulletin2015;41:S193-4. [CSZG: 29687]">Paliperidone depot1M 2015</a> and <a href="./references#CD008016-bbs2-0035" title="BellLKS , TurkozI , KimE . Paliperidone palmitate once-every-3-months in adults with early illness schizophrenia. Early Intervention in Psychiatry2019;13(3):667-72. BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of paliperidone palmitate 3 month formulation: a randomized, double-blind, placebo-controlled study. Schizophrenia Bulletin2015;41:S302. [CSZG: 29393]BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of paliperidone palmitate 3-month formulation in schizophrenia: a randomized, double-blind, placebo-controlled study. European Psychiatry2015;30:272. [CSZG: 32149]BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry2015;72(8):830-9. [CSZG: 33027]ChirilaC , ZhengQ , SawyerrG , NuamahI . Healthcare resource use of paliperidone palmitate 3-month injection vs placebo. In: 168th Annual Meeting of American Psychiatric Association; Toronto, Canada. May 16-20, 2015. [CSZG: 33035]GopalS , FureyM , HibarD , KolbH , SaadZ , SavitzA , et al. Potential biomarkers of impending schizophrenia relapse. Biological Psychiatry2017;(10 Suppl):S126-S127. [CSZG: 36107]GopalS , XuH , McQuarrieK , SavitzA , NuamahI , WoodruffK , et al. Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies. NPJ Schizophrenia2017;3(1):23. [CSZG: 36325]MathewsM , NuamahI , SavitzA , GopalS . Efficacy and safety of paliperidone palmitate 3-month formulation vs placebo for relapse prevention of Schizophrenia: Treatment effect using a number needed to treat analysis. Biological Psychiatry2017;81(10 Suppl 1):S350-1. [CSZG: 36437]NCT01529515. A study of paliperidone palmitate 3 month formulation for the treatment of patients with schizophrenia. http://ClinicalTrials.gov/show/NCT015295152012. [CSZG: 23705]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone depot3M 2015</a>). </p> <p>Four studies were rated with a high risk of bias for subjective outcomes. <a href="./references#CD008016-bbs2-0073" title="BoonstraG , BurgerH , GrobbeDE , KahnRS . Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial. International Journal of Psychiatry in Clinical Practice2011;15(2):128-34. [CSZG: 22940]BoonstraG . Schizophrenia termination of pharmacotherapy-STOP-trial. Current Controlled Trials2005. [CSZG: 14487] [ISRCTN: 6332944]">Various drugs 2011</a> was an open study, without providing any further information. In <a href="./references#CD008016-bbs2-0055" title="CaffeyEM , DiamondLS , FrankTV , GrasbergerJC , HermanL , KlettCJ , et al. Discontinuation or reduction of chemotherapy in chronic schizophrenics. Journal of Chronic Diseases1964;17:347-58. [CSZG: 3153]CaffeyEM , ForrestIS , FrankTV , KlettCJ . Phenothiazine excretion in chronic schizophrenics. American Journal of Psychiatry1963;120:578-82. [CSZG: 420]">Various drugs 1964a</a>, the placebo group received medication only every other day and blinding was not fully maintained. <a href="./references#CD008016-bbs2-0059" title="MortonMR . A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia. American Journal of Psychiatry1968;124:1585-8. [CSZG: 2092]">Various drugs 1968</a> and <a href="./references#CD008016-bbs2-0063" title="BlackburnHL , AllenJL . Behavioral effects of interrupting and resuming tranquilizing medication among schizophrenics. Journal of Nervous and Mental Disease1981;133:303-8. [CSZG: 8369]">Various drugs 1981a</a> reported that nurses had made correct guesses as to who was on drug and who was on placebo. </p> <p>In the other 64 studies, we rated the risk of bias for subjective outcomes as 'unclear'. With the exception of <a href="./references#CD008016-bbs2-0072" title="GaebelW , FrickU , KopckeW , LindenM , MuellerP , Mueller SpahnF , et al. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse?British Journal of Psychiatry Supplementum1993;163:8-12. [CSZG: 831]GaebelW , JannerM , FrommannN , PietzckerA , KopckeW , LindenM , et al. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophrenia Research2002;53(1-2):145-59. [CSZG: 8197]GaebelW , MoellerHJ . Treatment strategies in first episode schizophrenia. In: Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan. 2002. [CSZG: 8597]PietzckerA , GaebelW , KoepckeW , LindenM , MuellerP , Mueller-SpahnF , et al. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia - 2-year results of a German multicenter study. Journal of Psychiatric Research1993;27:321-39. [CSZG: 3944]PietzckerA , GaebelW , KopckeW , LindenM , MullerP , Muller-Spahn, et al. A German multicenter study on the neuroleptic long-term therapy of schizophrenic patients. Preliminary report. Pharmacopsychiatry1986;19:161-6. [CSZG: 3943]">Various drugs 1993</a> (an open trial with rating scales being additionally rated by a second blind assessor), all these 64 studies were described as double‐blind. But as antipsychotic drugs have adverse effects we considered that we should make a conservative judgment about the success of blinding. Many of these reports did not provide any details about how double‐blind conditions were maintained. It was usually just stated that the studies were "double‐blind" or it was simply indicated that "identical capsules" were used. Some studies using depot antipsychotic drugs reported that sesame oil injections were used in the placebo groups (e.g. <a href="./references#CD008016-bbs2-0016" title="KeskinerA , HoldenJMC , ItilTM . Maintenance treatment of schizophrenic outpatients with a depot phenothiazine. Psychosomatics1968;9:166-71. [CSZG: 1312]KeskinerA , SimeonJ , FinkM , ItilTM . Long-acting phenothiazine (fluphenazine decanoate) treatment of psychosis. Archives of General Psychiatry1968;18:477-81. KingDJ , DevaneyN , CooperSJ , BlomqvistM , MitchelMJ . Pharmacokinetics and antipsychotic effect of remoxipride in chronic schizophrenic patients. Journal of Psychopharmacology1990;4:83-9. [CSZG: 1323]Kinross-WrightJ , CharalampousKD . A controlled study of a very long-acting phenothiazine preparation. International Journal of Neuropsychiatry1965;1:66-70. [CSZG: 1335]">Fluphenazine depot 1968</a> and <a href="./references#CD008016-bbs2-0067" title="GardosG , ColeJO , RapkinRM , LaBrieRA , BaquelodE , MooreP , et al. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures. Archives of General Psychiatry1984;41:1030-5. ">Various drugs 1984a</a>). </p> </section> <section id="CD008016-sec-0109"> <h4 class="title">Incomplete outcome data</h4> <p>The number of participants leaving the studies early was frequently high leading to a judgement of high risk of bias in 30 included studies. The most frequent reason for leaving the studies early was 'relapse', because many studies had predefined in their protocols that once participants had relapsed they had to discontinue the trial. This had two consequences: the primary outcome relapse was frequently not affected by attrition, because most participants reached this end point. However, there was a risk of bias for other outcomes (e.g. adverse effects), because the <i>reasons</i> for leaving the studies early differed between participants on placebo (mainly relapse/inefficacy) and participants on antipsychotic drugs (other reasons). </p> <p>Only 19 studies used survival analyses to examine relapse rates, while most others simply counted the numbers of participants who relapsed. We, therefore, had to restrict this review to analysis of relapse rates rather than more sensitive parameters such as 'time to relapse'. </p> <p> <div class="table" id="CD008016-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Studies reporting survival analyses</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008016-bbs2-0002" title="CorrellC , KohegyiE , ZhaoC , BakerRA , McQuadeR , SalzmanP , et al. Oral aripiprazole is an effective maintenance treatment in adolescents with schizophrenia. Neuropsychopharmacology2014:S349-S350. [CSZG: 29288]CorrellCU , KohegyiE , ZhaoC , BakerRA , McQuadeR , SalzmanPM , et al. Oral aripiprazole as maintenance treatment in adolescent schizophrenia: results from a 52-week, randomized, placebo-controlled withdrawal study. Journal of the American Academy of Child and Adolescent Psychiatry2017;56(9):784-92. [CSZG: 36321]NCT01149655. A long-term multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of aripiprazole (opc 14597) as maintenance treatment in adolescent patients with schizophrenia. http://ClinicalTrials.gov/show/NCT011496552010. [CSZG: 21085]">Aripiprazole 2017</a>; <a href="./references#CD008016-bbs2-0003" title="BakerR , FleischhackerW , SanchezR , PerryP , JinN , JohnsonB , et al. Long-term safety and tolerability of once-monthly aripiprazole intramuscular depot for maintenance treatment in schizophrenia. International Journal of Neuropsychopharmacology2012;15:111. [CSZG: 28035]BakerRA , CarsonWH , PerryPP , SanchezR , ZhaoJ , McQuadeRD , et al. Effects of aripiprazole once-monthly vs placebo on domains of personal and social performance in younger and older patients with schizophrenia. CNS Spectrums2013;18(6):376-7. [CSZG: 28526]BakerRA , EramoA , CarsonWH , PerryP , SanchezR , ZhaoJ , et al. Effects of aripiprazole once-monthly vs. placebo on domains of personal and social performance in younger and older patients with schizophrenia. Schizophrenia Bulletin2013;39(Suppl 1):S321-S322. [CSZG: 28131]BakerRA , EramoA , NylanderAG , TsaiLF , Peters-StricklandTS , KosticD , et al. The effect of previous dose or oral aripiprazole (10 or 30 mg/day) on the efficacy and tolerability of aripiprazole once-monthly: Results from post-hoc analyses from two double-blind, randomized, controlled trials. Schizophrenia Research2014;153:S293. [CSZG: 29386]CarsonWH , PerryPP , SanchezR , JinN , ForbesRA , McQuadeRD , et al. Effects of ARI-IM-depot on secondary efficacy outcomes in maintenance treatment of schizophrenia. International Journal of Neuropsychopharmacology2012;15:112-3. [CSZG: 28030]EramoA , FleischhackerWW , SanchezR , PerryP , JinN , JohnsonB , et al. A placebo-controlled study of efficacy and safety of aripiprazole oncemonthly for long-term maintenance treatment in schizophrenia. European Psychiatry2013;28(1):1. [CSZG: 28187]EramoA , FleischhackerWW , SanchezR , TsaiLF , Peters-StricklandTS , BakerRA , et al. All-cause discontinuation and safety of aripiprazole once-monthly for the treatment of schizophrenia: A pooled analysis of two double-blind, randomized, controlled trials. Schizophrenia Research2014;153:S174. [CSZG: 29437]FleischhackerWW , BakerRA , EramoA , SanchezR , TsaiLF , Peters-StricklandT , et al. Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies. Schizophrenia Research2014;159(2-3):415-20. [CSZG: 32163]FleischhackerWW , PerryP , SanchezR , JinN , Peters-StricklandT , JohnsonB , et al. Functional outcomes with aripiprazole once-monthly in two double-blind, placebo- and active-controlled studies (aspire us 246 and aspire eu 247) for the treatment of schizophrenia. Value in Health2013;16(7):A550. [CSZG: 28480]FleischhackerWW , SanchezR , JohnsonB , JinN , ForbesRA , McQuadeR , et al. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. International Clinical Psychopharmacology2013;28:171-6. [CSZG: 28391]FleischhackerWW , SanchezR , Lan-FengT , Peters-StricklandT , BakerRA , EramoA , et al. Safety and Effectiveness of Aripiprazole Oncemonthly for the Treatment of Schizophrenia: A Pooled Analysis of Two Double-blind, Randomized, Controlled Trials. Neuropsychopharmacology2013;38:S394-S395. [CSZG: 28459]KaneJM , SanchezR , BakerRA , EramoA , Peters-StricklandT , PerryPP , et al. Patient-centered outcomes with aripiprazole once-monthly for maintenance treatment in patients with schizophrenia: Results from two multicenter, randomized, double-blind studies. Clinical Schizophrenia and Related Psychoses2015;9(2):79-87. [CSZG: 32183]KaneJM , SanchezR , PerryPP , JinN , JohnsonB , ForbesRA , et al. Efficacy of aripiprazole-IM-depot for long-term maintenance treatment of schizophrenia. International Journal of Neuropsychopharmacology2012;15:S119. [CSZG: 28033]KaneJM , SanchezR , PerryPP , JinN , JohnsonBR , ForbesRA , et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: A 52-week, multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2012;73(5):617-24. [CSZG: 24369]LozeJ , CarsonWH , PerryPP , SanchezR , JinN , ForbesRA , et al. Psychosocial and overall effectiveness of aripiprazole intramuscular depot vs. placebo for maintenance treatment in schizophrenia. European Neuropsychopharmacology2012;22:S328. [CSZG: 24886]NCT00705783. Aripiprazole (OPC-14597) as maintenance treatment in patients with schizophrenia. https://www.ClinicalTrials.gov/ct/show/2008. [CSZG: 16546]SanchezR , JohnsonB , JinN , ForbesRA , CarsonWH , McQuadeRD , et al. Patient-reported outcomes (PROs) with aripiprazole intramuscular depot (ARI-IMD) for maintenance treatment in schizophrenia. International Journal of Neuropsychopharmacology2012;15:133. [CSZG: 28040]SanchezR , PerryPP , JinN , Johnson, RA Forbes, RD McQuade, WH, et al. A placebo-controlled study of efficacy/ safety of aripiprazole intramuscular depot for long-term maintenance treatment of schizophrenia. European Neuropsychopharmacology2012;(Suppl 2):S327. [CSZG: 24893]">Aripiprazole depot 2012</a>; <a href="./references#CD008016-bbs2-0004" title="KaneJM , MackleM , Snow-AdamiL , ZhaoJ , SzegediA , PanagidesJ . A randomised placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. Journal of Clinical Psychiatry2011;72(3):349-55. [CSZG: 22873]KaneJM , MackleM , Snow-AdamiL , ZhaoJ , SzegediA , PanagidesJ . Double-blind, placebo-controlled trial of asenapine in prevention of relapse after long-term treatment of schizophrenia. International Journal of Neuropsychopharmacology2010;13:223. [CSZG: 21634]MackleM , Snow-AdamiL , ZhaoJ , SzegediA , PanagidesJ . Double-blind, placebo-controlled trial of asenapine in prevention of relapse after long-term treatment of schizophrenia. European Neuropsychopharmacology2009;19(Suppl 3):S543. [CSZG: 19377]NCT00150176. A randomized, placebo-controlled, double-blind trial of asenapine in the prevention of relapse after long-term treatment of schizophrenia. https://www.ClinicalTrials.gov/ct/show/2005. [CSZG: 14708] The NHSC . Asenapine (Saphris) for schizophrenia. Report2010. [CSZG: 21910]">Asenapine 2011</a>; <a href="./references#CD008016-bbs2-0005" title="BakerR , HobartM , ForbesA , OuyangJ , WeillerE . Effect of brexpiprazole on long-term functioning in adults with schizophrenia. Australian and New Zealand Journal of Psychiatry2017;51(Suppl 1):148. [CSZG: 35955]CorrellCU , ShiL , WeissC , HobartM , EramoA , DuffyRA , et al. Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice of cross-titration schedules in a post-hoc analysis of a randomized double-blind maintenance treatment study. CNS Spectrums2019;24(5):507-17. FleischhackerWW , HobartM , OuyangJ , ForbesA , PfisterS , McQuadeR , et al. Brexpiprazole (OPC-34712) efficacy and safety as maintenance therapy in adults with schizophrenia: Randomised, double-blind, placebo-controlled study. European Neuropsychopharmacology2015;25:S527. [CSZG: 33322]FleischhackerWW , HobartM , OuyangJ , ForbesA , PfisterS , McQuadeRD , et al. Efficacy and sfety of Brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. International Journal of Neuropsychopharmacology2017;20(1):11-21. [CSZG: 35475]NCT01668797. Efficacy, Safety, and tolerability of Brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia. https://ClinicalTrials.gov/show/NCT016687972012. [CSZG: 35608]TherrienF , WeissC , JinN , BakerRA , MacKenzieE , MeehanSR . Effect of brexpiprazole on patient functioning in patients with schizophrenia: results from a long-term, randomised, double-blind, placebo-controlled, maintenance study. Neuropsychopharmacology2017;43((Suppl.1)):S244-S245. [CSZG: 37935]WeillerE , HobartM , PfsterS , ForbesA , OuyangJ , WeissC . Effect of brexpiprazole on long-term remission in adults with schizophrenia: Results from a randomized, double-blind, placebo-controlled, maintenance study. Schizophrenia Bulletin2017;43:S202-3. [CSZG: 36050]WeissC , ForbesA , HobartM , PfsterS , OuyangJ , WeillerE . Short-term and long-term efficacy of brexpiprazole in adults with schizophrenia: Effect across marder factors. Schizophrenia Bulletin2017;43:S155. [CSZG: 36051]WeissC , OuyangJ , EramoA , DuffyRA , WeillerE , BakerRA . Switching patients with acute schizophrenia to brexpiprazole: post-hoc analysis of a double-blind randomized maintenance treatment study. Neuropsychopharmacology2015;40:S227-8. [CSZG: 33450]WeissC , WeillerE , HobartM , OuyangJ . Effect of brexpiprazole on weight and metabolic parameters: analysis of a maintenance trial in schizophrenia. European Neuropsychopharmacology2016;26:S556. [CSZG: 35746]">Brexpiprazole 2017</a>; <a href="./references#CD008016-bbs2-0006" title='CorrellCU , PotkinSG , DurgamS , ChangCT , SzatmariB , LaszlovszkyI , et al. Sustained remission with cariprazine treatment: post-hoc analysis of a randomised, double-blind, schizophrenia relapse prevention trial. Europan Neuropsychopharmacology2017;27((Suppl. 4)):S935-S936. [CSZG: 37757]CorrellCU , PotkinSG , ZhongY , HarsányiJ , SzatmáriB , EarleyW . Long-term remission with cariprazine treatment in patients with schizophrenia: a post-hoc analysis of a randomized, double-blind, placebo.controlled relapse prevention trial. Journal of Clinical Psychiatry2019;80(2):18m12495. DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Corrigendum to "Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial" [Schizophr. Res. 176 (2016) 264-71]. Schizophrenia Research2017;InPress:InPress. [CSZG: 35204]DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A double-blind, placebo-controlled trial. European Neuropsychopharmacology2015;25:S512-3. [CSZG: 33317]DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophrenia Research2016;176(2-3):264-71. [CSZG: 35204]DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: additional analysis from a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2015;40:S380-1. [CSZG: 33316]EarleyW , GuoH , LuchiniR . Modified cariprazine relapse prevention clinical trial results. Schizophrenia Research2018;199:452-3. KunovacJ , KaneJ , DurgamS , ChangCT , NemethG , LaszlovszkyI , et al. Characteristics associated with relapse in patients with schizophrenia: Post hoc analysis of a randomized, double-blind, placebo-controlled, cariprazine relapse prevention trial. Schizophrenia Bulletin2017;43:S166-7. [CSZG: 36002]NCT01412060. Cariprazine relative to placebo in the prevention of relapse of symptoms in patients with schizophrenia. http://ClinicalTrials.gov/show/NCT014120602011. [CSZG: 23106]PotkinS , CorrellC , ChangCT , SzatmariB , LaszlovszkyI , EarleyW . Long-term remission with cariprazine treatment in patients with schizophrenia: a post hoc analysis of a randomized, double-blind, placebo-controlled, relapse prevention trial. Schizophrenia Bulletin2017;43:S118. [CSZG: 36026]'>Cariprazine 2016</a>; <a href="./references#CD008016-bbs2-0027" title="CTRI/2010/091/001409. A clinical trial to study prevention of relapse in patients with schizophrenia reveiving either flexible dose iloperidone or placebo in long-term use.. http://ctri.nic.in/Clinicaltrials/login.php2010. NCT01291511. Efficacy in prevention of relapse of schizophrenia in subjects taking either placebo or iloperidone. http://ClinicalTrials.gov/show/NCT012915112011. [CSZG: 22671]WeidenPJ , ManningR , WolfgangCD , RyanJM , MancioneL , HanG , et al. A randomized trial of iloperidone for prevention of relapse in schizophrenia: the REPRIEVE study. CNS drugs2016;30(8):735-47. [CSZG: 35243]">Iloperidone 2016</a>; <a href="./references#CD008016-bbs2-0028" title="NCT01435928. PEARL Schizophrenia Maintenance. http://ClinicalTrials.gov/show/NCT014359282011. [CSZG: 23439]TandonR , CucchiaroJ , PhillipsD , HernandezD , MaoY , PikalovA , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Journal of Psychopharmacology2016;30(1):69-77. [CSZG: 33434]TandonR , LoebelA , PhilipsD , PikalovA , Hernandez D MaoY , et al. Lurasidone for maintenance of efficacy in patients with schizophrenia. European Neuropsychopharmacology2014;24(Suppl 2):S559-560. [CSZG: 27840]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , CucchiaroJ . A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Schizophrenia Research2014;153(1):S372. [CSZG: 29681]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Int J Neuropsychopharmacol2014;17:S153-154. [CSZG: 29954]">Lurasidone 2016</a>; <a href="./references#CD008016-bbs2-0030" title="Beasley C Jr, HamiltonS , DossenbachM . Relapse prevention with olanzapine. European Neuropsychopharmacology2000;10(Suppl 3):S304. [CSZG: 4620]BeasleyCM , HamiltonSH , DossenbachM . Relapse prevention with olanzapine. Schizophrenia Research2000;41(1):196-7. [CSZG: 4874]BeasleyCM , SuttonVK , HamiltonSH , WalkerDJ , DossenbachM , TaylorCC , et al. A double-blind, randomised, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. Journal of Clinical Psychopharmacology2003;23:582-94. [CSZG: 10010]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD , PickarD . Does maintenance treatment with atypical antipsychotics worsen quality of life among stable patients with schizophrenia?Neuropsychopharmacology2005;30(S1):S189. [CSZG: 13107]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD . Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?Journal of Clinical Psychopharmacology2006;26:40-4. [CSZG: 14454]BeasleyCM , WalkerDJ , SuttonVK , AlakaK , NaberD , NamjoshiM . The effectiveness of olanzapine versus placebo in maintaining the quality of life in stabilized patients with schizophrenia. European Neuropsychopharmacology2003;13:S342. [CSZG: 9849]EliLilly Company. Olanzapine relapse prevention versus placebo in the treatment of schizophrenia. http://www.Clinicalstudyresults.org/.2005. [CSZG: 18733]">Olanzapine 2003</a>; <a href="./references#CD008016-bbs2-0031" title="Eerdekens. Evaluate the efficacy in the prevention of recurrence of the symptoms of schizophrenia. Sponsor: Johnson &amp; Johnson Pharmaceutical Research &amp; Development, LL.C2010. [CTG: NCT00111189]KramerM , KushnerS , SherrJ , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study. Schizophrenia Bulletin2007;33(2):438. [CSZG: 15185]KramerM , KushnerS , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia treated with paliperidone extended-release tablets. European Neuropsychopharmacology2006;16(Suppl 4):S386. [CSZG: 13313]KramerM , KushnerS , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study. International Journal of Neuropsychopharmacology2006;9(Suppl 1):S274. [CSZG: 19545]KramerM , SimpsonG , MaciulisV , KushnerS , LiuY , LimP , et al. One-year open-label safety and efficacy study of paliperidone extended-release. CNS Spectrums2010;15(8):506-14. [CSZG: 20885]KramerM , SimpsonG , MaciulisV , KushnerS , VijapurkarU , LimP , et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2007;27:6-14. [CSZG: 13907]MarkowitzM , FuDJ , LevitanB , GopalS , TurkozI , AlphsL . Long-acting injectable paliperidone palmitate versus oral paliperidone extended release. Annals of General Psychiatry2013;12:22. [CSZG: 28633]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone 2007</a>; <a href="./references#CD008016-bbs2-0032" title="RuiQ , WangY , LiangS , LiuY , WuY , WuQ , et al. Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry2014;53:45-53. [CSZG: 29320]ZhangH , LiH , LiuY , WuC , WuQ , NuamahI . Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia. Neuropsychiatric Disease and Treatment2016;12:69-77. [CSZG: 33455]">Paliperidone 2014</a>; <a href="./references#CD008016-bbs2-0033" title="AlphsL , BossieC , Kern-SliwaJ , Ma Y-W, HaskinsJT . Paliperidone palmitate: clinical response in subjects with schizophrenia with recent vs. longer-term duration of illness. In: Proceedings of the 162nd Annual Meeting of the American Psychiatric Association. San Francisco, CA., 2009 May 16-21. [CSZG: 19067]EmsleyR , NuamahI , GopalS , HoughD , FleischhackerWW . Relapse after antipsychotic discontinuation in schizophrenia as a withdrawal phenomenon vs illness recurrence: a post hoc analysis of a randomized placebo-controlled study. Journal of Clinical Psychiatry 2018 Jun;79(4):17m11874. [CSZG: 38184]EmsleyR , NuamahI , HoughD , GopalS . Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophrenia Research2012;138(1):29-34. [CSZG: 24214]GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM , HoughD . A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. Journal of Psychopharmacology2011;25(5):685-97. [CSZG: 22903]GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Long-term efficacy, safety and tolerability of paliperidone palmitate in patients with schizophrenia. In: Proceedings of the 162nd Annual Meeting of the American Psychiatric Association. San Francisco, CA, 2009 May 16-21. [CSZG: 19076]HoughD , GopalS , VijapukarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate in prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. In: Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8, Washington DC, USA. 2008. [CSZG: 16486]HoughD , GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. In: Proceedings of the 63rd Annual Convention of the Society of Biological Psychiatry. Washington, DC, USA: Elsevier Science Inc, 2008:S285-6. [CSZG: 20281]HoughD , GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Biological Psychiatry2008;63(7 Suppl):285S-6S. [CSZG: 19530]HoughD , GopalS , VjapukarU , LimP , MorozowaM , EerdekensM . Paliperidone palmitate maintenance treatment in delaying the time to relapse in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. Schizophrenia Research2010;116:107-17. [CSZG: 19704]HulihanJ , BossieCA , FuDJ , Kern SliwaJ , Ma Y-W, AlphsLD . Remission with continued paliperidone palmitate treatment in stable subjects with schizophrenia. Schizophrenia Research2012;136:S252. [CSZG: 29467]KozmaCM , SlatonT , DiraniR , FastenauJ , GopalS , HoughD . Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate. Current Medical Resarch and Opinion2011;27(8):1603-11. SliwaJK , BossieCA , Fu DJ, TurkozI , AlphsL . Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia. Neuropsychiatric Disease and Treatment2012;8:375-85. [CSZG: 28007]SliwaJK , FuDJ , BossieCA , et al. Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate. BMC Psychiatry2014;14:S52. [CSZG: 29148]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone depot1M 2010</a>; <a href="./references#CD008016-bbs2-0034" title="BossieC , TurkozI , AlphsL , FuDJ . Monotherapy with once monthly paliperidone palmitate for psychotic, depressive, and manic symptoms in schizoaffective disorder. Schizophrenia Bulletin2015;41:S303. [CSZG: 29400]BossieCA , TurkozI , AlphsL , MahalchickL , FuDJ . Paliperidone palmitate once-monthly treatment in recent onset and chronic illness patients with schizoaffective disorder. Journal of Nervous and Mental Ddisease2017;205(4):324-8. [CSZG: 35417]FuDJ , AlphsL , LindenmayerJP , SchoolerN , SimonsonRB , TurkozI , et al. Paliperidone palmitate long-acting injectable delays psychotic and mood symptom relapse in schizoaffective disorder. European Neuropsychopharmacology2014;24:S534-5. [CSZG: 27785]FuDJ , BossieC , TurkozI , MahalchickL , AlphsL . Paliperidone palmitate treatment response in early and chronic illness schizoaffective disorder patients. Schizophrenia Bulletin2015;41:S312. [CSZG: 29446]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Effect of paliperidone palmitate once-monthly in improving and maintaining functioning in subjects with schizoaffective disorder using the domains of the personal and social performance scale. Neuropsychopharmacology2014;39:S365. [CSZG: 29278]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate delays relapse in patients with schizoaffective disorder. Biological Psychiatry2014;1:263S. [CSZG: 28974]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate long-acting injectable in acute exacerbation of schizoaffective disorder. Schizophrenia Bulletin2013;39:S331. [CSZG: 28167]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate once-monthly injectable treatment for acute exacerbations of schizoaffective disorder. Journal of Clinical Psychopharmacology2016;36(4):372-6. [CSZG: 35803]FuDJ , TurkozI , SimonsonRB , WallingDP , SchoolerNR , LindenmayerJP , et al. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. Journal of Clinical Psychiatry2015;76(3):253-62. [CSZG: 29752]FuDJ , TurkozI , WallingD , LindenmayerJP , SchoolerNR , AlphsL . Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder. Schizophrenia Research2018;192:185-93. [CSZG: 35804]JoshiK , LinJ , Lingohr-SmithM , FuD . Medical cost reductions for paliperidone palmitate versus placebo in randomized double-blind trial of patients with schizoaffective disorder. Journal of Managed Care and Specialty Pharmacy2015;21:536-7. JoshiK , LinJ , Lingohr-SmithM , FuDJ . Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder. Journal of Medical Economics2015;18:629-36. [CSZG: 33677]NCT01193153. A study to evaluate the efficacy of paliperidone palmitate in the prevention of relapse of the symptoms of schizoaffective disorder. http://ClinicalTrials.gov/show/NCT011931532010. [CSZG: 21094]TurkozI , FuDJ , WallingD , SchoolerNR , LindenmayerJP , SimonsonRB , et al. Effect of paliperidone palmitate once-monthly in improving and maintaining functioning in subjects with schizoaffective disorder using the domains of the personal and social performance scale. Schizophrenia Bulletin2015;41:S193-4. [CSZG: 29687]">Paliperidone depot1M 2015</a>; <a href="./references#CD008016-bbs2-0035" title="BellLKS , TurkozI , KimE . Paliperidone palmitate once-every-3-months in adults with early illness schizophrenia. Early Intervention in Psychiatry2019;13(3):667-72. BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of paliperidone palmitate 3 month formulation: a randomized, double-blind, placebo-controlled study. Schizophrenia Bulletin2015;41:S302. [CSZG: 29393]BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of paliperidone palmitate 3-month formulation in schizophrenia: a randomized, double-blind, placebo-controlled study. European Psychiatry2015;30:272. [CSZG: 32149]BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry2015;72(8):830-9. [CSZG: 33027]ChirilaC , ZhengQ , SawyerrG , NuamahI . Healthcare resource use of paliperidone palmitate 3-month injection vs placebo. In: 168th Annual Meeting of American Psychiatric Association; Toronto, Canada. May 16-20, 2015. [CSZG: 33035]GopalS , FureyM , HibarD , KolbH , SaadZ , SavitzA , et al. Potential biomarkers of impending schizophrenia relapse. Biological Psychiatry2017;(10 Suppl):S126-S127. [CSZG: 36107]GopalS , XuH , McQuarrieK , SavitzA , NuamahI , WoodruffK , et al. Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies. NPJ Schizophrenia2017;3(1):23. [CSZG: 36325]MathewsM , NuamahI , SavitzA , GopalS . Efficacy and safety of paliperidone palmitate 3-month formulation vs placebo for relapse prevention of Schizophrenia: Treatment effect using a number needed to treat analysis. Biological Psychiatry2017;81(10 Suppl 1):S350-1. [CSZG: 36437]NCT01529515. A study of paliperidone palmitate 3 month formulation for the treatment of patients with schizophrenia. http://ClinicalTrials.gov/show/NCT015295152012. [CSZG: 23705]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone depot3M 2015</a>; <a href="./references#CD008016-bbs2-0045" title="D1441C00131. A 1-year, international, multicenter, randomized, double-blind, parallel-group, placebo-controlled phase IV study to evaluate prevention of relapse in patients in stable condition with chronic schizophrenia receiving either quetiapine fumarate IR (SEROQUEL) or placebo. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=3852003. D1444C00004. A 1-year, international, multicenter, randomized, double-blind, parallelgroup, placebo-controlled phase iii study to evaluate prevention of relapse in patients in stable condition with chronic schizophrenia receiving either sustained-release quetiapine fumarate (SEROQUEL) or placebo. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=14182006. NCT00228462. A 1-year, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study to evaluate prevention of relapse in patients in stable chronic schizophrenia receiving either sustained-release quetiapine fumarate (SEROQUEL) or placebo (abbreviated). https://www.ClinicalTrials.gov/ct/show/2005. [CSZG: 14874]PeuskensJ , TrivediJ , MalyarovS , BrecherM , SvenssonO , MillerF , et al. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomised, placebo-controlled trial in clinically stable patients. Psychiatry2007;4(11):34-50. [CSZG: 16025]PeuskensJ , TrivediJK , BrecherM , MillerF , Study I . Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: Post-hoc analysis of data from a randomized withdrawal, placebo-controlled study. International Clinical Psychopharmacology2010;25(3):183-7. [CSZG: 20670]PeuskensJ , TrivediJK , BrecherM , SvenssonO , MillerF , MeulienD . Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate. In: Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA. 2008. [CSZG: 16500]PeuskensJ , TrivediJK , BrecherM , SvenssonO , MillerF , MeulienD . Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate. Schizophrenia Research2008;98:14-5. [CSZG: 16344]PeuskensJ , TrivediJK , MalyarovS , BrecherM , SvenssonO , MillerF , et al. A randomized, placebo-controlled, relapse-prevention study with once-daily quetiapine sustained release in patients with schizophrenia. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28-Apr 1; Colorado Springs, Colorado, USA2007. [CSZG: 15271]PeuskensJC , TrivediJK , MalyarovS , BrecherM , SvenssonO , MillerF , et al. A randomized, placebo-controlled, relapse-prevention study with once daily quetiapine sustained release in patients with schizophrenia. Schizophrenia Bulletin2007;33(2):453. [CSZG: 15225]">Quetiapine 2007</a>; <a href="./references#CD008016-bbs2-0069" title="CrowTJ , MacMillanJF , JohnsonAL , JohnstoneEC . A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry1986;148:120-7. [CSZG: 648]">Various drugs 1986a</a>; <a href="./references#CD008016-bbs2-0072" title="GaebelW , FrickU , KopckeW , LindenM , MuellerP , Mueller SpahnF , et al. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse?British Journal of Psychiatry Supplementum1993;163:8-12. [CSZG: 831]GaebelW , JannerM , FrommannN , PietzckerA , KopckeW , LindenM , et al. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophrenia Research2002;53(1-2):145-59. [CSZG: 8197]GaebelW , MoellerHJ . Treatment strategies in first episode schizophrenia. In: Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan. 2002. [CSZG: 8597]PietzckerA , GaebelW , KoepckeW , LindenM , MuellerP , Mueller-SpahnF , et al. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia - 2-year results of a German multicenter study. Journal of Psychiatric Research1993;27:321-39. [CSZG: 3944]PietzckerA , GaebelW , KopckeW , LindenM , MullerP , Muller-Spahn, et al. A German multicenter study on the neuroleptic long-term therapy of schizophrenic patients. Preliminary report. Pharmacopsychiatry1986;19:161-6. [CSZG: 3943]">Various drugs 1993</a>; <a href="./references#CD008016-bbs2-0073" title="BoonstraG , BurgerH , GrobbeDE , KahnRS . Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial. International Journal of Psychiatry in Clinical Practice2011;15(2):128-34. [CSZG: 22940]BoonstraG . Schizophrenia termination of pharmacotherapy-STOP-trial. Current Controlled Trials2005. [CSZG: 14487] [ISRCTN: 6332944]">Various drugs 2011</a>; <a href="./references#CD008016-bbs2-0074" title="AratoM , O'ConnorR , BradburyJE , MeltzerH . Long-term ziprasidone in schizophrenia. In: Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 - Jun 4; Toronto, Ontario, Canada. 1998. [CSZG: 3189]AratoM , O'ConnorR , BradburyJE , MeltzerH . The efficacy of ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. In: Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK. Amsterdam, Netherlands: Cambridge University Press, 1998. [CSZG: 3188]AratoM , O'ConnorR , BradburyJE , MeltzerH . Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. In: Proceedings of the 9th Congress of the Association of European Psychiatrists; 1998 Sep 20-24; Copenhagen, Denmark. 1998. [CSZG: 3190]AratoM , O'ConnorR , BradburyJE , MeltzerH . Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. Schizophrenia Research1999;36(1-3):270. [CSZG: 5626]AratoM , O'ConnorR , MeltzerH , BradburyJ . Ziprasidone: efficacy in the prevention of relapse and in the long-term treatment of negative symptoms of chronic schizophrenia. In: Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria. 1997. [CSZG: 245]AratoM , O'ConnorR , MeltzerHY . A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. International Clinical Psychopharmacology2002;17:207-15. [CSZG: 18486]BernardoM , AranzaJR , Rubio-TerresC , RejasJ . Cost-effectiveness analysis of schizophrenia relapse prevention. Clinical Drug Investigation. New Zealand2006;26(8):447-57. [CSZG: 13898]BernardoM , AranzaJR , Rubio-TerresC , RejasJ . Cost-effectiveness analysis of the prevention of relapse in schizophrenia in the ZEUS longitudinal study Ziprasidone Extended Use in Schizophrenia (ZEUS). Acta Espanolas de Psiquiatria2007;35(4):259-62. [CSZG: 15396]MeltzerHY , O´ConnorR . Long-term efficacy of ziprasidone in schizophrenia. Schizophrenia research2001;(1-2):S. 239. [CSZG: 6050]MeltzerHY , O´ConnorR . Path analysis of the ZEUS study provides evidence of a direct effect of ziprasidone on primary negative symptoms in chronic, stable schizophrenia. Conference Poster1997. [CSZG: 2033]MeltzerHY , O'ConnorR . Long-term efficacy of ziprasidone in schizophrenia: results of two controlled trials. In: Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico. 2000. [CSZG: 7609]O'ConnorR , SchoolerNR . Penultimate observation carried forward (POCF): a new approach to analysis of long-term symptom change in chronic relapsing conditions [letter]. Schizophrenia Research2003;60:319-20. [CSZG: 9365]Pfizer 2000. Multicentre double-blind study of ziprasidone versus placebo in relapse prevention for hospitalised patients with chronic or subchronic schizophrenia. Study report Unpublished. SchoolerN . A basis for optimism: the implications of long term treatment. In: Proceedings of the 9th Congress of the Association of European Psychiatrists; 1998 Sep 20-24; Copenhagen, Denmark. 1998. [CSZG: 5864]">Ziprasidone 2002</a>; <a href="./references#CD008016-bbs2-0075" title="CooperSJ , ButlerA , TweedJ , RaniwallaJ , WelchC . Zotepine in the prevention of relapse. Biological Psychiatry1997;42:41s. [CSZG: 17007]CooperSJ , ButlerA , TweedJ , RaniwallaJ , WelchC . Zotepine in the prevention of relapse. In: Proceedings of the 6th World Congress of Biological Psychiatry; 1997 June 22-27; Nice, France. 1997. [CSZG: 569]CooperSJ , ButlerA , TweedJ , WelchC , RaniwallaJ . Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacology2000;150:237-43. [CSZG: 5732]CooperSJ , ButlerA , TweedJA , WelchCP , WightonAJ , ApplebyP , et al. Zotepine is effective in preventing recurrence in patients with chronic schizophrenia. In: Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31 - Nov 4; Paris, France. 1998. [CSZG: 5784]CooperSJ , ButlerA , TweedJA , WelchCP , WightonAJ , ApplebyP , et al. Zotepine is effective in preventing recurrence in patients with chronic schizophrenia. Schizophrenia Research2000;41:207-8. [CSZG: 4925]">Zotepine 2000</a>. </p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD008016-sec-0110"> <h4 class="title">Selective reporting</h4> <p>We judged 63 studies to be free of selective reporting. However, many did not (sufficiently) report on predefined outcomes. </p> <p> <div class="table" id="CD008016-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Studies with insufficient reporting of pre‐defined outcomes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008016-bbs2-0001" title="BakerRA , MeyerJM , KaplitaS , ForbesA , GrossmanF , PikalovA , MarcusRN . Long-term effects of aripiprazole on the lipid profiles of patients with schizophrenia in a 26-week placebo-controlled trial. Schizophrenia Bulletin2007;33(2):S419. [CSZG: 15132]CarsonW , McQuadeR , SahaA , TorbeynsA , StockE . Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia. European Neuropsychopharmacology2002;12(Suppl 3):S288. [CSZG: 9067]CarsonW , PigottT , SahaA , AliM , McQuadeRD , TorbeynsAF , et al. Aripiprazole vs placebo in the treatment of stable, chronic schizophrenia. In: Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [CSZG: 9986]CarsonW , WeidenP , WaldeckR , TafesseE , CisloP , L'ItalienG , IwamotoT . Aripiprazole is not associated with increased diabetes risk: a long-term model. Schizophrenia Research2004;67(Suppl 1):181. [CSZG: 13175]CarsonWH , IngenitoGG , McQuadeRD , StockEG , IwamotoT . Schizophrenia: safety/tolerability of aripiprazole. In: Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan. 2002. [CSZG: 19426]CarsonWH , PigottTA , SahaAR , AliMW , McQuadeRD , TorbeynsAF , et al. Aripiprazole vs placebo in the treatment of chronic schizophrenia. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S187. [CSZG: 8326]CaseyD , SahaA , MarcusR , CarsonWH , McQuadeRD , TorbeynsAF , et al. Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia. Schizophrenia Research2003;60:276. [CSZG: 9689]CaseyD , StockE , JodyD , KaplitaS , SahaA , ListonH , et al. Long-term treatment with aripiprazole: effects on plasma lipis levels and glycaemic control. Int J Neuropsychopharmacol 2004 Jun;7(Suppl 2):S417. [CSZG: 13177]DubitskyGM , HarrisR , LaughrenT , HardemanS . Abilify (aripiprazole) tablets; medical review part 1. http://www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm2002:1-50. [CSZG: 9980]DubitskyGM , HarrisR , LaughrenT , HardemanS . Abilify (aripiprazole) tablets; medical review part 2. http://www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm2002:50-110. [CSZG: 9981]DubitskyGM , HarrisR , LaughrenT , HardemanS . Abilify (aripiprazole) tablets; medical review part 3. http://www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm2002:111-75. [CSZG: 9982]DubitskyGM , HarrisR , LaughrenT , HardemanS . Abilify (aripiprazole) tablets; medical review part 4. http://www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm2002:176-232. [CSZG: 9983]MarderSR , KaplitaS , SahaAR , Carson WH Jr, TorbeynsA , StockEG . Glycemic control and plasma lipids in long-term aripiprazole treatment. In: Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [CSZG: 9799]McQuadeR , KosticD , MarcusR , CarsonW , TorbeynsA , KerselaersW , YoccaF . Aripiprazole versus olanzapine in a 52-week, open-label extension study. Schizophrenia Bulletin2005;31:S496-7. [CSZG: 11624]MortimerAM . Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia. Evidence-Based Mental Health2004;7(2):41. [CSZG: 13962]PigottTA , CarsonWH , SahaAR , TorbeynsAF , StockEG , IngenitoGG . Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. Journal of Clinical Psychiatry2003;64:1048-56. [CSZG: 9896]PigottTA , SahaAR , AliMW , McQuadeRD , TorbeynsAF , WilliamHC , et al. Aripiprazole versus placebo in the treatment of chronic schizophrenia. In: Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [CSZG: 9018]StockE , MarderSR , JodyD , KaplitaS , SahaA , CarsonW , et al. Plasma lipids levels and glycemic control in long-term treatment with aripiprazole. European Neuropsychopharmacology2003;13(4):S327. [CSZG: 9854]TorbeynsA , MarderSR , CarsonW , JodyD , KaplitaS , SabaA , et al. Glycemic control and plasma lipids in long-term treatment with aripiprazole. Schizophrenia Research2004;67(1):192-3. [CSZG: 11339]">Aripiprazole 2003</a>, <a href="./references#CD008016-bbs2-0024" title="RuskinPE , NymanG . Discontinuation of neuroleptic medication in older, outpatient schizophrenics. A placebo-controlled, double-blind trial. Journal of Nervous and Mental Disease1991;179:212-4. [CSZG: 2471]">Haloperidol 1991</a>, <a href="./references#CD008016-bbs2-0027" title="CTRI/2010/091/001409. A clinical trial to study prevention of relapse in patients with schizophrenia reveiving either flexible dose iloperidone or placebo in long-term use.. http://ctri.nic.in/Clinicaltrials/login.php2010. NCT01291511. Efficacy in prevention of relapse of schizophrenia in subjects taking either placebo or iloperidone. http://ClinicalTrials.gov/show/NCT012915112011. [CSZG: 22671]WeidenPJ , ManningR , WolfgangCD , RyanJM , MancioneL , HanG , et al. A randomized trial of iloperidone for prevention of relapse in schizophrenia: the REPRIEVE study. CNS drugs2016;30(8):735-47. [CSZG: 35243]">Iloperidone 2016</a>, <a href="./references#CD008016-bbs2-0028" title="NCT01435928. PEARL Schizophrenia Maintenance. http://ClinicalTrials.gov/show/NCT014359282011. [CSZG: 23439]TandonR , CucchiaroJ , PhillipsD , HernandezD , MaoY , PikalovA , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Journal of Psychopharmacology2016;30(1):69-77. [CSZG: 33434]TandonR , LoebelA , PhilipsD , PikalovA , Hernandez D MaoY , et al. Lurasidone for maintenance of efficacy in patients with schizophrenia. European Neuropsychopharmacology2014;24(Suppl 2):S559-560. [CSZG: 27840]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , CucchiaroJ . A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Schizophrenia Research2014;153(1):S372. [CSZG: 29681]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Int J Neuropsychopharmacol2014;17:S153-154. [CSZG: 29954]">Lurasidone 2016</a>, <a href="./references#CD008016-bbs2-0030" title="Beasley C Jr, HamiltonS , DossenbachM . Relapse prevention with olanzapine. European Neuropsychopharmacology2000;10(Suppl 3):S304. [CSZG: 4620]BeasleyCM , HamiltonSH , DossenbachM . Relapse prevention with olanzapine. Schizophrenia Research2000;41(1):196-7. [CSZG: 4874]BeasleyCM , SuttonVK , HamiltonSH , WalkerDJ , DossenbachM , TaylorCC , et al. A double-blind, randomised, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. Journal of Clinical Psychopharmacology2003;23:582-94. [CSZG: 10010]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD , PickarD . Does maintenance treatment with atypical antipsychotics worsen quality of life among stable patients with schizophrenia?Neuropsychopharmacology2005;30(S1):S189. [CSZG: 13107]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD . Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?Journal of Clinical Psychopharmacology2006;26:40-4. [CSZG: 14454]BeasleyCM , WalkerDJ , SuttonVK , AlakaK , NaberD , NamjoshiM . The effectiveness of olanzapine versus placebo in maintaining the quality of life in stabilized patients with schizophrenia. European Neuropsychopharmacology2003;13:S342. [CSZG: 9849]EliLilly Company. Olanzapine relapse prevention versus placebo in the treatment of schizophrenia. http://www.Clinicalstudyresults.org/.2005. [CSZG: 18733]">Olanzapine 2003</a>, <a href="./references#CD008016-bbs2-0036" title="BaroF , BrugmansJ , DomR , Van LommelR . Maintenance therapy of chronic psychotic patients with a weekly oral dose of R 16341. A controlled double-blind study. Journal of Clinical Pharmacology1970;10:330-41. [CSZG: 297]">Penfluridol 1970</a>, <a href="./references#CD008016-bbs2-0039" title="VandecasteeleAJ , VereeckenJL . A double-blind clinical evaluation of penfluridol (R 16 341) as a maintenance therapy in schizophrenia. Acta Psychiatrica Scandinavica1974;50:346-53. [CSZG: 2919]">Penfluridol 1974c</a>, <a href="./references#CD008016-bbs2-0045" title="D1441C00131. A 1-year, international, multicenter, randomized, double-blind, parallel-group, placebo-controlled phase IV study to evaluate prevention of relapse in patients in stable condition with chronic schizophrenia receiving either quetiapine fumarate IR (SEROQUEL) or placebo. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=3852003. D1444C00004. A 1-year, international, multicenter, randomized, double-blind, parallelgroup, placebo-controlled phase iii study to evaluate prevention of relapse in patients in stable condition with chronic schizophrenia receiving either sustained-release quetiapine fumarate (SEROQUEL) or placebo. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=14182006. NCT00228462. A 1-year, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study to evaluate prevention of relapse in patients in stable chronic schizophrenia receiving either sustained-release quetiapine fumarate (SEROQUEL) or placebo (abbreviated). https://www.ClinicalTrials.gov/ct/show/2005. [CSZG: 14874]PeuskensJ , TrivediJ , MalyarovS , BrecherM , SvenssonO , MillerF , et al. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomised, placebo-controlled trial in clinically stable patients. Psychiatry2007;4(11):34-50. [CSZG: 16025]PeuskensJ , TrivediJK , BrecherM , MillerF , Study I . Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: Post-hoc analysis of data from a randomized withdrawal, placebo-controlled study. International Clinical Psychopharmacology2010;25(3):183-7. [CSZG: 20670]PeuskensJ , TrivediJK , BrecherM , SvenssonO , MillerF , MeulienD . Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate. In: Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA. 2008. [CSZG: 16500]PeuskensJ , TrivediJK , BrecherM , SvenssonO , MillerF , MeulienD . Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate. Schizophrenia Research2008;98:14-5. [CSZG: 16344]PeuskensJ , TrivediJK , MalyarovS , BrecherM , SvenssonO , MillerF , et al. A randomized, placebo-controlled, relapse-prevention study with once-daily quetiapine sustained release in patients with schizophrenia. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28-Apr 1; Colorado Springs, Colorado, USA2007. [CSZG: 15271]PeuskensJC , TrivediJK , MalyarovS , BrecherM , SvenssonO , MillerF , et al. A randomized, placebo-controlled, relapse-prevention study with once daily quetiapine sustained release in patients with schizophrenia. Schizophrenia Bulletin2007;33(2):453. [CSZG: 15225]">Quetiapine 2007</a>, <a href="./references#CD008016-bbs2-0046" title="NCT00658645. A multinational, randomised, double-blind, fixed-dose, bifeprunox study combining a 12-week placebo-controlled, quetiapine-referenced phase with a 12-month quetiapine-controlled phase in patients with schizophrenia. https://www.clinicaltrials.gov/ct2/show/NCT00658645?term=NCT00658645&amp;rank=1. [CSZG: 16241]">Quetiapine 2009a</a>, <a href="./references#CD008016-bbs2-0047" title="NCT00704509. A multinational, randomised, double-blind, fixed-dose, bifeprunox study combining a 12-week placebo-controlled, quetiapine-referenced phase with a 12-month quetiapine-controlled phase in patients with schizophrenia. https://www.clinicaltrials.gov/ct2/show/NCT00704509?term=NCT00704509&amp;rank=1. [CSZG: 16566]">Quetiapine 2009b</a>, <a href="./references#CD008016-bbs2-0053" title="OlsonGW , PetersonDB . Intermittent chemotherapy for chronic psychiatric inpatients. Journal of Nervous and Mental Disease1962;134:1459. [CSZG: 38115]OlsonGW , PetersonDB . Sudden removal of tranquilizing drugs from chronic psychiatric patients. Journal of Mental and Nervous Disease1960;131:252-5. ">Various drugs 1962a</a>, <a href="./references#CD008016-bbs2-0075" title="CooperSJ , ButlerA , TweedJ , RaniwallaJ , WelchC . Zotepine in the prevention of relapse. Biological Psychiatry1997;42:41s. [CSZG: 17007]CooperSJ , ButlerA , TweedJ , RaniwallaJ , WelchC . Zotepine in the prevention of relapse. In: Proceedings of the 6th World Congress of Biological Psychiatry; 1997 June 22-27; Nice, France. 1997. [CSZG: 569]CooperSJ , ButlerA , TweedJ , WelchC , RaniwallaJ . Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacology2000;150:237-43. [CSZG: 5732]CooperSJ , ButlerA , TweedJA , WelchCP , WightonAJ , ApplebyP , et al. Zotepine is effective in preventing recurrence in patients with chronic schizophrenia. In: Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31 - Nov 4; Paris, France. 1998. [CSZG: 5784]CooperSJ , ButlerA , TweedJA , WelchCP , WightonAJ , ApplebyP , et al. Zotepine is effective in preventing recurrence in patients with chronic schizophrenia. Schizophrenia Research2000;41:207-8. [CSZG: 4925]">Zotepine 2000</a>, </p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD008016-sec-0111"> <h4 class="title">Other potential sources of bias</h4> <p>We judged 44 studies to be free of other potential sources of bias ‐ as far as we could detect. However, for six trials this was unclear (please see table below). Fourteen studies were terminated prematurely after pre‐planned interim analyses. One study had baseline imbalances in terms of the mean number of previous hospitalisations and mean age and duration of illness (<a href="./references#CD008016-bbs2-0045" title="D1441C00131. A 1-year, international, multicenter, randomized, double-blind, parallel-group, placebo-controlled phase IV study to evaluate prevention of relapse in patients in stable condition with chronic schizophrenia receiving either quetiapine fumarate IR (SEROQUEL) or placebo. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=3852003. D1444C00004. A 1-year, international, multicenter, randomized, double-blind, parallelgroup, placebo-controlled phase iii study to evaluate prevention of relapse in patients in stable condition with chronic schizophrenia receiving either sustained-release quetiapine fumarate (SEROQUEL) or placebo. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=14182006. NCT00228462. A 1-year, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study to evaluate prevention of relapse in patients in stable chronic schizophrenia receiving either sustained-release quetiapine fumarate (SEROQUEL) or placebo (abbreviated). https://www.ClinicalTrials.gov/ct/show/2005. [CSZG: 14874]PeuskensJ , TrivediJ , MalyarovS , BrecherM , SvenssonO , MillerF , et al. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomised, placebo-controlled trial in clinically stable patients. Psychiatry2007;4(11):34-50. [CSZG: 16025]PeuskensJ , TrivediJK , BrecherM , MillerF , Study I . Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: Post-hoc analysis of data from a randomized withdrawal, placebo-controlled study. International Clinical Psychopharmacology2010;25(3):183-7. [CSZG: 20670]PeuskensJ , TrivediJK , BrecherM , SvenssonO , MillerF , MeulienD . Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate. In: Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA. 2008. [CSZG: 16500]PeuskensJ , TrivediJK , BrecherM , SvenssonO , MillerF , MeulienD . Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate. Schizophrenia Research2008;98:14-5. [CSZG: 16344]PeuskensJ , TrivediJK , MalyarovS , BrecherM , SvenssonO , MillerF , et al. A randomized, placebo-controlled, relapse-prevention study with once-daily quetiapine sustained release in patients with schizophrenia. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28-Apr 1; Colorado Springs, Colorado, USA2007. [CSZG: 15271]PeuskensJC , TrivediJK , MalyarovS , BrecherM , SvenssonO , MillerF , et al. A randomized, placebo-controlled, relapse-prevention study with once daily quetiapine sustained release in patients with schizophrenia. Schizophrenia Bulletin2007;33(2):453. [CSZG: 15225]">Quetiapine 2007</a>). This trial was also terminated prematurely. For <a href="./references#CD008016-bbs2-0022" title="SampathG , ShahA , KrskaJ , SoniSD . Neuroleptic discontinuation in the very stable schizophrenic patient - relapse rates and serum neuroleptic levels. Human Psychopharmacology1992;7:255-64. [CSZG: 2493]SoniSD , MallikA , SchiffAA . Sulpiride in negative schizophrenia: a placebo-controlled double-blind assessment. Human Psychopharmacology1990;5:233-8. [CSZG: 2697]">Fluphenazine depot 1992</a>, there were imbalances of gender and baseline medication. In five studies participants who relapsed were discontinued and their code was broken, which can be a threat for blinding (<a href="./references#CD008016-bbs2-0008" title="FreemanLS , AlsonE . Prolonged withdrawal of chlorpromazine in chronic patients. Diseases of the Nervous System1962;23:522-5. [CSZG: 809]">Chlorpromazine 1962</a>; <a href="./references#CD008016-bbs2-0050" title="HershonHI , KennedyPF , McGuireRJ . Persistence of extra-pyramidal disorders and psychiatric relapse after withdrawal of long-term phenothiazine therapy. British Journal of Psychiatry1972;120(554):41-50. [CSZG: 1001]StevensBC . Role of fluphenazine decanoate in lessening the burden of chronic schizophrenics on the community. Psychological Medicine1973;3:141-58. [CSZG: 2739]">Trifluoperazine 1972</a>; <a href="./references#CD008016-bbs2-0051" title="GrossM , HitchmanIL , ReevesWP , LawrenceJ , NewellPC . Discontinuation of treatment with ataractic drugs. A preliminary report. American Journal of Psychiatry1960;116:931-2. [CSZG: 927]">Various drugs 1960</a>; <a href="./references#CD008016-bbs2-0059" title="MortonMR . A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia. American Journal of Psychiatry1968;124:1585-8. [CSZG: 2092]">Various drugs 1968</a>; <a href="./references#CD008016-bbs2-0069" title="CrowTJ , MacMillanJF , JohnsonAL , JohnstoneEC . A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry1986;148:120-7. [CSZG: 648]">Various drugs 1986a</a>) as can be administration of additional antipsychotic drugs in case of deterioration (<a href="./references#CD008016-bbs2-0016" title="KeskinerA , HoldenJMC , ItilTM . Maintenance treatment of schizophrenic outpatients with a depot phenothiazine. Psychosomatics1968;9:166-71. [CSZG: 1312]KeskinerA , SimeonJ , FinkM , ItilTM . Long-acting phenothiazine (fluphenazine decanoate) treatment of psychosis. Archives of General Psychiatry1968;18:477-81. KingDJ , DevaneyN , CooperSJ , BlomqvistM , MitchelMJ . Pharmacokinetics and antipsychotic effect of remoxipride in chronic schizophrenic patients. Journal of Psychopharmacology1990;4:83-9. [CSZG: 1323]Kinross-WrightJ , CharalampousKD . A controlled study of a very long-acting phenothiazine preparation. International Journal of Neuropsychiatry1965;1:66-70. [CSZG: 1335]">Fluphenazine depot 1968</a>). In <a href="./references#CD008016-bbs2-0054" title="TroshinskyC , AaronsonHG , StoneRK . Maintenance phenothiazines in aftercare of schizophrenic patients. Pennsylvania Psychiatric Bulletin1962;2:11-5. [CSZG: 2855]">Various drugs 1962b</a>, three out of 19 participants in the placebo group continued to receive active medication (also terminated prematurely). </p> <p> <div class="table" id="CD008016-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Unclear if free from 'other biases'</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008016-bbs2-0015" title="KaneJM , RifkinA , QuitkinF , NayakD , Ramos-LorenziJ . Fluphenazine vs. placebo in patients with remitted, acute first-episode schizophrenia. Archives of General Psychiatry1982;39:70-3. [CSZG: 1304]KaneJM , RifkinA , WoernerM , ReardonG . Low-dose neuroleptics in outpatient schizophrenics. Psychopharmacology Bulletin1982;18:20-1. [CSZG: 1602]">Fluphenazine 1982</a>, <a href="./references#CD008016-bbs2-0028" title="NCT01435928. PEARL Schizophrenia Maintenance. http://ClinicalTrials.gov/show/NCT014359282011. [CSZG: 23439]TandonR , CucchiaroJ , PhillipsD , HernandezD , MaoY , PikalovA , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Journal of Psychopharmacology2016;30(1):69-77. [CSZG: 33434]TandonR , LoebelA , PhilipsD , PikalovA , Hernandez D MaoY , et al. Lurasidone for maintenance of efficacy in patients with schizophrenia. European Neuropsychopharmacology2014;24(Suppl 2):S559-560. [CSZG: 27840]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , CucchiaroJ . A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Schizophrenia Research2014;153(1):S372. [CSZG: 29681]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Int J Neuropsychopharmacol2014;17:S153-154. [CSZG: 29954]">Lurasidone 2016</a>, <a href="./references#CD008016-bbs2-0029" title="DellvaMA , TollefsonGD , MattlerCA , KinonBJ , GrundySL . A controlled, double-blind investigation of the clozapine discontinuation syndrome with conversion to either olanzapine or placebo. Schizophrenia Research1999;36:277-8. [CSZG: 5651]TollefsonGD , DellvaMA , MattlerCA , KaneJM , WirshingDA , KinonBJ , et al. Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. Journal of Clinical Psychopharmacology1999;19:435-43. [CSZG: 5305]TollefsonGD , DellvaMA , MattlerCA , KinonBJ , GrundySL . A controlled, double-blind investigation of the clozapine discontinuation syndrome with conversion to either olanzapine or placebo. In: Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31 - Nov 4; Paris, France. 1998. [CSZG: 4859]">Olanzapine 1999</a>, <a href="./references#CD008016-bbs2-0055" title="CaffeyEM , DiamondLS , FrankTV , GrasbergerJC , HermanL , KlettCJ , et al. Discontinuation or reduction of chemotherapy in chronic schizophrenics. Journal of Chronic Diseases1964;17:347-58. [CSZG: 3153]CaffeyEM , ForrestIS , FrankTV , KlettCJ . Phenothiazine excretion in chronic schizophrenics. American Journal of Psychiatry1963;120:578-82. [CSZG: 420]">Various drugs 1964a</a>, <a href="./references#CD008016-bbs2-0071" title="McCreadieRG , WilesD , GrantS , CrockettGT , MahmoodZ , LivingstonMG , et al. The Scottish first episode schizophrenia study. VII two-year follow-up. Acta Psychiatrica Scandinavica1989;80:597-602. [CSZG: 3968]Scottish Schizophrenia Research Group. The Scottish First Episode Schizophrenia Study II. Treatment. British Journal of Psychiatry1987;150:334-8. [CSZG: 3969]Scottish Schizophrenia Research Group. The Scottish First Episode Schizophrenia Study V. One-year follow-up. British Journal of Psychiatry1988;152:470-476. [CSZG: 3970]Scottish Schizophrenia Research Group. The Scottish First Episode Schizophrenia Study. III. Cognitive performance. British Journal of Psychiatry1987;150:338-340. [CSZG: 16867]Scottish Schizophrenia Research Group. The Scottish first episode schizophrenia study. VIII. Five-year follow-up. British Journal of Psychiatry1992;161:496-500. [CSZG: 2542]">Various drugs 1989</a>, <a href="./references#CD008016-bbs2-0070" title="SpohnHE , CoyneL , LarsonJ , MittlemanF , SprayJ , HayesK . Episodic and residual thought pathology in chronic schizophrenics: effect of neuroleptics. Schizophrenia Bulletin1986;12:394-407. [CSZG: 2712]">Various drugs 1986b</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Terminated prematurely after pre‐planned interim analyses</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008016-bbs2-0002" title="CorrellC , KohegyiE , ZhaoC , BakerRA , McQuadeR , SalzmanP , et al. Oral aripiprazole is an effective maintenance treatment in adolescents with schizophrenia. Neuropsychopharmacology2014:S349-S350. [CSZG: 29288]CorrellCU , KohegyiE , ZhaoC , BakerRA , McQuadeR , SalzmanPM , et al. Oral aripiprazole as maintenance treatment in adolescent schizophrenia: results from a 52-week, randomized, placebo-controlled withdrawal study. Journal of the American Academy of Child and Adolescent Psychiatry2017;56(9):784-92. [CSZG: 36321]NCT01149655. A long-term multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of aripiprazole (opc 14597) as maintenance treatment in adolescent patients with schizophrenia. http://ClinicalTrials.gov/show/NCT011496552010. [CSZG: 21085]">Aripiprazole 2017</a>, <a href="./references#CD008016-bbs2-0003" title="BakerR , FleischhackerW , SanchezR , PerryP , JinN , JohnsonB , et al. Long-term safety and tolerability of once-monthly aripiprazole intramuscular depot for maintenance treatment in schizophrenia. International Journal of Neuropsychopharmacology2012;15:111. [CSZG: 28035]BakerRA , CarsonWH , PerryPP , SanchezR , ZhaoJ , McQuadeRD , et al. Effects of aripiprazole once-monthly vs placebo on domains of personal and social performance in younger and older patients with schizophrenia. CNS Spectrums2013;18(6):376-7. [CSZG: 28526]BakerRA , EramoA , CarsonWH , PerryP , SanchezR , ZhaoJ , et al. Effects of aripiprazole once-monthly vs. placebo on domains of personal and social performance in younger and older patients with schizophrenia. Schizophrenia Bulletin2013;39(Suppl 1):S321-S322. [CSZG: 28131]BakerRA , EramoA , NylanderAG , TsaiLF , Peters-StricklandTS , KosticD , et al. The effect of previous dose or oral aripiprazole (10 or 30 mg/day) on the efficacy and tolerability of aripiprazole once-monthly: Results from post-hoc analyses from two double-blind, randomized, controlled trials. Schizophrenia Research2014;153:S293. [CSZG: 29386]CarsonWH , PerryPP , SanchezR , JinN , ForbesRA , McQuadeRD , et al. Effects of ARI-IM-depot on secondary efficacy outcomes in maintenance treatment of schizophrenia. International Journal of Neuropsychopharmacology2012;15:112-3. [CSZG: 28030]EramoA , FleischhackerWW , SanchezR , PerryP , JinN , JohnsonB , et al. A placebo-controlled study of efficacy and safety of aripiprazole oncemonthly for long-term maintenance treatment in schizophrenia. European Psychiatry2013;28(1):1. [CSZG: 28187]EramoA , FleischhackerWW , SanchezR , TsaiLF , Peters-StricklandTS , BakerRA , et al. All-cause discontinuation and safety of aripiprazole once-monthly for the treatment of schizophrenia: A pooled analysis of two double-blind, randomized, controlled trials. Schizophrenia Research2014;153:S174. [CSZG: 29437]FleischhackerWW , BakerRA , EramoA , SanchezR , TsaiLF , Peters-StricklandT , et al. Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies. Schizophrenia Research2014;159(2-3):415-20. [CSZG: 32163]FleischhackerWW , PerryP , SanchezR , JinN , Peters-StricklandT , JohnsonB , et al. Functional outcomes with aripiprazole once-monthly in two double-blind, placebo- and active-controlled studies (aspire us 246 and aspire eu 247) for the treatment of schizophrenia. Value in Health2013;16(7):A550. [CSZG: 28480]FleischhackerWW , SanchezR , JohnsonB , JinN , ForbesRA , McQuadeR , et al. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. International Clinical Psychopharmacology2013;28:171-6. [CSZG: 28391]FleischhackerWW , SanchezR , Lan-FengT , Peters-StricklandT , BakerRA , EramoA , et al. Safety and Effectiveness of Aripiprazole Oncemonthly for the Treatment of Schizophrenia: A Pooled Analysis of Two Double-blind, Randomized, Controlled Trials. Neuropsychopharmacology2013;38:S394-S395. [CSZG: 28459]KaneJM , SanchezR , BakerRA , EramoA , Peters-StricklandT , PerryPP , et al. Patient-centered outcomes with aripiprazole once-monthly for maintenance treatment in patients with schizophrenia: Results from two multicenter, randomized, double-blind studies. Clinical Schizophrenia and Related Psychoses2015;9(2):79-87. [CSZG: 32183]KaneJM , SanchezR , PerryPP , JinN , JohnsonB , ForbesRA , et al. Efficacy of aripiprazole-IM-depot for long-term maintenance treatment of schizophrenia. International Journal of Neuropsychopharmacology2012;15:S119. [CSZG: 28033]KaneJM , SanchezR , PerryPP , JinN , JohnsonBR , ForbesRA , et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: A 52-week, multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2012;73(5):617-24. [CSZG: 24369]LozeJ , CarsonWH , PerryPP , SanchezR , JinN , ForbesRA , et al. Psychosocial and overall effectiveness of aripiprazole intramuscular depot vs. placebo for maintenance treatment in schizophrenia. European Neuropsychopharmacology2012;22:S328. [CSZG: 24886]NCT00705783. Aripiprazole (OPC-14597) as maintenance treatment in patients with schizophrenia. https://www.ClinicalTrials.gov/ct/show/2008. [CSZG: 16546]SanchezR , JohnsonB , JinN , ForbesRA , CarsonWH , McQuadeRD , et al. Patient-reported outcomes (PROs) with aripiprazole intramuscular depot (ARI-IMD) for maintenance treatment in schizophrenia. International Journal of Neuropsychopharmacology2012;15:133. [CSZG: 28040]SanchezR , PerryPP , JinN , Johnson, RA Forbes, RD McQuade, WH, et al. A placebo-controlled study of efficacy/ safety of aripiprazole intramuscular depot for long-term maintenance treatment of schizophrenia. European Neuropsychopharmacology2012;(Suppl 2):S327. [CSZG: 24893]">Aripiprazole depot 2012</a>, <a href="./references#CD008016-bbs2-0005" title="BakerR , HobartM , ForbesA , OuyangJ , WeillerE . Effect of brexpiprazole on long-term functioning in adults with schizophrenia. Australian and New Zealand Journal of Psychiatry2017;51(Suppl 1):148. [CSZG: 35955]CorrellCU , ShiL , WeissC , HobartM , EramoA , DuffyRA , et al. Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice of cross-titration schedules in a post-hoc analysis of a randomized double-blind maintenance treatment study. CNS Spectrums2019;24(5):507-17. FleischhackerWW , HobartM , OuyangJ , ForbesA , PfisterS , McQuadeR , et al. Brexpiprazole (OPC-34712) efficacy and safety as maintenance therapy in adults with schizophrenia: Randomised, double-blind, placebo-controlled study. European Neuropsychopharmacology2015;25:S527. [CSZG: 33322]FleischhackerWW , HobartM , OuyangJ , ForbesA , PfisterS , McQuadeRD , et al. Efficacy and sfety of Brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. International Journal of Neuropsychopharmacology2017;20(1):11-21. [CSZG: 35475]NCT01668797. Efficacy, Safety, and tolerability of Brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia. https://ClinicalTrials.gov/show/NCT016687972012. [CSZG: 35608]TherrienF , WeissC , JinN , BakerRA , MacKenzieE , MeehanSR . Effect of brexpiprazole on patient functioning in patients with schizophrenia: results from a long-term, randomised, double-blind, placebo-controlled, maintenance study. Neuropsychopharmacology2017;43((Suppl.1)):S244-S245. [CSZG: 37935]WeillerE , HobartM , PfsterS , ForbesA , OuyangJ , WeissC . Effect of brexpiprazole on long-term remission in adults with schizophrenia: Results from a randomized, double-blind, placebo-controlled, maintenance study. Schizophrenia Bulletin2017;43:S202-3. [CSZG: 36050]WeissC , ForbesA , HobartM , PfsterS , OuyangJ , WeillerE . Short-term and long-term efficacy of brexpiprazole in adults with schizophrenia: Effect across marder factors. Schizophrenia Bulletin2017;43:S155. [CSZG: 36051]WeissC , OuyangJ , EramoA , DuffyRA , WeillerE , BakerRA . Switching patients with acute schizophrenia to brexpiprazole: post-hoc analysis of a double-blind randomized maintenance treatment study. Neuropsychopharmacology2015;40:S227-8. [CSZG: 33450]WeissC , WeillerE , HobartM , OuyangJ . Effect of brexpiprazole on weight and metabolic parameters: analysis of a maintenance trial in schizophrenia. European Neuropsychopharmacology2016;26:S556. [CSZG: 35746]">Brexpiprazole 2017</a>,<a href="./references#CD008016-bbs2-0006" title='CorrellCU , PotkinSG , DurgamS , ChangCT , SzatmariB , LaszlovszkyI , et al. Sustained remission with cariprazine treatment: post-hoc analysis of a randomised, double-blind, schizophrenia relapse prevention trial. Europan Neuropsychopharmacology2017;27((Suppl. 4)):S935-S936. [CSZG: 37757]CorrellCU , PotkinSG , ZhongY , HarsányiJ , SzatmáriB , EarleyW . Long-term remission with cariprazine treatment in patients with schizophrenia: a post-hoc analysis of a randomized, double-blind, placebo.controlled relapse prevention trial. Journal of Clinical Psychiatry2019;80(2):18m12495. DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Corrigendum to "Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial" [Schizophr. Res. 176 (2016) 264-71]. Schizophrenia Research2017;InPress:InPress. [CSZG: 35204]DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A double-blind, placebo-controlled trial. European Neuropsychopharmacology2015;25:S512-3. [CSZG: 33317]DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophrenia Research2016;176(2-3):264-71. [CSZG: 35204]DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: additional analysis from a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2015;40:S380-1. [CSZG: 33316]EarleyW , GuoH , LuchiniR . Modified cariprazine relapse prevention clinical trial results. Schizophrenia Research2018;199:452-3. KunovacJ , KaneJ , DurgamS , ChangCT , NemethG , LaszlovszkyI , et al. Characteristics associated with relapse in patients with schizophrenia: Post hoc analysis of a randomized, double-blind, placebo-controlled, cariprazine relapse prevention trial. Schizophrenia Bulletin2017;43:S166-7. [CSZG: 36002]NCT01412060. Cariprazine relative to placebo in the prevention of relapse of symptoms in patients with schizophrenia. http://ClinicalTrials.gov/show/NCT014120602011. [CSZG: 23106]PotkinS , CorrellC , ChangCT , SzatmariB , LaszlovszkyI , EarleyW . Long-term remission with cariprazine treatment in patients with schizophrenia: a post hoc analysis of a randomized, double-blind, placebo-controlled, relapse prevention trial. Schizophrenia Bulletin2017;43:S118. [CSZG: 36026]'>Cariprazine 2016</a>, <a href="./references#CD008016-bbs2-0027" title="CTRI/2010/091/001409. A clinical trial to study prevention of relapse in patients with schizophrenia reveiving either flexible dose iloperidone or placebo in long-term use.. http://ctri.nic.in/Clinicaltrials/login.php2010. NCT01291511. Efficacy in prevention of relapse of schizophrenia in subjects taking either placebo or iloperidone. http://ClinicalTrials.gov/show/NCT012915112011. [CSZG: 22671]WeidenPJ , ManningR , WolfgangCD , RyanJM , MancioneL , HanG , et al. A randomized trial of iloperidone for prevention of relapse in schizophrenia: the REPRIEVE study. CNS drugs2016;30(8):735-47. [CSZG: 35243]">Iloperidone 2016</a>, <a href="./references#CD008016-bbs2-0030" title="Beasley C Jr, HamiltonS , DossenbachM . Relapse prevention with olanzapine. European Neuropsychopharmacology2000;10(Suppl 3):S304. [CSZG: 4620]BeasleyCM , HamiltonSH , DossenbachM . Relapse prevention with olanzapine. Schizophrenia Research2000;41(1):196-7. [CSZG: 4874]BeasleyCM , SuttonVK , HamiltonSH , WalkerDJ , DossenbachM , TaylorCC , et al. A double-blind, randomised, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. Journal of Clinical Psychopharmacology2003;23:582-94. [CSZG: 10010]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD , PickarD . Does maintenance treatment with atypical antipsychotics worsen quality of life among stable patients with schizophrenia?Neuropsychopharmacology2005;30(S1):S189. [CSZG: 13107]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD . Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?Journal of Clinical Psychopharmacology2006;26:40-4. [CSZG: 14454]BeasleyCM , WalkerDJ , SuttonVK , AlakaK , NaberD , NamjoshiM . The effectiveness of olanzapine versus placebo in maintaining the quality of life in stabilized patients with schizophrenia. European Neuropsychopharmacology2003;13:S342. [CSZG: 9849]EliLilly Company. Olanzapine relapse prevention versus placebo in the treatment of schizophrenia. http://www.Clinicalstudyresults.org/.2005. [CSZG: 18733]">Olanzapine 2003</a>, <a href="./references#CD008016-bbs2-0031" title="Eerdekens. Evaluate the efficacy in the prevention of recurrence of the symptoms of schizophrenia. Sponsor: Johnson &amp; Johnson Pharmaceutical Research &amp; Development, LL.C2010. [CTG: NCT00111189]KramerM , KushnerS , SherrJ , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study. Schizophrenia Bulletin2007;33(2):438. [CSZG: 15185]KramerM , KushnerS , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia treated with paliperidone extended-release tablets. European Neuropsychopharmacology2006;16(Suppl 4):S386. [CSZG: 13313]KramerM , KushnerS , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study. International Journal of Neuropsychopharmacology2006;9(Suppl 1):S274. [CSZG: 19545]KramerM , SimpsonG , MaciulisV , KushnerS , LiuY , LimP , et al. One-year open-label safety and efficacy study of paliperidone extended-release. CNS Spectrums2010;15(8):506-14. [CSZG: 20885]KramerM , SimpsonG , MaciulisV , KushnerS , VijapurkarU , LimP , et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2007;27:6-14. [CSZG: 13907]MarkowitzM , FuDJ , LevitanB , GopalS , TurkozI , AlphsL . Long-acting injectable paliperidone palmitate versus oral paliperidone extended release. Annals of General Psychiatry2013;12:22. [CSZG: 28633]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone 2007</a>, <a href="./references#CD008016-bbs2-0032" title="RuiQ , WangY , LiangS , LiuY , WuY , WuQ , et al. Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry2014;53:45-53. [CSZG: 29320]ZhangH , LiH , LiuY , WuC , WuQ , NuamahI . Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia. Neuropsychiatric Disease and Treatment2016;12:69-77. [CSZG: 33455]">Paliperidone 2014</a>, <a href="./references#CD008016-bbs2-0033" title="AlphsL , BossieC , Kern-SliwaJ , Ma Y-W, HaskinsJT . Paliperidone palmitate: clinical response in subjects with schizophrenia with recent vs. longer-term duration of illness. In: Proceedings of the 162nd Annual Meeting of the American Psychiatric Association. San Francisco, CA., 2009 May 16-21. [CSZG: 19067]EmsleyR , NuamahI , GopalS , HoughD , FleischhackerWW . Relapse after antipsychotic discontinuation in schizophrenia as a withdrawal phenomenon vs illness recurrence: a post hoc analysis of a randomized placebo-controlled study. Journal of Clinical Psychiatry 2018 Jun;79(4):17m11874. [CSZG: 38184]EmsleyR , NuamahI , HoughD , GopalS . Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophrenia Research2012;138(1):29-34. [CSZG: 24214]GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM , HoughD . A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. Journal of Psychopharmacology2011;25(5):685-97. [CSZG: 22903]GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Long-term efficacy, safety and tolerability of paliperidone palmitate in patients with schizophrenia. In: Proceedings of the 162nd Annual Meeting of the American Psychiatric Association. San Francisco, CA, 2009 May 16-21. [CSZG: 19076]HoughD , GopalS , VijapukarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate in prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. In: Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8, Washington DC, USA. 2008. [CSZG: 16486]HoughD , GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. In: Proceedings of the 63rd Annual Convention of the Society of Biological Psychiatry. Washington, DC, USA: Elsevier Science Inc, 2008:S285-6. [CSZG: 20281]HoughD , GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Biological Psychiatry2008;63(7 Suppl):285S-6S. [CSZG: 19530]HoughD , GopalS , VjapukarU , LimP , MorozowaM , EerdekensM . Paliperidone palmitate maintenance treatment in delaying the time to relapse in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. Schizophrenia Research2010;116:107-17. [CSZG: 19704]HulihanJ , BossieCA , FuDJ , Kern SliwaJ , Ma Y-W, AlphsLD . Remission with continued paliperidone palmitate treatment in stable subjects with schizophrenia. Schizophrenia Research2012;136:S252. [CSZG: 29467]KozmaCM , SlatonT , DiraniR , FastenauJ , GopalS , HoughD . Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate. Current Medical Resarch and Opinion2011;27(8):1603-11. SliwaJK , BossieCA , Fu DJ, TurkozI , AlphsL . Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia. Neuropsychiatric Disease and Treatment2012;8:375-85. [CSZG: 28007]SliwaJK , FuDJ , BossieCA , et al. Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate. BMC Psychiatry2014;14:S52. [CSZG: 29148]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone depot1M 2010</a>, <a href="./references#CD008016-bbs2-0035" title="BellLKS , TurkozI , KimE . Paliperidone palmitate once-every-3-months in adults with early illness schizophrenia. Early Intervention in Psychiatry2019;13(3):667-72. BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of paliperidone palmitate 3 month formulation: a randomized, double-blind, placebo-controlled study. Schizophrenia Bulletin2015;41:S302. [CSZG: 29393]BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of paliperidone palmitate 3-month formulation in schizophrenia: a randomized, double-blind, placebo-controlled study. European Psychiatry2015;30:272. [CSZG: 32149]BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry2015;72(8):830-9. [CSZG: 33027]ChirilaC , ZhengQ , SawyerrG , NuamahI . Healthcare resource use of paliperidone palmitate 3-month injection vs placebo. In: 168th Annual Meeting of American Psychiatric Association; Toronto, Canada. May 16-20, 2015. [CSZG: 33035]GopalS , FureyM , HibarD , KolbH , SaadZ , SavitzA , et al. Potential biomarkers of impending schizophrenia relapse. Biological Psychiatry2017;(10 Suppl):S126-S127. [CSZG: 36107]GopalS , XuH , McQuarrieK , SavitzA , NuamahI , WoodruffK , et al. Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies. NPJ Schizophrenia2017;3(1):23. [CSZG: 36325]MathewsM , NuamahI , SavitzA , GopalS . Efficacy and safety of paliperidone palmitate 3-month formulation vs placebo for relapse prevention of Schizophrenia: Treatment effect using a number needed to treat analysis. Biological Psychiatry2017;81(10 Suppl 1):S350-1. [CSZG: 36437]NCT01529515. A study of paliperidone palmitate 3 month formulation for the treatment of patients with schizophrenia. http://ClinicalTrials.gov/show/NCT015295152012. [CSZG: 23705]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone depot3M 2015</a>, <a href="./references#CD008016-bbs2-0045" title="D1441C00131. A 1-year, international, multicenter, randomized, double-blind, parallel-group, placebo-controlled phase IV study to evaluate prevention of relapse in patients in stable condition with chronic schizophrenia receiving either quetiapine fumarate IR (SEROQUEL) or placebo. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=3852003. D1444C00004. A 1-year, international, multicenter, randomized, double-blind, parallelgroup, placebo-controlled phase iii study to evaluate prevention of relapse in patients in stable condition with chronic schizophrenia receiving either sustained-release quetiapine fumarate (SEROQUEL) or placebo. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=14182006. NCT00228462. A 1-year, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study to evaluate prevention of relapse in patients in stable chronic schizophrenia receiving either sustained-release quetiapine fumarate (SEROQUEL) or placebo (abbreviated). https://www.ClinicalTrials.gov/ct/show/2005. [CSZG: 14874]PeuskensJ , TrivediJ , MalyarovS , BrecherM , SvenssonO , MillerF , et al. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomised, placebo-controlled trial in clinically stable patients. Psychiatry2007;4(11):34-50. [CSZG: 16025]PeuskensJ , TrivediJK , BrecherM , MillerF , Study I . Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: Post-hoc analysis of data from a randomized withdrawal, placebo-controlled study. International Clinical Psychopharmacology2010;25(3):183-7. [CSZG: 20670]PeuskensJ , TrivediJK , BrecherM , SvenssonO , MillerF , MeulienD . Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate. In: Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA. 2008. [CSZG: 16500]PeuskensJ , TrivediJK , BrecherM , SvenssonO , MillerF , MeulienD . Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate. Schizophrenia Research2008;98:14-5. [CSZG: 16344]PeuskensJ , TrivediJK , MalyarovS , BrecherM , SvenssonO , MillerF , et al. A randomized, placebo-controlled, relapse-prevention study with once-daily quetiapine sustained release in patients with schizophrenia. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28-Apr 1; Colorado Springs, Colorado, USA2007. [CSZG: 15271]PeuskensJC , TrivediJK , MalyarovS , BrecherM , SvenssonO , MillerF , et al. A randomized, placebo-controlled, relapse-prevention study with once daily quetiapine sustained release in patients with schizophrenia. Schizophrenia Bulletin2007;33(2):453. [CSZG: 15225]">Quetiapine 2007</a>, <a href="./references#CD008016-bbs2-0046" title="NCT00658645. A multinational, randomised, double-blind, fixed-dose, bifeprunox study combining a 12-week placebo-controlled, quetiapine-referenced phase with a 12-month quetiapine-controlled phase in patients with schizophrenia. https://www.clinicaltrials.gov/ct2/show/NCT00658645?term=NCT00658645&amp;rank=1. [CSZG: 16241]">Quetiapine 2009a</a>, <a href="./references#CD008016-bbs2-0047" title="NCT00704509. A multinational, randomised, double-blind, fixed-dose, bifeprunox study combining a 12-week placebo-controlled, quetiapine-referenced phase with a 12-month quetiapine-controlled phase in patients with schizophrenia. https://www.clinicaltrials.gov/ct2/show/NCT00704509?term=NCT00704509&amp;rank=1. [CSZG: 16566]">Quetiapine 2009b</a>, <a href="./references#CD008016-bbs2-0073" title="BoonstraG , BurgerH , GrobbeDE , KahnRS . Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial. International Journal of Psychiatry in Clinical Practice2011;15(2):128-34. [CSZG: 22940]BoonstraG . Schizophrenia termination of pharmacotherapy-STOP-trial. Current Controlled Trials2005. [CSZG: 14487] [ISRCTN: 6332944]">Various drugs 2011</a> </p> </td> </tr> </tbody> </table> </div> </p> </section> </section> <section id="CD008016-sec-0112"> <h3 class="title" id="CD008016-sec-0112">Effects of interventions</h3> <p>See: <a href="./full#CD008016-tbl-0001"><b>Summary of findings 1</b> Maintenance treatment with antipsychotic drugs versus placebo/no treatment for schizophrenia</a> </p> <section id="CD008016-sec-0113"> <h4 class="title">1. Comparison 1. Maintenance treatment with antipsychotic drugs versus placebo/no treatment </h4> <section id="CD008016-sec-0114"> <h5 class="title">1.1 Relapse</h5> <p>Antipsychotic medication was clearly more effective than placebo in preventing relapse in studies lasting up to three months (percentage of participants relapsed drug 12% versus placebo 35%, 44 randomised controlled trials (RCTs), n = 6362, risk ratio (RR) 0.34, 95% confidence intervals (CI) 0.28 to 0.40, number needed to treat for an additional beneficial outcome (NNTB) 4, 95% CI 3 to 5, <a href="./references#CD008016-fig-0011" title="">Analysis 1.1</a>); four to six months (drug 18% versus placebo 49%, 49 RCTs, n = 7599, RR 0.36, 95% CI 0.31 to 0.42, NNTB 3, 95% CI 3 to 4, <a href="./references#CD008016-fig-0011" title="">Analysis 1.1</a>); seven to 12 months (primary outcome: drug 24% versus placebo 61%, 30 RCTs, n = 4249, RR 0.38, 95% CI 0.32 to 0.45, NNTB 3, 95% CI 2 to 3; high‐certainty evidence, <a href="./references#CD008016-fig-0011" title="">Analysis 1.1</a>); more than 12 months (drug 31% versus placebo 68%, 10 RCTs, n = 1786, RR 0.46, 95% CI 0.33 to 0.64, NNTB 3, CI 2 to 4, <a href="./references#CD008016-fig-0011" title="">Analysis 1.1</a>), and all studies combined (drug 22% versus placebo 58%, 71 RCTs, n = 8666, RR 0.35, 95% CI 0.30 to 0.40, NNTB 3, 95% CI 2 to 3, <a href="./references#CD008016-fig-0012" title="">Analysis 1.2</a>). There was considerable heterogeneity of study results up to three months (P &lt;.0001, I<sup>2</sup>=50%), four to six months (P &lt; 0.00001, I<sup>2</sup> = 68%), seven to 12 months (P &lt; 0.00001, I<sup>2</sup> = 71%), more than 12 months (P &lt; 0.00001, I<sup>2</sup> = 90%); and all studies combined (P &lt; 0.00001, I<sup>2</sup> = 78%). However, in all studies the relapse rates were lower in the antipsychotic drug group than in the placebo group. Therefore, the heterogeneity expressed a difference in the magnitude of the superiority rather than in the direction of the effect. Subgroup analyses and meta‐regressions showed that the heterogeneity may be in part explained by study duration and differences between oral and depot medication (see sections 2.5 and 2.10 below). </p> <p>The funnel plot of the primary outcome 'relapse at 12 months' was asymmetrical (see <a href="#CD008016-fig-0006">Figure 6</a>), and this was corroborated by Egger's regression test (intercept ‐1.39, t value 2.46, degrees of freedom (df) 28, P = 0.02042, <a href="./references#CD008016-bbs2-0191" title="EggerM , Davey-SmithG , SchneiderM , MinderCS . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;13:629-34.">Egger 1997</a>) and a contour‐enhanced funnel‐plot (<a href="./references#CD008016-bbs2-0226" title="PetersJL , SuttonAJ , JonesDR , AbramsKR , RushtonL . Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. Journal of Clinical Epidemiology2008;61:991-6.">Peters 2008</a>, the plot can be received from the authors upon request). However, when adjusted by Duval's trim and fill method (<a href="./references#CD008016-bbs2-0190" title="DuvalS , TweedieR . Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics2000;56:455-63.">Duval 2000</a>) the RR did not change substantially (RR 0.45, 95% CI 0.38 to 0.54), neither did it when only large studies (defined as &gt; 200 participants) were included (10 RCTs, n = 2950, RR 0.37, 95% CI 0.31 to 0.45, <a href="./references#CD008016-fig-0057" title="">Analysis 3.5</a>). </p> <div class="figure" id="CD008016-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Maintenance treatment with antipsychotic drugs versus placebo/no treatment, outcome: Relapse" data-id="CD008016-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Maintenance treatment with antipsychotic drugs versus placebo/no treatment, outcome: Relapse </p> </div> </div> </div> </section> <section id="CD008016-sec-0115"> <h5 class="title">1.2 Leaving the study early</h5> <section id="CD008016-sec-0116"> <h6 class="title">1.2.1 Due to any reason (acceptability of treatment)</h6> <p>Studies lasting up to three months (drug 9% versus placebo 29%, 11 RCTs, n = 517, RR 0.34, 95% CI 0.17 to 0.67); between four to six months (drug 22% versus placebo 44%, 18 RCTs, n = 1792, RR 0.49, 95% CI 0.37 to 0.65, NNTB 6, 95% CI 4 to 10); between seven to 12 months (drug 36% versus placebo 62%, 24 RCTs, n = 3951, RR 0.56, 95% CI 0.48 to 0.65, NNTB 4, 95% CI 3 to 5), high‐certainty evidence; and more than 12 months (drug 35% versus placebo 53%, 5 RCTs, n = 741, RR 0.64, 95% CI 0.51 to 0.82) showed a clear difference in favour of antipsychotic medication. Overall, there was a clear difference ‐ to conventional levels of statistical significance ‐ in favour of antipsychotic medication (drug 30% versus placebo 54%, 56 RCTs, n = 7001, RR 0.54, 95% CI 0.49 to 0.61, NNTB 4, 95% CI 4 to 6, <a href="./references#CD008016-fig-0013" title="">Analysis 1.3</a>). There was considerable heterogeneity within the group of studies lasting up to six months (P =.005, I<sup>2</sup> = 54%), in studies lasting up to12 months (P &lt; 0.00001, I<sup>2</sup>= 80%) and in all studies combined (P &lt; 0.00001, I<sup>2</sup> = 69%), but again this reflected heterogeneity in the degree of superiority rather than in the direction of the effect. </p> </section> <section id="CD008016-sec-0117"> <h6 class="title">1.2.2 Due to adverse events (overall tolerability)</h6> <p>There was not a clear difference in studies lasting up to three months (drug 1% versus placebo 0%, 10 RCTs, n = 371, RR 2.84, 95% CI 0.12 to 65.34); four to six months (drug 4% versus placebo 4%, 15 RCTs, n = 1852, RR 1.20, 95% 95% CI 0.63 to 2,28); and seven to 12 months (drug 5% versus placebo 4%, 23 RCTs, n = 3870, RR 1.16, 95% CI 0.69 to 1.97), while the difference was statistically significant in studies lasting more than 12 months (drug 4% versus placebo 1%, 5 RCTs, n = 534, RR 5.70, 95% CI 1.28 to 25.33, NNTB 50, 95% CI 17 to 50). Overall, there was not a clear difference between groups (drug 5% versus placebo 3%, 53 RCTs, n = 6627, RR 1.27, 95% CI 0.85 to 1.89, <a href="./references#CD008016-fig-0014" title="">Analysis 1.4</a>). There was some heterogeneity in the group of studies lasting seven to 12 months (P = 0.009, I<sup>2</sup> = 48%) and overall (P = 0.007, I<sup>2</sup> = 43%). A possible explanation is that in particular, in recent trials not only tolerability‐related adverse events, but also efficacy‐related adverse events (e.g. exacerbation of psychosis) were summarised as "leaving the study due to adverse events". This may explain the clearest outlier (<a href="./references#CD008016-bbs2-0030" title="Beasley C Jr, HamiltonS , DossenbachM . Relapse prevention with olanzapine. European Neuropsychopharmacology2000;10(Suppl 3):S304. [CSZG: 4620]BeasleyCM , HamiltonSH , DossenbachM . Relapse prevention with olanzapine. Schizophrenia Research2000;41(1):196-7. [CSZG: 4874]BeasleyCM , SuttonVK , HamiltonSH , WalkerDJ , DossenbachM , TaylorCC , et al. A double-blind, randomised, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. Journal of Clinical Psychopharmacology2003;23:582-94. [CSZG: 10010]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD , PickarD . Does maintenance treatment with atypical antipsychotics worsen quality of life among stable patients with schizophrenia?Neuropsychopharmacology2005;30(S1):S189. [CSZG: 13107]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD . Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?Journal of Clinical Psychopharmacology2006;26:40-4. [CSZG: 14454]BeasleyCM , WalkerDJ , SuttonVK , AlakaK , NaberD , NamjoshiM . The effectiveness of olanzapine versus placebo in maintaining the quality of life in stabilized patients with schizophrenia. European Neuropsychopharmacology2003;13:S342. [CSZG: 9849]EliLilly Company. Olanzapine relapse prevention versus placebo in the treatment of schizophrenia. http://www.Clinicalstudyresults.org/.2005. [CSZG: 18733]">Olanzapine 2003</a>), where all leaving due to adverse events were efficacy‐related. Removing this study and <a href="./references#CD008016-bbs2-0074" title="AratoM , O'ConnorR , BradburyJE , MeltzerH . Long-term ziprasidone in schizophrenia. In: Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 - Jun 4; Toronto, Ontario, Canada. 1998. [CSZG: 3189]AratoM , O'ConnorR , BradburyJE , MeltzerH . The efficacy of ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. In: Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK. Amsterdam, Netherlands: Cambridge University Press, 1998. [CSZG: 3188]AratoM , O'ConnorR , BradburyJE , MeltzerH . Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. In: Proceedings of the 9th Congress of the Association of European Psychiatrists; 1998 Sep 20-24; Copenhagen, Denmark. 1998. [CSZG: 3190]AratoM , O'ConnorR , BradburyJE , MeltzerH . Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. Schizophrenia Research1999;36(1-3):270. [CSZG: 5626]AratoM , O'ConnorR , MeltzerH , BradburyJ . Ziprasidone: efficacy in the prevention of relapse and in the long-term treatment of negative symptoms of chronic schizophrenia. In: Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria. 1997. [CSZG: 245]AratoM , O'ConnorR , MeltzerHY . A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. International Clinical Psychopharmacology2002;17:207-15. [CSZG: 18486]BernardoM , AranzaJR , Rubio-TerresC , RejasJ . Cost-effectiveness analysis of schizophrenia relapse prevention. Clinical Drug Investigation. New Zealand2006;26(8):447-57. [CSZG: 13898]BernardoM , AranzaJR , Rubio-TerresC , RejasJ . Cost-effectiveness analysis of the prevention of relapse in schizophrenia in the ZEUS longitudinal study Ziprasidone Extended Use in Schizophrenia (ZEUS). Acta Espanolas de Psiquiatria2007;35(4):259-62. [CSZG: 15396]MeltzerHY , O´ConnorR . Long-term efficacy of ziprasidone in schizophrenia. Schizophrenia research2001;(1-2):S. 239. [CSZG: 6050]MeltzerHY , O´ConnorR . Path analysis of the ZEUS study provides evidence of a direct effect of ziprasidone on primary negative symptoms in chronic, stable schizophrenia. Conference Poster1997. [CSZG: 2033]MeltzerHY , O'ConnorR . Long-term efficacy of ziprasidone in schizophrenia: results of two controlled trials. In: Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico. 2000. [CSZG: 7609]O'ConnorR , SchoolerNR . Penultimate observation carried forward (POCF): a new approach to analysis of long-term symptom change in chronic relapsing conditions [letter]. Schizophrenia Research2003;60:319-20. [CSZG: 9365]Pfizer 2000. Multicentre double-blind study of ziprasidone versus placebo in relapse prevention for hospitalised patients with chronic or subchronic schizophrenia. Study report Unpublished. SchoolerN . A basis for optimism: the implications of long term treatment. In: Proceedings of the 9th Congress of the Association of European Psychiatrists; 1998 Sep 20-24; Copenhagen, Denmark. 1998. [CSZG: 5864]">Ziprasidone 2002</a> (where details about dropout due to adverse events were not presented), results in the data becoming homogeneous. Statistically significantly more patients in the antipsychotic group left early for adverse events at 12 months (RR 1.56, 95% CI 1.04 to 2.34; heterogeneity test: P = 0.4, I² = 5%), and overall (RR 1.51, 95% CI 1.07 to 2.13; heterogeneity test: P = 0.23, I² = 15%). </p> </section> <section id="CD008016-sec-0118"> <h6 class="title">1.2.3 Due to inefficacy</h6> <p>Studies lasting up to three months (drug 5% versus placebo 27%, 11 RCTs, n = 421, RR 0.21, 95% CI 0.07 to 0.64), four to six months (drug 14% versus placebo 36%, 16 RCTs, n = 1661, RR 0.41, 95% CI 0.31 to 0.54, NNTB 5, 95% CI 3 to 9), seven to 12 months (drug 18% versus placebo 46%, 24 RCTs, n = 3951, RR 0.37, 95% CI 0.31 to 0.44, NNTB 3, 95% CI 3 to 4), and more than 12 months (drug 11% versus placebo 25%, 4 RCTs, n = 504, RR 0.43, 95% CI 0.29 to 0.64) showed a clear difference in favour of antipsychotic medication. Overall, there was a statistically significant difference in favour of antipsychotic medication (drug 16% versus placebo 40%, 55 RCTs, n = 6537, RR 0.38, 95% CI 0.32 to 0.43, NNTB 4, 95% CI 3 to 5, <a href="./references#CD008016-fig-0015" title="">Analysis 1.5</a>). The results at three months (P = 0.05, I<sup>2</sup> = 50%), at seven to 12 months (P &lt; 0.0001, I<sup>2</sup> = 64%) and pooling all studies (P &lt; 0.0001, I<sup>2</sup>= 50%) were heterogeneous, but, with the exception of <a href="./references#CD008016-bbs2-0041" title="ChannabasavannaSM , MichaelA . Penfluridol maintenance therapy in schizophrenia: a controlled study. Indian Journal of Psychiatry1987;29(4):333-6. [CSZG: 1094]">Penfluridol 1987</a> and <a href="./references#CD008016-bbs2-0056" title="MarjerrisonG , IrvineD , StewartCN , WilliamsR , MatheuH , DemayM . Withdrawal of long-term phenothiazines from chronically hospitalized psychiatric patients. Canadian Psychiatric Association Journal1964;9(4):290-8. [CSZG: 4833]">Various drugs 1964b</a>, all studies showed at least a trend in favour of antipsychotic drugs. Thus, again, we feel the heterogeneity reflected differences in the degree of superiority rather than in the direction of the effect. Re‐inspection of <a href="./references#CD008016-bbs2-0041" title="ChannabasavannaSM , MichaelA . Penfluridol maintenance therapy in schizophrenia: a controlled study. Indian Journal of Psychiatry1987;29(4):333-6. [CSZG: 1094]">Penfluridol 1987</a> and <a href="./references#CD008016-bbs2-0056" title="MarjerrisonG , IrvineD , StewartCN , WilliamsR , MatheuH , DemayM . Withdrawal of long-term phenothiazines from chronically hospitalized psychiatric patients. Canadian Psychiatric Association Journal1964;9(4):290-8. [CSZG: 4833]">Various drugs 1964b</a> did not reveal clear reasons why these studies showed a slight trend in favour of placebo. </p> </section> </section> <section id="CD008016-sec-0119"> <h5 class="title">1.3 Global state</h5> <section id="CD008016-sec-0120"> <h6 class="title">1.3.1 Number of participants improved (at least minimally)</h6> <p>Studies in the up to three months category (drug 46% versus placebo 6%, 3 RCTs, n 0 = 119, RR 4.76, 95% CI 1.65 to 13.68, NNTB 3, 95% CI 2 to 6), and studies in the four to six months category (drug 30% versus placebo 11%, 8 RCTs, n=1037, RR 2.33, 95% CI 1.69 to 3.21, NNTB 4, 95% CI 2 to 8) showed a clear significant difference in favour of antipsychotic medication. The impression was the same in the seven to 12 months category (drug 24% versus placebo 15%, 4 RCTs, n = 388, RR 1.67, 95% CI 0.89 to 3.13), and in studies lasting more than 12 months (drug 23% versus placebo 17%, 1 RCT, n = 334, RR 1.36, 95% CI 0.88 to 2.09), but the difference did not reach conventional levels of statistical significance. When all studies were combined drugs were again significantly superior to switching to placebo (drug 29% versus placebo 13%, 16 RCTs, n = 1878, RR 2.12, 95% CI 1.58 to 2.85, NNTB 5, CI 3 to 8, <a href="./references#CD008016-fig-0016" title="">Analysis 1.6</a>). No significant heterogeneity was found. </p> <p><b>1.3.2 Number of participants in symptomatic remission</b> </p> <p>This outcome was added to the list of outcomes for this update. One small study in the four to six months category (drug 70% versus placebo 40%, 1 RCT, n = 40, RR 1.75, 95% CI 0.79 to 3.87, NNTB 3, 95% CI 2 to 20) and studies in the seven to 12 months category (drug 52% versus placebo 31%, 5 RCTs, n = 807, RR 1.70,95% CI 1.11 to 2.59, NNTB 5, 95% CI 3 to 14) showed a significant difference in favour of antipsychotic medication. Again, the impression was the same in one small study in the up to three months category (drug 50% versus placebo 20%, 1 RCT, n = 20, RR 2.50, 95% CI 0.63 to 10.00), but the difference was not statistically significant. When all studies were combined drugs were clearly superior to placebo (drug 53% versus placebo 31%, 7 RCTs, n = 867, RR 1.73, 95% CI 1.20 to 2.48, NNTB 5, 95% CI 3 to 10, <a href="./references#CD008016-fig-0017" title="">Analysis 1.7</a>). There were heterogeneous results at 12 months (P &lt; 0.0001, I<sup>2</sup> = 82%) and overall (P = 0.0007, I<sup>2</sup> = 74%), but by removing the only study that clearly was outlying (<a href="./references#CD008016-bbs2-0002" title="CorrellC , KohegyiE , ZhaoC , BakerRA , McQuadeR , SalzmanP , et al. Oral aripiprazole is an effective maintenance treatment in adolescents with schizophrenia. Neuropsychopharmacology2014:S349-S350. [CSZG: 29288]CorrellCU , KohegyiE , ZhaoC , BakerRA , McQuadeR , SalzmanPM , et al. Oral aripiprazole as maintenance treatment in adolescent schizophrenia: results from a 52-week, randomized, placebo-controlled withdrawal study. Journal of the American Academy of Child and Adolescent Psychiatry2017;56(9):784-92. [CSZG: 36321]NCT01149655. A long-term multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of aripiprazole (opc 14597) as maintenance treatment in adolescent patients with schizophrenia. http://ClinicalTrials.gov/show/NCT011496552010. [CSZG: 21085]">Aripiprazole 2017</a>) all others showed concurred on the direction of effect in favour of antipsychotic drugs, and heterogeneity expressed differences in the degree of superiority rather than in the direction of effect (all the studies combined: P = 0.16, I<sup>2</sup> = 37%). This may be explained by the different criteria used to define symptomatic remission among the studies. </p> <p><b>1.3.3 Number of participants in sustained remission</b> </p> <p>This outcome was added to the list of outcomes for the current update. Studies in the seven to 12 months category (drug 27% versus placebo 16%, 6 RCTs, n = 1443, RR 1.83, 95% CI 1.49 to 2.25, NNTB 7, 95% CI 5 to 12), studies in the more than 12 months category (drug 76% versus placebo 61%, 2 RCTs, n = 364, RR 1.29, 95% CI 1.13 to 1.47, NNTB 6, 95% CI 4 to 10), and all the studies combined (drug 36% versus placebo 26%, 8 RCTs, n = 1807, RR 1.67, 95% CI 1.28 to 2.19, NNTB 7, 95% CI 5 to 10, <a href="./references#CD008016-fig-0018" title="">Analysis 1.8</a>) showed a clear and statistically significant difference in favour of antipsychotic medication. The results pooling all the studies were slightly heterogeneous (P =.03, I<sup>2</sup>= 55%), but the direction of effect was the same among all the studies, reflecting at least a trend in favour of antipsychotic drugs. </p> <p><b>1.3.4. Number of participants in recovery</b> </p> <p>No data were available for this outcome.</p> </section> </section> <section id="CD008016-sec-0121"> <h5 class="title">1.4. Service use</h5> <section id="CD008016-sec-0122"> <h6 class="title">1.4.1 Number of participants hospitalised</h6> <p>Studies lasting seven to 12 months (drug 4% versus placebo 13%, 11 RCTs, n = 2119, RR 0.36, 95% CI 0.23 to 0.56, NNTB 10, 95% CI 6 to 20), and more than 12 months (drug 17% versus placebo 31%, 4 RCTs, n = 965, RR 0.55, 95% CI 0.44 to 0.69, NNTB 7, 95% CI 3 to 10) showed a statistically and clinically significant difference in favour of antipsychotic medication. There was no clear difference for studies lasting up to three months (drug 4% versus placebo 7%, 2 RCTs, n = 55, RR 0.42, 95% CI 0.04 to 4.06), but these short‐term data are only based on two small studies. Again, the difference was not statistically significant in four studies lasting four to six months (drug 3% versus placebo 11%, 4 RCTs, n = 419, RR 0.19, 95% CI 0.03 to 1.32). Overall, there was a clear difference in favour of antipsychotic medication (drug 7% versus placebo 18%, 21 RCTs, n = 3558, RR 0.43, 95% CI 0.32 to 0.57, NNTB 8, 95% CI 6 to 14,high‐certainty evidence; <a href="./references#CD008016-fig-0019" title="">Analysis 1.9</a>). There was some heterogeneity for studies lasting four to six months (P =.04, I<sup>2</sup> = 63%), but all studies showed favoured antipsychotic drugs. </p> </section> <section id="CD008016-sec-0123"> <h6 class="title">1.4.2 Number of participants discharged</h6> <p>Three studies in inpatients reported on the number of participants who could be discharged. There was no significant difference between groups (drug 5% versus placebo 1%, 3 RCTs, n = 404, RR 2.76, 95% CI 0.69 to 11.06, <a href="./references#CD008016-fig-0020" title="">Analysis 1.10</a>). All the three studies lasted four to six months. </p> </section> </section> <section id="CD008016-sec-0124"> <h5 class="title">1.5 Death</h5> <section id="CD008016-sec-0125"> <h6 class="title">1.5.1 Any</h6> <p>In tota,l there were nine deaths in the drug group and eight deaths in the placebo group. There was no significant difference between groups in studies lasting up to three months (drug 0% versus placebo 0%, 3 RCTs, n = 415, RR not estimable), between four to six months (drug 0.9% versus placebo 0.2%, 6 RCTs, n = 1159, RR 2.30, 95% CI 0.59 to 8.98), seven to 12 months (drug 0.1% versus placebo 0.5%, 15 RCTs, n = 3273, RR 0.35, 95% CI 0.11 to 1.12), in one study lasting more than 12 months (drug 1.2% versus placebo 0%, 1 RCT, n = 334, RR 5.18, 95% CI 0.25 to 107.12), and in all studies combined (drug 0.3% versus placebo 0.3%, 25 RCTs, n = 5181, RR 0.90, 95% CI 0.39 to 2.11, <a href="./references#CD008016-fig-0021" title="">Analysis 1.11</a>). </p> </section> <section id="CD008016-sec-0126"> <h6 class="title">1.5.2 Due to natural causes</h6> <p>Studies lasting up to three months (drug 0% versus placebo 0%, 2 RCTs, n = 379, RR not estimable), four to six months (drug 0.9% versus placebo 0.2%, 6 RCTs, n = 1159, RR 2.30, 95% CI 0.59 to 8.98), seven to 12 months (drug 0.1% versus placebo 0.1%, 16 RCTs, n = 3354, RR 0.53, 95% CI 0.11 to 2.58), in one study lasting more than 12 months (drug 0.6% versus placebo 0%, 1 RCT, n = 334, RR 3.11, 95% CI 0.13 to 75.78), and in all studies combined (drug 0.3% versus placebo 0.1%, 25 RCTs, n=5226, RR 1.35, 95% CI 0.50 to 3.6, <a href="./references#CD008016-fig-0022" title="">Analysis 1.12</a>) did not reveal a significant difference between groups. </p> </section> </section> <section id="CD008016-sec-0127"> <h5 class="title">1.6. Suicidal behaviour</h5> <p><b>1.6.1 Death due to suicide</b> </p> <p>Studies up to three months (drug 0% versus placebo 0%, 3 RCTs, n = 415, RR not estimable), four to six months (drug 0% versus placebo 0%, 3 RCTs, n = 1033, RR not estimable), seven to 12 months (drug 0% versus placebo 0.2%, 12 RCTs, n = 2852, RR 0.35, 95% CI 0.06 to 2.21), one study lasting more than 12 months (drug 0.6% versus placebo 0%, 1 RCT, n = 334, RR 3.11, 95% CI 0.13 to 75.78), and all studies combined irrespective of their duration (drug 0.04% versus placebo 0.1%, 19 RCTs, n = 4634, RR 0.60, 95% CI 0.12 to 2.97,low‐certainty evidence; <a href="./references#CD008016-fig-0023" title="">Analysis 1.13</a>) did not show clear differences. </p> <section id="CD008016-sec-0128"> <h6 class="title">1.6.2 Number of participants with suicide attempts</h6> <p>There was also no clear difference in terms of suicide attempts in two studies lasting four to six months (drug 0.3% versus placebo 0%, 3 RCTs, n = 776, RR 3.00, 95% CI 0.13 to 71.51), and seven to 12 months (drug 0.2% versus placebo 0.5%, 9 RCTs, n = 2347, RR 0.48, 95% CI 0.13 to 1.69). Also, when all studies were combined irrespective or their duration, there was no difference between groups (drug 0.2% versus placebo 0.3%, 12 RCTs, n = 3123, RR 0.61, 95% CI 0.19 to 1.99, <a href="./references#CD008016-fig-0024" title="">Analysis 1.14</a>). </p> </section> <section id="CD008016-sec-0129"> <h6 class="title">1.6.3 Number of participants with suicide ideation</h6> <p>There was no significant difference in the number of participants with suicidal ideation in one study in the up to three months category (drug 0% versus placebo 6%, 1 RCT, n = 49, RR 0.17, 95% CI 0.01 to 3.88), in one study in the four to six months category (drug 0% versus placebo 0%, 1 RCT, n = 386, RR not estimable), in studies in the seven to 12 months category (drug 0.9% versus placebo 2%, 10 RCTs, n = 2486, RR 0.52, 95% CI 0.24 to 1.09), in one study lasting more than 12 months (drug 3% versus placebo 2.4%, 1 RCT, n = 334, RR 1.30, 95% CI 0.35 to 4.74), and in all studies combined irrespective of duration (drug 1% versus placebo 1.8%, 13 RCTs, n = 3255, RR 0.61, 95% CI 0.99 to 1.16, <a href="./references#CD008016-fig-0025" title="">Analysis 1.15</a>). </p> </section> </section> <section id="CD008016-sec-0130"> <h5 class="title">1.7 Violent/aggressive behaviour</h5> <p>There were data in one small study in the up to three months category (drug 0% versus placebo 8%, 1 RCT, n = 26, RR 0.33, 95% CI 0.01 to 7.50), two studies in the four to six months category (drug 4% versus placebo 9%, 2 RCTs, n = 350, RR 0.46, 95% CI 0.2 to 1.08), and one study lasting more than 12 months (drug 0% versus placebo 1%, 1 RCT, n = 334, RR 0.21, 95% CI 0.01 to 4.28). We found no clear difference in the number of participants with aggressive behaviour. However, in studies lasting seven to 12 months (drug 1% versus placebo 5%, 8 RCTs, n = 2146, RR 0.35, 95% CI 0.19 to 0.66, NNTB 50, 95% CI 20 to 100), and in all studies combined irrespective of their duration (drug 1% versus placebo 5%, 12 RCTs, n=2856, RR 0.37, 95% CI 0.24 to 0.59, <a href="./references#CD008016-fig-0026" title="">Analysis 1.16</a>) fewer participants in the drug group than in the placebo group were violent/aggressive. </p> </section> <section id="CD008016-sec-0131"> <h5 class="title">1.8 Adverse effects</h5> <section id="CD008016-sec-0132"> <h6 class="title">1.8.1 At least one adverse effect</h6> <p>One study in the up to three months category (drug 36% versus placebo 69%, 1 RCT, n = 49, RR 0.53, 95% CI 0.30 to 0.93, NNTB 3, 95% CI 2 to 25) showed a clear difference between groups. Four studies in the four to six months category (drug 49% versus placebo 52%, 4 RCTs, n = 1079, RR 0.98, 95% CI 0.85 to 1.12) studies lasting seven to 12 months (drug 42% versus placebo 34%, 12 RCTs, n = 2890, RR 1.15, 95% CI 0.99 to 1.33), and all studies combined irrespective of their duration (drug 44% versus placebo 38%, 18 RCTs, n = 4352, RR 1.10, 95% CI 0.98 to 1.25, <a href="./references#CD008016-fig-0027" title="">Analysis 1.17</a>) did not indicate a clear difference between groups. This was statistically significant, however, in one study lasting more than 12 months (drug 39% versus placebo 22%, 1 RCT, n = 334, RR 1.75, 95% CI 1.24 to 2.45). The results at 12 months (P = 0.004, I<sup>2</sup> = 60%) and overall (P &lt; 0.0001, I<sup>2</sup> = 66%) were heterogeneous. Similarly to the outcome 'leaving the study early due to adverse events' (see Section 1.2.2 above) it should be noted that in particular in recent trials efficacy‐related events can also be adverse events that may in part explain the heterogeneity. <a href="./references#CD008016-bbs2-0023" title="OtaKY , KurlandAA . A double-blind comparison of haloperidol oral concentrate, haloperidol solutabs and placebo in the treatment of chronic schizophrenia. Journal of Clinical Pharmacology1973;13:99-110. [CSZG: 2318]">Haloperidol 1973</a> even showed clearly more adverse events in the placebo group. The authors discussed this finding as withdrawal effects after abrupt stopping of medication. However, excluding this outlying study did not change the results (all studies pooled: RR 1.13, 95% CI 1.00 to 1.27; heterogeneity test: P = 0.0002, I² = 64%). </p> </section> <section id="CD008016-sec-0133"> <h6 class="title">1.8.2 Movement disorders</h6> <section id="CD008016-sec-0134"> <p><b>1.8.2.1 At least one movement disorder</b></p> <p>Studies lasting up to three months (drug 29% versus placebo 10%, 4 RCTs, n = 158, RR 2.42, 95% CI 0.70 to 8.33) did not reveal any difference between groups. However, studies lasting four to six months (drug 18% versus placebo 11%, 8 RCTs, n = 1658, RR 1.45, 95% CI 1.06 to 1.99), seven to 12 months (drug 12% versus placebo 6%, 16 RCTs, n = 3126, RR 1.55, 95% CI 1.17 to 2.05), and all studies combined irrespective of their duration (drug 14% versus placebo 8%, 29 RCTs, n =5276, RR 1.52, 95% CI 1.25 to 1.85, number needed to treat for an additional harmful outcome (NNTH) 20, 95% CI 14 to 50, <a href="./references#CD008016-fig-0028" title="">Analysis 1.18</a>) showed a clear and statistically significant difference in favour of placebo. In one study lasting more than 12 months the difference between groups did not reach conventio nal levels of statistical significance (drug 9% versus placebo 7%, 1 RCT, n = 334, RR 1.21, 95% CI 0.58 to 2.54). </p> </section> <section id="CD008016-sec-0135"> <p><b>1.8.2.2 Akathisia</b></p> <p>Studies in the up to three‐month category (drug 14% versus placebo 4%, 2 RCTs, n = 69, RR 2.68, 95% CI 0.49 to 14.82), in the four to six months category (drug 9% versus placebo 2%, 6 RCTs, n = 1191, RR 2.14, 95% CI 0.50 to 9.11), in the seven to 12 months category (drug 5% versus placebo 3%, 12 RCTs, n = 2620, RR 1.07, 95% CI 0.71 to 1.61), one study in the more than 12 months category (drug 3% versus placebo 2%, 1 RCT, n = 334, RR 1.73, 95% CI 0.42 to 7.11), and all studies combined irrespective of their duration (drug 6% versus placebo 3%, 21 RCTs, n = 4214, RR 1.49, 95% CI 0.93 to 2.38, <a href="./references#CD008016-fig-0029" title="">Analysis 1.19</a>) did not show clear differences. Results at six months (P = 0.009, I<sup>2</sup> = 67%) were heterogeneous due to one outlying trial (<a href="./references#CD008016-bbs2-0062" title="ClarkML , HuberWK , HillD , WoodF , CostiloeJP . Pimozide in chronic schizophrenic outpatients. Diseases of the Nervous System1975;36(3):137-41. [CSZG: 1235]Clark. Pimozide vs thioridazine vs placebo. Bulletin1973;9:59-63. [CSZG: 4106]">Various drugs 1975</a>) in which more participants in the placebo group had akathisia. Re‐inspection of this study did not reveal an obvious explanation. Removing this study reduced heterogeneity and then statistically significantly more participants in the drug group suffered from this adverse effect (RR 4.07, 95% CI 1.46 to 11.33; heterogeneity test: P = 0.24, I<sup>2</sup> = 27%). </p> </section> <section id="CD008016-sec-0136"> <p><b>1.8.2.3 Akinesia</b></p> <p>There was no clear difference in the one small study in the up to three months category (drug 6% versus placebo 6%, 1 RCT, n = 49, RR 0.97, 95% CI 0.09 to 9.92), nor in two studies lasting between seven and 12 months (drug 0% versus placebo 0,01%, 2 RCTs, n = 348, RR 0.16, 95% CI 0.01 to 3.98), nor in all the three studies combined (drug 1% versus placebo 1%, 3 RCTs, n = 397, RR 0.52, 95% CI 0.08 to 3.42, <a href="./references#CD008016-fig-0030" title="">Analysis 1.20</a>). </p> </section> <section id="CD008016-sec-0137"> <p><b>1.8.2.4 Dyskinesia</b></p> <p>Three studies in the four to six months category (drug 2% versus placebo 13%, 3 RCTs, n = 418, RR 0.31, 95% CI 0.11 to 0.84), and all studies combined (drug 1% versus placebo 4%, 18 RCTs, n = 3200, RR 0.55, 95% CI 0.33 to 0.91, <a href="./references#CD008016-fig-0031" title="">Analysis 1.21</a>) showed a clear difference in favour of antipsychotic medication. There was no difference in one study in the up to three months category (drug 3% versus placebo 0%, 1 RCT, n = 49, RR 1.50, 95% CI 0.06 to 34.91), in studies in the seven to 12 months category (drug 2% versus placebo 2%, 13 RCTs, n = 2399, RR 0.69, 95% CI 0.37 to 1.27), and in one study lasting more than 12 months (drug 1% versus placebo 2%, 1 RCT, n = 334, RR 0.35, 95% CI 0.04 to 3.29). </p> </section> <section id="CD008016-sec-0138"> <p><b>1.8.2.5 Dystonia</b></p> <p>For dystonia there was no clear difference in the one study in the up to three months category (drug 6% versus placebo 0%, 1 RCT, n = 49, RR 2.50, 95% CI 0.13 to 49.22), two studies in the four to six months category (drug 16% versus placebo 9%, 2 RCTs, n = 382, RR 1.75, 95% CI 0.94 to 3.29), studies in the seven to 12 months category (drug 1% versus placebo 1%, 9 RCTs, n = 2002, RR 1.63, 95% CI 0.65 to 4.09), and one study in the more than 12 months category (drug 0% versus placebo 1%, 1 RCT, n = 334, RR 0.21, 95% CI 0.01 to 4.28). When all studies were pooled irrespective of their duration, there was a suggestion of superiority of placebo but this did not quite reach conventional levels of statistical significance (drug 4% versus placebo 2%, 13 RCTs, n = 2767, RR 1.63, 95% CI 0.99 to 2.7, <a href="./references#CD008016-fig-0032" title="">Analysis 1.22</a>). </p> </section> <section id="CD008016-sec-0139"> <p><b>1.8.2.6 Rigor</b></p> <p>There was never any clear difference between groups in terms of rigor. Two studies in the up to three months category (drug 19% versus placebo 15%, 2 RCTs, n = 69, RR 1.2, 95% CI 0.22 to 6.62), three studies in the four to six months category (drug 17% versus placebo 8%, 3 RCTs, n = 160, RR 1.98, 95% CI 0.67 to 5.85), four studies in the seven to 12 months category (drug 1% versus placebo 0%, 4 RCTs, n = 693, RR 1.80, 95% CI 0.29‐2.79), and all studies combined (drug 6% versus placebo 2%, 9 RCTs, n = 922, RR 1.39, 95% CI 0.70 to 2.79, <a href="./references#CD008016-fig-0033" title="">Analysis 1.23</a>) did not suggest a clear difference between groups. </p> </section> <section id="CD008016-sec-0140"> <p><b>1.8.2.7 Tremor</b></p> <p>Two studies in the up to three months category (drug 23% versus placebo 15%, 2 RCTs, n=69, RR 1.20, 95% CI 0.46 to 3.16), three studies in the four to six months category (drug 8% versus placebo 10%, 3 RCTs, n = 160, RR 0.92, 95% CI 0.33 to 2.61), one study in the more than 12 months category (drug 1% versus placebo 2%, 1 RCT, n = 334, RR 0.52, 95% CI 0.10 to 2.79), and all studies combined (drug 5% versus placebo 3%, 18 RCTs, n = 3353, RR 1.37, 95% CI 0.95 to 1.98, <a href="./references#CD008016-fig-0034" title="">Analysis 1.24</a>) did not reveal clear differences in terms of tremor. Only the 12 studies in the seven to 12 months category showed a clear superiority for placebo (drug 5% versus placebo 2%, 12 RCTs, n = 2790, RR 1.62, 95% CI 1.04 to 2.54). </p> </section> <section id="CD008016-sec-0141"> <p><b>1.8.2.8 Use of antiparkinson medication</b></p> <p>No clear differences were found in the four to six months category (drug 22% versus placebo 13%, 3 RCTs, n = 841, RR 1.53, 95% CI 0.90 to 2.61) and in one study in the more than 12 months category (drug 19% versus placebo 19%, 1 RCT, n = 334, RR 1.00, 95% CI 0.64 to 1.57). In the seven to 12 months category (drug 23% versus placebo 17%, 9 RCTs, n = 1733, RR 1.37, 95% CI 1.06 to 1.78, NNTH 11, 95% CI 7 to 33) and overall, there was a clear difference in favour of placebo (drug 22% versus placebo 16%, 13 RCTs, n = 2908, RR 1.35, 95% CI 1.10 to 1.65, NNTH 13, 95% CI 8 to 33, <a href="./references#CD008016-fig-0035" title="">Analysis 1.25</a>). </p> </section> </section> <section id="CD008016-sec-0142"> <h6 class="title">1.8.3 Sedation</h6> <p>One small study in the up to three months category (drug 0% versus placebo 20%, 1 RCT, n = 20, RR 0.20, 95% CI 0.01 to 3.70), showed no clear difference. This also applied to studies lasting between four to six months (drug 6% versus placebo 3%, 7 RCTs, n = 1880, RR 1.37, 95% CI 0.89 to 2.12), and one study lasting more than 12 months (drug 1% versus placebo 1%, 1 RCT, n = 334, RR 1.04, 95% CI 0.15 to 7.27). Studies lasting between seven and 12 months (drug 11% versus placebo 7%, 9 RCTs, n = 1844, RR 1.78, 95% CI 1.25 to 2.53), and all studies combined (drug 8% versus placebo 5%, 18 RCTs, n = 4078, RR 1.52, 95% CI 1.24 to 1.86, NNTH 50, 95% CI not significant, <a href="./references#CD008016-fig-0036" title="">Analysis 1.26</a>) showed a clear difference in favour of placebo. </p> </section> <section id="CD008016-sec-0143"> <h6 class="title">1.8.4 Weight gain</h6> <p>Four studies in the four to six months category showed no clear difference (drug 5% versus placebo 3%, 4 RCTs, n = 1039, RR 1.49, 95% CI 0.81 to 2.73). However, studies lasting seven to 12 months (drug 10% versus placebo 7%, 14 RCTs, n = 3394, RR 1.80, 95% CI 1.17 to 2.77, NNTH 25, 5% CI 17 to 50), one study lasting more than 12 months (drug 13% versus placebo 6%, 1 RCT, n = 334, RR 2.18, 95% CI 1.06 to 4.48), and all studies combined (drug 9% versus placebo 6%, 19 RCTs, n = 4767, RR 1.69, 95% CI 1.21 to 2.35, NNTH 25, 95% CI 20 to 50, <a href="./references#CD008016-fig-0037" title="">Analysis 1.27</a>) did suggest a clear difference in favour of placebo. There was some heterogeneity in the 12 months results (P=0.006, I<sup>2</sup>=56%) and pooling all the studies (P=0.02, I<sup>2</sup>=45%). Removing the clearest outliers (<a href="./references#CD008016-bbs2-0006" title='CorrellCU , PotkinSG , DurgamS , ChangCT , SzatmariB , LaszlovszkyI , et al. Sustained remission with cariprazine treatment: post-hoc analysis of a randomised, double-blind, schizophrenia relapse prevention trial. Europan Neuropsychopharmacology2017;27((Suppl. 4)):S935-S936. [CSZG: 37757]CorrellCU , PotkinSG , ZhongY , HarsányiJ , SzatmáriB , EarleyW . Long-term remission with cariprazine treatment in patients with schizophrenia: a post-hoc analysis of a randomized, double-blind, placebo.controlled relapse prevention trial. Journal of Clinical Psychiatry2019;80(2):18m12495. DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Corrigendum to "Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial" [Schizophr. Res. 176 (2016) 264-71]. Schizophrenia Research2017;InPress:InPress. [CSZG: 35204]DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A double-blind, placebo-controlled trial. European Neuropsychopharmacology2015;25:S512-3. [CSZG: 33317]DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophrenia Research2016;176(2-3):264-71. [CSZG: 35204]DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: additional analysis from a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2015;40:S380-1. [CSZG: 33316]EarleyW , GuoH , LuchiniR . Modified cariprazine relapse prevention clinical trial results. Schizophrenia Research2018;199:452-3. KunovacJ , KaneJ , DurgamS , ChangCT , NemethG , LaszlovszkyI , et al. Characteristics associated with relapse in patients with schizophrenia: Post hoc analysis of a randomized, double-blind, placebo-controlled, cariprazine relapse prevention trial. Schizophrenia Bulletin2017;43:S166-7. [CSZG: 36002]NCT01412060. Cariprazine relative to placebo in the prevention of relapse of symptoms in patients with schizophrenia. http://ClinicalTrials.gov/show/NCT014120602011. [CSZG: 23106]PotkinS , CorrellC , ChangCT , SzatmariB , LaszlovszkyI , EarleyW . Long-term remission with cariprazine treatment in patients with schizophrenia: a post hoc analysis of a randomized, double-blind, placebo-controlled, relapse prevention trial. Schizophrenia Bulletin2017;43:S118. [CSZG: 36026]'>Cariprazine 2016</a>, <a href="./references#CD008016-bbs2-0028" title="NCT01435928. PEARL Schizophrenia Maintenance. http://ClinicalTrials.gov/show/NCT014359282011. [CSZG: 23439]TandonR , CucchiaroJ , PhillipsD , HernandezD , MaoY , PikalovA , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Journal of Psychopharmacology2016;30(1):69-77. [CSZG: 33434]TandonR , LoebelA , PhilipsD , PikalovA , Hernandez D MaoY , et al. Lurasidone for maintenance of efficacy in patients with schizophrenia. European Neuropsychopharmacology2014;24(Suppl 2):S559-560. [CSZG: 27840]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , CucchiaroJ . A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Schizophrenia Research2014;153(1):S372. [CSZG: 29681]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Int J Neuropsychopharmacol2014;17:S153-154. [CSZG: 29954]">Lurasidone 2016</a>, <a href="./references#CD008016-bbs2-0027" title="CTRI/2010/091/001409. A clinical trial to study prevention of relapse in patients with schizophrenia reveiving either flexible dose iloperidone or placebo in long-term use.. http://ctri.nic.in/Clinicaltrials/login.php2010. NCT01291511. Efficacy in prevention of relapse of schizophrenia in subjects taking either placebo or iloperidone. http://ClinicalTrials.gov/show/NCT012915112011. [CSZG: 22671]WeidenPJ , ManningR , WolfgangCD , RyanJM , MancioneL , HanG , et al. A randomized trial of iloperidone for prevention of relapse in schizophrenia: the REPRIEVE study. CNS drugs2016;30(8):735-47. [CSZG: 35243]">Iloperidone 2016</a>), which showed greater weight gain in the placebo group, reduced heterogeneity, but only to some degree and, overall, antipsychotic drugs did seem to cause more weight gain (all studies combined: RR 2.01, 95% CI 1.43 to 2.81, heterogeneity test: P = 0.12, I<sup>2</sup> = 30%) The heterogeneity expressed differences more in the degree of weight gain rather than in the direction of effect. This may be partially explained by the use of different criteria to define and report weight gain among the original studies. </p> </section> </section> <section id="CD008016-sec-0144"> <h5 class="title">1.9 Satisfaction with care (any published rating scale)</h5> <p><b>1.9.1 Number of participants satisfied</b> </p> <p>No data on this outcome were available in the original review. In this update, drug was clearly superior to placebo in one study in the seven to 12 months category (drug 74% versus placebo 63%, 1 RCT, n = 403, RR 1.19, 95% CI 1.02 to 1.38), and in one study lasting more than 12 months (drug 84% versus placebo 69%, 1 RCT, n = 334, RR 1.22, 95% CI 1.08 to 1.38). When the two studies were combined, the difference remained statistically (drug 78% versus placebo 66%, 2 RCTs, n = 737, RR 1.21, 95% CI 1.10 to 1.33; <a href="./references#CD008016-fig-0038" title="">Analysis 1.28</a>). No heterogeneity was identified (P=0.75, I<sup>2</sup> = 0%). </p> <p><b>1.9.2 Number of carers satisfied</b> </p> <p>No data were available for this outcome.</p> </section> <section id="CD008016-sec-0145"> <h5 class="title">1.10 Quality of life (any published rating scale)</h5> <p>Studies were divided in subgroups according to time points and rating scales used; endpoint and change data were presented in separate subgroups. Seven studies provided data on this outcome (two studies lasting up to 3 months, four studies in the seven to 12 months category and one study lasting more than 12 months). Across different subgroups, the superiority of drugs was not always clear, with effect sizes ranging from minimum mean difference (MD) ‐2.00 (2 RCTs, 379 participants, 95% CI ‐5.80 to 1.80) to maximum MD ‐ 11.36 (1 RCT, 304 participants, 95% CI ‐14.67 to ‐8.05) (<a href="./references#CD008016-fig-0039" title="">Analysis 1.29</a>). As an additional analysis, all the studies (across different time points and scales) were combined and a standardised mean difference (SMD) was calculated: antipsychotic drugs were found clearly and statistically significantly superior to placebo (7 RCTs, n = 1573, SMD ‐0.32 95% CI ‐0.57 to ‐0.07, <a href="./references#CD008016-fig-0040" title="">Analysis 1.30</a>). Tentative back‐calculation to the Schizophrenia Quality of Life Scale (used in <a href="./references#CD008016-bbs2-0031" title="Eerdekens. Evaluate the efficacy in the prevention of recurrence of the symptoms of schizophrenia. Sponsor: Johnson &amp; Johnson Pharmaceutical Research &amp; Development, LL.C2010. [CTG: NCT00111189]KramerM , KushnerS , SherrJ , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study. Schizophrenia Bulletin2007;33(2):438. [CSZG: 15185]KramerM , KushnerS , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia treated with paliperidone extended-release tablets. European Neuropsychopharmacology2006;16(Suppl 4):S386. [CSZG: 13313]KramerM , KushnerS , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study. International Journal of Neuropsychopharmacology2006;9(Suppl 1):S274. [CSZG: 19545]KramerM , SimpsonG , MaciulisV , KushnerS , LiuY , LimP , et al. One-year open-label safety and efficacy study of paliperidone extended-release. CNS Spectrums2010;15(8):506-14. [CSZG: 20885]KramerM , SimpsonG , MaciulisV , KushnerS , VijapurkarU , LimP , et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2007;27:6-14. [CSZG: 13907]MarkowitzM , FuDJ , LevitanB , GopalS , TurkozI , AlphsL . Long-acting injectable paliperidone palmitate versus oral paliperidone extended release. Annals of General Psychiatry2013;12:22. [CSZG: 28633]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone 2007</a> and <a href="./references#CD008016-bbs2-0033" title="AlphsL , BossieC , Kern-SliwaJ , Ma Y-W, HaskinsJT . Paliperidone palmitate: clinical response in subjects with schizophrenia with recent vs. longer-term duration of illness. In: Proceedings of the 162nd Annual Meeting of the American Psychiatric Association. San Francisco, CA., 2009 May 16-21. [CSZG: 19067]EmsleyR , NuamahI , GopalS , HoughD , FleischhackerWW . Relapse after antipsychotic discontinuation in schizophrenia as a withdrawal phenomenon vs illness recurrence: a post hoc analysis of a randomized placebo-controlled study. Journal of Clinical Psychiatry 2018 Jun;79(4):17m11874. [CSZG: 38184]EmsleyR , NuamahI , HoughD , GopalS . Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophrenia Research2012;138(1):29-34. [CSZG: 24214]GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM , HoughD . A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. Journal of Psychopharmacology2011;25(5):685-97. [CSZG: 22903]GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Long-term efficacy, safety and tolerability of paliperidone palmitate in patients with schizophrenia. In: Proceedings of the 162nd Annual Meeting of the American Psychiatric Association. San Francisco, CA, 2009 May 16-21. [CSZG: 19076]HoughD , GopalS , VijapukarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate in prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. In: Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8, Washington DC, USA. 2008. [CSZG: 16486]HoughD , GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. In: Proceedings of the 63rd Annual Convention of the Society of Biological Psychiatry. Washington, DC, USA: Elsevier Science Inc, 2008:S285-6. [CSZG: 20281]HoughD , GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Biological Psychiatry2008;63(7 Suppl):285S-6S. [CSZG: 19530]HoughD , GopalS , VjapukarU , LimP , MorozowaM , EerdekensM . Paliperidone palmitate maintenance treatment in delaying the time to relapse in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. Schizophrenia Research2010;116:107-17. [CSZG: 19704]HulihanJ , BossieCA , FuDJ , Kern SliwaJ , Ma Y-W, AlphsLD . Remission with continued paliperidone palmitate treatment in stable subjects with schizophrenia. Schizophrenia Research2012;136:S252. [CSZG: 29467]KozmaCM , SlatonT , DiraniR , FastenauJ , GopalS , HoughD . Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate. Current Medical Resarch and Opinion2011;27(8):1603-11. SliwaJK , BossieCA , Fu DJ, TurkozI , AlphsL . Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia. Neuropsychiatric Disease and Treatment2012;8:375-85. [CSZG: 28007]SliwaJK , FuDJ , BossieCA , et al. Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate. BMC Psychiatry2014;14:S52. [CSZG: 29148]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone depot1M 2010</a>) yielded a MD of 4.4 points. When pooling all the studies, there was significant heterogeneity (P =.01, I<sup>2</sup> = 64%), which may be in part due to the use of different scales (see <a href="#CD008016-sec-0174">Discussion</a>, 2.9 below), but the direction of effect was the same in all studies. </p> </section> <section id="CD008016-sec-0146"> <h5 class="title">1.11 Number of participants in employment</h5> <p>There was no clear difference in terms of number of people employed in two studies in the seven to 12 months category (drug 48% versus placebo 50%, 2 RCTs, n = 259, RR 0.96, 95% CI 0.75 to 1.23), nor in the one study lasting more than 12 months (drug 31% versus placebo 22%, 1 RCT, n = 334, RR 1.39, 95% CI 0.97 to 2.00), nor in all the studies combined (drug 39% versus placebo 34%, 3 RCTs, n = 593, RR 1.08, 95% CI 0.82 to 1.41, <a href="./references#CD008016-fig-0041" title="">Analysis 1.31</a>). </p> </section> <section id="CD008016-sec-0147"> <h5 class="title">1.12 Social functioning (any published rating scale)</h5> <p>This outcome was added to the list of outcomes for the present update. Studies were divided in subgroups according to time points and rating scales used. Endpoint and change data were presented separately in subgroups. Antipsychotic medication was clearly rated as superior to placebo in terms of participants´ social functioning in studies in the up to three months category (3 RCTs, n = 499, MD ‐4.32, 95% CI ‐6.69 to ‐1.94), in the four to six months category (1 RCT, n = 270, MD ‐2.00, 95% CI ‐3.60 to ‐0.40), in studies lasting seven to 12 months (10 RCTs, n = 2490, MD ‐4.89 95% CI ‐6.00 to ‐3.79), and in the one study lasting more than 12 months (1 RCT, n = 334, MD ‐3.60 CI ‐6.76 to ‐0.44) (<a href="./references#CD008016-fig-0042" title="">Analysis 1.32</a>). As an additional analysis, all studies were combined irrespective of their duration and the scale used, and a standardised mean difference calculated. This analysis also showed superiority of active drugs to placebo (15 RCTs, n=3588, SMD ‐0.43 CI ‐0.53 to ‐0.34,moderate‐certainty evidence; <a href="./references#CD008016-fig-0043" title="">Analysis 1.33</a>). Tentative back‐calculation to the Personal and Social Performance schedule (used in 10 out of 15 studies) yielded an MD of 5.2 points. There was heterogeneity when pooling all the studies (P=.03, I<sup>2</sup> = 45%) which may be partially explained by the use of different scales (see <a href="#CD008016-sec-0174">Discussion</a> 2.11 below), but all the studies showed a result tending to favour antipsychotic drugs. </p> </section> </section> <section id="CD008016-sec-0148"> <h4 class="title">2. Subgroup analyses (relapse at 12 months)</h4> <p>All subgroup analyses were conducted only on the primary outcome 'relapse at sevevn to 12 months'. </p> <section id="CD008016-sec-0149"> <h5 class="title">2.1 Participants with a first episode of psychosis</h5> <p>There was no clear difference between studies that included only people with a first episode (drug 26% versus placebo 61%, 8 RCTs, n = 528, RR 0.47, 95% CI 0.38 to 0.58) and studies in people who had already experienced several episodes (drug 23% versus placebo 59%, 24 RCTs, n = 3585, RR 0.38, 95% CI 0.31 to 0.46); (test for subgroup differences: Chi<sup>2</sup> =2.12, df = 1 (P = 0.15), I<sup>2</sup> = 52.8%, <a href="./references#CD008016-fig-0044" title="">Analysis 2.1</a>). </p> </section> <section id="CD008016-sec-0150"> <h5 class="title">2.2 Participants in remission at baseline</h5> <p>There was also no difference between the results of studies that included only participants who were in remission at baseline (drug 27% versus placebo 52%, 10 RCTs, n = 1050, RR 0.44, 95% CI 0.33 to 0.60) and the rest of the studies (drug 22% versus placebo 62%, 19 RCTs, n = 3063, RR 0.36, 95% CI 0.30 to 0.44); (test for subgroup differences: Chi<sup>2</sup> = 1.25, df =1 (P = 0.26), I<sup>2</sup> = 20%, <a href="./references#CD008016-fig-0045" title="">Analysis 2.2</a>). </p> </section> <section id="CD008016-sec-0151"> <h5 class="title">2.3 Participants who had been stable for various periods before entering the trials</h5> <p>Five studies included only participants who were stable for at least one month. Antipsychotic drugs significantly reduced relapse rates compared to placebo (drug 22% versus placebo 65%, 6 RCTs, n = 574, RR 0.32, 95% CI 0.20 to 0.50). The same pattern was found for studies with participants stable at least three months (drug 1% versus placebo 54%, 10 RCTS, n = 2250, RR 0.34, 95% CI 0.26 to 0.43), stable at least 12 months (drug 21% versus placebo 60%, 5 RCTs, n = 326, RR 0.31, 95% CI 0.17 to 0.57), and at least three to six years (drug 22% versus placebo 63%, 2 RCTs, n = 54, RR 0.38, 95% CI 0.18 to 0.78). One small study included participants who were stable for at least six months and the difference between drug and placebo was not statistically significant (drug 10% versus placebo 30%, 1 RCT, n = 20, RR 0.33, 95% CI 0.04 to 2.69). Overall, there was no clear difference between the different durations of pre‐trial stability (test for subgroup differences: Chi² = 0.21, df = 4 (P =1.00), I² = 0%, <a href="./references#CD008016-fig-0046" title="">Analysis 2.3</a>). </p> </section> <section id="CD008016-sec-0152"> <h5 class="title">2.4 Abrupt withdrawal versus tapering</h5> <p>There was no clear difference between studies in which antipsychotics were abruptly withdrawn (drug 27% versus placebo 62%, 18 RCTs, n = 2348, RR 0.43, 95% CI 0.35 to 0.53) or slowly tapered (drug 18% versus placebo 56%, 11 RCTs, n = 1765, RR 0.33, 95% CI 0.24 to 0.44); (test for subgroup differences: Chi<sup>2</sup> = 2.37, df = 1 (P = 0.12), I<sup>2</sup> = 57.8%, <a href="./references#CD008016-fig-0047" title="">Analysis 2.4</a>). </p> </section> <section id="CD008016-sec-0153"> <h5 class="title">2.5 to 2.6 Single antipsychotic drugs and depot versus oral medication</h5> <p>The test for subgroups differences between single antipsychotics was not statistically significant( Chi<sup>2</sup> =15.08, df =9 (P = 0.09), I² = 40.3%, <a href="./references#CD008016-fig-0048" title="">Analysis 2.5</a>). When the subgroup of studies using depot antipsychotics (drug 17% versus placebo 55%, 10 RCTs, n = 1705, RR 0.30, 95% CI 0.23 to 0.39) was compared with the subgroup of studies using oral antipsychotics (drug 29% versus placebo 63%, 16 RCTs, n = 2187, RR 0.46, 95% CI 0.38 to 0.55) a clear, statistically significant superiority of the depot formulations emerged (test for subgroup differences: Chi<sup>2</sup> =6.87, df =1 (P =0.009), I<sup>2</sup> =85.4%, <a href="./references#CD008016-fig-0049" title="">Analysis 2.6</a>). </p> </section> <section id="CD008016-sec-0154"> <h5 class="title">2.7 First‐ versus second‐generation antipsychotic drugs</h5> <p>There was no clear difference in reduction of relapse risk between first‐generation antipsychotics (drug 24% versus placebo 62%, 18 RCTs, n=1430, RR 0.35, 95% CI 0.25 to 0.48) and second‐generation antipsychotics (drug 23% versus placebo 58%, 11 RCTs, n = 2683, RR 0.39, 95% CI 0.32 to 0.48)(test for subgroup differences: Chi<sup>2</sup> = 0.36, df = 1 (P = 0.55), I<sup>2</sup> = 0%, <a href="./references#CD008016-fig-0050" title="">Analysis 2.7</a>). </p> </section> <section id="CD008016-sec-0155"> <h5 class="title">2.8 Appropriate versus unclear allocation concealment</h5> <p>The degree of relapse reduction by antipsychotics was not different in studies that used appropriate allocation concealment (drug 22% versus placebo 59%, 13 RCTs, n = 2708, RR 0.37, 95% CI 0.30 to 0.45) and studies in which this was unclear (drug 25% versus placebo 61%, 16 RCTs, n = 1405, RR 0.41, 95% CI 0.30 to 0.54); (test for subgroup differences: Chi<sup>2</sup> = 0.29, df = 1 (P = 0.59), I<sup>2</sup> = 0%, <a href="./references#CD008016-fig-0051" title="">Analysis 2.8</a>). </p> </section> <section id="CD008016-sec-0156"> <h5 class="title">2.9 Blinded versus open trials</h5> <p>The relapse risk reduction by antipsychotics was slightly larger in two open trials (drug 17% versus placebo 65%, 2 RCTs, n = 257, RR 0.26, 95% CI 0.17 to 0.39) than in the double‐blind studies (drug 24% versus placebo 59%, 27 RCTs, n = 3856, RR 0.40, 95% CI 0.33 to 0.48); (test for subgroup differences: Chi<sup>2</sup> = 3.57, df = 1 (P = 0.06), I<sup>2</sup> = 72%, <a href="./references#CD008016-fig-0052" title="">Analysis 2.9</a>). </p> </section> <section id="CD008016-sec-0157"> <h5 class="title">2.10 Meta‐regressions</h5> <p>All meta‐regressions were conducted only on the primary outcome 'relapse at seven to 12 months', except for the meta‐regression on study duration, which was performed on all the studies reporting data on relapse (using the longest time point available). </p> <section id="CD008016-sec-0158"> <h6 class="title">2.10.1 Severity of illness at baseline (relapse at 12 months)</h6> <p>The studies used many different scales (e.g. Clinical Global Impression scale (CGI), Brief Psychiatric Rating Scale (BPRS), Positive and Negative Syndrome Scale (PANSS)) to assess participants' severity at baseline. Therefore, a meta‐regression based on a scale‐defined severity of the illness was impossible. The subgroup analysis comparing participants in remission at baseline with the rest of the studies did not yield a significant difference (see Section 2.2 above). </p> </section> <section id="CD008016-sec-0159"> <h6 class="title">2.10.2 Duration the participants were stable before the start of the study (relapse at 12 months) </h6> <p>There was no clear effect on the difference in relapse risk at seven to 12 months based on the duration the participants had been stable before they entered the studies (slope 0.0002, CI ‐0.0029 to 0.0033, P = 0.904, see <a href="#CD008016-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD008016-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Meta‐regression on duration of clinical stability before study start (relapse at 12 months)The size of the bubbles is proportional to the inverse variance of the treatment effect." data-id="CD008016-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Meta‐regression on duration of clinical stability before study start (relapse at 12 months) </p> <p>The size of the bubbles is proportional to the inverse variance of the treatment effect.</p> </div> </div> </div> </section> <section id="CD008016-sec-0160"> <h6 class="title">2.10.3 Duration of taper in the placebo group (relapse at 12 months)</h6> <p>There was also no clear effect on the difference in relapse risk at seven to 12 months based on how rapidly the medication was withdrawn from the placebo group (slope ‐0.0005, CI ‐0.0120 to 0.0110, P =0.934, see <a href="#CD008016-fig-0008">Figure 8</a>). </p> <div class="figure" id="CD008016-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Meta‐regression on duration of taper in the placebo group (relapse at 12 months)The size of the bubbles is proportional to the inverse variance of treatment effect." data-id="CD008016-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Meta‐regression on duration of taper in the placebo group (relapse at 12 months)</p> <p>The size of the bubbles is proportional to the inverse variance of treatment effect.</p> </div> </div> </div> </section> <section id="CD008016-sec-0161"> <h6 class="title">2.10.4 Mean dose in chlorpromazine equivalents (relapse at 12 months)</h6> <p>When the mean dose in chlorpromazine equivalents used in the antipsychotic drug groups was taken into the meta‐regression, yet again there was no clear statistically significant effect on the difference in relapse risk at seven to 12 months (slope 0.0002, CI ‐0.0007 to 0.0011, P = 0.703, see <a href="#CD008016-fig-0009">Figure 9</a>). </p> <div class="figure" id="CD008016-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Meta‐regression on mean dose in chlorpromazine equivalents (relapse at 12 months)The size of the bubbles is proportional to the inverse variance of treatment effect." data-id="CD008016-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Meta‐regression on mean dose in chlorpromazine equivalents (relapse at 12 months)</p> <p>The size of the bubbles is proportional to the inverse variance of treatment effect.</p> </div> </div> </div> </section> <section id="CD008016-sec-0162"> <h6 class="title">2.10.5 Study duration (relapse, all studies included)</h6> <p>There was, however, a clear statistically significant association in study duration with the difference relapse risk between antipsychotic drugs and placebo. The superiority of antipsychotic drugs was smaller in longer trials than in shorter studies (slope =0.0065 95% CI 0.0026 to 0.0104, P =0.001, see <a href="#CD008016-fig-0010">Figure 10</a>). </p> <div class="figure" id="CD008016-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Meta‐regression on study duration (relapse, all studies included).The size of the bubbles is proportional to the inverse variance of treatment effect." data-id="CD008016-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Meta‐regression on study duration (relapse, all studies included).</p> <p>The size of the bubbles is proportional to the inverse variance of treatment effect.</p> </div> </div> </div> </section> </section> </section> <section id="CD008016-sec-0163"> <h4 class="title">3. Sensitivity analyses (relapse at 12 months)</h4> <p>All sensitivity analyses were conducted only for the primary outcome 'relapse at seven to 12 months'. </p> <section id="CD008016-sec-0164"> <h5 class="title">3.1 Exclusion of studies for which randomisation was implied because they were double‐blind</h5> <p>There was one study (<a href="./references#CD008016-bbs2-0071" title="McCreadieRG , WilesD , GrantS , CrockettGT , MahmoodZ , LivingstonMG , et al. The Scottish first episode schizophrenia study. VII two-year follow-up. Acta Psychiatrica Scandinavica1989;80:597-602. [CSZG: 3968]Scottish Schizophrenia Research Group. The Scottish First Episode Schizophrenia Study II. Treatment. British Journal of Psychiatry1987;150:334-8. [CSZG: 3969]Scottish Schizophrenia Research Group. The Scottish First Episode Schizophrenia Study V. One-year follow-up. British Journal of Psychiatry1988;152:470-476. [CSZG: 3970]Scottish Schizophrenia Research Group. The Scottish First Episode Schizophrenia Study. III. Cognitive performance. British Journal of Psychiatry1987;150:338-340. [CSZG: 16867]Scottish Schizophrenia Research Group. The Scottish first episode schizophrenia study. VIII. Five-year follow-up. British Journal of Psychiatry1992;161:496-500. [CSZG: 2542]">Various drugs 1989</a>) for the primary outcome relapse seven to 12 months that was not explicitly described as randomised, although randomisation was likely because it was double blind. Excluding this study did not change the overall results (drug 23% versus placebo 59%, 28 RCTs, n=4098, RR 0.39, 95% CI 0.33 to 0.46, NNTB 3, 95% CI 2 to 3, <a href="./references#CD008016-fig-0053" title="">Analysis 3.1</a>). </p> </section> <section id="CD008016-sec-0165"> <h5 class="title">3.2 Exclusion of randomised, open studies</h5> <p>There were two randomised, open studies (<a href="./references#CD008016-bbs2-0072" title="GaebelW , FrickU , KopckeW , LindenM , MuellerP , Mueller SpahnF , et al. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse?British Journal of Psychiatry Supplementum1993;163:8-12. [CSZG: 831]GaebelW , JannerM , FrommannN , PietzckerA , KopckeW , LindenM , et al. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophrenia Research2002;53(1-2):145-59. [CSZG: 8197]GaebelW , MoellerHJ . Treatment strategies in first episode schizophrenia. In: Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan. 2002. [CSZG: 8597]PietzckerA , GaebelW , KoepckeW , LindenM , MuellerP , Mueller-SpahnF , et al. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia - 2-year results of a German multicenter study. Journal of Psychiatric Research1993;27:321-39. [CSZG: 3944]PietzckerA , GaebelW , KopckeW , LindenM , MullerP , Muller-Spahn, et al. A German multicenter study on the neuroleptic long-term therapy of schizophrenic patients. Preliminary report. Pharmacopsychiatry1986;19:161-6. [CSZG: 3943]">Various drugs 1993</a>; <a href="./references#CD008016-bbs2-0073" title="BoonstraG , BurgerH , GrobbeDE , KahnRS . Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial. International Journal of Psychiatry in Clinical Practice2011;15(2):128-34. [CSZG: 22940]BoonstraG . Schizophrenia termination of pharmacotherapy-STOP-trial. Current Controlled Trials2005. [CSZG: 14487] [ISRCTN: 6332944]">Various drugs 2011</a>). Excluding these studies did not change the overall results (drug 24% versus placebo 59%, 27 RCTs, n = 3856, RR 0.40, 95% CI 0.33 to 0.48, NNTB 3, 95% CI 2 to 3, <a href="./references#CD008016-fig-0054" title="">Analysis 3.2</a>). </p> </section> <section id="CD008016-sec-0166"> <h5 class="title">3.3 Fixed‐effect model</h5> <p>When a fixed‐effect model was applied, antipsychotic medication remained significantly more effective than placebo in preventing relapse (drug 23% versus placebo 59%, 29 RCTs, n = 4113, RR 0.38, 95% CI 0.35 to 0.41, NNTB 3, 95% CI 3 to 3, <a href="./references#CD008016-fig-0055" title="">Analysis 3.3</a>). </p> </section> <section id="CD008016-sec-0167"> <h5 class="title">3.4 Original authors' assumptions on attrition</h5> <p>There was no important difference if the original data of the authors' rather than our assumption on participants who had discontinued the studies was applied (drug 23% versus placebo 59%, 29 RCTs, n = 4113, RR 0.39, 95% CI 0.32 to 0.46, NNTB 3, 95% CI 2 to 3, <a href="./references#CD008016-fig-0056" title="">Analysis 3.4</a>). </p> </section> <section id="CD008016-sec-0168"> <h5 class="title">3.5 Inclusion of large studies only (&gt;200 participants)</h5> <p>Including only large studies did not markedly change the effect size (see publication bias above, <a href="./references#CD008016-fig-0057" title="">Analysis 3.5</a>). </p> </section> <section id="CD008016-sec-0169"> <h5 class="title">3.6 Exclusion of studies that used clinical criteria to diagnose the participants</h5> <p>Excluding studies that did not use standardised diagnostic criteria did not change the overall results (drug 25% versus placebo 60%, 22 RCTs, n = 4054, RR 0.41, 95% CI 0.34 to 0.48, NNTB 3, 95% CI 2 to 3, <a href="./references#CD008016-fig-0058" title="">Analysis 3.6</a>). </p> </section> <section id="CD008016-sec-0170"> <h5 class="title">3.7 to 3.9 Inclusion of only those participants who had been in the trials without a relapse for three, six and nine months </h5> <p>Even when only participants who had not relapsed for three (drug 13% versus placebo 43%, 29 RCTs, n = 4622, RR 0.32, 95% CI 0.24 to 0.42, NNTB 5, 95% CI 3 to 10, <a href="./references#CD008016-fig-0059" title="">Analysis 3.7</a>), six (drug 11% versus placebo 39%, 20 RCTs, n = 2549, RR 0.30, 95% CI 0.20 to 0.45, NNTB 3, 95% CI 2 to 3, <a href="./references#CD008016-fig-0060" title="">Analysis 3.8</a>), or nine months (drug 9% versus placebo 32%; 15 RCTs, n = 1806, RR 0.32, 95% CI 0.19 to 0.52, NNTB 3, 95% CI 2 to 3, <a href="./references#CD008016-fig-0061" title="">Analysis 3.9</a>), after study start were included in the analysis, antipsychotic drugs were still clearly more effective than placebo. In the review update, data concerning this analysis were extracted from the start, due to a systematic error in the imputation of non‐relapsed patients in the original review, but the original findings were comparable to the current ones (<a href="./references#CD008016-bbs2-0253" title="LeuchtS , TardyM , KomossaK , HeresS , KisslingW , SalantiG , et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: systematic review and meta-analysis. Lancet2012;379(9831):2063-71.">Leucht 2012a</a>, <a href="./references#CD008016-bbs2-0254" title="LeuchtS , TardyM , KomossaK , HeresS , KisslingW , DavisJM . Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD008016. [DOI: 10.1002/14651858.CD008016.pub2]">Leucht 2012b</a>). </p> </section> <section id="CD008016-sec-0171"> <h5 class="title">3.10 Exclusion of studies with unclear randomisation methods</h5> <p>Excluding studies with unclear randomisation methods did not markedly change the overall results (drug 22% versus placebo 59%, 11 RCTs, n = 2644, RR 0.36, 95% CI 0.29 to 0.43, <a href="./references#CD008016-fig-0062" title="">Analysis 3.10</a>). </p> </section> <section id="CD008016-sec-0172"> <h5 class="title">3.11 Exclusion of studies with unclear allocation concealment methods</h5> <p>Excluding studies with unclear allocation concealment methods did not markedly change the overall results (drug 22% versus placebo 59%, 13 RCTs, n = 2708, RR 0.37, 95% CI 0.30 to 0.45, <a href="./references#CD008016-fig-0063" title="">Analysis 3.11</a>). </p> </section> </section> <section id="CD008016-sec-0173"> <h4 class="title"><i>'Summary of findings' table</i> </h4> <p>The results of seven a priori chosen outcomes ‐ relapse (seven to 12 months), leaving the study early due to any reason, service use (number of patients hospitalised), death due to suicide, quality of life, number of patients in employment and social functioning ‐ were considered more closely in a 'Summary of findings' table (see <a href="./full#CD008016-tbl-0001">summary of findings Table 1</a>). Based on this tool, we considered the results for the outcomes relapse, leaving the studies early due to any reason and rehospitalisation to be high, for social functioning to be moderate, for suicide to be poor, and for quality of life and employment to be very poor. This is consistent with the judgements emerging from the original review data. The judgements derived from this instrument were used for the discussion section of the review (see <a href="#CD008016-sec-0175">Summary of main results</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008016-sec-0174" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008016-sec-0174"></div> <section id="CD008016-sec-0175"> <h3 class="title" id="CD008016-sec-0175">Summary of main results</h3> <section id="CD008016-sec-0176"> <h4 class="title">1. General</h4> <p>This review currently includes 75 studies involving 9145 participants that compared antipsychotic maintenance treatment with placebo. The included studies were published over a long period (from 1959 to 2017) and in different settings (e.g. inpatients and outpatients) and different countries. Despite this variety, the results consistently demonstrated a superiority of antipsychotic drugs in the primary outcome relapse at seven to 12 months. This superiority remained robust in a number of sensitivity analyses. However, many included studies were relatively small; 47 randomised fewer than 100 people and 34 fewer than 50 people. Many trials were of short duration, only four studies lasted two years and only one study had a duration of three years. Thus, nothing is known from trials about the effects of antipsychotic drugs compared with placebo after three years. Furthermore, while almost all studies reported on relapse and leaving the study early, all other outcomes were much more sparsely recorded (e.g. adverse effects, quality of life, employment status, subjective outcomes such as participants' satisfaction with care). As it is unfortunately typical for randomised trials in schizophrenia, the methods of randomisation, allocation concealment and blinding were frequently not reported. However, as those studies that reported appropriate allocation methods yielded similar results, this potential source of bias should not challenge the overall findings. </p> <p>All the results emerging from the review update are in line with those of the original review (<a href="./references#CD008016-bbs2-0253" title="LeuchtS , TardyM , KomossaK , HeresS , KisslingW , SalantiG , et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: systematic review and meta-analysis. Lancet2012;379(9831):2063-71.">Leucht 2012a</a>, <a href="./references#CD008016-bbs2-0254" title="LeuchtS , TardyM , KomossaK , HeresS , KisslingW , DavisJM . Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD008016. [DOI: 10.1002/14651858.CD008016.pub2]">Leucht 2012b</a>). For the current review update, some additional outcomes were investigated: antipsychotic drugs were found to be significantly superior to placebo in terms of promoting clinical remission status and better social functioning. No data were available on the efficacy of these drugs in terms of promoting recovery. </p> </section> <section id="CD008016-sec-0177"> <h4 class="title">2. Treatment effects</h4> <section id="CD008016-sec-0178"> <h5 class="title">2.1 Relapse</h5> <p>The results demonstrate that antipsychotic drugs reduce relapse rates more effectively than placebo. This effect was apparent as early as three months after discontinuation of antipsychotic drugs and remained significant in studies between 13 and 36 months. However, studies lasting longer than 12 months were scarce. This is even more important since the meta‐regression on study duration showed that the difference in patients with a relapse between drug and placebo gets smaller over time (<a href="#CD008016-fig-0007">Figure 7</a>). There were frequent instances of significant heterogeneity, which may be due to differences in drugs, participants (e.g. degree of severity at baseline), or definitions of relapse. Nevertheless, almost all individual studies favoured antipsychotic drugs and therefore the heterogeneity reflected differences in the degree of superiority rather than differences in the direction of the effect. We continued to feel justified that this finding has a high degree of certainty. </p> </section> <section id="CD008016-sec-0179"> <h5 class="title">2.2 Leaving the study early</h5> <p>Clearly fewer in the drug group than in the placebo group left the studies early because of 'any reason' or due to inefficacy of treatment. Leaving a study because of 'any reason' is often considered to be a measure of acceptability of treatment. We would be hesitant to apply this interpretation here because relapses were the most frequent reason for leaving the studies early and in many studies it was predefined by the protocol that participants had to discontinue once they had relapsed. Therefore, it was not really the participants' choice ('acceptability') to remain in a trial or not, and leaving the study early reflected efficacy rather than tolerability. </p> <p>That more in the placebo group left the studies early due to 'inefficacy of treatment' supports the relapse‐preventing effect of antipsychotics. </p> <p>There was no difference in the number of participants leaving the studies early 'due to adverse events'. It should be noted that events such as 'worsening of psychosis' are, by definition, also recorded as adverse events ‐ especially in more recent trials. In part, this may explain the significant heterogeneity of results. Moreover, this mix of tolerability‐ and efficacy‐related adverse events shows that 'leaving the studies early due to adverse events' is not an ideal measure of overall tolerability. </p> </section> <section id="CD008016-sec-0180"> <h5 class="title">2.3 Global state</h5> <p>In the current update, the effect of antipsychotic drugs on the participants' clinical picture, when compared to placebo, was addressed in various ways. </p> <p>When investigating the number of participants at least minimally improved at follow‐up (Clinical Global Impression ‐ Improvement score, or similar rating instruments), the results showed that antipsychotic drugs improved participants' global state more than placebo. But these findings also show that many participants were 'stable', but not in remission at study start. If they had all been in remission, further improvements would not have been possible. This demonstrates the importance of our subgroup analysis on people in remission at baseline. </p> <p>The number of participants in symptomatic remission was addressed as an outcome for this update, along with the number of participants in sustained remission and in recovery. Symptomatic remission was defined following available criteria (e.g. <a href="./references#CD008016-bbs2-0172" title="AndreasenNC , Carpenter WT Jr, KaneJM , LasserRA , MarderSR , WeinbergerDR . Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry2005;162(3):441-9.">Andreasen 2005</a> without time criterion) or considering being "at least mildly ill" (Clinical Global Impression ‐ Severity score or similar rating instruments) as a threshold. It could represent a cross‐sectional vision of the patients' severity of illness at various time points. Our results showed that antipsychotic drugs were significantly superior to placebo, even though only seven studies provided data on this outcome. All single studies showed at least a trend in favour of antipsychotic drugs, so that heterogeneity reflected differences in the degree of superiority rather than in the direction of the effect. Heterogeneity could also be explained by differences in the degree of severity at baseline, so that an unclear proportion of patients either achieved or maintained the remission level across the studies. </p> <p>Eight studies lasting more than six months showed a significant superiority of antipsychotic drugs for sustained remission, which was defined as stabilised remission status for at least six months. Only a slight heterogeneity was found when pooling all the study results. Both symptomatic and sustained remission are important outcomes for schizophrenia patients, with the latter one being more linked to the possibility to fulfil a role in society and to achieve functional remission, but not representing it. </p> <p>Among the included studies, no data were actually found on recovery, which can be multidimensionally conceptualised as comprising both objective (symptom severity and level of functioning) and subjective elements, such as quality of life and satisfaction with care (<a href="./references#CD008016-bbs2-0244" title="VitaA , BarlatiS . Recovery from schizophrenia: is it possible?Curr Opin Psychiatry2018;31(00):1-10.">Vita 2018</a>). We suggest that future long‐term studies should report at least sustained remission, or report data on both remission definitions separately: two studies included in the present review reported them separately (<a href="./references#CD008016-bbs2-0002" title="CorrellC , KohegyiE , ZhaoC , BakerRA , McQuadeR , SalzmanP , et al. Oral aripiprazole is an effective maintenance treatment in adolescents with schizophrenia. Neuropsychopharmacology2014:S349-S350. [CSZG: 29288]CorrellCU , KohegyiE , ZhaoC , BakerRA , McQuadeR , SalzmanPM , et al. Oral aripiprazole as maintenance treatment in adolescent schizophrenia: results from a 52-week, randomized, placebo-controlled withdrawal study. Journal of the American Academy of Child and Adolescent Psychiatry2017;56(9):784-92. [CSZG: 36321]NCT01149655. A long-term multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of aripiprazole (opc 14597) as maintenance treatment in adolescent patients with schizophrenia. http://ClinicalTrials.gov/show/NCT011496552010. [CSZG: 21085]">Aripiprazole 2017</a>; <a href="./references#CD008016-bbs2-0045" title="D1441C00131. A 1-year, international, multicenter, randomized, double-blind, parallel-group, placebo-controlled phase IV study to evaluate prevention of relapse in patients in stable condition with chronic schizophrenia receiving either quetiapine fumarate IR (SEROQUEL) or placebo. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=3852003. D1444C00004. A 1-year, international, multicenter, randomized, double-blind, parallelgroup, placebo-controlled phase iii study to evaluate prevention of relapse in patients in stable condition with chronic schizophrenia receiving either sustained-release quetiapine fumarate (SEROQUEL) or placebo. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=14182006. NCT00228462. A 1-year, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study to evaluate prevention of relapse in patients in stable chronic schizophrenia receiving either sustained-release quetiapine fumarate (SEROQUEL) or placebo (abbreviated). https://www.ClinicalTrials.gov/ct/show/2005. [CSZG: 14874]PeuskensJ , TrivediJ , MalyarovS , BrecherM , SvenssonO , MillerF , et al. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomised, placebo-controlled trial in clinically stable patients. Psychiatry2007;4(11):34-50. [CSZG: 16025]PeuskensJ , TrivediJK , BrecherM , MillerF , Study I . Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: Post-hoc analysis of data from a randomized withdrawal, placebo-controlled study. International Clinical Psychopharmacology2010;25(3):183-7. [CSZG: 20670]PeuskensJ , TrivediJK , BrecherM , SvenssonO , MillerF , MeulienD . Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate. In: Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA. 2008. [CSZG: 16500]PeuskensJ , TrivediJK , BrecherM , SvenssonO , MillerF , MeulienD . Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate. Schizophrenia Research2008;98:14-5. [CSZG: 16344]PeuskensJ , TrivediJK , MalyarovS , BrecherM , SvenssonO , MillerF , et al. A randomized, placebo-controlled, relapse-prevention study with once-daily quetiapine sustained release in patients with schizophrenia. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28-Apr 1; Colorado Springs, Colorado, USA2007. [CSZG: 15271]PeuskensJC , TrivediJK , MalyarovS , BrecherM , SvenssonO , MillerF , et al. A randomized, placebo-controlled, relapse-prevention study with once daily quetiapine sustained release in patients with schizophrenia. Schizophrenia Bulletin2007;33(2):453. [CSZG: 15225]">Quetiapine 2007</a>). Functional outcome is also a priority target for therapeutic interventions in schizophrenia; future trials should therefore focus on clinical remission, as well as social functioning and recovery data. </p> </section> <section id="CD008016-sec-0181"> <h5 class="title">2.4 Service use</h5> <p>Fewer participants in the drug group had to be re‐hospitalised when compared with those allocated to placebo. Again, there was moderate heterogeneity, but all individual studies favoured to some degree the antipsychotic drugs. This finding is important, because in many industrialised countries hospitalisation contributes considerably to the direct cost of schizophrenia. Only 17 studies provided data on this outcome. Although it should be noted that only 34 trials were conducted in outpatients (in inpatients rehospitalisation cannot be an outcome), and although it depends on the setting how easily patients are admitted, this relatively hard and easy‐to‐measure outcome should be recorded in all future trials. </p> <p>Many older trials were conducted in inpatient settings. Under these circumstances it was of interest to analyse whether the participants could be stabilised to such an extent that they could be discharged at the end of the trial. There was no clear difference between drug and placebo; however, only three trials contributed to this outcome and results are inconclusive. </p> </section> <section id="CD008016-sec-0182"> <h5 class="title">2.5 Death and suicidal behaviour</h5> <p>There was no clear difference in the number of participants dying for any reason, natural causes or suicide. There was also no difference in the number of suicide attempts and suicidal ideation; however, in most studies the outcome death was not clearly reported. This is problematic, because there is some epidemiological evidence that long‐term treatment with antipsychotic drugs may increase mortality (<a href="./references#CD008016-bbs2-0229" title="RayWA , ChungCP , MurrayKT , HallK , SteinCM . Atypical antipsychotic drugs and the risk of sudden cardiac death. New England Journal of Medicine2009;360:225-35.">Ray 2009</a>; <a href="./references#CD008016-bbs2-0247" title="WeinmannS , ReadJ , AderholdV . Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophrenia Research2009;113(1):1-11.">Weinmann 2009</a>). Conversely, it is hoped that maintenance treatment with antipsychotic drugs might reduce suicides and another epidemiological study showed that treatment with antipsychotic drugs was associated with reduced mortality (<a href="./references#CD008016-bbs2-0240" title="TiihonenJ , LönnqvistJ , WahlbeckK , KlaukkaT , NiskanenL , TanskanenA , et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet2009;374:620-7.">Tiihonen 2009</a>). We feel that future long‐term studies should consistently report this hard and important outcome. </p> </section> <section id="CD008016-sec-0183"> <h5 class="title">2.6 Violent/aggressive behaviour</h5> <p>Fewer participants in the antipsychotic drug group had aggressive episodes. Although this finding is based on only 12 trials, it is an argument in favour of the use of antipsychotic drugs for maintenance treatment. Although the overall incidence is low, violence seems to be more frequent among people with schizophrenia compared to the general population contributing to the stigma of the disorder (<a href="./references#CD008016-bbs2-0246" title="WalshE , BuchananA , FahyT . Violence and schizophrenia: examining the evidence. British Journal of Psychiatry2002;180:490-5.">Walsh 2002</a>). </p> </section> <section id="CD008016-sec-0184"> <h5 class="title">2.7 Adverse effects</h5> <p>Adverse effects were often poorly and incompletely reported. Nevertheless, antipsychotic drugs produced more movement disorders in terms of at least one movement disorder, akathisia (after removing an outlier) and use of antiparkinson medication. They also produced more sedation and weight gain. We highlight that we combined all antipsychotic drugs in the analysis, but antipsychotic drugs differ largely in their risk for these adverse events. For example, high‐potency conventional antipsychotic drugs, such as haloperidol, produce many movement disorders while many newer, so‐called second‐generation antipsychotic drugs, such as olanzapine, are associated with significant weight gain (<a href="./references#CD008016-bbs2-0213" title="LeuchtS , CorvesC , ArbterD , EngelR , LiC , DavisJM . A meta-analysis comparing second-generation and first-generation antipsychotics for schizophrenia. Lancet2009;373:31-41.">Leucht 2009</a>). Therefore, our tolerability findings are not generalisable to all compounds. Dyskinesia was the only outcome that occurred more frequently in the placebo group. At first glance this finding is peculiar. We speculate that these dyskinesias frequently were withdrawal dyskinesia after abrupt stopping of antipsychotic drugs rather than tardive dyskinesia. However, it was usually not clearly reported when this adverse event occurred. This is another example for a need of better side‐effect reporting in randomised schizophrenia trials (<a href="./references#CD008016-bbs2-0225" title="PapanikolaouPN , ChurchillR , WahlbeckK , IoannidisJP . Safety reporting in randomised trials of mental health interventions. American Journal of Psychiatry2004;161:1692-7.">Papanikolaou 2004</a>; <a href="./references#CD008016-bbs2-0227" title="PopeA , AdamsC , PatonC , WeaverT , BarnesTR . Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used. British Journal of Psychiatry2010;197:67-72.">Pope 2010</a>). </p> </section> <section id="CD008016-sec-0185"> <h5 class="title">2.8 Satisfaction with care</h5> <p>No data on either participant's or carer's satisfaction with care were available in the original review. However, in this update, two studies provided data on participant's satisfaction with care. Results were inconclusive due to the small number of participants included in the analysis; however, a significant superiority of drug to placebo was shown. We suggest that future trials should focus on this important outcome, in order to have the possibility to build reliable conclusions on this point. </p> </section> <section id="CD008016-sec-0186"> <h5 class="title">2.9 Quality of life</h5> <p>Seven studies reported this outcome, which was evaluated using different rating instruments: two studies (<a href="./references#CD008016-bbs2-0031" title="Eerdekens. Evaluate the efficacy in the prevention of recurrence of the symptoms of schizophrenia. Sponsor: Johnson &amp; Johnson Pharmaceutical Research &amp; Development, LL.C2010. [CTG: NCT00111189]KramerM , KushnerS , SherrJ , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study. Schizophrenia Bulletin2007;33(2):438. [CSZG: 15185]KramerM , KushnerS , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia treated with paliperidone extended-release tablets. European Neuropsychopharmacology2006;16(Suppl 4):S386. [CSZG: 13313]KramerM , KushnerS , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study. International Journal of Neuropsychopharmacology2006;9(Suppl 1):S274. [CSZG: 19545]KramerM , SimpsonG , MaciulisV , KushnerS , LiuY , LimP , et al. One-year open-label safety and efficacy study of paliperidone extended-release. CNS Spectrums2010;15(8):506-14. [CSZG: 20885]KramerM , SimpsonG , MaciulisV , KushnerS , VijapurkarU , LimP , et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2007;27:6-14. [CSZG: 13907]MarkowitzM , FuDJ , LevitanB , GopalS , TurkozI , AlphsL . Long-acting injectable paliperidone palmitate versus oral paliperidone extended release. Annals of General Psychiatry2013;12:22. [CSZG: 28633]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone 2007</a>, <a href="./references#CD008016-bbs2-0033" title="AlphsL , BossieC , Kern-SliwaJ , Ma Y-W, HaskinsJT . Paliperidone palmitate: clinical response in subjects with schizophrenia with recent vs. longer-term duration of illness. In: Proceedings of the 162nd Annual Meeting of the American Psychiatric Association. San Francisco, CA., 2009 May 16-21. [CSZG: 19067]EmsleyR , NuamahI , GopalS , HoughD , FleischhackerWW . Relapse after antipsychotic discontinuation in schizophrenia as a withdrawal phenomenon vs illness recurrence: a post hoc analysis of a randomized placebo-controlled study. Journal of Clinical Psychiatry 2018 Jun;79(4):17m11874. [CSZG: 38184]EmsleyR , NuamahI , HoughD , GopalS . Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophrenia Research2012;138(1):29-34. [CSZG: 24214]GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM , HoughD . A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. Journal of Psychopharmacology2011;25(5):685-97. [CSZG: 22903]GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Long-term efficacy, safety and tolerability of paliperidone palmitate in patients with schizophrenia. In: Proceedings of the 162nd Annual Meeting of the American Psychiatric Association. San Francisco, CA, 2009 May 16-21. [CSZG: 19076]HoughD , GopalS , VijapukarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate in prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. In: Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8, Washington DC, USA. 2008. [CSZG: 16486]HoughD , GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. In: Proceedings of the 63rd Annual Convention of the Society of Biological Psychiatry. Washington, DC, USA: Elsevier Science Inc, 2008:S285-6. [CSZG: 20281]HoughD , GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Biological Psychiatry2008;63(7 Suppl):285S-6S. [CSZG: 19530]HoughD , GopalS , VjapukarU , LimP , MorozowaM , EerdekensM . Paliperidone palmitate maintenance treatment in delaying the time to relapse in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. Schizophrenia Research2010;116:107-17. [CSZG: 19704]HulihanJ , BossieCA , FuDJ , Kern SliwaJ , Ma Y-W, AlphsLD . Remission with continued paliperidone palmitate treatment in stable subjects with schizophrenia. Schizophrenia Research2012;136:S252. [CSZG: 29467]KozmaCM , SlatonT , DiraniR , FastenauJ , GopalS , HoughD . Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate. Current Medical Resarch and Opinion2011;27(8):1603-11. SliwaJK , BossieCA , Fu DJ, TurkozI , AlphsL . Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia. Neuropsychiatric Disease and Treatment2012;8:375-85. [CSZG: 28007]SliwaJK , FuDJ , BossieCA , et al. Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate. BMC Psychiatry2014;14:S52. [CSZG: 29148]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone depot1M 2010</a>) used the Self‐report Quality of Life Scale (SQLS), two studies (<a href="./references#CD008016-bbs2-0046" title="NCT00658645. A multinational, randomised, double-blind, fixed-dose, bifeprunox study combining a 12-week placebo-controlled, quetiapine-referenced phase with a 12-month quetiapine-controlled phase in patients with schizophrenia. https://www.clinicaltrials.gov/ct2/show/NCT00658645?term=NCT00658645&amp;rank=1. [CSZG: 16241]">Quetiapine 2009a</a>, <a href="./references#CD008016-bbs2-0047" title="NCT00704509. A multinational, randomised, double-blind, fixed-dose, bifeprunox study combining a 12-week placebo-controlled, quetiapine-referenced phase with a 12-month quetiapine-controlled phase in patients with schizophrenia. https://www.clinicaltrials.gov/ct2/show/NCT00704509?term=NCT00704509&amp;rank=1. [CSZG: 16566]">Quetiapine 2009b</a>) used the Schizophrenia Quality of Life (S‐QoL); considering the other three studies, each one applied one different rating scale: <a href="./references#CD008016-bbs2-0030" title="Beasley C Jr, HamiltonS , DossenbachM . Relapse prevention with olanzapine. European Neuropsychopharmacology2000;10(Suppl 3):S304. [CSZG: 4620]BeasleyCM , HamiltonSH , DossenbachM . Relapse prevention with olanzapine. Schizophrenia Research2000;41(1):196-7. [CSZG: 4874]BeasleyCM , SuttonVK , HamiltonSH , WalkerDJ , DossenbachM , TaylorCC , et al. A double-blind, randomised, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. Journal of Clinical Psychopharmacology2003;23:582-94. [CSZG: 10010]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD , PickarD . Does maintenance treatment with atypical antipsychotics worsen quality of life among stable patients with schizophrenia?Neuropsychopharmacology2005;30(S1):S189. [CSZG: 13107]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD . Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?Journal of Clinical Psychopharmacology2006;26:40-4. [CSZG: 14454]BeasleyCM , WalkerDJ , SuttonVK , AlakaK , NaberD , NamjoshiM . The effectiveness of olanzapine versus placebo in maintaining the quality of life in stabilized patients with schizophrenia. European Neuropsychopharmacology2003;13:S342. [CSZG: 9849]EliLilly Company. Olanzapine relapse prevention versus placebo in the treatment of schizophrenia. http://www.Clinicalstudyresults.org/.2005. [CSZG: 18733]">Olanzapine 2003</a> used the Heinrichs Carpenter Quality of Life Scale (QLS), <a href="./references#CD008016-bbs2-0028" title="NCT01435928. PEARL Schizophrenia Maintenance. http://ClinicalTrials.gov/show/NCT014359282011. [CSZG: 23439]TandonR , CucchiaroJ , PhillipsD , HernandezD , MaoY , PikalovA , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Journal of Psychopharmacology2016;30(1):69-77. [CSZG: 33434]TandonR , LoebelA , PhilipsD , PikalovA , Hernandez D MaoY , et al. Lurasidone for maintenance of efficacy in patients with schizophrenia. European Neuropsychopharmacology2014;24(Suppl 2):S559-560. [CSZG: 27840]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , CucchiaroJ . A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Schizophrenia Research2014;153(1):S372. [CSZG: 29681]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Int J Neuropsychopharmacol2014;17:S153-154. [CSZG: 29954]">Lurasidone 2016</a> applied the EuroQOL Visual Analog Scale (EQ5D‐VAS) and <a href="./references#CD008016-bbs2-0064" title="CheungHK . Schizophrenics fully remitted on neuroleptics for 3-5 years - to stop or continue drugs?British Journal of Psychiatry1981;138:490-4. [CSZG: 460]">Various drugs 1981b</a> used the Symptom Questionnaire of Kellner and Sheffield. Four studies showed better quality of life in the antipsychotic drug groups and three studies showed no significant difference; when all the studies were combined, the superiority of active medication was statistically significant. Due to the small number of trials this finding is not robust and more evidence is needed. Furthermore, the seven trials applied different rating scales, providing heterogeneous conclusions in terms of statistical significance. However, the direction of effect was always consistent across the trials, tending to favour antipsychotic drugs. The relevance of the actual finding is, however, high, because we had assumed that due to their side effects antipsychotic drugs could worsen quality of life. If confirmed by further trials, improved quality of life would be another strong argument for maintenance treatment with antipsychotic drugs. As a limitation, it needs to be considered that patients with a relapse were typically included in this outcome. For evaluating the quality of life of patients while taking maintenance treatment (and experiencing side effects), the quality‐of‐life‐ratings before recurrence of psychotic symptoms would be of additional interest. However, these data were not typically 'not available'. A targeted update review performed by another team in 2016 (New Reference), found that maintenance treatment may make little or no difference to quality of life (standardised mean difference (SMD) ‐0.42 95% confidence interval (CI) ‐0.96 to 0.13, 4 RCTs, 804 participants). In that review, four studies (all included in the present review) were included (<a href="./references#CD008016-bbs2-0028" title="NCT01435928. PEARL Schizophrenia Maintenance. http://ClinicalTrials.gov/show/NCT014359282011. [CSZG: 23439]TandonR , CucchiaroJ , PhillipsD , HernandezD , MaoY , PikalovA , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Journal of Psychopharmacology2016;30(1):69-77. [CSZG: 33434]TandonR , LoebelA , PhilipsD , PikalovA , Hernandez D MaoY , et al. Lurasidone for maintenance of efficacy in patients with schizophrenia. European Neuropsychopharmacology2014;24(Suppl 2):S559-560. [CSZG: 27840]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , CucchiaroJ . A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Schizophrenia Research2014;153(1):S372. [CSZG: 29681]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Int J Neuropsychopharmacol2014;17:S153-154. [CSZG: 29954]">Lurasidone 2016</a>, <a href="./references#CD008016-bbs2-0030" title="Beasley C Jr, HamiltonS , DossenbachM . Relapse prevention with olanzapine. European Neuropsychopharmacology2000;10(Suppl 3):S304. [CSZG: 4620]BeasleyCM , HamiltonSH , DossenbachM . Relapse prevention with olanzapine. Schizophrenia Research2000;41(1):196-7. [CSZG: 4874]BeasleyCM , SuttonVK , HamiltonSH , WalkerDJ , DossenbachM , TaylorCC , et al. A double-blind, randomised, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. Journal of Clinical Psychopharmacology2003;23:582-94. [CSZG: 10010]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD , PickarD . Does maintenance treatment with atypical antipsychotics worsen quality of life among stable patients with schizophrenia?Neuropsychopharmacology2005;30(S1):S189. [CSZG: 13107]BeasleyCM , SuttonVK , TaylorCC , SethuramanG , DossenbachM , NaberD . Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?Journal of Clinical Psychopharmacology2006;26:40-4. [CSZG: 14454]BeasleyCM , WalkerDJ , SuttonVK , AlakaK , NaberD , NamjoshiM . The effectiveness of olanzapine versus placebo in maintaining the quality of life in stabilized patients with schizophrenia. European Neuropsychopharmacology2003;13:S342. [CSZG: 9849]EliLilly Company. Olanzapine relapse prevention versus placebo in the treatment of schizophrenia. http://www.Clinicalstudyresults.org/.2005. [CSZG: 18733]">Olanzapine 2003</a>, <a href="./references#CD008016-bbs2-0031" title="Eerdekens. Evaluate the efficacy in the prevention of recurrence of the symptoms of schizophrenia. Sponsor: Johnson &amp; Johnson Pharmaceutical Research &amp; Development, LL.C2010. [CTG: NCT00111189]KramerM , KushnerS , SherrJ , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study. Schizophrenia Bulletin2007;33(2):438. [CSZG: 15185]KramerM , KushnerS , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia treated with paliperidone extended-release tablets. European Neuropsychopharmacology2006;16(Suppl 4):S386. [CSZG: 13313]KramerM , KushnerS , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study. International Journal of Neuropsychopharmacology2006;9(Suppl 1):S274. [CSZG: 19545]KramerM , SimpsonG , MaciulisV , KushnerS , LiuY , LimP , et al. One-year open-label safety and efficacy study of paliperidone extended-release. CNS Spectrums2010;15(8):506-14. [CSZG: 20885]KramerM , SimpsonG , MaciulisV , KushnerS , VijapurkarU , LimP , et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2007;27:6-14. [CSZG: 13907]MarkowitzM , FuDJ , LevitanB , GopalS , TurkozI , AlphsL . Long-acting injectable paliperidone palmitate versus oral paliperidone extended release. Annals of General Psychiatry2013;12:22. [CSZG: 28633]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone 2007</a> and <a href="./references#CD008016-bbs2-0064" title="CheungHK . Schizophrenics fully remitted on neuroleptics for 3-5 years - to stop or continue drugs?British Journal of Psychiatry1981;138:490-4. [CSZG: 460]">Various drugs 1981b</a>). Quality of life was measured using four different rating scales in the four studies and back‐estimated to SQLS. When inspecting the studies mentioned above, it was noted that in the targeted update the <a href="./references#CD008016-bbs2-0028" title="NCT01435928. PEARL Schizophrenia Maintenance. http://ClinicalTrials.gov/show/NCT014359282011. [CSZG: 23439]TandonR , CucchiaroJ , PhillipsD , HernandezD , MaoY , PikalovA , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Journal of Psychopharmacology2016;30(1):69-77. [CSZG: 33434]TandonR , LoebelA , PhilipsD , PikalovA , Hernandez D MaoY , et al. Lurasidone for maintenance of efficacy in patients with schizophrenia. European Neuropsychopharmacology2014;24(Suppl 2):S559-560. [CSZG: 27840]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , CucchiaroJ . A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Schizophrenia Research2014;153(1):S372. [CSZG: 29681]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Int J Neuropsychopharmacol2014;17:S153-154. [CSZG: 29954]">Lurasidone 2016</a> results were entered in the wrong direction of effect, with higher scores indicating improvement (the opposite as in the other studies). The analysis based on the four studies was performed again using the statistical method applied by the targeted update team, considering this mistake (SMD ‐0.46 95% CI ‐0.93 to 0.00, P = 0.05). </p> </section> <section id="CD008016-sec-0187"> <h5 class="title">2.10 Number of participants in employment</h5> <p>Only three studies addressed this outcome and did not find a significant difference. This finding is inconclusive and highlights the limitations of the current evidence. It is clear that antipsychotic drugs suppress symptoms of schizophrenia, but whether this also leads to better functional outcomes is unclear. A review suggested that 80% to 90% of people with schizophrenia are not employed (<a href="./references#CD008016-bbs2-0219" title="MarwahaS , JohnsonS . Schizophrenia and employment? A review. Social Psychiatry and Psychiatric Epidemiology2004;39:337-49.">Marvaha 2004</a>). In this review update we therefore investigated the effects of antipsychotic drugs on social functioning (see next paragraph). </p> </section> <section id="CD008016-sec-0188"> <h5 class="title">2.11 Social functioning</h5> <p>Fifteen studies reported this outcome. The studies applied different rating scales: 10 studies used Performance and Social Participation schedule (<a href="./references#CD008016-bbs2-0003" title="BakerR , FleischhackerW , SanchezR , PerryP , JinN , JohnsonB , et al. Long-term safety and tolerability of once-monthly aripiprazole intramuscular depot for maintenance treatment in schizophrenia. International Journal of Neuropsychopharmacology2012;15:111. [CSZG: 28035]BakerRA , CarsonWH , PerryPP , SanchezR , ZhaoJ , McQuadeRD , et al. Effects of aripiprazole once-monthly vs placebo on domains of personal and social performance in younger and older patients with schizophrenia. CNS Spectrums2013;18(6):376-7. [CSZG: 28526]BakerRA , EramoA , CarsonWH , PerryP , SanchezR , ZhaoJ , et al. Effects of aripiprazole once-monthly vs. placebo on domains of personal and social performance in younger and older patients with schizophrenia. Schizophrenia Bulletin2013;39(Suppl 1):S321-S322. [CSZG: 28131]BakerRA , EramoA , NylanderAG , TsaiLF , Peters-StricklandTS , KosticD , et al. The effect of previous dose or oral aripiprazole (10 or 30 mg/day) on the efficacy and tolerability of aripiprazole once-monthly: Results from post-hoc analyses from two double-blind, randomized, controlled trials. Schizophrenia Research2014;153:S293. [CSZG: 29386]CarsonWH , PerryPP , SanchezR , JinN , ForbesRA , McQuadeRD , et al. Effects of ARI-IM-depot on secondary efficacy outcomes in maintenance treatment of schizophrenia. International Journal of Neuropsychopharmacology2012;15:112-3. [CSZG: 28030]EramoA , FleischhackerWW , SanchezR , PerryP , JinN , JohnsonB , et al. A placebo-controlled study of efficacy and safety of aripiprazole oncemonthly for long-term maintenance treatment in schizophrenia. European Psychiatry2013;28(1):1. [CSZG: 28187]EramoA , FleischhackerWW , SanchezR , TsaiLF , Peters-StricklandTS , BakerRA , et al. All-cause discontinuation and safety of aripiprazole once-monthly for the treatment of schizophrenia: A pooled analysis of two double-blind, randomized, controlled trials. Schizophrenia Research2014;153:S174. [CSZG: 29437]FleischhackerWW , BakerRA , EramoA , SanchezR , TsaiLF , Peters-StricklandT , et al. Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies. Schizophrenia Research2014;159(2-3):415-20. [CSZG: 32163]FleischhackerWW , PerryP , SanchezR , JinN , Peters-StricklandT , JohnsonB , et al. Functional outcomes with aripiprazole once-monthly in two double-blind, placebo- and active-controlled studies (aspire us 246 and aspire eu 247) for the treatment of schizophrenia. Value in Health2013;16(7):A550. [CSZG: 28480]FleischhackerWW , SanchezR , JohnsonB , JinN , ForbesRA , McQuadeR , et al. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. International Clinical Psychopharmacology2013;28:171-6. [CSZG: 28391]FleischhackerWW , SanchezR , Lan-FengT , Peters-StricklandT , BakerRA , EramoA , et al. Safety and Effectiveness of Aripiprazole Oncemonthly for the Treatment of Schizophrenia: A Pooled Analysis of Two Double-blind, Randomized, Controlled Trials. Neuropsychopharmacology2013;38:S394-S395. [CSZG: 28459]KaneJM , SanchezR , BakerRA , EramoA , Peters-StricklandT , PerryPP , et al. Patient-centered outcomes with aripiprazole once-monthly for maintenance treatment in patients with schizophrenia: Results from two multicenter, randomized, double-blind studies. Clinical Schizophrenia and Related Psychoses2015;9(2):79-87. [CSZG: 32183]KaneJM , SanchezR , PerryPP , JinN , JohnsonB , ForbesRA , et al. Efficacy of aripiprazole-IM-depot for long-term maintenance treatment of schizophrenia. International Journal of Neuropsychopharmacology2012;15:S119. [CSZG: 28033]KaneJM , SanchezR , PerryPP , JinN , JohnsonBR , ForbesRA , et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: A 52-week, multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2012;73(5):617-24. [CSZG: 24369]LozeJ , CarsonWH , PerryPP , SanchezR , JinN , ForbesRA , et al. Psychosocial and overall effectiveness of aripiprazole intramuscular depot vs. placebo for maintenance treatment in schizophrenia. European Neuropsychopharmacology2012;22:S328. [CSZG: 24886]NCT00705783. Aripiprazole (OPC-14597) as maintenance treatment in patients with schizophrenia. https://www.ClinicalTrials.gov/ct/show/2008. [CSZG: 16546]SanchezR , JohnsonB , JinN , ForbesRA , CarsonWH , McQuadeRD , et al. Patient-reported outcomes (PROs) with aripiprazole intramuscular depot (ARI-IMD) for maintenance treatment in schizophrenia. International Journal of Neuropsychopharmacology2012;15:133. [CSZG: 28040]SanchezR , PerryPP , JinN , Johnson, RA Forbes, RD McQuade, WH, et al. A placebo-controlled study of efficacy/ safety of aripiprazole intramuscular depot for long-term maintenance treatment of schizophrenia. European Neuropsychopharmacology2012;(Suppl 2):S327. [CSZG: 24893]">Aripiprazole depot 2012</a>, <a href="./references#CD008016-bbs2-0005" title="BakerR , HobartM , ForbesA , OuyangJ , WeillerE . Effect of brexpiprazole on long-term functioning in adults with schizophrenia. Australian and New Zealand Journal of Psychiatry2017;51(Suppl 1):148. [CSZG: 35955]CorrellCU , ShiL , WeissC , HobartM , EramoA , DuffyRA , et al. Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice of cross-titration schedules in a post-hoc analysis of a randomized double-blind maintenance treatment study. CNS Spectrums2019;24(5):507-17. FleischhackerWW , HobartM , OuyangJ , ForbesA , PfisterS , McQuadeR , et al. Brexpiprazole (OPC-34712) efficacy and safety as maintenance therapy in adults with schizophrenia: Randomised, double-blind, placebo-controlled study. European Neuropsychopharmacology2015;25:S527. [CSZG: 33322]FleischhackerWW , HobartM , OuyangJ , ForbesA , PfisterS , McQuadeRD , et al. Efficacy and sfety of Brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. International Journal of Neuropsychopharmacology2017;20(1):11-21. [CSZG: 35475]NCT01668797. Efficacy, Safety, and tolerability of Brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia. https://ClinicalTrials.gov/show/NCT016687972012. [CSZG: 35608]TherrienF , WeissC , JinN , BakerRA , MacKenzieE , MeehanSR . Effect of brexpiprazole on patient functioning in patients with schizophrenia: results from a long-term, randomised, double-blind, placebo-controlled, maintenance study. Neuropsychopharmacology2017;43((Suppl.1)):S244-S245. [CSZG: 37935]WeillerE , HobartM , PfsterS , ForbesA , OuyangJ , WeissC . Effect of brexpiprazole on long-term remission in adults with schizophrenia: Results from a randomized, double-blind, placebo-controlled, maintenance study. Schizophrenia Bulletin2017;43:S202-3. [CSZG: 36050]WeissC , ForbesA , HobartM , PfsterS , OuyangJ , WeillerE . Short-term and long-term efficacy of brexpiprazole in adults with schizophrenia: Effect across marder factors. Schizophrenia Bulletin2017;43:S155. [CSZG: 36051]WeissC , OuyangJ , EramoA , DuffyRA , WeillerE , BakerRA . Switching patients with acute schizophrenia to brexpiprazole: post-hoc analysis of a double-blind randomized maintenance treatment study. Neuropsychopharmacology2015;40:S227-8. [CSZG: 33450]WeissC , WeillerE , HobartM , OuyangJ . Effect of brexpiprazole on weight and metabolic parameters: analysis of a maintenance trial in schizophrenia. European Neuropsychopharmacology2016;26:S556. [CSZG: 35746]">Brexpiprazole 2017</a>, <a href="./references#CD008016-bbs2-0006" title='CorrellCU , PotkinSG , DurgamS , ChangCT , SzatmariB , LaszlovszkyI , et al. Sustained remission with cariprazine treatment: post-hoc analysis of a randomised, double-blind, schizophrenia relapse prevention trial. Europan Neuropsychopharmacology2017;27((Suppl. 4)):S935-S936. [CSZG: 37757]CorrellCU , PotkinSG , ZhongY , HarsányiJ , SzatmáriB , EarleyW . Long-term remission with cariprazine treatment in patients with schizophrenia: a post-hoc analysis of a randomized, double-blind, placebo.controlled relapse prevention trial. Journal of Clinical Psychiatry2019;80(2):18m12495. DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Corrigendum to "Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial" [Schizophr. Res. 176 (2016) 264-71]. Schizophrenia Research2017;InPress:InPress. [CSZG: 35204]DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A double-blind, placebo-controlled trial. European Neuropsychopharmacology2015;25:S512-3. [CSZG: 33317]DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophrenia Research2016;176(2-3):264-71. [CSZG: 35204]DurgamS , EarleyW , LiR , LiD , LuK , LaszlovszkyI , et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: additional analysis from a randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology2015;40:S380-1. [CSZG: 33316]EarleyW , GuoH , LuchiniR . Modified cariprazine relapse prevention clinical trial results. Schizophrenia Research2018;199:452-3. KunovacJ , KaneJ , DurgamS , ChangCT , NemethG , LaszlovszkyI , et al. Characteristics associated with relapse in patients with schizophrenia: Post hoc analysis of a randomized, double-blind, placebo-controlled, cariprazine relapse prevention trial. Schizophrenia Bulletin2017;43:S166-7. [CSZG: 36002]NCT01412060. Cariprazine relative to placebo in the prevention of relapse of symptoms in patients with schizophrenia. http://ClinicalTrials.gov/show/NCT014120602011. [CSZG: 23106]PotkinS , CorrellC , ChangCT , SzatmariB , LaszlovszkyI , EarleyW . Long-term remission with cariprazine treatment in patients with schizophrenia: a post hoc analysis of a randomized, double-blind, placebo-controlled, relapse prevention trial. Schizophrenia Bulletin2017;43:S118. [CSZG: 36026]'>Cariprazine 2016</a>, <a href="./references#CD008016-bbs2-0031" title="Eerdekens. Evaluate the efficacy in the prevention of recurrence of the symptoms of schizophrenia. Sponsor: Johnson &amp; Johnson Pharmaceutical Research &amp; Development, LL.C2010. [CTG: NCT00111189]KramerM , KushnerS , SherrJ , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study. Schizophrenia Bulletin2007;33(2):438. [CSZG: 15185]KramerM , KushnerS , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia treated with paliperidone extended-release tablets. European Neuropsychopharmacology2006;16(Suppl 4):S386. [CSZG: 13313]KramerM , KushnerS , VijapurkarU , LimP , EerdekensM . Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study. International Journal of Neuropsychopharmacology2006;9(Suppl 1):S274. [CSZG: 19545]KramerM , SimpsonG , MaciulisV , KushnerS , LiuY , LimP , et al. One-year open-label safety and efficacy study of paliperidone extended-release. CNS Spectrums2010;15(8):506-14. [CSZG: 20885]KramerM , SimpsonG , MaciulisV , KushnerS , VijapurkarU , LimP , et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology2007;27:6-14. [CSZG: 13907]MarkowitzM , FuDJ , LevitanB , GopalS , TurkozI , AlphsL . Long-acting injectable paliperidone palmitate versus oral paliperidone extended release. Annals of General Psychiatry2013;12:22. [CSZG: 28633]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone 2007</a>, <a href="./references#CD008016-bbs2-0032" title="RuiQ , WangY , LiangS , LiuY , WuY , WuQ , et al. Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry2014;53:45-53. [CSZG: 29320]ZhangH , LiH , LiuY , WuC , WuQ , NuamahI . Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia. Neuropsychiatric Disease and Treatment2016;12:69-77. [CSZG: 33455]">Paliperidone 2014</a>, <a href="./references#CD008016-bbs2-0033" title="AlphsL , BossieC , Kern-SliwaJ , Ma Y-W, HaskinsJT . Paliperidone palmitate: clinical response in subjects with schizophrenia with recent vs. longer-term duration of illness. In: Proceedings of the 162nd Annual Meeting of the American Psychiatric Association. San Francisco, CA., 2009 May 16-21. [CSZG: 19067]EmsleyR , NuamahI , GopalS , HoughD , FleischhackerWW . Relapse after antipsychotic discontinuation in schizophrenia as a withdrawal phenomenon vs illness recurrence: a post hoc analysis of a randomized placebo-controlled study. Journal of Clinical Psychiatry 2018 Jun;79(4):17m11874. [CSZG: 38184]EmsleyR , NuamahI , HoughD , GopalS . Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophrenia Research2012;138(1):29-34. [CSZG: 24214]GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM , HoughD . A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. Journal of Psychopharmacology2011;25(5):685-97. [CSZG: 22903]GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Long-term efficacy, safety and tolerability of paliperidone palmitate in patients with schizophrenia. In: Proceedings of the 162nd Annual Meeting of the American Psychiatric Association. San Francisco, CA, 2009 May 16-21. [CSZG: 19076]HoughD , GopalS , VijapukarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate in prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. In: Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8, Washington DC, USA. 2008. [CSZG: 16486]HoughD , GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. In: Proceedings of the 63rd Annual Convention of the Society of Biological Psychiatry. Washington, DC, USA: Elsevier Science Inc, 2008:S285-6. [CSZG: 20281]HoughD , GopalS , VijapurkarU , LimP , MorozovaM , EerdekensM . Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Biological Psychiatry2008;63(7 Suppl):285S-6S. [CSZG: 19530]HoughD , GopalS , VjapukarU , LimP , MorozowaM , EerdekensM . Paliperidone palmitate maintenance treatment in delaying the time to relapse in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. Schizophrenia Research2010;116:107-17. [CSZG: 19704]HulihanJ , BossieCA , FuDJ , Kern SliwaJ , Ma Y-W, AlphsLD . Remission with continued paliperidone palmitate treatment in stable subjects with schizophrenia. Schizophrenia Research2012;136:S252. [CSZG: 29467]KozmaCM , SlatonT , DiraniR , FastenauJ , GopalS , HoughD . Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate. Current Medical Resarch and Opinion2011;27(8):1603-11. SliwaJK , BossieCA , Fu DJ, TurkozI , AlphsL . Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia. Neuropsychiatric Disease and Treatment2012;8:375-85. [CSZG: 28007]SliwaJK , FuDJ , BossieCA , et al. Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate. BMC Psychiatry2014;14:S52. [CSZG: 29148]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone depot1M 2010</a>, <a href="./references#CD008016-bbs2-0034" title="BossieC , TurkozI , AlphsL , FuDJ . Monotherapy with once monthly paliperidone palmitate for psychotic, depressive, and manic symptoms in schizoaffective disorder. Schizophrenia Bulletin2015;41:S303. [CSZG: 29400]BossieCA , TurkozI , AlphsL , MahalchickL , FuDJ . Paliperidone palmitate once-monthly treatment in recent onset and chronic illness patients with schizoaffective disorder. Journal of Nervous and Mental Ddisease2017;205(4):324-8. [CSZG: 35417]FuDJ , AlphsL , LindenmayerJP , SchoolerN , SimonsonRB , TurkozI , et al. Paliperidone palmitate long-acting injectable delays psychotic and mood symptom relapse in schizoaffective disorder. European Neuropsychopharmacology2014;24:S534-5. [CSZG: 27785]FuDJ , BossieC , TurkozI , MahalchickL , AlphsL . Paliperidone palmitate treatment response in early and chronic illness schizoaffective disorder patients. Schizophrenia Bulletin2015;41:S312. [CSZG: 29446]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Effect of paliperidone palmitate once-monthly in improving and maintaining functioning in subjects with schizoaffective disorder using the domains of the personal and social performance scale. Neuropsychopharmacology2014;39:S365. [CSZG: 29278]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate delays relapse in patients with schizoaffective disorder. Biological Psychiatry2014;1:263S. [CSZG: 28974]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate long-acting injectable in acute exacerbation of schizoaffective disorder. Schizophrenia Bulletin2013;39:S331. [CSZG: 28167]FuDJ , TurkozI , SimonsonRB , WallingD , SchoolerN , LindenmayerJP , et al. Paliperidone palmitate once-monthly injectable treatment for acute exacerbations of schizoaffective disorder. Journal of Clinical Psychopharmacology2016;36(4):372-6. [CSZG: 35803]FuDJ , TurkozI , SimonsonRB , WallingDP , SchoolerNR , LindenmayerJP , et al. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. Journal of Clinical Psychiatry2015;76(3):253-62. [CSZG: 29752]FuDJ , TurkozI , WallingD , LindenmayerJP , SchoolerNR , AlphsL . Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder. Schizophrenia Research2018;192:185-93. [CSZG: 35804]JoshiK , LinJ , Lingohr-SmithM , FuD . Medical cost reductions for paliperidone palmitate versus placebo in randomized double-blind trial of patients with schizoaffective disorder. Journal of Managed Care and Specialty Pharmacy2015;21:536-7. JoshiK , LinJ , Lingohr-SmithM , FuDJ . Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder. Journal of Medical Economics2015;18:629-36. [CSZG: 33677]NCT01193153. A study to evaluate the efficacy of paliperidone palmitate in the prevention of relapse of the symptoms of schizoaffective disorder. http://ClinicalTrials.gov/show/NCT011931532010. [CSZG: 21094]TurkozI , FuDJ , WallingD , SchoolerNR , LindenmayerJP , SimonsonRB , et al. Effect of paliperidone palmitate once-monthly in improving and maintaining functioning in subjects with schizoaffective disorder using the domains of the personal and social performance scale. Schizophrenia Bulletin2015;41:S193-4. [CSZG: 29687]">Paliperidone depot1M 2015</a>, <a href="./references#CD008016-bbs2-0035" title="BellLKS , TurkozI , KimE . Paliperidone palmitate once-every-3-months in adults with early illness schizophrenia. Early Intervention in Psychiatry2019;13(3):667-72. BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of paliperidone palmitate 3 month formulation: a randomized, double-blind, placebo-controlled study. Schizophrenia Bulletin2015;41:S302. [CSZG: 29393]BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of paliperidone palmitate 3-month formulation in schizophrenia: a randomized, double-blind, placebo-controlled study. European Psychiatry2015;30:272. [CSZG: 32149]BerwaertsJ , LiuY , GopalS , NuamahI , XuH , SavitzA , et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry2015;72(8):830-9. [CSZG: 33027]ChirilaC , ZhengQ , SawyerrG , NuamahI . Healthcare resource use of paliperidone palmitate 3-month injection vs placebo. In: 168th Annual Meeting of American Psychiatric Association; Toronto, Canada. May 16-20, 2015. [CSZG: 33035]GopalS , FureyM , HibarD , KolbH , SaadZ , SavitzA , et al. Potential biomarkers of impending schizophrenia relapse. Biological Psychiatry2017;(10 Suppl):S126-S127. [CSZG: 36107]GopalS , XuH , McQuarrieK , SavitzA , NuamahI , WoodruffK , et al. Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies. NPJ Schizophrenia2017;3(1):23. [CSZG: 36325]MathewsM , NuamahI , SavitzA , GopalS . Efficacy and safety of paliperidone palmitate 3-month formulation vs placebo for relapse prevention of Schizophrenia: Treatment effect using a number needed to treat analysis. Biological Psychiatry2017;81(10 Suppl 1):S350-1. [CSZG: 36437]NCT01529515. A study of paliperidone palmitate 3 month formulation for the treatment of patients with schizophrenia. http://ClinicalTrials.gov/show/NCT015295152012. [CSZG: 23705]WangD , GopalS , BakerS , NarayanVA . Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia2018;4(1):10. ">Paliperidone depot3M 2015</a>, <a href="./references#CD008016-bbs2-0046" title="NCT00658645. A multinational, randomised, double-blind, fixed-dose, bifeprunox study combining a 12-week placebo-controlled, quetiapine-referenced phase with a 12-month quetiapine-controlled phase in patients with schizophrenia. https://www.clinicaltrials.gov/ct2/show/NCT00658645?term=NCT00658645&amp;rank=1. [CSZG: 16241]">Quetiapine 2009a</a>; <a href="./references#CD008016-bbs2-0047" title="NCT00704509. A multinational, randomised, double-blind, fixed-dose, bifeprunox study combining a 12-week placebo-controlled, quetiapine-referenced phase with a 12-month quetiapine-controlled phase in patients with schizophrenia. https://www.clinicaltrials.gov/ct2/show/NCT00704509?term=NCT00704509&amp;rank=1. [CSZG: 16566]">Quetiapine 2009b</a>), while in the other five studies, different rating scales were applied in one study each: the Global Assessment of Functioning (<a href="./references#CD008016-bbs2-0074" title="AratoM , O'ConnorR , BradburyJE , MeltzerH . Long-term ziprasidone in schizophrenia. In: Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 - Jun 4; Toronto, Ontario, Canada. 1998. [CSZG: 3189]AratoM , O'ConnorR , BradburyJE , MeltzerH . The efficacy of ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. In: Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK. Amsterdam, Netherlands: Cambridge University Press, 1998. [CSZG: 3188]AratoM , O'ConnorR , BradburyJE , MeltzerH . Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. In: Proceedings of the 9th Congress of the Association of European Psychiatrists; 1998 Sep 20-24; Copenhagen, Denmark. 1998. [CSZG: 3190]AratoM , O'ConnorR , BradburyJE , MeltzerH . Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. Schizophrenia Research1999;36(1-3):270. [CSZG: 5626]AratoM , O'ConnorR , MeltzerH , BradburyJ . Ziprasidone: efficacy in the prevention of relapse and in the long-term treatment of negative symptoms of chronic schizophrenia. In: Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria. 1997. [CSZG: 245]AratoM , O'ConnorR , MeltzerHY . A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. International Clinical Psychopharmacology2002;17:207-15. [CSZG: 18486]BernardoM , AranzaJR , Rubio-TerresC , RejasJ . Cost-effectiveness analysis of schizophrenia relapse prevention. Clinical Drug Investigation. New Zealand2006;26(8):447-57. [CSZG: 13898]BernardoM , AranzaJR , Rubio-TerresC , RejasJ . Cost-effectiveness analysis of the prevention of relapse in schizophrenia in the ZEUS longitudinal study Ziprasidone Extended Use in Schizophrenia (ZEUS). Acta Espanolas de Psiquiatria2007;35(4):259-62. [CSZG: 15396]MeltzerHY , O´ConnorR . Long-term efficacy of ziprasidone in schizophrenia. Schizophrenia research2001;(1-2):S. 239. [CSZG: 6050]MeltzerHY , O´ConnorR . Path analysis of the ZEUS study provides evidence of a direct effect of ziprasidone on primary negative symptoms in chronic, stable schizophrenia. Conference Poster1997. [CSZG: 2033]MeltzerHY , O'ConnorR . Long-term efficacy of ziprasidone in schizophrenia: results of two controlled trials. In: Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico. 2000. [CSZG: 7609]O'ConnorR , SchoolerNR . Penultimate observation carried forward (POCF): a new approach to analysis of long-term symptom change in chronic relapsing conditions [letter]. Schizophrenia Research2003;60:319-20. [CSZG: 9365]Pfizer 2000. Multicentre double-blind study of ziprasidone versus placebo in relapse prevention for hospitalised patients with chronic or subchronic schizophrenia. Study report Unpublished. SchoolerN . A basis for optimism: the implications of long term treatment. In: Proceedings of the 9th Congress of the Association of European Psychiatrists; 1998 Sep 20-24; Copenhagen, Denmark. 1998. [CSZG: 5864]">Ziprasidone 2002</a>), the Global Assessment Scale (<a href="./references#CD008016-bbs2-0020" title="GoldbergSC , ShenoyRS , SadlerA , HamerR , RossB . The effects of a drug holiday on relapse and tardive dyskinesia in chronic schizophrenics. Psychopharmacology Bulletin1981;17:116-7. [CSZG: 5007]ShenoyRS , SadlerAG , GoldbergSC , HamerRM , RossB . Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics. Journal of Clinical Psychopharmacology1981;1:141-5. [CSZG: 2577]">Fluphenazine depot 1981</a>) and its Children version (<a href="./references#CD008016-bbs2-0002" title="CorrellC , KohegyiE , ZhaoC , BakerRA , McQuadeR , SalzmanP , et al. Oral aripiprazole is an effective maintenance treatment in adolescents with schizophrenia. Neuropsychopharmacology2014:S349-S350. [CSZG: 29288]CorrellCU , KohegyiE , ZhaoC , BakerRA , McQuadeR , SalzmanPM , et al. Oral aripiprazole as maintenance treatment in adolescent schizophrenia: results from a 52-week, randomized, placebo-controlled withdrawal study. Journal of the American Academy of Child and Adolescent Psychiatry2017;56(9):784-92. [CSZG: 36321]NCT01149655. A long-term multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of aripiprazole (opc 14597) as maintenance treatment in adolescent patients with schizophrenia. http://ClinicalTrials.gov/show/NCT011496552010. [CSZG: 21085]">Aripiprazole 2017</a>), the Specific Levels of Functioning (<a href="./references#CD008016-bbs2-0028" title="NCT01435928. PEARL Schizophrenia Maintenance. http://ClinicalTrials.gov/show/NCT014359282011. [CSZG: 23439]TandonR , CucchiaroJ , PhillipsD , HernandezD , MaoY , PikalovA , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Journal of Psychopharmacology2016;30(1):69-77. [CSZG: 33434]TandonR , LoebelA , PhilipsD , PikalovA , Hernandez D MaoY , et al. Lurasidone for maintenance of efficacy in patients with schizophrenia. European Neuropsychopharmacology2014;24(Suppl 2):S559-560. [CSZG: 27840]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , CucchiaroJ . A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Schizophrenia Research2014;153(1):S372. [CSZG: 29681]TandonR , LoebelA , PhilipsD , PikalovA , HernandezD , MaoY , et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Int J Neuropsychopharmacol2014;17:S153-154. [CSZG: 29954]">Lurasidone 2016</a>) and the Sheehan Disability Schedule (<a href="./references#CD008016-bbs2-0027" title="CTRI/2010/091/001409. A clinical trial to study prevention of relapse in patients with schizophrenia reveiving either flexible dose iloperidone or placebo in long-term use.. http://ctri.nic.in/Clinicaltrials/login.php2010. NCT01291511. Efficacy in prevention of relapse of schizophrenia in subjects taking either placebo or iloperidone. http://ClinicalTrials.gov/show/NCT012915112011. [CSZG: 22671]WeidenPJ , ManningR , WolfgangCD , RyanJM , MancioneL , HanG , et al. A randomized trial of iloperidone for prevention of relapse in schizophrenia: the REPRIEVE study. CNS drugs2016;30(8):735-47. [CSZG: 35243]">Iloperidone 2016</a>). For that reason, effects were analysed separately using MDs. At all time points and with all the scales used, the direction of effect was in favour of antipsychotic treatment, mostly (in 13 out of 15 studies) statistically significant. As an additional analysis, all studies were combined across different rating scales and time points using SMD. This analysis also showed statistically significant superiority of active medication. Analysing the studies using different statistical methods would probably not have changed the conclusions, since all the studies revealed at least a trend in favour of active drugs. As social functioning is regarded as one of the areas which should be taken into account for recovery beyond clinical remission, this is an important finding for clinical practice. It has been argued that functional remission is a more important criterion for recovery than being symptom free in order to be able to fulfil private and professional roles and to achieve social integration (<a href="./references#CD008016-bbs2-0181" title="BurnsT , PatrickD . Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatrica Scandinavica2007;116:403-18.">Burns 2007</a>, <a href="./references#CD008016-bbs2-0244" title="VitaA , BarlatiS . Recovery from schizophrenia: is it possible?Curr Opin Psychiatry2018;31(00):1-10.">Vita 2018</a>). Future trials should continue to consider social functioning as one of the outcomes, and, if our finding is confirmed, improved social functioning is another argument in favour of maintenance treatment with antipsychotic drugs in schizophrenia patients. As in the assessment of quality of life, it needs to be considered as a limitation that patients with a relapse were typically included in this outcome. For evaluating the social functioning of patients while taking maintenance treatment, the social‐functioning ratings before recurrence of psychotic symptoms would be of additional interest. However, tthese data were not typically not available. </p> </section> </section> <section id="CD008016-sec-0189"> <h4 class="title">3. Publication bias</h4> <p>The funnel plot was clearly asymmetrical suggesting the possibility of a publication bias. However, other reasons than unpublished studies can make funnel plots asymmetrical. For example, small studies are often conducted in single centres with very motivated investigators who make sure that drugs are compliantly taken. This may be more difficult in large, multi‐centre studies. To examine the impact of potentially undetected small studies we undertook a sensitivity analysis in which we only included larger studies (which we defined by a sample size of at least 200). In this group of studies there was still a clear reduction of the relapse risk at 12 months by antipsychotic drugs. Therefore, even if only the larger studies were considered, the finding of the superiority of antipsychotic drugs for relapse‐prevention is not threatened. Duval's and Tweedy's trim and fill method did also not suggest a substantial effect from missing small trials (<a href="./references#CD008016-bbs2-0190" title="DuvalS , TweedieR . Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics2000;56:455-63.">Duval 2000</a>). </p> </section> <section id="CD008016-sec-0190"> <h4 class="title">4. Subgroup analyses and investigation of heterogeneity</h4> <p>The heterogeneity of many results was statistically significant, which was expected in a review that pooled different drugs and doses, that combined studies that used different relapse definitions, and that were published over a period of 50 years. Nevertheless, in most studies the direction of the effects was the same. Therefore, the heterogeneity reflected only differences in the degree of superiority in relapse prevention. Moreover, most subgroup analyses and meta‐regressions did not reveal any statistically significant differences. This finding is important, because it may be interpreted that the relapse‐preventing effects of antipsychotic drugs can be generalised to many patients. </p> <section id="CD008016-sec-0191"> <h5 class="title">4.1 People with a first episode of schizophrenia and people in remission</h5> <p>The effects of antipsychotic drugs were similar in first‐episode compared to multiple‐episode participants and if participants were in remission at baseline or not. First‐episode and remitted people with schizophrenia are thought to have a better prognosis, but our results suggest that theybenefit equally from antipsychotic relapse prevention. Approximately 20% of people with a first episode of schizophrenia will not have a second episode within five years (<a href="./references#CD008016-bbs2-0230" title="RobinsonD , WoernerMG , AlvirJM , BilderR , GoldmanR , GeislerS , et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry1999;56:241-7.">Robinson 1999</a>), but identification of this subgroup in advance is more than problematic. </p> </section> <section id="CD008016-sec-0192"> <h5 class="title">4.2 People who had been stable for various periods before entering the trials</h5> <p>The relapse‐preventing effects of antipsychotic drugs were independent from the duration that participants had been stable before entering the studies. Even in those participants who had been stable for up to three to six years (<a href="./references#CD008016-bbs2-0022" title="SampathG , ShahA , KrskaJ , SoniSD . Neuroleptic discontinuation in the very stable schizophrenic patient - relapse rates and serum neuroleptic levels. Human Psychopharmacology1992;7:255-64. [CSZG: 2493]SoniSD , MallikA , SchiffAA . Sulpiride in negative schizophrenia: a placebo-controlled double-blind assessment. Human Psychopharmacology1990;5:233-8. [CSZG: 2697]">Fluphenazine depot 1992</a>; <a href="./references#CD008016-bbs2-0064" title="CheungHK . Schizophrenics fully remitted on neuroleptics for 3-5 years - to stop or continue drugs?British Journal of Psychiatry1981;138:490-4. [CSZG: 460]">Various drugs 1981b</a>) relapse rates were higher among placebo‐treated than among drug‐treated individuals. This is important for the recommended duration of antipsychotic maintenance treatment in guidelines, because it can be argued that even patients who have taken antipsychotic drugs for such a duration still benefit from them. However, as only two small studies (<a href="./references#CD008016-bbs2-0022" title="SampathG , ShahA , KrskaJ , SoniSD . Neuroleptic discontinuation in the very stable schizophrenic patient - relapse rates and serum neuroleptic levels. Human Psychopharmacology1992;7:255-64. [CSZG: 2493]SoniSD , MallikA , SchiffAA . Sulpiride in negative schizophrenia: a placebo-controlled double-blind assessment. Human Psychopharmacology1990;5:233-8. [CSZG: 2697]">Fluphenazine depot 1992</a>; <a href="./references#CD008016-bbs2-0064" title="CheungHK . Schizophrenics fully remitted on neuroleptics for 3-5 years - to stop or continue drugs?British Journal of Psychiatry1981;138:490-4. [CSZG: 460]">Various drugs 1981b</a>) with a total of only 54 participants contributed to this finding, more evidence is clearly needed for solid recommendations. </p> </section> <section id="CD008016-sec-0193"> <h5 class="title">4.3 Abrupt versus gradual withdrawal of antipsychotic drugs</h5> <p>There is a theory that long‐term treatment with antipsychotic drugs leads to a compensatory up‐regulation of dopamine receptors. If antipsychotic drugs are withdrawn abruptly, dopamine receptors are hypersensitive, leading to rebound psychosis (<a href="./references#CD008016-bbs2-0222" title="MoncrieffJ . Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatrica Scandinavica2006;114(1):3-13.">Moncrieff 2006</a>). This phenomenon has been called 'supersensitivity psychosis'. In contrast to the now outdated report by <a href="./references#CD008016-bbs2-0243" title="VigueraAC , BaldessariniRJ , HegartyJD , vanKammenDP , TohenM . Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Archives of General Psychiatry1997;54:49-55.">Viguera 1997</a>, we did not find a difference in relapse reduction between studies in which drugs were abruptly or gradually withdrawn, neither in a dichotomised subgroup analysis applying the same cut‐off as <a href="./references#CD008016-bbs2-0243" title="VigueraAC , BaldessariniRJ , HegartyJD , vanKammenDP , TohenM . Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Archives of General Psychiatry1997;54:49-55.">Viguera 1997</a> (who defined gradual withdrawal by a taper duration of at least three weeks or stopping depot antipsychotic drugs that have a long half‐life), nor in a meta‐regression with duration of taper as a continuous parameter. It should be noted that subgroup analysis and meta‐regression are observational, crude methods and can, therefore, not rule out this theory which needs thorough investigation. It is also possible that supersensitivity psychosis explains a part of the decreasing effect sizes in longer trials (see <a href="#CD008016-fig-0007">Figure 7</a> and below). We would therefore strongly recommend slow tapering of antipsychotic drugs, if withdrawal is needed. </p> </section> <section id="CD008016-sec-0194"> <h5 class="title">4.4 Single antipsychotic drugs, depot versus oral medication and first‐generation versus second‐generation antipsychotic drugs </h5> <p>There were no differences between the single antipsychotic drugs used apart from depot antipsychotic drugs (in particular depot formulations of haloperidol and fluphenazine) being more effective than oral antipsychotic drugs. Although this result fits to the theory that depot antipsychotic drugs improve the adherence that is crucial for relapse prevention, subgroup analyses are of observational nature. Only head‐to‐head comparisons of oral and depot antipsychotic drugs can decide whether the latter are more effective. A recent update of our systematic review on this question (<a href="./references#CD008016-bbs2-0216" title="LeuchtC , HeresS , KaneJM , KisslingW , DavisJM , LeuchtS . Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials. Schizophrenia Research2011;127:83-92.">Leucht 2011</a>) did not find a difference between oral and depot medication (<a href="./references#CD008016-bbs2-0207" title="KishimotoT , RobenzadehA , LeuchtC , LeuchtS , WatanabeK , MimuraM , et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophrenia Bulletin2014;40(1):192-213.">Kishimoto 2014</a>). As a group, so‐called second‐generation antipsychotic drugs did not differ in relapse reduction from first‐generation antipsychotic drugs. This supports previous suggestions that this classification should be abandoned, because there is no single definition that fits to all drugs that are considered to be second‐generation or atypical antipsychotic drugs (<a href="./references#CD008016-bbs2-0213" title="LeuchtS , CorvesC , ArbterD , EngelR , LiC , DavisJM . A meta-analysis comparing second-generation and first-generation antipsychotics for schizophrenia. Lancet2009;373:31-41.">Leucht 2009</a>). </p> </section> <section id="CD008016-sec-0195"> <h5 class="title">4.5 Appropriate versus unclear allocation concealment methods</h5> <p>There was no difference between the effect estimates of studies that used appropriate and unclear allocation concealment methods. It should, however, be noted that the original analyses on this question found larger differences between studies with appropriate and inappropriate allocation concealment than between appropriate and unclear allocation concealment (e.g. <a href="./references#CD008016-bbs2-0232" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273:408-12.">Schulz 1995</a>). Studies with inappropriate allocation concealment were excluded a priori from our review. </p> </section> <section id="CD008016-sec-0196"> <h5 class="title">4.6 Open versus double‐blind studies</h5> <p>Open trials were associated with a stronger difference between drugs and placebo than blinded trials, but as there were only two open RCTs (<a href="./references#CD008016-bbs2-0072" title="GaebelW , FrickU , KopckeW , LindenM , MuellerP , Mueller SpahnF , et al. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse?British Journal of Psychiatry Supplementum1993;163:8-12. [CSZG: 831]GaebelW , JannerM , FrommannN , PietzckerA , KopckeW , LindenM , et al. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophrenia Research2002;53(1-2):145-59. [CSZG: 8197]GaebelW , MoellerHJ . Treatment strategies in first episode schizophrenia. In: Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan. 2002. [CSZG: 8597]PietzckerA , GaebelW , KoepckeW , LindenM , MuellerP , Mueller-SpahnF , et al. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia - 2-year results of a German multicenter study. Journal of Psychiatric Research1993;27:321-39. [CSZG: 3944]PietzckerA , GaebelW , KopckeW , LindenM , MullerP , Muller-Spahn, et al. A German multicenter study on the neuroleptic long-term therapy of schizophrenic patients. Preliminary report. Pharmacopsychiatry1986;19:161-6. [CSZG: 3943]">Various drugs 1993</a>; <a href="./references#CD008016-bbs2-0073" title="BoonstraG , BurgerH , GrobbeDE , KahnRS . Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial. International Journal of Psychiatry in Clinical Practice2011;15(2):128-34. [CSZG: 22940]BoonstraG . Schizophrenia termination of pharmacotherapy-STOP-trial. Current Controlled Trials2005. [CSZG: 14487] [ISRCTN: 6332944]">Various drugs 2011</a>), the impact of this effect was small. </p> </section> <section id="CD008016-sec-0197"> <h5 class="title">4.7 Meta‐regression on study duration</h5> <p>There was a statistically significant association between longer study duration and smaller relapse reduction by antipsychotic drugs compared with placebo. This result could indicate that antipsychotic drugs lose their efficacy over time. We emphasise that there are also other possible explanations for this counter‐intuitive finding. Participants' severity in shorter and longer trials could be different, and notably the decreasing relapse‐preventing effects could also be an effect of decreasing drug compliance over time. However, studies that last longer than two years and either use depot antipsychotic drugs or thoroughly monitor compliance are needed to investigate the long‐term effects of antipsychotic drugs. Moreover, as antipsychotics prevent relapses, more patients in the drug group stayed in the study as compared to placebo (see also <a href="#CD008016-sec-0174">Discussion</a>, section 2.2. "Leaving the study early due to any reasons"). Consequentely, at later time points, there were more at risk for relapse in the drug group than in the placebo group, and the difference in relapses between drug and placebo may get smaller due to this imbalance for people at risk (<a href="./references#CD008016-bbs2-0184" title="DavisJM . Overview: maintenance therapy in psychiatry: I. Schizophrenia. American Journal of Psychiatry1975;132(12):1237-45.">Davis 1975</a>). Such a phenomenon is indeed expected should antipsychotics not completely prevent but only delay the occurrence of relapses (at least for a proportion of patients). </p> </section> <section id="CD008016-sec-0198"> <h5 class="title">5. Sensitivity analyses</h5> <p>The results of the primary outcome were not much different when studies that were not clearly described as randomised were excluded, when open studies were excluded, when a fixed‐effect model instead of a random‐effects model was applied, when we used the original authors' assumptions on dropouts instead of our approach, when studies with unclear randomisation or allocation concealment methods were excluded, when only large trials were included, and when studies that did not use operational criteria to diagnose the participants were excluded. These sensitivity analyses underline the robustness of the results. </p> <p>A final sensitivity analysis in which we analysed only those participants who had not relapsed for various durations after study start again addressed supersensitivity psychosis. It revealed that even in those participants who had not relapsed for nine months, subsequent relapse rates were clearly lower in the drug group than in the placebo group. This finding opposes the theory that many relapses were merely rebound effects after rapid withdrawal (<a href="./references#CD008016-bbs2-0222" title="MoncrieffJ . Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatrica Scandinavica2006;114(1):3-13.">Moncrieff 2006</a>). </p> </section> </section> </section> <section id="CD008016-sec-0199"> <h3 class="title" id="CD008016-sec-0199">Overall completeness and applicability of evidence</h3> <p>The 75 included studies were conducted in various settings (e.g. inpatients and outpatients, different countries, stable superiority antipsychotic drugs in trials from different years), populations (e.g. participants in remission at baseline or not), and methods (e.g. different definitions of relapse). Therefore, we believe that the evidence is quite complete and applicable to routine care. There are, however, several limitations. While almost all studies reported on relapse, there is much less evidence on other outcomes such as hospitalisation, remission, employment status and adverse events, which were often inadequately reported. There were very few studies that lasted longer than one year. Thus, the long‐term effects of maintenance treatment are less clear. Finally, in most studies antipsychotic drugs were withdrawn abruptly. There is a theory that long‐term treatment leads to changes in dopamine receptors ('hypersensitivity psychosis') and re‐emergence of symptoms after abrupt withdrawal (<a href="./references#CD008016-bbs2-0222" title="MoncrieffJ . Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatrica Scandinavica2006;114(1):3-13.">Moncrieff 2006</a>). One study (<a href="./references#CD008016-bbs2-0029" title="DellvaMA , TollefsonGD , MattlerCA , KinonBJ , GrundySL . A controlled, double-blind investigation of the clozapine discontinuation syndrome with conversion to either olanzapine or placebo. Schizophrenia Research1999;36:277-8. [CSZG: 5651]TollefsonGD , DellvaMA , MattlerCA , KaneJM , WirshingDA , KinonBJ , et al. Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. Journal of Clinical Psychopharmacology1999;19:435-43. [CSZG: 5305]TollefsonGD , DellvaMA , MattlerCA , KinonBJ , GrundySL . A controlled, double-blind investigation of the clozapine discontinuation syndrome with conversion to either olanzapine or placebo. In: Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31 - Nov 4; Paris, France. 1998. [CSZG: 4859]">Olanzapine 1999</a>) was excluded from the original review due to the fact that it provided for a very short duration of follow‐up (three to five days) after abrupt withdrawal (tapering of three to 12 days), and it was therefore difficult to unequivocally distinguish between withdrawal/rebound phenomenon and illness recurrence. In the update we decided to include the study. Sensitivity analyses of the outcomes which the study contributed to were performed, and excluding the study did not change the results. Although our meta‐regression and sensitivity analysis did not detect an effect, future studies should withdraw antipsychotic drugs gradually rather than abruptly and to rule out or confirm this, supersensitivity psychosis should be an important research agenda. </p> </section> <section id="CD008016-sec-0200"> <h3 class="title" id="CD008016-sec-0200">Quality of the evidence</h3> <p>In the review update, judgements on the quality of evidence were consistent with those of the original review. Almost all studies were randomised and double‐blind but for most details were not presented. Therefore it is unclear whether the studies were adequately randomised, whether treatment allocation was really concealed and whether blinding worked. Concerning blinding this may be less important in objective outcomes such as death or weight gain. Concerning allocation concealment we at least found that there was no difference in the primary outcome between studies that used appropriate and unclear methods. Dropout rates were often high, partly because it was specified in many studies' methods that participants had to discontinue once they relapsed. This poses mainly a problem for outcomes other than relapse. While relapse and leaving the studies early was quite consistently reported, the evidence about other outcomes was much more scarce. Without original study protocols being available we cannot judge with absolute certainty whether these were not measured or whether there were cases of selective reporting. The current approach to report only those outcomes that occurred in at least 5% to 10% of the participants should be abandoned, because rare but important side effects might be overlooked. </p> <p>The most recent studies were often terminated early after pre‐planned interim analyses: this kind of design is clearly useful for practical and ethical reasons, but in the context of meta‐analyses it could be linked to the risk of overestimating treatment effects, especially when the studies stopped early contribute substantial weight in the analysis of some outcomes. However, this potential source of bias was not judged to threaten the quality of the overall evidence, with only a few exceptions (e.g. quality of life data). In individual trials there were also other problems, such as too high or too low doses, early termination of studies, baseline imbalances etc. In summary, the overall quality of the studies according to these criteria is moderate. Nevertheless, due to the consistency of the results in subgroup and sensitivity analyses, the overall superiority of antipsychotic drugs in reducing relapse rates is not challenged. </p> </section> <section id="CD008016-sec-0201"> <h3 class="title" id="CD008016-sec-0201">Potential biases in the review process</h3> <p>Wedecided a priori to pool all antipsychotic drugs in this review. We feel that this is justified for efficacy‐related outcomes, because most antipsychotic drugs do not differ in efficacy and if differences exist between some antipsychotic drugs, these are not large (<a href="./references#CD008016-bbs2-0213" title="LeuchtS , CorvesC , ArbterD , EngelR , LiC , DavisJM . A meta-analysis comparing second-generation and first-generation antipsychotics for schizophrenia. Lancet2009;373:31-41.">Leucht 2009</a>; <a href="./references#CD008016-bbs2-0217" title="LeuchtS , CiprianiA , SpineliL , MavridisM , OreyD , RichterF , et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet2013;382(9896):951962.">Leucht 2013</a>). The decision to pool all studies irrespective of the antipsychotic drug used is more problematic for adverse effects, because antipsychotic drugs differ to a large extent in this regard. Thus, any differences in side effects compared to placebo cannot be generalised to all antipsychotic compounds. Similarly, we analysed only a selection of common and important adverse effects, but many others exist. </p> <p>The study search was mainly based on the Cochrane Schizophrenia Group’s register of trials. This is largely made up of searches of published literature. It is possible that there are unpublished studies that we are not aware of and there is a possibility of publication bias, although the funnel plot may also be asymmetrical due to other factors. </p> <p>As a minor point, the 2017 update‐search did not include all antipsychotic drugs but was restricted to 35 different antipsychotics (including all second‐generation antipsychotics and the most important first‐generation antipsychotics). Therefore, theoretically, studies on specific first‐generation drugs that were not listed, could have been missed. However, we deem it unlikely that many studies (if any at all) with these specific old drugs have been performed after 2008. More sensitive time‐to‐relapse data derived from survival analyses that are considered more appropriate measures were not available for most studies, and, therefore, we had to restrict ourselves to the number of participants relapsed. </p> <p>We have chosen to use the random‐effects model for our analyses, which does not assume that the populations from which the different trials are derived are the same. This technique does emphasise the results from smaller trials and it is these studies that are likely to be most prone to bias. Nevertheless, the results of a fixed‐effect model in a sensitivity analysis of the primary outcome were similar. </p> <p>Finally, we highlight that many subgroup and meta‐regression analyses were conducted in this review, many of which were added post‐hoc ‐ after requests from reviewers. This raises the problem of type I errors (i.e. chance findings due to multiple testing). </p> </section> <section id="CD008016-sec-0202"> <h3 class="title" id="CD008016-sec-0202">Agreements and disagreements with other studies or reviews</h3> <p>We are aware of five other reviews that compared maintenance treatment with any antipsychotic drug with placebo (<a href="./references#CD008016-bbs2-0184" title="DavisJM . Overview: maintenance therapy in psychiatry: I. Schizophrenia. American Journal of Psychiatry1975;132(12):1237-45.">Davis 1975</a>; <a href="./references#CD008016-bbs2-0174" title="BaldessariniRJ . Chemotherapy in Psychiatry: Principles and Practice. Cambridge, MA: Harvard University Press, 1985.">Baldessarini 1985</a>; <a href="./references#CD008016-bbs2-0196" title="GilbertP , HarrisMJ , McAdamsLA , BowersMB , CharneyDS , GlazerWM . Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Archives of General Psychiatry1995;52:173-88.">Gilbert 1995</a>; <a href="./references#CD008016-bbs2-0250" title="ZhaoYJ , LinL , TengM , KhooAL , SohLB , FurukawaTA , et al. Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials. BJPsych Open2016;2(1):59-66.">Zhao 2016</a>; <a href="./references#CD008016-bbs2-0206" title="KishiT , IkutaT , MatsuiY , InadaK , MatsudaY , MishimaK , et al. Effect of discontinuation vs maintenance of antipsychotic medication on relapse rates in patients with remitted/stable first-episode psychosis: a meta-analysis. Psychological Medicine2019;49(5):772-9.">Kishi 2019</a>). All were consistent with our results because they found that people with schizophrenia who were withdrawn from antipsychotic drugs relapsed significantly more frequently than those who continued them. However, some of these reports did not meet modern criteria of systematic reviews, did not analyse relapse at different points in time and did not address any other outcome. A review by some members of the current review team was restricted to second‐generation antipsychotics (<a href="./references#CD008016-bbs2-0215" title="LeuchtS , ArbterD , EngelRR , KisslingW , DavisJM . How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Molecular Psychiatry2009;14:429-47.">Leucht 2009b</a>, an update of <a href="./references#CD008016-bbs2-0210" title="LeuchtS , BarnesTR , KisslingW , EngelRR , CorrellC , KaneJM . Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomised, controlled trials. American Journal of Psychiatry2003;160:1209-22.">Leucht 2003</a>). Second‐generation antipsychotic drugs clearly reduced relapse rates compared to placebo and the relative risk was similar to that in the current review (RR 0.41, 95% CI 0.28 to 0.59), but the absolute risk difference was smaller (RD 0.20, 95% CI 0.11 to 0.30). The previous review included only seven trials and the inclusion criteria were different (e.g. studies that only followed up acute‐phase responders (a design that corrupts randomisation) were also included and participants were not required to be stable on antipsychotic drugs or to be on antipsychotic drugs at all at study start). </p> <p>In terms of Cochrane Reviews, <a href="./references#CD008016-bbs2-0169" title="AlmerieMQ , AlkhateebH , EssaliA , MatarHE , RezkE . Cessation of medication for people with schizophrenia already stable on chlorpromazine. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD006329. [DOI: 10.1002/14651858.CD006329]">Almerie 2007</a> examined withdrawal of chlorpromazine compared to placebo and also found a significant relapse risk reduction. In the targeted update of this review, which was performed in 2016 (see New Reference) and included 22 RCTs (4334 participants), data on the primary outcome (relapse at one year) were consistent in essence with our results (10 RCTs, RR 0.50, 95% CI 0.38 to 0.66), as well as data on violent/aggressive behaviour. The targeted update also provided data on remission (participants not in remission at one year; 4 RCTs, RR 0.75, 95% CI 0.66 to 0.86); no data on recovery were found, the same as in the present review. As specified before (see <a href="#CD008016-sec-0174">Discussion</a>, section 2.9), basing on the targeted update, data maintenance treatment with antipsychotic drugs may make only little difference to quality of life in people with schizophrenia; however, the analysis was based on four studies, and data of one study were entered in the wrong direction of effect; in the present review the superiority of antipsychotic drugs was found to be statistically significant (data based on seven studies), although the certainty of evidence for this outcome was judged as poor due to limitations concerning study design, indirectness and imprecision. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008016-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram (results of the original search)For the review update in 2018: 3 reports describing the 2 studies originally excluded from quantitative synthesis were moved to excluded studies (no usable data for outcomes of interest); 3 reports on 1 study, originally excluded (short duration of follow‐up), were moved to included studies; one report originally included as independent study was moved as secondary publication of another included study." data-id="CD008016-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram (results of the original search)</p> <p>For the review update in 2018: 3 reports describing the 2 studies originally excluded from quantitative synthesis were moved to excluded studies (no usable data for outcomes of interest); 3 reports on 1 study, originally excluded (short duration of follow‐up), were moved to included studies; one report originally included as independent study was moved as secondary publication of another included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/full#CD008016-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram (results of the 2017/2018/2019 update search and combined results of the original search and the update search)" data-id="CD008016-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram (results of the 2017/2018/2019 update search and combined results of the original search and the update search) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/full#CD008016-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Size of trial over time" data-id="CD008016-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-03.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Size of trial over time</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/full#CD008016-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-03.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-FIG-04" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008016-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/full#CD008016-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-FIG-05" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008016-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/full#CD008016-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Maintenance treatment with antipsychotic drugs versus placebo/no treatment, outcome: Relapse" data-id="CD008016-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-06.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Maintenance treatment with antipsychotic drugs versus placebo/no treatment, outcome: Relapse </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/full#CD008016-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Meta‐regression on duration of clinical stability before study start (relapse at 12 months)The size of the bubbles is proportional to the inverse variance of the treatment effect." data-id="CD008016-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-07.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Meta‐regression on duration of clinical stability before study start (relapse at 12 months) </p> <p>The size of the bubbles is proportional to the inverse variance of the treatment effect.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/full#CD008016-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Meta‐regression on duration of taper in the placebo group (relapse at 12 months)The size of the bubbles is proportional to the inverse variance of treatment effect." data-id="CD008016-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-08.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Meta‐regression on duration of taper in the placebo group (relapse at 12 months)</p> <p>The size of the bubbles is proportional to the inverse variance of treatment effect.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/full#CD008016-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Meta‐regression on mean dose in chlorpromazine equivalents (relapse at 12 months)The size of the bubbles is proportional to the inverse variance of treatment effect." data-id="CD008016-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-09.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Meta‐regression on mean dose in chlorpromazine equivalents (relapse at 12 months)</p> <p>The size of the bubbles is proportional to the inverse variance of treatment effect.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/full#CD008016-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-FIG-10" target="_blank"><b></b></a></p> </div><img alt="Meta‐regression on study duration (relapse, all studies included).The size of the bubbles is proportional to the inverse variance of treatment effect." data-id="CD008016-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-10.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-FIG-10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Meta‐regression on study duration (relapse, all studies included).</p> <p>The size of the bubbles is proportional to the inverse variance of treatment effect.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/full#CD008016-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-FIG-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 1: Relapse: 1. Within pre‐specified time periods" data-id="CD008016-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 1: Relapse: 1. Within pre‐specified time periods </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 2: Relapse: 2. Independent of duration" data-id="CD008016-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 2: Relapse: 2. Independent of duration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 3: Leaving the study early: 1. Due to any reason (acceptability of treatment)" data-id="CD008016-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 3: Leaving the study early: 1. Due to any reason (acceptability of treatment) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 4: Leaving the study early: 2. Due to adverse events (overall tolerability)" data-id="CD008016-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 4: Leaving the study early: 2. Due to adverse events (overall tolerability) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 5: Leaving the study early: 3. Due to inefficacy" data-id="CD008016-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 5: Leaving the study early: 3. Due to inefficacy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 6: Global state: number of participants improved (at least minimally)" data-id="CD008016-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 6: Global state: number of participants improved (at least minimally) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 7: Global state: number of participants in symptomatic remission" data-id="CD008016-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 7: Global state: number of participants in symptomatic remission </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 8: Global state: number of participants in sustained remission" data-id="CD008016-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 8: Global state: number of participants in sustained remission </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 9: Service use: number of participants hospitalised" data-id="CD008016-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 9: Service use: number of participants hospitalised </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 10: Service use: number of participants discharged" data-id="CD008016-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 10: Service use: number of participants discharged </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 11: Death: due to any reason" data-id="CD008016-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 11: Death: due to any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 12: Death: due to natural causes" data-id="CD008016-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 12: Death: due to natural causes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 13: Death: due to suicide" data-id="CD008016-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 13: Death: due to suicide </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 14: Number with suicide attempts" data-id="CD008016-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 14: Number with suicide attempts </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 15: Number with suicide ideation" data-id="CD008016-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 15: Number with suicide ideation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 16: Violent/aggressive behaviour" data-id="CD008016-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 16: Violent/aggressive behaviour </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 17: Adverse effects: at least one adverse event" data-id="CD008016-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 17: Adverse effects: at least one adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 18: Adverse effects: movement disorders: at least one movement disorder" data-id="CD008016-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 18: Adverse effects: movement disorders: at least one movement disorder </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 19: Adverse effects: movement disorders: akathisia" data-id="CD008016-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 19: Adverse effects: movement disorders: akathisia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 20: Adverse effects: movement disorders: akinesia" data-id="CD008016-fig-0030" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 20: Adverse effects: movement disorders: akinesia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 21: Adverse effects: movement disorders: dyskinesia" data-id="CD008016-fig-0031" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 21: Adverse effects: movement disorders: dyskinesia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 22: Adverse effects: movement disorders: dystonia" data-id="CD008016-fig-0032" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 22: Adverse effects: movement disorders: dystonia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 23: Adverse effects: movement disorders: rigor" data-id="CD008016-fig-0033" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 23: Adverse effects: movement disorders: rigor </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 24: Adverse effects: movement disorders: tremor" data-id="CD008016-fig-0034" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 24: Adverse effects: movement disorders: tremor </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 25: Adverse effects: movement disorders: use of antiparkinson medication" data-id="CD008016-fig-0035" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 25: Adverse effects: movement disorders: use of antiparkinson medication </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 26: Adverse effects: sedation" data-id="CD008016-fig-0036" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 26: Adverse effects: sedation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 27: Adverse effects: weight gain" data-id="CD008016-fig-0037" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 27: Adverse effects: weight gain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.28" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 28: Participant´s satisfaction with care" data-id="CD008016-fig-0038" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.28.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.28.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 28: Participant´s satisfaction with care </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.28.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.29" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 29: Quality of life (various scales, different timepoints)" data-id="CD008016-fig-0039" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.29.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.29.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 29: Quality of life (various scales, different timepoints) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.29.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.30" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 30: Quality of life (across all scales and timepoints)" data-id="CD008016-fig-0040" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.30.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.30.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 30: Quality of life (across all scales and timepoints) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.30.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.31" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 31: Number of participants in employment" data-id="CD008016-fig-0041" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.31.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.31.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 31: Number of participants in employment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.31.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.32" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 32: Social Functioning (various scales, different timepoints)" data-id="CD008016-fig-0042" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.32.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.32.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 32: Social Functioning (various scales, different timepoints) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.32.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-001.33" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 33: Social Functioning (across all scales and timepoints)" data-id="CD008016-fig-0043" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.33.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-001.33.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1: Maintenance treatment with antipsychotic drugs versus placebo/no treatment, Outcome 33: Social Functioning (across all scales and timepoints) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-001.33.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis (relapse at 12 months), Outcome 1: Subgroup analysis: participants with a first episode" data-id="CD008016-fig-0044" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis (relapse at 12 months), Outcome 1: Subgroup analysis: participants with a first episode </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis (relapse at 12 months), Outcome 2: Subgroup analysis: participants in remission at baseline" data-id="CD008016-fig-0045" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis (relapse at 12 months), Outcome 2: Subgroup analysis: participants in remission at baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis (relapse at 12 months), Outcome 3: Subgroup analysis: various durations of stability before entering the study" data-id="CD008016-fig-0046" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis (relapse at 12 months), Outcome 3: Subgroup analysis: various durations of stability before entering the study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis (relapse at 12 months), Outcome 4: Subgroup analysis: abrupt withdrawal versus tapering" data-id="CD008016-fig-0047" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis (relapse at 12 months), Outcome 4: Subgroup analysis: abrupt withdrawal versus tapering </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis (relapse at 12 months), Outcome 5: Subgroup analysis: single antipsychotic drugs" data-id="CD008016-fig-0048" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis (relapse at 12 months), Outcome 5: Subgroup analysis: single antipsychotic drugs </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis (relapse at 12 months), Outcome 6: Subgroup analysis: depot versus oral drugs" data-id="CD008016-fig-0049" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis (relapse at 12 months), Outcome 6: Subgroup analysis: depot versus oral drugs </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis (relapse at 12 months), Outcome 7: Subgroup analysis: first‐ versus second‐generation antipsychotic drugs" data-id="CD008016-fig-0050" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis (relapse at 12 months), Outcome 7: Subgroup analysis: first‐ versus second‐generation antipsychotic drugs </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis (relapse at 12 months), Outcome 8: Subgroup analysis: appropriate versus unclear allocation concealment" data-id="CD008016-fig-0051" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis (relapse at 12 months), Outcome 8: Subgroup analysis: appropriate versus unclear allocation concealment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis (relapse at 12 months), Outcome 9: Subgroup analysis: blinded versus open trials" data-id="CD008016-fig-0052" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis (relapse at 12 months), Outcome 9: Subgroup analysis: blinded versus open trials </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis (relapse at 12 months), Outcome 1: Exclusion of studies that were not explicitly described as randomised" data-id="CD008016-fig-0053" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis (relapse at 12 months), Outcome 1: Exclusion of studies that were not explicitly described as randomised </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis (relapse at 12 months), Outcome 2: Exclusion of non‐double‐blind studies" data-id="CD008016-fig-0054" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis (relapse at 12 months), Outcome 2: Exclusion of non‐double‐blind studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis (relapse at 12 months), Outcome 3: Fixed‐effects model" data-id="CD008016-fig-0055" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis (relapse at 12 months), Outcome 3: Fixed‐effects model </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis (relapse at 12 months), Outcome 4: Original authors' assumptions on dropouts" data-id="CD008016-fig-0056" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis (relapse at 12 months), Outcome 4: Original authors' assumptions on dropouts </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis (relapse at 12 months), Outcome 5: Inclusion of only large studies (&gt; 200 participants)" data-id="CD008016-fig-0057" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis (relapse at 12 months), Outcome 5: Inclusion of only large studies (&gt; 200 participants) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis (relapse at 12 months), Outcome 6: Exclusion of studies with clinical diagnosis" data-id="CD008016-fig-0058" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis (relapse at 12 months), Outcome 6: Exclusion of studies with clinical diagnosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis (relapse at 12 months), Outcome 7: Three months stable" data-id="CD008016-fig-0059" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis (relapse at 12 months), Outcome 7: Three months stable </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis (relapse at 12 months), Outcome 8: Six months stable" data-id="CD008016-fig-0060" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis (relapse at 12 months), Outcome 8: Six months stable</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis (relapse at 12 months), Outcome 9: Nine months stable" data-id="CD008016-fig-0061" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis (relapse at 12 months), Outcome 9: Nine months stable </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis (relapse at 12 months), Outcome 10: Exclusion of studies with unclear randomisation method" data-id="CD008016-fig-0062" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis (relapse at 12 months), Outcome 10: Exclusion of studies with unclear randomisation method </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008016-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/urn:x-wiley:14651858:media:CD008016:CD008016-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis (relapse at 12 months), Outcome 11: Exclusion of studies with unclear allocation concealment method" data-id="CD008016-fig-0063" src="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_t/tCD008016-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis (relapse at 12 months), Outcome 11: Exclusion of studies with unclear allocation concealment method </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/media/CDSR/CD008016/image_n/nCD008016-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD008016-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Design of a future study</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Methods</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised ‐ clearly described generation of sequence and concealment of allocation<br/>Blinding: double ‐ described and tested<br/>Duration: 3 years </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>People with schizophrenia or schizophrenia‐like disorder in remission for at least one month<br/>N = 500<br/>Age: any<br/>Sex: both<br/>History: any (specify duration of illness) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interventions</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Any antipsychotic drug (flexible dose within appropriate range)</p> <p>2. Placebo (after gradual ‐ rather than abrupt ‐ withdrawal of the previous antipsychotic drug) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapse (primary outcome)</p> <p>Rehospitalisation for psychosis</p> <p>Global state (number of participants improved, in symptomatic and sustained remission)</p> <p>Global state (number of participants in recovery)</p> <p>Leaving the study early (including specific causes)</p> <p>Death (natural and unnatural causes)</p> <p>Violent behaviour</p> <p>Quality of life</p> <p>Satisfaction with care and other measures of subjective well‐being/recovery</p> <p>Side‐effects (well reported)</p> <p>Social functioning, employment and other measures of functioning</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Design of a future study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/full#CD008016-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008016-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Maintenance treatment with antipsychotic drugs versus placebo/no treatment for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Maintenance treatment with antipsychotic drugs versus placebo/no treatment for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> schizophrenia<br/><b>Setting:</b> inpatients and outpatients<br/><b>Intervention:</b> maintenance treatment with antipsychotic drugs<br/><b>Comparison:</b> placebo/no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Maintenance treatment with antipsychotic drugs versus placebo/no treatment</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse: 7 to 12 months</b> </p> <p>Follow‐up: 7‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>606 per 1.000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>230 per 1.000</b><br/>(194 to 273) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.38</b><br/>(0.32 to 0.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4249<br/>(30 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>⊕⊕⊕⊕</b> <br/><b>HIGH</b><sup>1 2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early: due to any reason (acceptability of treatment)</b> </p> <p>Follow‐up: 1‐24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>541 per 1.000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>292 per 1.000</b><br/>(265 to 330) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.54</b><br/>(0.49 to 0.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7001<br/>(56 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>⊕⊕⊕⊕</b> <br/><b>HIGH</b><sup>5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use: number of participants hospitalised</b> </p> <p>Follow‐up: 1‐36 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>177 per 1.000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>76 per 1.000</b><br/>(57 to 101) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.43</b><br/>(0.32 to 0.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3558<br/>(21 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>⊕⊕⊕⊕</b> <br/><b>HIGH</b><sup>6 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death: due to suicide</b> </p> <p>Follow‐up: 1‐15 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1.000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1.000</b><br/>(0 to 4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.60</b><br/>(0.12 to 2.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4634<br/>(19 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>⊕⊕⊝⊝</b> <br/><b>LOW</b><sup>6 8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life (various scales; low score=better)</b> </p> <p>Follow‐up: 3‐18 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean quality of life in the intervention group was <b>0.32 standard deviations lower</b> (from 0.57 to 0.07 standard deviations lower), with lower scores reflecting a better condition. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1573<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>⊕⊕⊝⊝</b> <br/><b>LOW</b><sup>5 6 9 10 11</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.32 (‐0.57 to ‐0.07)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants in employment</b> </p> <p>Follow‐up: 9‐15 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>344 per 1.000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>372 per 1.000</b><br/>(282 to 486) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b><br/>(0.82 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>593<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>⊕⊕⊝⊝</b> <br/><b>LOW</b><sup>6 12 13</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Social functioning (various scales; low score=better)</b> </p> <p>Follow‐up: 1‐15 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean social functioning in the intervention group was <b>0.43 standard deviations lower</b> (from 0.53 to 0.34 standard deviations lower), with lower scores reflecting a better condition. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3588<br/>(15 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>⊕⊕⊕⊝</b> <br/><b>MODERATE</b><sup>6 14 15</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.43 (‐0.53 to ‐0.34)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Publication bias: rated 'undetected' ‐ although the funnel plot was asymmetrical, the trim and fill test did not change the point estimate and the point estimate was also similar when only large studies were included (<a href="./references#CD008016-fig-0057" title="">Analysis 3.5</a>). </p> <p><sup>2</sup> Risk of bias: rated 'no' ‐ many studies did not report the methods for sequence generation and/or allocation concealment. However, in subgroup analysis (<a href="./references#CD008016-fig-0051" title="">Analysis 2.8</a>) studies reporting high standards of methods showed a similar effect size as compared to studies with unclear methods. Also, in a sensitivity analysis excluding studies with unclear methods (<a href="./references#CD008016-fig-0062" title="">Analysis 3.10</a> and <a href="./references#CD008016-fig-0063" title="">Analysis 3.11</a>), the effect sizes did not change substantially. Early terminated studies were not judged to contribute substantial weight to this outcome. </p> <p><sup>3</sup> Inconsistency: rated 'no' ‐ the P value for heterogeneity was statistically significant and the I<sup>2</sup> higher than 50%. However, results of individual studies differed rather in magnitude of effect (which could be partly explained by subgroup analyses) rather than in direction of effect. Therefore, this inconsistency does not challenge the overall results. </p> <p><sup>4</sup> No indirectness was found in terms of study population nor of interventions. In terms of outcome, we followed the original authors definitions of relapse. These definitions used different criteria, but all addressed symptomatic deterioration related to relapse. Therefore, this was not judged to lead to indirectness. </p> <p><sup>5</sup> Inconsistency: rated 'no' ‐ the P value for heterogeneity was statistically significant and the I‐square higher than 50%. However, results of individual studies differed rather in magnitude of effect than in direction of effect, which was the same in almost all the studies. Therefore, this inconsistency does not challenge the overall results. </p> <p><sup>6</sup> Publication bias: it is unlikely that a study was unpublished because of unfavourable data in a secondary outcome. As a possible publication bias had no effect on the results for the primary outcome (relapse at 7 to 12 months), we deem that there was no relevant publication bias for this secondary outcome. </p> <p><sup>7</sup> Indirectness: hospitalisation due to relapse was our primary interest, but in some studies reasons for hospitalisation were unclearly reported. Overall, we do not deem that this uncertainty was an important source of indirectness. </p> <p><sup>8</sup> Imprecision: rated 'very serious' ‐ only few studies with few events contributed data to this outcome. The CI was wide, ranging from substantial harm to substantial benefit. </p> <p><sup>9</sup> Risk of bias: rated 'serious' ‐ five out of seven studies were terminated early after interim analyses, possibly leading to overestimation of effect. </p> <p><sup>10</sup> Indirectness: some rating scales used in the studies have been criticised for eventually not measuring what people understand by quality of life. However, it was decided not to further lower the quality of evidence for this outcome after downgrading for other factors, despite some uncertainty. </p> <p><sup>11</sup> Imprecise data ‐ only a few studies provided data for this outcome and the confidence interval was large. </p> <p><sup>12</sup> Indirectness: rated 'serious' ‐ the only three studies included mixed groups of employed and non‐employed participants at baseline, and it is unclear whether employment was supported or competitive employment. </p> <p><sup>13</sup> Imprecision: rated 'serious' ‐ only three studies contributed to this event which depends on various factors (e.g. the existence of supported employment, rural versus service economy etc). </p> <p><sup>14</sup> Risk of bias: rated 'serious' ‐ eleven out of fifteen studies were terminated early after interim analyses, possibly leading to overestimation of effects. </p> <p><sup>15</sup> Indirectness: rated 'no' ‐ different rating scales were used in the studies, but this was not judged to challenge the results. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Maintenance treatment with antipsychotic drugs versus placebo/no treatment for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/full#CD008016-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008016-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Maintenance treatment with antipsychotic drugs versus placebo/no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Relapse: 1. Within pre‐specified time periods <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.33, 0.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.28, 0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 4‐6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.31, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 7‐12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.32, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 &gt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.33, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Relapse: 2. Independent of duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.30, 0.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Leaving the study early: 1. Due to any reason (acceptability of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.49, 0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.17, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.37, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3951</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.48, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 &gt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>741</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.51, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Leaving the study early: 2. Due to adverse events (overall tolerability) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6627</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.85, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.84 [0.12, 65.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.63, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3870</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.69, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.4 &gt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>534</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.70 [1.28, 25.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Leaving the study early: 3. Due to inefficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.32, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.07, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1661</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.31, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3951</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.31, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.4 &gt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.29, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Global state: number of participants improved (at least minimally) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1878</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [1.58, 2.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.76 [1.65, 13.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1037</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.33 [1.69, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.89, 3.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.4 &gt;12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.88, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Global state: number of participants in symptomatic remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>867</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.20, 2.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [0.63, 10.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [0.79, 3.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>807</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.11, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Global state: number of participants in sustained remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1807</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.28, 2.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [1.49, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 &gt;12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [1.13, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Service use: number of participants hospitalised <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.32, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.04, 4.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.03, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.23, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.4 &gt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>965</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.44, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Service use: number of participants discharged <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.76 [0.69, 11.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.76 [0.69, 11.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Death: due to any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.39, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [0.59, 8.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.11, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.4 &gt;12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.18 [0.25, 107.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Death: due to natural causes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.50, 3.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [0.59, 8.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.3 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.11, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.4 &gt;12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.11 [0.13, 75.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Death: due to suicide <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4634</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.12, 2.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1033</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.3 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.06, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.4 &gt;12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.11 [0.13, 75.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Number with suicide attempts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.19, 1.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>776</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 71.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.13, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Number with suicide ideation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.33, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.01, 3.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.3 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.24, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.4 &gt;12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.35, 4.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Violent/aggressive behaviour <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.24, 0.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.20, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.3 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.19, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.4 &gt;12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 4.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Adverse effects: at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.98, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.1 up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.30, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.2 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1079</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.85, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.3 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.99, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.4 &gt;12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [1.24, 2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Adverse effects: movement disorders: at least one movement disorder <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [1.25, 1.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.1 up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.42 [0.70, 8.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.2 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.06, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.3 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.17, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.4 &gt;12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.58, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Adverse effects: movement disorders: akathisia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.93, 2.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.1 up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.68 [0.49, 14.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.2 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.14 [0.50, 9.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.3 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.71, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.4 &gt;12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.42, 7.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Adverse effects: movement disorders: akinesia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>397</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.08, 3.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.1 up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.09, 9.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.2 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 3.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Adverse effects: movement disorders: dyskinesia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.33, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.1 up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.06, 34.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.2 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.11, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.3 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.37, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.4 &gt;12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.04, 3.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 Adverse effects: movement disorders: dystonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2767</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.99, 2.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.1 up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [0.13, 49.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.2 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [0.94, 3.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.3 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.65, 4.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.4 &gt;12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 4.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.23 Adverse effects: movement disorders: rigor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.70, 2.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.23.1 up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.22, 6.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.23.2 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [0.67, 5.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.23.3 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.29, 11.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.24 Adverse effects: movement disorders: tremor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.95, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.1 up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.46, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.2 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.33, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.3 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2790</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [1.04, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.4 &gt;12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.10, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.25 Adverse effects: movement disorders: use of antiparkinson medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.10, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.25.1 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.90, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.25.2 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.06, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.25.3 &gt;12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.64, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.26 Adverse effects: sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4078</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [1.24, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.26.1 up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 3.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.26.2 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.89, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.26.3 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1844</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.25, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.26.4 &gt;12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.15, 7.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.27 Adverse effects: weight gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4767</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.21, 2.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.27.1 4 to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1039</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.81, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.27.2 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.17, 2.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.27.3 &gt;12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [1.06, 4.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.28 Participant´s satisfaction with care <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.10, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.28.1 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [1.02, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.28.2 &gt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.08, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.29 Quality of life (various scales, different timepoints) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.29.1 up to 3 months ‐ Schizophrenia Quality of Life at endpoint (low score=better)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.00 [‐5.80, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.29.2 7 to 12 months ‐ Self‐report Quality of Life Scale change from baseline to endpoint (low score=better) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>595</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.10 [‐6.32, ‐1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.29.3 7 to 12 months ‐ Heinrichs Carpenter Quality of Life Scale change from baseline to endpoint (low score=better) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.36 [‐14.67, ‐8.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.29.4 7 to 12 months ‐ European Quality of Life Visual Analog Scale at endpoint (low score=better) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.30 [‐23.41, 10.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.29.5 &gt; 12 months ‐ Symptom Questionnaire of Kellner and Sheffield at endpoint (low score=better) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.90 [‐14.33, 4.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.30 Quality of life (across all scales and timepoints) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.32 [‐0.57, ‐0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.31 Number of participants in employment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.82, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.31.1 7 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.75, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.31.2 &gt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.97, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.32 Social Functioning (various scales, different timepoints) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.1 up to 3 months ‐ Personal and Social Performance at endpoint (low score=better)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.66 [‐11.50, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.2 up to 3 months ‐ Global Assessment Scale at endpoint (low score=better)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.61 [‐4.66, ‐2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.3 4 to 6 months ‐ Sheehan Disability Schedule change from baseline to endpoint (low score=better) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.00 [‐3.60, ‐0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.4 7 to 12 months ‐ Personal and Social Performance change from baseline to endpoint (low score=better) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1823</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.92 [‐5.96, ‐3.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.5 7 to 12 months ‐ Global Assessment of Functioning at endpoint (low score=better)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.80 [‐13.22, ‐4.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.6 7 to 12 months ‐ Specific Levels of Functioning change from baseline to endpoint (low score=better) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.40 [‐4.85, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.7 7 to 12 months ‐ Children Global Assessment Scale change from baseline to endpoint (low score=better) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.60 [‐9.84, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.8 &gt; 12 months ‐ Personal and Social Performance change from baseline to endpoint (low score=better) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.60 [‐6.76, ‐0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.33 Social Functioning (across all scales and timepoints) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.43 [‐0.53, ‐0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Maintenance treatment with antipsychotic drugs versus placebo/no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008016-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis (relapse at 12 months)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Subgroup analysis: participants with a first episode <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.33, 0.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 first episode</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.38, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 not first episode</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.31, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Subgroup analysis: participants in remission at baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.32, 0.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 in remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1050</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.33, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 not in remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3063</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.30, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Subgroup analysis: various durations of stability before entering the study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 stable at least 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.20, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 stable at least 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.26, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 stable at least 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 2.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.4 stable at least 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.17, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.5 stable at least 3 to 6 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.18, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Subgroup analysis: abrupt withdrawal versus tapering <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Abrupt withdrawal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.35, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Taper</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1765</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.24, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Subgroup analysis: single antipsychotic drugs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.36, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Fluphenazine depot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.14, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.3 Haloperidol depot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.04, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.4 Various, mixed groups of antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>705</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.27, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.5 Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.34, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.6 Paliperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.31, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.7 Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.14, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.8 Brexpiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.23, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.9 Ziprasidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.39, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.10 Cariprazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.38, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Subgroup analysis: depot versus oral drugs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 depot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1705</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.23, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.38, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Subgroup analysis: first‐ versus second‐generation antipsychotic drugs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 First‐generation antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.25, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 Second‐generation antipsychotic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.32, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Subgroup analysis: appropriate versus unclear allocation concealment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.32, 0.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 appropriate allocation concealment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.30, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.2 unclear allocation concealment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.30, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Subgroup analysis: blinded versus open trials <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.32, 0.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 blinded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.33, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.2 unblinded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.17, 0.39]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis (relapse at 12 months)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008016-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sensitivity analysis (relapse at 12 months)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Exclusion of studies that were not explicitly described as randomised <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4098</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.33, 0.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Exclusion of non‐double‐blind studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.33, 0.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Fixed‐effects model <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.35, 0.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Original authors' assumptions on dropouts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.32, 0.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Inclusion of only large studies (&gt; 200 participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2950</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.31, 0.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Exclusion of studies with clinical diagnosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.34, 0.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Three months stable <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.24, 0.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Six months stable <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.20, 0.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Nine months stable <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1806</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.19, 0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Exclusion of studies with unclear randomisation method <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.29, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 Exclusion of studies with unclear allocation concealment method <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.30, 0.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sensitivity analysis (relapse at 12 months)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008016.pub3/references#CD008016-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008016.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008016-note-0020">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008016-note-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008016-note-0019">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD008016-note-0017">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD008016-note-0011">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD008016-note-0016">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD008016-note-0012">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD008016-note-0010">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD008016-note-0015">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008016-note-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD008016-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008016\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008016\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008016\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008016\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008016\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008016\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008016\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008016\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008016\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008016\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008016\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008016\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008016\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008016\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008016\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008016\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008016\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008016\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=STpJR8yz&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008016.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008016.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008016.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008016.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008016.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714549633"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008016.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714549637"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008016.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d715e5f37937f',t:'MTc0MDcxNDU1MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 